東北大学研究者紹介

研究者詳細

ホーム

日本語 English

ジングウ　ケイイチ

神宮　啓一

Keiichi Jingu

所属

大学院医学系研究科　医科学専攻　内科病態学講座（放射線腫瘍学分野）

職名

教授

学位

博士（医学）（東北大学）

researchmap

https://researchmap.jp/kjingu-jr

J-GLOBAL ID

201301030628400579

プロフィール

1995年3月福岡県立福岡高等学校卒業
2002年3月東北大学医学部卒業
2007年3月東北大学大学院医学系研究科放射線腫瘍学分野博士課程修了
2007年4月～2007年11月東北大学病院放射線治療科医員
2007年12月～2008年3月東北大学病院放射線治療科助手
2008年4月～2010年6月 (独)放射線医学総合研究所重粒子医科学センター
2010年7月～2011年3月東北大学病院放射線部助教
2011年4月～2012年1月東北大学病院放射線治療科講師
2012年1月～2012年3月スタンフォード大学放射線治療科客員研究員
2012年4月～現職

経歴 5

2012年4月～継続中

東北大学大学院　医学系研究科放射線腫瘍学分野　教授
2012年1月～ 2012年3月

スタンフォード大学　客員研究員
2011年4月～ 2012年3月

東北大学　大学病院　講師
2010年7月～ 2011年3月

東北大学病院　放射線部　助教
2008年4月～ 2010年6月

放射線医学総合研究所　重粒子医科学センター病院　医師

学歴 2

東北大学大学院　医学系研究科

2004年4月～ 2007年3月
東北大学　医学部

1996年4月～ 2002年3月

所属学協会 6

日本癌治療学会
米国放射線腫瘍学会
日本頭頸部癌学会
日本食道学会
日本医学放射線学会
日本放射線腫瘍学会

︎全件表示 ︎最初の5件までを表示

研究キーワード 20

放射線心筋障害
放射線心筋障害予防効果
放射線適応
放射線感受性
標準的放射線治療
早期の癌
臨床試験
各種臓器がん
定位放射線治療
放射線治療学
PET
小線源治療
QOL
強度変調放射線治療(IMRT)
放射線
放射線治療
放射線、X線
癌
放射線増感剤
X線

研究分野 1

ライフサイエンス / 放射線科学 /

受賞 9

Clinical Research Award

2022年9月　第5回腫瘍循環器学会
第6回優秀査読者賞

2021年11月　日本放射線腫瘍学会
第5回優秀査読者賞

2020年10月　日本放射線腫瘍学会
第４回優秀査読者賞

2019年11月　日本放射線腫瘍学会
第19回梅垣賞

2013年10月　日本放射線腫瘍学会
Best of ASTRO

2011年10月　米国放射線腫瘍学会
第20回日本放射線腫瘍学会総会 Gold Prize

2007年12月　日本放射線腫瘍学会
第66回日本医学放射線学会総会 Bronze Medal

2007年4月　日本医学放射線学会
第65回日本医学放射線学会総会 Silver Medal

2006年4月　日本医学放射線学会

︎全件表示 ︎最初の5件までを表示

論文 377

Radiotherapy treatment planning for esophageal cancer: JASTRO guidelines 2024 for radiotherapy treatment planning. 国際誌

Keiichi Jingu, Keiji Nihei, Yoshinori Ito, Masahiko Okamoto, Hiroshi Doi, Hirofumi Ogawa, Masakatsu Onozawa, Terufumi Kawamoto, Norio Katoh, Atsuya Takeda, Hirokazu Makishima, Hiroshi Mayahara, Hideya Yamazaki, Keiko Nemoto Murofushi, Kayoko Tsujino, Hiroshi Igaki, Takashi Uno

Journal of radiation research　2025年6月3日

DOI： 10.1093/jrr/rraf029 　

詳細を見る詳細を閉じる

The Japanese Society for Radiation Oncology (JASTRO) Guidelines for Radiotherapy Treatment Planning have been revised every four years to incorporate the latest findings since the publication of the first edition in 2004. This is a review which presents the 2024 JASTRO Guidelines for radiotherapy treatment planning for esophageal cancer in English. Regarding the treatment of esophageal cancer, various new findings have emerged over the past 4 years, leading to significant updates in the 2020 edition, particularly in the following six areas: (i) additional details on indications for superficial cancer, (ii) inclusion of clinical trial results (JCOG1109) for neoadjuvant chemotherapy and chemoradiotherapy in locally advanced cases in Japan, (iii) updated references on prophylactic lymph node irradiation, (iv) updates on IMRT, (v) revisions in accordance with the 5th edition of the Esophageal Cancer Treatment Guidelines, and (vi) additions of FOLFOX to concurrent chemotherapy regimens.
Continuous measurement of radioactivity for a patient with chronic kidney disease during radioactive iodine therapy and hemodialysis: a case report

Takuma Usuzaki, Hiroyasu Kodama, Mariko Miyazaki, Keiichi Jingu

International Cancer Conference Journal　2025年4月9日
出版者・発行元： Springer Science and Business Media LLC
DOI： 10.1007/s13691-025-00756-z 　

eISSN：2192-3183

詳細を見る詳細を閉じる

Abstract The half-life of radioactive iodine (RAI) is prolonged in patients with chronic kidney disease (CKD) because RAI is mainly excreted by the kidneys. There is little information on the RAI half-life in patients with dialysis-dependent CKD (CKDG5d). Estimating the RAI half-life in a patient’s body provides important information for treatment planning. In this paper, we report a 68-year-old woman of CKDG5d who underwent postsurgical RAI therapy for papillary adenocarcinoma of the thyroid. We administered 15 mCi (0.56 GBq) RAI (¹³¹I) and continuously measured the dose equivalent rate. The results were summarized into hourly values of dose equivalent rate. Based on the measurements, we estimated the RAI half-life in the patient’s body using a semi-log plot and linear regression analysis. In addition, we calculated the integrated doses for caregivers and the public using coefficients of 0.5 and 0.25, respectively. The half-life in the patient’s body was 7.2 days (95% confidence interval, 4.8–14.4). The integrated doses for caregivers and the public were 0.23 mSv and 0.11 mSv, respectively. RAI therapy for a CKDG5d patient should be planned on the basis of the biological dynamics of ¹³¹I. Accumulation of more cases should lead to the establishment of a treatment strategy for patients undergoing RAI therapy and hemodialysis.
Efficacy and safety of diffusing alpha-emitter radiation therapy (DaRT) for head and neck cancer recurrence after radiotherapy.

Ryo-Ichi Yoshimura, Kazuma Toda, Hiroshi Watanabe, Masahiko Miura, Ryoichi Notake, Naoya Murakami, Hiroshi Igaki, Satoshi Nakamura, Rei Umezawa, Noriyuki Kadoya, Keiichi Jingu, Jun Itami

International journal of clinical oncology　2025年2月19日

DOI： 10.1007/s10147-025-02720-6 　

詳細を見る詳細を閉じる

BACKGROUND: To evaluate the efficacy and safety of diffusing alpha-emitter radiation therapy (DaRT) for recurrent head and neck cancer (rHNC) after radiotherapy. METHODS: This study was a multicenter prospective clinical trial. Eligibility criteria included all patients with biopsy-proven rHNC and history of radiotherapy. The efficacy of DaRT was evaluated in terms of tumor shrinkage after 10 weeks of DaRT seed implantation. To assess safety of DaRT, radioactivity levels in blood and urine were measured, and incidence and grade of adverse events (AEs) were evaluated. RESULTS: Between 2019 and 2021, DaRT was performed in 11 patients and completed in 10 patients with 11 tumors. The tumor sites included the tongue (n = 3), buccal mucosa (2), lips (2), floor of the mouth (1), soft palate (1), nose (1), and subcutaneous layer (1). Nine tumors were confirmed to be squamous cell carcinoma, and the remaining two tumors were basal cell carcinoma and neuroblastoma. Complete response (CR) and partial response (PR) were observed in three and six patients, respectively. The response rate was 81.8%. The maximum average radioactivity levels in blood and urine were 42.5 Bq/cm3 and 8.4 Bq/cm3, respectively, on the second day after implantation. Forty AEs were observed in all 11 patients, including 22 Grade 1 AEs, 16 Grade 2, and 2 Grade 3 (hypertension and seed remnants). CONCLUSION: The initial response of rHNC after radiotherapy to DaRT was favorable, and the incidence and grade of AEs were acceptable, as compared to existing therapies.
Utilization and regional disparities of radiotherapy in cancer treatment in Japan: a longitudinal study using NDB open data. 国際誌

Kazuya Takeda, Rei Umezawa, Takaya Yamamoto, Noriyoshi Takahashi, Hiroshi Onishi, Keiichi Jingu

Journal of radiation research　66　(1)　82-88　2025年1月22日

DOI： 10.1093/jrr/rrae100 　

詳細を見る詳細を閉じる

The National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB) is a database that stores anonymized information on medical receipts and health checkups in Japan. The NDB Open Data is a publicly accessible summary table of the NDB database. To reveal annual trends and regional disparities in radiotherapy utilization in Japan, we analyzed the NDB Open Data tables for a 9-year period from 2014 to 2022. We extracted medical cost codes for radiotherapy management fees and specific types of radiotherapy, such as stereotactic irradiation (STI) and intensity-modulated radiotherapy (IMRT), to analyze nationwide changes over time. To investigate regional disparities, we counted the three subitems representing 3-dimensional conformal radiotherapy (3D-CRT), IMRT, and STI for each prefecture per year. The utilization of advanced radiotherapy techniques, such as IMRT (199% increase), increased, while the use of simpler forms of irradiation, such as 1 or 2-opposite fields irradiation (40% decrease), decreased in the period from 2014 to 2022. Regarding regional disparities, the coefficients of variation in 47 prefectures for 3D-CRT remained relatively stable at 0.17 in 2014 and 0.18 in 2022, while the coefficients of variation for IMRT and STI decreased from 0.64 and 0.39 in 2014 to 0.31 and 0.36 in 2022, respectively. The popularization of IMRT was correlated with the number of certified radiation oncologists in the prefecture. In conclusion, although the utilization of high-precision radiotherapy in Japan has been increasing and regional differences have been diminishing, there are still persistent disparities.
Radiomics and dosiomics approaches to estimate lung function after stereotactic body radiation therapy in patients with lung tumors.

Yoshiro Ieko, Noriyuki Kadoya, Shohei Tanaka, Koyo Kikuchi, Takaya Yamamoto, Hisanori Ariga, Keiichi Jingu

Radiological physics and technology　2025年1月14日

DOI： 10.1007/s12194-024-00877-9 　

詳細を見る詳細を閉じる

Lung function assessment is essential for determining the optimal treatment strategy for radiation therapy in patients with lung tumors. This study aimed to develop radiomics and dosiomics approaches to estimate pulmonary function test (PFT) results in post-stereotactic body radiation therapy (SBRT). Sixty-four patients with lung tumors who underwent SBRT were included. Models were created to estimate the PFT results at 0-6 months (Cohort 1) and 6-24 months (Cohort 2) after SBRT. Radiomics and dosiomics features were extracted from the computed tomography (CT) images and dose distributions, respectively. To estimate the PFT results, Models A (dose-volume histogram [DVH] + radiomics features) and B (DVH + radiomics + dosiomics features) were created. In the PFT results, the forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) were estimated using each model, and the ratio of FEV1 to FVC (FEV1/FVC) was calculated. The Pearson's correlation coefficient (Pearson r) and area under the curve (AUC) for FEV1/FVC (< 70%) were calculated. The models were evaluated by comparing them with the conventional calculation formulae (Conventional). The Pearson r (FEV1/FVC) values were 0.30, 0.64, and 0.69 for Conventional and Models A and B (Cohort 2), respectively, and the AUC (FEV1/FVC < 70%) values were 0.63, 0.80, and 0.78, respectively. This study demonstrates the possibility of estimating lung function after SBRT using radiomics and dosiomics features based on planning CT images and dose distributions.
Evaluation of deep learning based dose prediction in head and neck cancer patients using two different types of input contours

Masahide Saito, Noriyuki Kadoya, Yuto Kimura, Hikaru Nemoto, Ryota Tozuka, Keiichi Jingu, Hiroshi Onishi

Journal of Applied Clinical Medical Physics　2024年9月16日
出版者・発行元： Wiley
DOI： 10.1002/acm2.14519 　

ISSN：1526-9914

eISSN：1526-9914

詳細を見る詳細を閉じる

Abstract Purpose This study evaluates deep learning (DL) based dose prediction methods in head and neck cancer (HNC) patients using two types of input contours. Materials and methods Seventy‐five HNC patients undergoing two‐step volumetric‐modulated arc therapy were included. Dose prediction was performed using the AIVOT prototype (AiRato.Inc, Sendai, Japan), a commercial software with an HD U‐net‐based dose distribution prediction system. Models were developed for the initial plan (46 Gy/23Fr) and boost plan (24 Gy/12Fr), trained with 65 cases and tested with 10 cases. The 8‐channel model used one target (PTV) and seven organs at risk (OARs), while the 10‐channel model added two dummy contours (PTV ring and spinal cord PRV). Predicted and deliverable doses, obtained through dose mimicking on another radiation treatment planning system, were evaluated using dose‐volume indices for PTV and OARs. Results For the initial plan, both models achieved approximately 2% prediction accuracy for the target dose and maintained accuracy within 3.2 Gy for OARs. The 10‐channel model outperformed the 8‐channel model for certain dose indices. For the boost plan, both models exhibited prediction accuracies of approximately 2% for the target dose and 1 Gy for OARs. The 10‐channel model showed significantly closer predictions to the ground truth for D50% and Dmean. Deliverable plans based on prediction doses showed little significant difference compared to the ground truth, especially for the boost plan. Conclusion DL‐based dose prediction using the AIVOT prototype software in HNC patients yielded promising results. While additional contours may enhance prediction accuracy, their impact on dose mimicking is relatively small.
Assessing knowledge about medical physics in language-generative AI with large language model: using the medical physicist exam.

Noriyuki Kadoya, Kazuhiro Arai, Shohei Tanaka, Yuto Kimura, Ryota Tozuka, Keisuke Yasui, Naoki Hayashi, Yoshiyuki Katsuta, Haruna Takahashi, Koki Inoue, Keiichi Jingu

Radiological physics and technology　2024年9月10日

DOI： 10.1007/s12194-024-00838-2 　

詳細を見る詳細を閉じる

This study aimed to evaluate the performance for answering the Japanese medical physicist examination and providing the benchmark of knowledge about medical physics in language-generative AI with large language model. We used questions from Japan's 2018, 2019, 2020, 2021 and 2022 medical physicist board examinations, which covered various question types, including multiple-choice questions, and mainly focused on general medicine and medical physics. ChatGPT-3.5 and ChatGPT-4.0 (OpenAI) were used. We compared the AI-based answers with the correct ones. The average accuracy rates were 42.2 ± 2.5% (ChatGPT-3.5) and 72.7 ± 2.6% (ChatGPT-4), showing that ChatGPT-4 was more accurate than ChatGPT-3.5 [all categories (except for radiation-related laws and recommendations/medical ethics): p value < 0.05]. Even with the ChatGPT model with higher accuracy, the accuracy rates were less than 60% in two categories; radiation metrology (55.6%), and radiation-related laws and recommendations/medical ethics (40.0%). These data provide the benchmark for knowledge about medical physics in ChatGPT and can be utilized as basic data for the development of various medical physics tools using ChatGPT (e.g., radiation therapy support tools with Japanese input).
Two-fractionated stereotactic magnetic resonance-guided adaptive radiation therapy for patients with prostate cancer (SMART PRO trial): protocol for a confirmatory clinical trial

Sadamoto Zenda, Tairo Kashihara, Tetsuo Saito, Hiroyuki Okamoto, Noriyuki Kadoya, Takahiro Chiba, Shin-ei Noda, Takashi Kawaguchi, Keiichi Jingu, Keiko Shibuya, Takashi Uno, Hiroshi Igaki

BMJ Open　14　(8)　e082899-e082899　2024年8月25日
出版者・発行元： BMJ
DOI： 10.1136/bmjopen-2023-082899 　

ISSN：2044-6055

eISSN：2044-6055

詳細を見る詳細を閉じる

Introduction In an MRI-guided linear accelerator (MR-LINAC) system, the planned doses for organs at risk and for tumours are assessed by MR imaging and re-contouring at every treatment. This allows treatment to be safer and more precise by ensuring that it is suitable for the state of the patient’s organs on that day, as well as by allowing images to be acquired during radiation therapy to prevent radiation while organs are in motion. Here, we will conduct a confirmatory study of two-fractionated stereotactic magnetic resonance-guided adaptive radiation therapy for patients with localised prostate cancer. Methods and analysis This will be a single-arm study to demonstrate the safety and efficacy of ultra-hypofractionated radiation (26 Gy/2 Fr) using an MR-LINAC system in patients with very low-intermediate risk prostate cancer. The primary endpoint will be the incidence of grade ≥2 acute urinary tract adverse events occurring within 90 days of the start of radiation therapy. The sample size has been determined to be 58. Ethics and dissemination This study is performed in accordance with Ethical Guidelines for Medical and Health Research Involving Human Subjects, published by Japan’s Ministry of Education, Science and Technology and the Ministry of Health, Labour and Welfare and the modified act on the Protection of Personal Information as well as the Declaration of Helsinki. This study was approved by the institutional ethics committee of the National Cancer Center on 20 November 2021. The findings of this trial will be submitted to an international peer-reviewed journal and the key findings will be presented at an international scientific conference. Authorship will be ascribed in accordance with the International Committee of Medical Journal Editors guidance. Trial registration number UMIN000049746.
Craniospinal irradiation for leptomeningeal metastasis of solid tumors: survival analysis and prognostic factors. 国際誌

Kazuya Takeda, Rei Umezawa, Takaya Yamamoto, Noriyoshi Takahashi, Keiichi Jingu

Journal of radiation research　2024年8月17日

DOI： 10.1093/jrr/rrae059 　

詳細を見る詳細を閉じる

We conducted a study to examine the treatment outcomes and prognostic factors for patients who underwent craniospinal irradiation (CSI) for leptomeningeal metastasis of solid tumors. This retrospective study included patients who received CSI for leptomeningeal metastasis at a single institute between 2010 and 2021. Data from clinical records and the radiation information system were obtained and analyzed. A total of 25 patients were included in the study. Eighteen patients (72%) completed the scheduled CSI. The median overall survival (OS) period was 4.8 months (95% confidence interval (CI): 3.2-10.0 months). Symptom relief was achieved in four out of 23 symptomatic patients (17%). Non-hematological adverse events occurred in 12 patients (48%), with 1 patient (4%) developing Grade 3 bacterial meningitis and the other patients having Grade 1-2 events. Twenty patients (80%) had hematological adverse events of Grade 3 or higher. Grade 4 hematologic toxicities occurred in 3 patients (12%) due to neutropenia and in 11 patients (44%) due to lymphopenia. In multivariate Cox regression analysis, the systemic immune-inflammation index (SII) was identified as the only significant parameter for predicting OS. The median OS periods for patients with SII < 607 and SII ≥ 607 were 6.1 and 2.1 months, respectively (P = 0.003). In conclusion, this study showed the treatment outcomes of CSI for leptomeningeal metastasis of solid tumors. It was shown that a high baseline SII was associated with shorter OS after CSI. The findings will contribute to the evaluation of prognosis after CSI.
Development of deep learning-based novel auto-segmentation for the prostatic urethra on planning CT images for prostate cancer radiotherapy.

Hisamichi Takagi, Ken Takeda, Noriyuki Kadoya, Koki Inoue, Shiki Endo, Noriyoshi Takahashi, Takaya Yamamoto, Rei Umezawa, Keiichi Jingu

Radiological physics and technology　2024年8月14日

DOI： 10.1007/s12194-024-00832-8 　

詳細を見る詳細を閉じる

Urinary toxicities are one of the serious complications of radiotherapy for prostate cancer, and dose-volume histogram of prostatic urethra has been associated with such toxicities in previous reports. Previous research has focused on estimating the prostatic urethra, which is difficult to delineate in CT images; however, these studies, which are limited in number, mainly focused on cases undergoing brachytherapy uses low-dose-rate sources and do not involve external beam radiation therapy (EBRT). In this study, we aimed to develop a deep learning-based method of determining the position of the prostatic urethra in patients eligible for EBRT. We used contour data from 430 patients with localized prostate cancer. In all cases, a urethral catheter was placed when planning CT to identify the prostatic urethra. We used 2D and 3D U-Net segmentation models. The input images included the bladder and prostate, while the output images focused on the prostatic urethra. The 2D model determined the prostate's position based on results from both coronal and sagittal directions. Evaluation metrics included the average distance between centerlines. The average centerline distances for the 2D and 3D models were 2.07 ± 0.87 mm and 2.05 ± 0.92 mm, respectively. Increasing the number of cases while maintaining equivalent accuracy as we did in this study suggests the potential for high generalization performance and the feasibility of using deep learning technology for estimating the position of the prostatic urethra.
Clinical significance of cerebral microbleeds in patients with germinoma who underwent long-term follow-up

Masayuki Kanamori, Shunji Mugikura, Osamu Iizuka, Naoko Mori, Yoshiteru Shimoda, Ichiyo Shibahara, Rei Umezawa, Keiichi Jingu, Ryuta Saito, Yukihiko Sonoda, Toshihiro Kumabe, Kyoko Suzuki, Hidenori Endo

Journal of Neuro-Oncology　170　(1)　173-184　2024年8月12日
出版者・発行元： Springer Science and Business Media LLC
DOI： 10.1007/s11060-024-04753-9 　

ISSN：0167-594X

eISSN：1573-7373

詳細を見る詳細を閉じる

Abstract Purpose This study identified the factors affecting cerebral microbleed (CMBs) development. Moreover, their effects on intelligence and memory and association with stroke in patients with germinoma who had long-term follow-up were evaluated. Methods This study included 64 patients with germinoma who were histologically and clinically diagnosed with and treated for germinoma. These patients were evaluated cross-sectionally, with a focus on CMBs on susceptibility-weighted magnetic resonance imaging (SWI), brain atrophy assessed through volumetric analysis, and intelligence and memory. Results The follow-up period was from 32 to 412 (median: 175.5) months. In total, 43 (67%) patients had 509 CMBs and 21 did not have CMBs. Moderate correlations were observed between the number of CMBs and time from initial treatments and recurrence was found to be a risk factor for CMB development. Increased temporal CMBs had a marginal effect on the processing speed and visual memory, whereas brain atrophy had a statistically significant effect on verbal, visual, and general memory and a marginal effect on processing speed. Before SWI acquisition and during the follow-up periods, eight strokes occurred in four patients. All of these patients had ≥ 15 CMBs on SWI before stroke onset. Meanwhile, 33 patients with < 14 CMBs or 21 patients without CMBs did not experience stroke. Conclusion Patients with a longer time from treatment initiation had a higher number of CMBs, and recurrence was a significant risk factor for CMB development. Furthermore, brain atrophy had a stronger effect on memory than CMBs. Increased CMBs predict the stroke onset.
Lymphopenia after palliative radiotherapy for vertebral metastases. 国際誌

Kazuya Takeda, Rei Umezawa, Takaya Yamamoto, Noriyoshi Takahashi, Yu Suzuki, Keita Kishida, So Omata, Keiichi Jingu

Journal of radiation research　65　(4)　523-531　2024年7月22日

DOI： 10.1093/jrr/rrae038 　

詳細を見る詳細を閉じる

Lymphopenia is a well-known side effect of radiotherapy and has been shown to have a negative impact on patient outcomes. However, the extent of lymphopenia caused by palliative radiotherapy and its effect on patient prognosis has not been clarified. The aim of this study was to determine the incidence and severity of lymphopenia after palliative radiotherapy for vertebral metastases and to determine their effects on patients' survival outcomes. We conducted a retrospective analysis for patients who underwent palliative radiotherapy for vertebral metastases and could be followed up for 12 weeks. Lymphocyte counts were documented at baseline and throughout the 12-week period following the start of radiotherapy and their medians and interquartile ranges (IQRs) were recorded. Exploratory analyses were performed to identify predictive factors for lymphopenia and its impact on overall survival (OS). A total of 282 cases that met the inclusion criteria were analyzed. The median baseline lymphocyte count was 1.26 × 103/μl (IQR: 0.89-1.72 × 103/μl). Peak lymphopenia occurred at a median of 26 days (IQR: 15-45 days) with a median nadir of 0.52 × 103/μl (IQR: 0.31-0.81 × 103/μl). Long-term analysis of patients surviving for 1 year showed that lymphopenia persisted at 1 year after radiotherapy. The main irradiation site, radiation field length and pretreatment lymphocyte count were significantly related to grade 3 or higher lymphopenia. Lymphopenia was identified as a significant predictor of OS by multivariate Cox regression analysis. This study demonstrated the incidence of lymphopenia after palliative radiotherapy for vertebral metastases and its effect on patients' OS.
Impact of dose distribution by a 3D planning system for brachytherapy with 198Au grains for head and neck cancer. 国際誌

Keita Kishida, Keiichi Jingu, Kengo Ito, Rei Umezawa, Takaya Yamamoto, Noriyoshi Takahashi, Yu Suzuki, So Omata, Hinako Harada, Yasuhiro Seki, Nanae Chiba, Shinsaku Okuda

Head & neck　2024年7月16日

DOI： 10.1002/hed.27874 　

詳細を見る詳細を閉じる

BACKGROUND: There has been no study in which the correlation between clinical results and dosimetry based on a 3D treatment planning system in patients with 198Au grains for head and neck cancer was evaluated. METHODS: Thirty-two patients who were treated with 198Au grains for head and neck cancer were reviewed. Twenty-five patients were treated with brachytherapy alone and seven patients were treated with a combination of brachytherapy and neoadjuvant external beam radiation therapy. RESULTS: With a median observation period of 60 months, the 5-year local control rate was 82.9%. V85Gy of CTV in patients with local recurrence tended to be lower than that in patients without local recurrence (p = 0.07). The maximum dose of the keratinized gingiva in patients in whom bone exposure occurred was significantly higher than that in patients in whom bone exposure did not occur (p = 0.001). CONCLUSIONS: Dose distribution with 198Au grains can predict local control and late adverse events.
Nicaraven attenuates the acquired radioresistance of established tumors in mouse models via PARP inhibition. 国際誌

Kai Huang, Chen Yan, Lina Abdelghany, Xu Zhang, Keiichi Jingu, Tao-Sheng Li

Molecular and cellular biochemistry　2024年3月11日

DOI： 10.1007/s11010-024-04958-6 　

詳細を見る詳細を閉じる

Nicaraven has been reported to inhibit the activity of poly (ADP-ribose) polymerase (PARP). In this study, we investigated the probable ability of nicaraven to attenuate cancer radioresistance during fractionated radiotherapy. Tumor models were established in C57BL/6 mice and BALB/c nude mice by subcutaneous injection of Lewis mouse lung carcinoma cancer cells and A549 human lung cancer cells, respectively. When the tumors had grown to approximately 100 mm3, we initiated fractionated radiotherapy. Nicaraven or saline was administered immediately after each irradiation exposure. Compared to saline treatment, nicaraven administration significantly induced gamma-H2AX foci formation and cell apoptosis in tumors at 1 or 3 days after an additional challenge exposure to 10 Gy and inhibited tumor growth during the short-term follow-up period, suggesting increased radiosensitivity of cancer cells. Moreover, the expression of PARP in tumor tissue was decreased by nicaraven administration. Our data suggest that nicaraven likely attenuates the acquired radioresistance of cancers through PARP inhibition.
Lymphocytopenia following adjuvant radiotherapy for breast cancer

Kazuya Takeda, Rei Umezawa, Takaya Yamamoto, Noriyoshi Takahashi, Yu Suzuki, Keita Kishida, So Omata, Keiichi Jingu

Precision Radiation Oncology　8　(1)　22-29　2024年3月

DOI： 10.1002/pro6.1221 　

eISSN：2398-7324
Beginning of clinical treatment using the 1.5 Tesla MR-Linac system in Japan: a narrative review. 国際誌

Noriyoshi Takahashi, Shohei Tanaka, Rei Umezawa, Takaya Yamamoto, Yu Suzuki, Keita Kishida, So Omata, Kazuhiro Arai, Yoshiyuki Katsuta, Noriyuki Kadoya, Keiichi Jingu

Translational cancer research　13　(2)　1131-1138　2024年2月29日

DOI： 10.21037/tcr-23-1649 　

詳細を見る詳細を閉じる

BACKGROUND AND OBJECTIVE: In the field of radiation therapy, image-guided radiotherapy (IGRT) technology has been gradually improving and highly accurate radiation treatment has been possible. Research on IGRT using 1.5 Tesla magnetic resonance imaging (MRI) began in 1999, and a radiation therapy device called 1.5 Tesla magnetic resonance linear accelerator (MR-Linac), which combines a linear accelerator with 1.5 Tesla MRI, was developed in Europe. The aim of this review is to present an overview of 1.5 Tesla MR-Linac with a review of the literature and our experience. METHODS: Reports related to 1.5 Tesla MR-Linac were searched for in PubMed and are discussed in relation to our experience. KEY CONTENT AND FINDINGS: The 1.5 Tesla MR-Linac enables IGRT using 1.5 Tesla MRI, further enhancing the precision of radiation therapy. Position verification by cone-beam computed tomography (CBCT) is performed in many institutions, but soft tissue contrast is often unclear in CBCT images of the abdomen and mediastinal organs. Since the 1.5 Tesla MR-Linac allows position verification using MRI, position verification can be performed using clear MRI even in regions where CBCT is unclear. With the 1.5 Tesla MR-Linac, it is possible to perform online adaptive radiotherapy (ART) using 1.5 Tesla MRI. Online ART is a method in which images are acquired while the patient is on the treatment table. The method is based on the current condition of the organs in the body on that day and an optimal treatment field is recreated. Additionally, it allows monitoring of tumor motion using cine images obtained by 1.5 Tesla MRI during the delivery of X-ray radiation. A previous report showed that patients with prostate cancer who received radiotherapy by MR-Linac had fewer side effects than those in patients who received conventional CBCT radiation therapy. CONCLUSIONS: The 1.5 Tesla MR-Linac obtained CE-mark certification in Europe in August 2018 and it has been used for clinical treatment. In Japan, clinical treatment using this device started in 2021. By using 1.5 Tesla MR-Linac, patients can be provided with higher precision radiotherapy. In this review, we provide an overview of 1.5 Tesla MR-Linac.
新型コロナウイルスワクチン接種後に放射線リコール現象が疑われた2症例

石川陽二郎, 梅澤玲, 山本貴也, 高橋紀善, 鈴木友, 神宮啓一, 伊藤謙吾, 古積麻衣子, 山田隆之

Japanese Journal of Radiology　42　(Suppl.)　3-3　2024年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
モンテカルロ線量計算用のAu198小線源モデルの構築

伊藤謙吾, 石川陽二郎, 古積麻衣子, 山田隆之, 岸田桂太, 神宮啓一

Japanese Journal of Radiology　42　(Suppl.)　3-3　2024年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
腎がん定位照射後にChronic expanding hematomaをきたした1例

石川陽二郎, 梅澤玲, 山本貴也, 高橋紀善, 鈴木友, 神宮啓一, 伊藤謙吾, 寺村聡司, 山田隆之

Japanese Journal of Radiology　42　(Suppl.)　7-7　2024年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
Investigation of intrafractional spinal cord and spinal canal movement during stereotactic MR-guided online adaptive radiotherapy for kidney cancer. 国際誌

Takaya Yamamoto, Shohei Tanaka, Noriyoshi Takahashi, Rei Umezawa, Yu Suzuki, Keita Kishida, So Omata, Kazuya Takeda, Hinako Harada, Kiyokazu Sato, Yoshiyuki Katsuta, Noriyuki Kadoya, Keiichi Jingu

PloS one　19　(10)　e0312032　2024年

DOI： 10.1371/journal.pone.0312032 　

詳細を見る詳細を閉じる

BACKGROUND AND PURPOSE: This study aimed to investigate the intrafractional movement of the spinal cord and spinal canal during MR-guided online adaptive radiotherapy (MRgART) for kidney cancer. MATERIALS AND METHODS: All patients who received stereotactic MRgART for kidney cancer between February 2022 and February 2024 were included in this study. Patients received 30-42 Gy in 3-fraction MRgART for kidney cancer using the Elekta Unity, which is equipped with a linear accelerator and a 1.5 Tesla MRI. MRI scans were performed at three points during each fraction: for online planning, position verification, and posttreatment assessment. The spinal cord was contoured from the upper edge of Th12 to the medullary cone, and the spinal canal was contoured from Th12 to L3, using the first MRI. These contours were adjusted to the second and third MR images via deformable image registration, and movements were measured. Margins were determined via the formula "1.3×Σ+0.5×σ" and 95% prediction intervals. RESULTS: A total of 22 patients (66 fractions) were analyzed. The median interval between the first and third MRI scans were 38 minutes. The mean ± standard deviation of the spinal cord movements after this interval were -0.01 ± 0.06 for the x-axis (right-left), 0.01 ± 0.14 for the y-axis (caudal-cranial), 0.07 ± 0.05 for the z-axis (posterior-anterior), and 0.15 ± 0.08 for the 3D distance, respectively. The correlation coefficients of the 3D distance between the spinal cord and the spinal canal was high (0.92). The calculated planning organ at risk volume margin for all directions was 0.11 cm for spinal cord. The 95% prediction intervals for the x-axis, y-axis, and z-axis were -0.11-0.09 cm, -0.23-0.25 cm and -0.14-0.03 cm, respectively. CONCLUSIONS: Margins are necessary in MRgART to compensate for intrafractional movement and ensure safe treatment delivery.
VMAT with DIBH in hypofractionated radiotherapy for left-sided breast cancer after breast-conserving surgery: results of a non-inferiority clinical study. 国際誌

Keiichi Jingu, Kengo Ito, Kiyokazu Sato, Rei Umezawa, Takaya Yamamoto, Noriyoshi Takahashi, Yu Suzuki, Keita Kishida, So Omata, Hinako Harada, Yasuhiro Seki, Nanae Chiba, Noriyuki Kadoya

Journal of radiation research　2023年12月12日

DOI： 10.1093/jrr/rrad096 　

詳細を見る詳細を閉じる

The purpose of this study was to show the safety of volumetric modulated arc therapy (VMAT) with deep inspiration breath-hold (DIBH) in hypofractionated radiotherapy for left-sided breast cancer after breast-conserving surgery in a clinical setting. Twenty-five Japanese women, aged 20-59 years, who were enrolled in this prospective non-inferiority study received VMAT under the condition of DIBH with 42.4 Gy/16 fractions for whole-breast irradiation (WBI) ± boost irradiation for the tumor bed to show the non-inferiority of VMAT with DIBH to conventional fractionated WBI with free breathing. The primary endpoint was the rate of occurrence of radiation dermatitis of Grade 3 or higher or pneumonitis of Grade 2 or higher within 6 months after the start of radiotherapy. This study was registered with UMIN00004321. All of the enrolled patients completed the planned radiotherapy without interruption. The evaluation of adverse events showed that three patients (12.0%) had Grade 2 radiation dermatitis. There was no other Grade 2 adverse event and there was no patient with an adverse event of Grade 3 or higher. Those results confirmed our hypothesis that the experimental treatment method is non-inferior compared with our historical results. There was no patient with locoregional recurrence or metastases. In conclusion, VMAT under the condition of DIBH in hypofractionated radiotherapy for left-sided breast cancer after breast-conserving surgery can be performed safely in a clinical setting.
Pre-treatment Evaluation of Patients Eligible for Whole Brain Radiation Therapy: The Risk of Hippocampal Metastases in a Retrospective Study of 248 Cases at a Single Institution. 国際誌

Yojiro Ishikawa, Rei Umezawa, Takaya Yamamoto, Noriyoshi Takahashi, Kazuya Takeda, Yu Suzuki, Keita Kishida, Satoshi Teramura, Kengo Ito, Keiichi Jingu

Cureus　15　(11)　e49170　2023年11月

DOI： 10.7759/cureus.49170 　

詳細を見る詳細を閉じる

Whole brain radiation therapy (WBRT) is effective for multiple brain metastases (BMs) but may impair neurocognitive function (NCF). The incidence of hippocampal metastasis (HM) is low, and the factors associated with the occurrence of HM remain unclear. This study aimed to assess the occurrence of limbic system metastasis (LSM), including HM, and to analyze the risk of HM. We retrospectively analyzed 248 patients who underwent three-dimensional conformal radiation therapy for BMs between May 2008 and October 2015. Gadolinium-enhanced brain MRI or CT scans were used for diagnosis. Statistical analysis involved assessing clinical factors, including age, gender, primary tumor, number of BMs, and maximum metastasis diameter, in relation to the presence of HMs using logistic regression and receiver operating characteristic (ROC) curve analysis. The median age at treatment was 62 years (range: 11-83 years). Primary lesion sites included the lung (n = 150; 60.5%), breast (n = 45; 18.1%), gastrointestinal tract (n = 18; 7.3%), and bone and soft tissue (n = 2; 0.8%). Histological cancer types included adenocarcinoma (n = 113; 45.6%), squamous cell carcinoma (n = 26; 10.5%), small cell carcinoma (n = 28; 11.3%), invasive ductal carcinoma (n = 35; 14.1%), sarcoma (n = 3; 1.2%), and others (n = 43; 17.3%). MRI or CT scans of the 248 patients were analyzed, indicating a total count of 2,163 brain metastases (median: five metastases per patient). HMs were identified in 18 (7.3%) patients. The most common location for LSMs was the cingulum/cingulate gyrus in 26 (10.5%) patients. In univariate and multivariate analyses, patients with 15 or fewer BMs had a significantly lower incidence of HMs (odds ratio (OR), 0.018 (95% confidence interval (CI), 0.030-0.24)) (p < 0.0001). A maximal tumor size of less than 2 cm significantly increased the incidence of HMs (OR, 13.8 (95%CI, 1.80-105.3)) (p = 0.0003). The presence of cingulum/cingulate gyrus metastases also demonstrated a significant increase in the incidence of HMs (OR, 9.42 (95%CI, 3.30-26.84)) (p < 0.0001). The present study has uncovered a novel association between a high number of metastases in the cingulate gyrus and the development of HMs. Patients with BMs eligible for WBRT with metastases in the cingulate gyrus may be at risk of developing HM.
The Impact of Pathological Grade Group 3 on Relapse-free Survival After Salvage Radiotherapy for Postoperative Prostate Cancer. 国際誌

Takaya Yamamoto, Rei Umezawa, Shuichi Shimada, Noriyoshi Takahashi, Kazuya Takeda, Y U Suzuki, Keita Kishida, S O Omata, Yuta Sato, Hinako Harada, Akihiro Ito, Keiichi Jingu

Anticancer research　43　(11)　5115-5125　2023年11月

DOI： 10.21873/anticanres.16712 　

詳細を見る詳細を閉じる

BACKGROUND/AIM: This retrospective study aimed to investigate the outcomes of relapse-free survival (RFS) after salvage radiation therapy (SRT) to the prostate bed for postoperative biochemical recurrence of prostate cancer. PATIENTS AND METHODS: A total of 87 patients were analyzed. There were 27, 32, and 24 patients with pathological grade groups of 1-2, 3, and 4-5, respectively. SRT doses of 64, 66 or 70 Gy were administered to 24, 3 and 60 patients, respectively. The Kaplan-Meier method was used to estimate time-to-event outcomes. The multiple imputations method was used to impute missing values, and Cox proportional-hazards models were applied for multivariate analyses. RESULTS: The median follow-up period for patients overall was 58.6 months. The 5-year RFS rates of the whole cohort was 59.4% and those for pathological grade groups 1-2, 3 and 4-5 were 88.9%, 37.7% and 39.5%, respectively. In multivariate analyses, higher pathological grade group [4-5 vs. 3 vs. 1-2: hazard radio (HR)=8.65, p<0.01], negative surgical resection margin (positive vs. negative: HR=0.41, p=0.02) and higher pre-salvage treatment serum prostate-specific antigen (cutoff value 0.31 ng/ml: HR=3.50, p<0.01) were significantly associated with poorer RFS. The cumulative incidences of grade 2 or more late rectal bleeding and late hematuria were 4.9% and 8.7%, respectively, at 5 years and 4.9% and 15.7%, respectively, at 8 years. These toxicities occurred only in the 70 Gy-treated arm. CONCLUSION: Our study revealed that pathological grade group 3 prostate cancer patients experienced moderately unfavorable RFS after SRT. Higher radiation doses might increase late toxicities without improving RFS.
放射線治療を受けた椎体転移患者における予後予測因子の検討

武田一也, 梅澤玲, 山本貴也, 高橋紀善, 鈴木友, 岸田桂太, 尾股聡, 神宮啓一

日本癌治療学会学術集会抄録集　61回　P32-4　2023年10月
出版者・発行元： (一社)日本癌治療学会
Glasgow prognostic score for assessing the efficacy of whole-brain radiation therapy in cases of recursive partitioning analysis class 2 and class 3 multiple brain metastases: a retrospective study. 国際誌

Yojiro Ishikawa, Rei Umezawa, Takaya Yamamoto, Noriyoshi Takahashi, Kazuya Takeda, Yu Suzuki, Keita Kishida, So Omata, Satoshi Teramura, Kengo Ito, Takayuki Yamada, Keiichi Jingu

Acta neurologica Belgica　2023年9月25日

DOI： 10.1007/s13760-023-02384-x 　

詳細を見る詳細を閉じる

PURPOSE: Whole-brain radiotherapy (WBRT) may not be beneficial for patients with brain metastases (BMs). The Glasgow Prognostic Score (GPS) is a suggested prognostic factor for malignancies. However, GPS has never been assessed in patients with BMs who have undergone WBRT. The purpose of this study was to determine whether GPS can be used to identify subgroups of patients with BMs who have a poor prognosis, such as recursive partitioning analysis (RPA) Class 2 and Class 3, and who will not receive clinical prognostic benefits from WBRT. MATERIALS AND METHODS: A total of 180 Japanese patients with BMs were treated with WBRT between May 2008 and October 2015. We examined GPS, age, Karnofsky Performance Status (KPS), RPA, graded prognostic assessment (GPA), number of lesions, tumor size, history of brain surgery, presence of clinical symptoms, and radiation doses. RESULTS: The overall median survival time (MST) was 6.1 months. seventeen patients (9.4%) were alive more than 2 years after WBRT. In univariate analysis, KPS ≤ 70 (p = 0.0066), GPA class 0-2 (p = 0.0008), > 3 BMs (p = 0.012), > 4 BMs (p = 0.02), patients who received ≥ 3 Gy per fraction (p = 0.0068), GPS ≥ 1 (p = 0.0003), and GPS ≥ 2 (p = 0.0009) were found to significantly decrease the MST. Patients who had brain surgery before WBRT (p = 0.036) had a longer survival. On multivariate analysis, GPS ≥ 1 (p = 0.008) was found to significantly decrease MST. CONCLUSION: Our results suggest that GPS ≥ 1 indicates a poor prognosis in patients undergoing WBRT for intermediate and poor prognosis BMs.
Acute hematologic toxicity of radiation therapy - a comprehensive analysis and predictive nomogram. 国際誌

Kazuya Takeda, Rei Umezawa, Takaya Yamamoto, Noriyoshi Takahashi, Yu Suzuki, Keita Kishida, So Omata, Keiichi Jingu

Journal of radiation research　2023年9月22日

DOI： 10.1093/jrr/rrad069 　

詳細を見る詳細を閉じる

To investigate radiation-induced cytopenia and establish predictive nomograms for hematological toxicity, we reviewed 3786 patients aged 18 or older who received radiation monotherapy between 2010 and 2021 for non-hematologic malignancies. We collected data on patient background, treatment content and hematologic toxicities for 12 weeks after the start of radiotherapy. The patients were randomly divided into training and test groups in 7:3 ratio. In the training group, we conducted ordered logistic regression analysis to identify predictive factors for neutropenia, lymphocytopenia, anemia and thrombocytopenia. Nomograms to predict Grade 2-4 cytopenia were generated and validated in the test group. Grade 3 or higher hematologic toxicities were observed in 9.7, 44.6, 8.3 and 3.1% of patients with neutropenia, lymphocytopenia, anemia and thrombocytopenia, respectively. We identified six factors for neutropenia grade, nine for lymphocytopenia grade and six for anemia grade with statistical significance. In the analysis of thrombocytopenia, the statistical model did not converge because of a small number of events. Nomograms were generated using factors with high predictive power. In evaluating the nomograms, we found high area under the receiver operating characteristic curve values (neutropenia; 0.75-0.85, lymphopenia; 0.89-0.91 and anemia; 0.85-0.86) in predicting Grade 2-4 cytopenia in the test group. We established predictive nomograms for neutropenia, leukocytopenia and anemia and demonstrated high reproducibility when validated in an independent cohort of patients.
Nicaraven Exerts a Limited Effect on Radiation-Induced Inhibition of Tumor Growth in a Subcutaneous Murine Tumor Model. 国際誌

Lina Abdelghany, Yong Xu, Reiko Sekiya, Chen Yan, Keiichi Jingu, Tao-Sheng Li

Radiation research　2023年9月13日

DOI： 10.1667/RADE-22-00212.1 　

詳細を見る詳細を閉じる

Nicaraven selectively protects normal tissue from radiation-induced injury. To further develop the clinical application of nicaraven for mitigating the side effects of cancer radiotherapy, we investigated the potential effect of nicaraven administration in radiation-induced inhibition of tumor growth. A subcutaneous tumor model was established in mice by the injection of Lewis lung cancer cells at the back of the chest. X-ray radiation was delivered to the thoracic area and different doses of nicaraven (0, 20, 50, 100 mg/kg) were administrated intraperitoneally pre- or post-irradiation. The tumor size was measured every other day. Mice were euthanized on day 30, and the tumor weight and the levels of cytokines in tumor tissue were measured. Pre- or post-irradiation administration of nicaraven up to a dose of 100 mg/kg did not significantly diminish the radiation-induced inhibition of tumor growth, but post-irradiation administration of 20 and 50 mg/kg nicaraven resulted in relatively lower tumor weight. The levels of IL-1β, IL-6, IL-10, MCP-1, MIP-2a, TGF-β1, VEGF, p53, p21, cyclin D1 and caspase-3 in tumor tissue did not change by nicaraven administration and were not significantly associated with the tumor weights. According to our experimental data, nicaraven will not significantly diminish the radiation-induced inhibition of tumor growth, even with pre-irradiation administration at a high dose.
A Quantitative Study on Mental Health, Sleep Quality, and Quality of Life among Family Members of Patients With First-Episode Cancer

Tomohiro Uchida, Keiichi Jingu, Akari Uno, Kang Lin, Liu Fengxia, Wang Shijie, Li Jingge, Kohei Akawaza, Hatsumi Yoshii

Illness, Crisis & Loss　2023年9月12日
出版者・発行元： SAGE Publications
DOI： 10.1177/10541373231201465 　

ISSN：1054-1373

eISSN：1552-6968

詳細を見る詳細を閉じる

This study investigated mental health, sleep quality, and quality of life among family members of patients with first-episode cancer. A survey was conducted with 39 family members of patients with cancer, using the Hospital Anxiety and Depression Scale (HADS), Pittsburgh Sleep Quality Index (PSQI), and Caregiver Quality of Life Index-Cancer (CQOLC). HADS scores indicated that 17 participants (43.6%) had adjustment and/or major depressive disorders. PSQI scores showed that 16 participants (42.1%) had sleep disturbances. However, CQOLC scores were higher than those in previous studies on families of patients with various stages of cancer. Although families of patients with first-episode cancer may not experience difficulties in their lives, their mental and physical conditions may be impaired. Healthcare providers should focus on the impact on the mental health and sleep needs of patients’ families caused by dealing with a loved one with cancer and offer support.
Evaluation of deep learning-based deliverable VMAT plan generated by prototype software for automated planning for prostate cancer patients. 国際誌

Noriyuki Kadoya, Yuto Kimura, Ryota Tozuka, Shohei Tanaka, Kazuhiro Arai, Yoshiyuki Katsuta, Hidetoshi Shimizu, Yuto Sugai, Takaya Yamamoto, Rei Umezawa, Keiichi Jingu

Journal of radiation research　64　(5)　842-849　2023年8月22日

DOI： 10.1093/jrr/rrad058 　

詳細を見る詳細を閉じる

This study aims to evaluate the dosimetric accuracy of a deep learning (DL)-based deliverable volumetric arc radiation therapy (VMAT) plan generated using DL-based automated planning assistant system (AIVOT, prototype version) for patients with prostate cancer. The VMAT data (cliDose) of 68 patients with prostate cancer treated with VMAT treatment (70-74 Gy/28-37 fr) at our hospital were used (n = 55 for training and n = 13 for testing). First, a HD-U-net-based 3D dose prediction model implemented in AIVOT was customized using the VMAT data. Thus, a predictive VMAT plan (preDose) comprising AIVOT that predicted the 3D doses was generated. Second, deliverable VMAT plans (deliDose) were created using AIVOT, the radiation treatment planning system Eclipse (version 15.6) and its vender-supplied objective functions. Finally, we compared these two estimated DL-based VMAT treatment plans-i.e. preDose and deliDose-with cliDose. The average absolute dose difference of all DVH parameters for the target tissue between cliDose and deliDose across all patients was 1.32 ± 1.35% (range: 0.04-6.21%), while that for all the organs at risks was 2.08 ± 2.79% (range: 0.00-15.4%). The deliDose was superior to the cliDose in all DVH parameters for bladder and rectum. The blinded plan scoring of deliDose and cliDose was 4.54 ± 0.50 and 5.0 ± 0.0, respectively (All plans scored ≥4 points, P = 0.03.) This study demonstrated that DL-based deliverable plan for prostate cancer achieved the clinically acceptable level. Thus, the AIVOT software exhibited a potential for automated planning with no intervention for patients with prostate cancer.
Evaluation of Unity 1.5 T MR-linac plan quality in patients with prostate cancer. 国際誌

Shohei Tanaka, Noriyuki Kadoya, Miyu Ishizawa, Yoshiyuki Katsuta, Kazuhiro Arai, Haruna Takahashi, Yushan Xiao, Noriyoshi Takahashi, Kiyokazu Sato, Ken Takeda, Keiichi Jingu

Journal of applied clinical medical physics　e14122　2023年8月10日

DOI： 10.1002/acm2.14122 　

詳細を見る詳細を閉じる

The Unity magnetic resonance (MR) linear accelerator (MRL) with MR-guided adaptive radiotherapy (MRgART) is capable of online MRgART where images are acquired on the treatment day and the radiation treatment plan is immediately replanned and performed. We evaluated the MRgART plan quality and plan reproducibility of the Unity MRL in patients with prostate cancer. There were five low- or moderate-risk and five high-risk patients who received 36.25 Gy or 40 Gy, respectively in five fractions. All patients underwent simulation magnetic resonance imaging (MRI) and five online adaptive MRI. We created plans for 5, 7, 9, 16, and 20 beams and for 60, 100, and 150 segments. We evaluated the target and organ doses for different number of beams and segments, respectively. Variation in dose constraint between the simulation plan and online adaptive plan was measured for each patient to assess plan reproducibility. The plan quality improved with the increasing number of beams. However, the proportion of significantly improved dose constraints decreased as the number of beams increased. For some dose parameters, there were statistically significant differences between 60 and 100 segments, and 100 and 150 segments. The plan of five beams exhibited limited reproducibility. The number of segments had minimal impact on plan reproducibility, but 60 segments sometimes failed to meet dose constraints for online adaptive plan. The optimization and delivery time increased with the number of beams and segments. We do not recommend using five or fewer beams for a reproducible and high-quality plan in the Unity MRL. In addition, many number of segments and beams may help meet dose constraints during online adaptive plan. Treatment with the Unity MRL should be performed with the appropriate number of beams and segments to achieve a good balance among plan quality, delivery time, and optimization time.
Recent Postoperative Radiotherapy for Left-sided Breast Cancer Does Not Increase Mortality of Heart Disease in Asians or Pacific Islanders: SEER Database Analysis. 国際誌

Keiichi Jingu, Rei Umezawa, Takaya Yamamoto, Noriyoshi Takahashi, Y U Suzuki, Keita Kishida, S O Omata, Hiroaki Ogawa, Yuta Sato, Hinako Harada, Yasuhiro Seki

Anticancer research　43　(8)　3571-3577　2023年8月

DOI： 10.21873/anticanres.16535 　

詳細を見る詳細を閉じる

BACKGROUND/AIM: The purpose of this study was to evaluate the impact of recent radiotherapy on mortality from heart disease in Asians or Pacific islanders with breast cancer using the Surveillance, Epidemiology, and End Results (SEER) database. PATIENTS AND METHODS: Asians or Pacific islanders with stage 0 or I (AJCC 6th) breast cancer between 2000 and 2015 were analyzed. The impact of radiotherapy for mortality from heart disease after treatment was evaluated by comparing patients who received radiotherapy for left-sided breast cancer, patients who received radiotherapy for right-sided breast cancer and patients who did not receive radiotherapy. RESULTS: In 25,684 Asians or Pacific islanders, the incidence of cardiac death was higher in patients who did not receive radiotherapy than in patients who received radiotherapy. Among patients who received external beam irradiation, the incidence of cardiac death was 2.00% for patients with left-sided breast cancer and 1.69% for patients with right-sided breast cancer, with no significant difference (chi-square test, p=0.427). In the period from 2000 to 2008, there was no significant difference between the cumulative heart-related death rates in patients who received radiotherapy and in patients who did not receive radiotherapy (Tarone-Ware test, p=0.406); however, in 2009-2015, the cumulative heart-related death rate in patients who did not receive radiotherapy was significantly higher than that in patients who received radiotherapy (log-rank test, p<0.001). CONCLUSION: Heart-related death after treatment for breast cancer is relatively rare in Asians or Pacific islanders. Since at least 2000, the cardiac impact of postoperative radiotherapy has not been significant.
Evaluation of the MVCT-based radiomic features as prognostic factor in patients with head and neck squamous cell carcinoma. 国際誌

Kota Abe, Noriyuki Kadoya, Kei Ito, Shohei Tanaka, Yujiro Nakajima, Shimpei Hashimoto, Yuhi Suda, Takashi Uno, Keiichi Jingu

BMC medical imaging　23　(1)　102-102　2023年8月1日

DOI： 10.1186/s12880-023-01055-w 　

詳細を見る詳細を閉じる

BACKGROUND: Megavoltage computed tomography (MVCT) images acquired during each radiotherapy session may be useful for delta radiomics. However, no studies have examined whether the MVCT-based radiomics has prognostic power. Therefore, the purpose of this study was to examine the prognostic power of the MVCT-based radiomics for head and neck squamous cell carcinoma (HNSCC) patients. METHODS: 100 HNSCC patients who received definitive radiotherapy were analyzed and divided into two groups: training (n = 70) and test (n = 30) sets. MVCT images obtained using TomoTherapy for the first fraction of radiotherapy and planning kilovoltage CT (kVCT) images obtained using Aquilion LB CT scanner were analyzed. Primary gross tumor volume (GTV) was propagated from kVCT to MVCT images using rigid registration, and 107 radiomic features were extracted from the GTV in MVCT and kVCT images. Least absolute shrinkage and selection operator (LASSO) Cox regression model was used to examine the association between overall survival (OS) and rad score calculated for each patient by weighting the feature value through the coefficient when features were selected. Then, the predictive values of MVCT-based and kVCT-based rad score and patient-, treatment-, and tumor-specific factors were evaluated. RESULTS: C-indices of the rad score for MVCT- and kVCT-based radiomics were 0.667 and 0.685, respectively. The C-indices of 6 clinical factors were 0.538-0.622. The 3-year OS was significantly different between high- and low-risk groups according to the MVCT-based rad score (50% vs. 83%; p < 0.01). CONCLUSIONS: Our results suggested that MVCT-based radiomics had stronger prognostic power than any single clinical factor and was a useful prognostic factor when predicting OS in HNSCC patients.
Development of a prediction model for head and neck volume reduction by clinical factors, dose-volume histogram parameters and radiomics in head and neck cancer 査読有り

Ishizawa M, Tanaka S, Takagi H, Kadoya N, Sato K, Umezawa R, Jingu K, Takeda K

J Radiat Res　2023年7月18日

DOI： 10.1093/jrr/rrad052 　
Clinical impact of multimodal treatment including chemoradiotherapy, conversion surgery and postoperative chemotherapy for borderline resectable and unresectable locally advanced pancreatic cancer without disease progression after gemcitabine plus nab-paclitaxel. 国際誌

Rei Umezawa, Masamichi Mizuma, Kei Nakagawa, Takaya Yamamoto, Noriyoshi Takahashi, Yu Suzuki, Keita Kishida, So Omata, Michiaki Unno, Keiichi Jingu

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]　2023年7月4日

DOI： 10.1016/j.pan.2023.07.002 　

詳細を見る詳細を閉じる

BACKGROUND: The purpose of this study was to investigate treatment outcomes of chemoradiotherapy (CRT) using S-1 with or without conversion surgery after gemcitabine plus nab-paclitaxel (GnP) for borderline resectable (BR) and unresectable locally advanced (UR-LA) pancreatic cancer. METHODS: From 2016 to 2020, patients without disease progression after GnP for BR or UR-LA pancreatic cancer underwent CRT with S-1. If distant metastasis was not detected after CRT, conversion surgery and oral administration of S-1 as postoperative adjuvant chemotherapy for at least 6 months was performed. RESULTS: Forty patients were included in the present study. The median number of cycles of GnP was 6. Surgery was performed after CRT in 25 patients. The median progression-free survival (PFS) and overall survival (OS) periods from the start of radiotherapy were 24.6 and 27.4 months, respectively. The OS periods from the start of radiotherapy in patients who underwent conversion surgery and those who did not undergo conversion surgery were 41.3 and 16.8 months, respectively. The PFS periods from the start of radiotherapy in patients who underwent surgery and those who did not undergo surgery were 28.3 and 8.6 months, respectively. Patients who were able to receive S-1 after conversion surgery for more than 6 months had better OS than those who were not (p = 0.039), although there was no significant difference of PFS (p = 0.365). CONCLUSIONS: In BR/UR-LA pancreatic cancer without disease progression after GnP, multimodal treatment including CRT, conversion surgery and the scheduled postoperative chemotherapy may be effective.
Clinical impact of radiation-induced myocardial damage detected by cardiac magnetic resonance imaging and dose-volume histogram parameters of the left ventricle as prognostic factors of cardiac events after chemoradiotherapy for esophageal cancer. 国際誌

Rei Umezawa, Hideki Ota, Hidenobu Takagi, Noriyuki Kadoya, Yujiro Nakajima, Noriyoshi Takahashi, Takaya Yamamoto, Kei Takase, Keiichi Jingu

Journal of radiation research　64　(4)　702-710　2023年6月12日

DOI： 10.1093/jrr/rrad040 　

詳細を見る詳細を閉じる

This prospective study aimed to evaluate whether radiation (RT)-induced myocardial damage by cardiac magnetic resonance (CMR) imaging could be a predictor of cardiac events after chemoradiotherapy (CRT) for esophageal cancer and determine the dose-volume histogram (DVH) parameters of the left ventricle (LV) in predicting cardiac events. CMR imaging was performed before and 6 months after CRT in patients receiving definitive CRT. RT-induced myocardial damage was defined as abnormal CMR findings indicating myocardial fibrosis corresponding to an isodose line of ≥30 Gy. The cutoff values of the LV DVH parameters were calculated using the receiver operating characteristic curve based on the presence of RT-induced myocardial damage. The prognostic factors related to cardiac events of Grade 3 or higher were examined. Twenty-three patients were enrolled in the study. RT-induced myocardial damage by late gadolinium enhancement and/or an increase of 100 ms or higher in native T1 post-CRT was detected in 10 of the 23 patients. LV V45 was the best predictive factor for RT-induced myocardial damage with a cutoff value of 2.1% and an area under the curve of 0.75. The median follow-up period was 82.1 months. The 5- and 7-year cumulative incidences of cardiac events of Grade 3 or higher were 14.7 and 22.4%, respectively. RT-induced myocardial damage and LV V45 were significant risk factors (P = 0.015 and P = 0.013, respectively). RT-induced myocardial damage is a significant predictor of cardiac events. LV V45 is associated with RT-induced myocardial damage and subsequent cardiac events.
Improvement of deep learning prediction model in patient-specific QA for VMAT with MLC leaf position map and patient's dose distribution. 国際誌

Ryota Tozuka, Noriyuki Kadoya, Seiji Tomori, Yuto Kimura, Tomohiro Kajikawa, Yuto Sugai, Yushan Xiao, Keiichi Jingu

Journal of applied clinical medical physics　e14055　2023年6月1日

DOI： 10.1002/acm2.14055 　

詳細を見る詳細を閉じる

PURPOSE: Deep learning-based virtual patient-specific quality assurance (QA) is a novel technique that enables patient QA without measurement. However, this method could be improved by further evaluating the optimal data to be used as input. Therefore, a deep learning-based model that uses multileaf collimator (MLC) information per control point and dose distribution in patient's CT as inputs was developed. METHODS: Overall, 96 volumetric-modulated arc therapy plans generated for prostate cancer treatment were used. We developed a model (Model 1) that can predict measurement-based gamma passing rate (GPR) for a treatment plan using data stored as a map reflecting the MLC leaf position at each control point (MLPM) and data of the dose distribution in patient's CT as inputs. The evaluation of the model was based on the mean absolute error (MAE) and Pearson's correlation coefficient (r) between the measured and predicted GPR. For comparison, we also analyzed models trained with the dose distribution in patient's CT alone (Model 2) and with dose distributions recalculated on a virtual phantom CT (Model 3). RESULTS: At the 2%/2 mm criterion, MAE[%] and r for Model 1, Model 2, and Model 3 were 2.32% ± 0.43% and 0.54 ± 0.03, 2.70% ± 0.26%, and 0.32 ± 0.08, and 2.96% ± 0.23% and 0.24 ± 0.22, respectively; at the 3%/3 mm criterion, these values were 1.25% ± 0.05% and 0.36 ± 0.18, 1.57% ± 0.35% and 0.19 ± 0.20, and 1.39% ± 0.32% and 0.17 ± 0.22, respectively. This result showed that Model 1 exhibited the lowest MAE and highest r at both criteria of 2%/2 mm and 3%3 mm. CONCLUSIONS: These findings showed that a model that combines the MLPM and dose distribution in patient's CT exhibited a better GPR prediction performance compared with the other two studied models.
Definitive radiotherapy consisting of external beam radiotherapy without central shielding and 3D image-guided brachytherapy for patients with cervical cancer: feasibility for Japanese patients and dose-response analyses for local control in the low-dose range. 国際誌

Takafumi Toita, Kentaro Wada, Shinya Sutani, Rei Umezawa, Hitoshi Maemoto, Noriko Ii, Tomoko Kawamura, Hitoshi Ikushima, Ryosuke Takenaka, Koji Konishi, Atsunori Yorozu, Keiichi Jingu, Takuro Ariga, Yoshihito Nomoto, Hideomi Yamashita

Japanese journal of clinical oncology　2023年3月27日

DOI： 10.1093/jjco/hyad022 　

詳細を見る詳細を閉じる

OBJECTIVE: To assess the feasibility of external beam radiotherapy without central shielding in definitive radiotherapy for Japanese patients with cervical cancer. METHODS: We retrospectively analysed the data of cervical cancer patients treated with definitive radiotherapy consisting of external beam radiotherapy without central shielding and three-dimensional-image-guided brachytherapy. RESULTS: The study included 167 patients (T1 + 2 = 108, T3 + 4 = 59) from eight Japanese institutions. For three-dimensional-image-guided brachytherapy, intra-cavitary and interstitial brachytherapy was utilized in 33 patients (20%). The median follow-up was 26.6 months (interquartile range, 20-43.2). The maximum rectal D2 (75 Gy)/bladder D2 (90 Gy) constraints were deviated by 6%/10% and 10%/5% for T1 + 2 and T3 + 4, respectively. The 2-year incidence of ≥grade 3 proctitis/cystitis was 4%/1% for T1 + 2 and 10%/2% for T3 + 4. The 2-year local progression-free survival was 89% for T1 + 2 and 82% for T3 + 4. For T1 + 2, the 2-year local progression-free survival for the high-risk clinical target volume D90 ≥ 68 Gy (indicated by receiver operating characteristic analysis; area under the curve = 0.711) was 92% versus 67% for <68 Gy (log-rank; P = 0.019). Cox multivariate analysis indicated that the high-risk clinical target volume D90 was one of independent predictors of local failure (P = 0.0006). For T3 + 4, the 2-year local progression-free survival was 87% for the high-risk clinical target volume <82 cm3 (area under the curve = 0.67) and 43% for ≥82 cm3 (P = 0.0004). Only the high-risk clinical target volume was an independent predictor of local failure (P = 0.0024). CONCLUSIONS: Definitive radiotherapy consisting of external beam radiotherapy without central shielding and three-dimensional-image-guided brachytherapy was feasible for Japanese patients with cervical cancer. Dose de-escalation from the current global standards is suggested for patients with T1 + 2 disease.
Cardiac impacts of postoperative radiotherapy for breast cancer in Japanese patients. 国際誌

Erika Segawa, Keiichi Jingu, Rei Umezawa, Takaya Yamamoto, Noriyoshi Takahashi, Noriyuki Kadoya, Ken Takeda

Journal of radiation research　2023年3月22日

DOI： 10.1093/jrr/rrad013 　

詳細を見る詳細を閉じる

Radiotherapy for breast cancer has attracted attention in Western countries because radiation to the heart can cause cardiac events. The purposes of this study were to evaluate the relationship between radiotherapy after breast-conserving surgery and the frequency of cardiac events in Japanese patients and to investigate the risk factors of cardiac events after postoperative radiotherapy in those patients. Female patients who received postoperative radiotherapy following breast-conserving surgery between 2007 and 2012 at our hospital were evaluated. In this study, we estimated the cumulative incidence of cardiac events including angina pectoris, myocardial infarction, ischemic heart disease, heart failure and cardiomyopathy after radiotherapy. Of 311 eligible patients, 7.1% of the patients had a smoking history, 20.3% of the patients were obese and 22.2% of the patients had hypertension. The median follow-up period was 118 months (interquartile range, 102-132 months). Twelve patients (3.9%) experienced cardiac events after treatment. The mean time to cardiac events was 126 months. The 10-year cumulative incidences of cardiac events after treatment were 4.2% and 4.3% for patients with left-sided and right-sided breast cancer, respectively, without a significant difference. Multivariate analysis showed that only hypertension was a risk factor for cardiac events (hazard ratio = 16.67, P = 0.0003). In conclusion, postoperative radiotherapy for breast cancer did not increase the incidence of cardiac events. Since at least 2007, postoperative radiotherapy for breast cancer has been safely performed without effects on the heart.
Development of a collapsed cone convolution/superposition dose calculation algorithm with a mass density-specific water kernel for magnetic resonance-guided radiotherapy

Kengo ITO, Yojiro Ishikawa, Satoshi Teramura, Noriyuki Kadoya, Yoshiyuki Katsuta, Shohei Tanaka, Ken Takeda, Keiichi Jingu, Takayuki Yamada

Journal of Radiation Research　2023年3月21日
出版者・発行元： Oxford University Press (OUP)
DOI： 10.1093/jrr/rrad011 　

ISSN：0449-3060

eISSN：1349-9157

詳細を見る詳細を閉じる

Abstract This study aimed to develop and validate a collapsed cone convolution for magnetic resonance-guided radiotherapy (CCCMR). The 3D energy deposition kernels (EDKs) were generated in water in a 1.5-T transverse magnetic field. The CCCMR corrects the inhomogeneity in simulation geometry by referring to the EDKs according to the mass density between the interaction and energy deposition points in addition to density scaling. Dose distributions in a water phantom and in slab phantoms with inserted inhomogeneities were calculated using the Monte Carlo (MC) and CCCMR. The percentage depth dose (PDD) and off-axis ratio (OAR) were compared, and the gamma passing rate (3%/2 mm) was evaluated. The CCCMR simulated asymmetric dose distributions in the simulation phantoms, especially the water phantom, and all PDD and OAR profiles were in good agreement with the findings of the MC. The gamma passing rates were &gt;99% for each field size and for the entire region. In the inhomogeneity phantoms, although the CCCMR underestimated dose in the low mass density regions, it could reconstruct dose changes at mass density boundaries. The gamma passing rate for the entire region was &gt;95% for the field size of 2 × 2 cm2, but it was 68.9–86.7% for the field sizes of ≥5 × 5 cm2. Conclusively, in water, the CCCMR can obtain dose distributions comparable to those with the MC. Although the dose differences between them were mainly in inhomogeneity regions, the possibility of the effective use of the CCCMR in small field sizes was demonstrated.
Impact of CT scan parameters on deformable image registration accuracy using deformable thorax phantom

Ryutaro Ikeda, Noriyuki Kadoya, Yujiro Nakajima, Shin Ishii, Takayuki Shibu, Keiichi Jingu

Journal of Applied Clinical Medical Physics　24　(5)　2023年2月25日
出版者・発行元： Wiley
DOI： 10.1002/acm2.13917 　

ISSN：1526-9914

eISSN：1526-9914

詳細を見る詳細を閉じる

Abstract The purpose of this study was to evaluate the deformable image registration (DIR) accuracy using various CT scan parameters with deformable thorax phantom. Our developed deformable thorax phantom (Dephan, Chiyoda Technol Corp, Tokyo, Japan) was used. The phantom consists of a base phantom, an inner phantom, and a motor‐derived piston. The base phantom is an acrylic cylinder phantom with a diameter of 180 mm, which simulates the chest wall. The inner phantom consists of deformable, 20 mm thick disk‐shaped sponges with 48 Lucite beads and 48 nylon cross‐wires which simulate the vascular and bronchial bifurcations of the lung. Peak‐exhale and peak‐inhale images of the deformable phantom were acquired using a CT scanner (Aquilion LB, TOSHIBA). To evaluate the impact of CT scan parameters on DIR accuracy, we used the four tube voltages (80, 100, 120, and 135 kV) and six reconstruction algorithms (FC11, FC13, FC15, FC41, FC44, and FC52). Intensity‐based DIR was performed between the two images using MIM Maestro (MIM software, Cleveland, USA). Fiducial markers (beads and cross‐wires) based target registration error (TRE) was used for quantitative evaluation of DIR. In case with different tube voltages, the range of average TRE were 4.44–5.69 mm (reconstruction algorithm: FC13). In case with different reconstruction algorithms, the range of average TRE were 4.26–4.59 mm (tube voltage: 120 kV). The TRE were differed by up to 3.0 mm (3.96–6.96 mm) depending on the combination of tube voltage and reconstruction algorithm. Our result indicated that CT scan parameters had moderate impact of TRE, especially for reconstruction algorithms for the deformable thorax phantom.
Development and validation of an [¹⁸F]FDG-PET/CT radiomic model for predicting progression-free survival for patients with stage II – III thoracic esophageal squamous cell carcinoma who are treated with definitive chemoradiotherapy

Noriyoshi Takahashi, Shohei Tanaka, Rei Umezawa, Kentaro Takanami, Kazuya Takeda, Takaya Yamamoto, Yu Suzuki, Yoshiyuki Katsuta, Noriyuki Kadoya, Keiichi Jingu

Acta Oncologica　62　(2)　1-7　2023年2月15日
出版者・発行元： Informa UK Limited
DOI： 10.1080/0284186x.2023.2178859 　

ISSN：0284-186X

eISSN：1651-226X
片側水腎症を伴ったdesmoid-type fibromatosisに対し放射線治療が著効した1例

石川陽二郎, 梅澤玲, 山本貴也, 高橋紀善, 武田一也, 鈴木友, 岸田桂太, 寺村聡司, 神宮啓一

Japanese Journal of Radiology　41　(Suppl.)　3-3　2023年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
膵炎を繰り返すIPMNに対して放射線治療を行った1例

針谷綾花, 高橋紀善, 梅澤玲, 山本貴也, 石川陽二郎, 武田一也, 鈴木友, 岸田桂太, 寺村聡司, 神宮啓一

Japanese Journal of Radiology　41　(Suppl.)　4-4　2023年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
肺定位放射線治療後の放射線肺障害の経時変化に関する検討

山本貴也, 勝田義之, 毛利詩菜, 梅澤玲, 石川陽二郎, 角谷倫之, 高橋紀善, 鈴木友, 武田一也, 岸田桂太, 神宮啓一

Japanese Journal of Radiology　41　(Suppl.)　8-8　2023年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
A phase II study of concurrent chemoradiotherapy with 5-fluorouracil and mitomycin-C for squamous cell carcinoma of the anal canal (the JROSG 10-2 trial). 国際誌

Keiko Nemoto Murofushi, Satoshi Itasaka, Mototsugu Shimokawa, Yuji Murakami, Takaya Yamamoto, Yasumasa Nishimura, Shigehiro Kudo, Takashi Sakamoto, Takuro Ariga, Etsuyo Ogo, Kentaro Taguchi, Keiichi Jingu, Kazuhiko Ogawa

Journal of radiation research　64　(1)　154-161　2023年1月20日

DOI： 10.1093/jrr/rrac069 　

詳細を見る詳細を閉じる

This study assessed the efficacy of chemoradiotherapy for squamous cell carcinoma of the anal canal (SCCAC). Patients with T1-4N0-3M0 SCCAC received chemoradiotherapy with 5-fluorouracil (5-FU, 800 mg/m2/day, 96-h infusion) and mitomycin-C (MMC, 10 mg/m2 bolus). Patients treated with 3-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiotherapy (IMRT) were administered 36.0 Gy in 20 fractions or 49.5 Gy in 33 fractions for elective nodal irradiation and 59.4 Gy in 33 fractions for primary tumor and metastatic nodal irradiation. The sample size was considered sufficient to estimate 95% confidence intervals (CIs) for the true 2-year disease-free survival (DFS) within a width of +15% when the expected true 2-year DFS was 70%. The primary endpoint was 2-year DFS. The secondary endpoints were 2-year overall survival (OS), locoregional control (LC), colostomy-free survival (CFS) and adverse events. Thirty-one patients were enrolled between January 2014 and July 2019. The median follow-up was 33.3 months (range, 16.2-65.8 months). Among the 31 patients, 13%, 32%, 16% and 39% had stage I, II, IIIA and IIIB disease, respectively. Thirty patients were treated with IMRT. Complete response (CR) was achieved in 27 patients. The 2-year DFS, OS, LC and CFS rates were 77.4% (95% CI, 58.4-88.5%), 93.5% (95% CI, 76.6-98.3%), 83.9% (95% CI, 65.5-92.9%) and 80.6% (95% CI, 61.9-90.8%), respectively. One patient experienced grade 3 late adverse events; however, no grade ≥ 4 late adverse events occurred. Good DFS with a low rate of late adverse events was observed. Chemoradiotherapy with 5-FU and MMC was effective for SCCAC.
Dosimetric impact of deformable image registration using radiophotoluminescent glass dosimeters with a physical geometric phantom. 国際誌

Siwaporn Sakulsingharoj, Noriyuki Kadoya, Shohei Tanaka, Kiyokazu Sato, Mitsuhiro Nakamura, Keiichi Jingu

Journal of applied clinical medical physics　e13890　2023年1月7日

DOI： 10.1002/acm2.13890 　

詳細を見る詳細を閉じる

PURPOSE: To study the dosimetry impact of deformable image registration (DIR) using radiophotoluminescent glass dosimeter (RPLD) and custom developed phantom with various inserts. METHODS: The phantom was developed to facilitate simultaneous evaluation of geometric and dosimetric accuracy of DIR. Four computed tomography (CT) images of the phantom were acquired with four different configurations. Four volumetric modulated arc therapy (VMAT) plans were computed for different phantom. Two different patterns were applied to combination of four phantom configurations. RPLD dose measurement was combined between corresponding two phantom configurations. DIR-based dose accumulation was calculated between corresponding two CT images with two commercial DIR software and various DIR parameter settings, and an open source software. Accumulated dose calculated using DIR was then compared with measured dose using RPLD. RESULTS: The mean ± standard deviation (SD) of dose difference was 2.71 ± 0.23% (range, 2.22%-3.01%) for tumor-proxy and 3.74 ± 0.79% (range, 1.56%-4.83%) for rectum-proxy. The mean ± SD of target registration error (TRE) was 1.66 ± 1.36 mm (range, 0.03-4.43 mm) for tumor-proxy and 6.87 ± 5.49 mm (range, 0.54-17.47 mm) for rectum-proxy. These results suggested that DIR accuracy had wide range among DIR parameter setting. CONCLUSIONS: The dose difference observed in our study was 3% for tumor-proxy and within 5% for rectum-proxy. The custom developed physical phantom with inserts showed potential for accurate evaluation of DIR-based dose accumulation. The prospect of simultaneous evaluation of geometric and dosimetric DIR accuracy in a single phantom may be useful for validation of DIR for clinical use.
Salvage craniospinal irradiation for recurrent intracranial germinoma: a single institution analysis

Masayuki Kanamori, Yoshiteru Shimoda, Rei Umezawa, Osamu Iizuka, Shunji Mugikura, Kyoko Suzuki, Hisanori Ariga, Keiichi Jingu, Ryuta Saito, Yukihiko Sonoda, Toshihiro Kumabe, Teiji Tominaga

Journal of Radiation Research　64　(2)　428-437　2023年1月5日
出版者・発行元： Oxford University Press (OUP)
DOI： 10.1093/jrr/rrac095 　

ISSN：0449-3060

eISSN：1349-9157

詳細を見る詳細を閉じる

Abstract This study investigated the effectiveness and safety of low-dose salvage craniospinal irradiation (CSI) for recurrent germinoma. We retrospectively reviewed long-term tumor control and late adverse effects in 15 recurrent germinoma patients treated at our hospital between 1983 and 2019. Following the first recurrence of germinoma, seven were treated with 24–30 Gy of salvage CSI, three underwent non-CSI, and five were treated with only chemotherapy. CSI achieved a significantly better recurrence-free survival rate after the first recurrence compared to other strategies (100% vs 33%, p &lt; 0.001: log-rank test). To evaluate the safety of salvage CSI, we assessed the outcomes at the final follow-up of seven patients who received salvage CSI at first recurrence and three patients who received salvage CSI at second recurrence. The median follow-up period was 220 months after initial treatment. Five patients who received 40–50 Gy of radiation therapy or underwent multiple radiation therapy before salvage CSI were classified into Group A, whereas five patients treated with platinum-based chemotherapy and 24–32 Gy of radiation therapy to the primary site, whole ventricle, or whole brain were classified into Group B. In Group A, one had endocrine dysfunction and the other had visual dysfunction. None were socially independent. Meanwhile, in Group B, no endocrine or visual dysfunction was found, and three patients were socially independent. Salvage CSI achieved excellent tumor control in recurrent germinoma and was safe in patients initially treated with low-dose radiation therapy and chemotherapy.
Survival prediction nomogram for patients with vertebral bone metastases treated with palliative radiotherapy. 国際誌

Kazuya Takeda, Rei Umezawa, Takaya Yamamoto, Noriyoshi Takahashi, Yu Suzuki, Keita Kishida, So Omata, Keiichi Jingu

Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology　28　(5)　646-653　2023年

DOI： 10.5603/rpor.97512 　

詳細を見る詳細を閉じる

BACKGROUND: In the treatment of vertebral bone metastases, estimating patient prognosis is important to select the optimal treatment strategy. The purpose of this study was to identify prognostic factors for vertebral bone metastases treated with palliative radiotherapy and to establish a nomogram for predicting patient survival. MATERIALS AND METHODS: We analyzed patients who underwent palliative radiotherapy for vertebral bone metastasis between January 2010 and December 2020 at a single institution. Exclusion criteria were as follows: (1) primary bone malignancy, (2) stereotactic body radiotherapy, (3) concurrent radiotherapy to sites other than the vertebral bone, (4) radiotherapy to other sites within 12 weeks before or after the current radiotherapy, and (5) lack of more than half of blood test data before radiotherapy. RESULTS: A total of 487 patients met the inclusion criteria. Clinical and hematologic data were collected from the patient record system. Patients were divided into training and test groups in a 7:3 ratio. Multivariate Cox regression analysis in the training cohort revealed six significant factors, including a history of chemotherapy, primary site (breast cancer, prostate cancer, or hematologic malignancy), use of analgesics, neutrophil-lymphocyte ratio, serum albumin, and lactate dehydrogenase. A prognostic nomogram was developed and validated in the test cohort. The area under the curve (AUC) values in predicting survival at 6, 24, and 60 months were 0.83, 0.88, and 0.88 in the training cohort and 0.85, 0.81, and 0.79 in the test cohort, respectively. CONCLUSIONS: This nomogram may help to select the treatment strategy for vertebral bone metastases.
A Retrospective Study of Clinical Outcomes for Patients with Esophageal Cancer Who Were Treated with Radiotherapy Alone. 国際誌

Noriyoshi Takahashi, Rei Umezawa, Takaya Yamamoto, Kazuya Takeda, Yu Suzuki, Keita Kishida, So Omata, Yuta Sato, Hinako Harada, Yasuhiro Seki, Keiichi Jingu

Gastrointestinal tumors　10　(1)　57-66　2023年

DOI： 10.1159/000539173 　

詳細を見る詳細を閉じる

INTRODUCTION: Patients with esophageal cancer who are in a poor general condition receive radiotherapy alone, but outcomes are often unsatisfactory. The aim of this study was to clarify recent outcomes of radiotherapy alone for esophageal cancer. METHODS: Patients who underwent 50 Gy or more of radiotherapy without chemotherapy were retrospectively reviewed. Endpoints were overall survival (OS), disease-specific survival (DSS), local control (LC), and progression-free survival (PFS). Survival curves were drawn using the Kaplan-Meier method, and predictors were analyzed using the Cox proportional hazards model. RESULTS: Sixty-nine patients were included. The median follow-up period was 17.9 months. The 5-year OS, DSS, LC, and PFS rates were 33.2%, 49.8%, 46.2%, and 16.8%, respectively. In the multivariate Cox proportional hazard model, clinical stage was a significant predictor for OS (hazard ratio [HR]: 4.42, 95% confidence interval [CI]: 1.80-11.17, p = 0.001), DSS (HR: 2.08, 95% CI: 1.43-3.12, p = 0.0001), LC (HR: 1.86, 95% CI: 1.28-2.74, p = 0.001), and PFS (HR: 1.65, 95% CI: 1.25-2.18, p = 0.0004). Radiation dose was a significant predictor for LC (HR: 0.87, 95% CI: 0.78-0.97, p = 0.018) and tumor location was a significant predictor for PFS (HR: 1.55, 95% CI: 1.10-2.19, p = 0.018). In subgroup analysis, the 5-year OS, DSS, LC, and PFS rates for stage I were 60.0%, 80.0%, 71.9%, and 46.1%, respectively. CONCLUSIONS: Stage, radiation dose, and tumor location are significant predictors for outcomes. Patients with stage I esophageal cancer can be cured by radiotherapy alone.
Retrospective analysis of local recurrence pattern by computed tomography image-guided intracavitary and interstitial brachytherapy for locally advanced cervical cancer in a single Japanese institution. 国際誌

Rei Umezawa, Hideki Tokunaga, Takaya Yamamoto, Shogo Shigeta, Noriyoshi Takahashi, Kazuya Takeda, Yu Suzuki, Keita Kishida, Kengo Ito, Noriyuki Kadoya, Muneaki Shimada, Keiichi Jingu

Brachytherapy　22　(4)　477-486　2023年

DOI： 10.1016/j.brachy.2023.04.008 　

詳細を見る詳細を閉じる

PURPOSE: The purpose of this study was to investigate the treatment results with focus on local control (LC) by computed tomography (CT)-guided intracavity brachytherapy and interstitial brachytherapy (ICBT/ISBT) for locally advanced cervical cancer (LACC). METHODS AND MATERIALS: Patients with LACC undergoing ICBT/ISBT at least once in our institution between January 2017 and June 2019 were analyzed retrospectively. The primary endpoint was local control (LC), and the secondary endpoints were progression-free survival (PFS), overall survival (OS), and late toxicities. Differences between patient subgroups for prognostic factors in LC, PFS, and OS were analyzed using the log-rank test. The recurrence patterns of LC were also investigated. RESULTS: Forty-four patients were included in the present study. The median high-risk clinical target volume (HR-CTV) at the initial brachytherapy was 48.2 cc. The median total dose of HR-CTV D90 (EQD2) was 70.7 Gy. The median followup period was 39.4 months. The 3-year LC, PFS and OS rates in all patients were 88.2%, 56.6%, and 65.4% (95% CI 50.3-78.0%), respectively. Corpus invasion and large HR-CTV (70 cc or more) were significant prognostic factors in LC, PFS, and OS. Marginal recurrences at the fundus of the uterus were detected in 3 of 5 patients in whom local recurrence was observed. Late toxicities of Grade 3 or higher were detected in 3 patients (6.8%). CONCLUSIONS: Favorable LC was achieved by performing CT-guided ICBT/ISBT for LACC. The brachytherapy strategy for patients with corpus invasion or large HR-CTV may need to be reconsidered.
Clinical significance of completion of radium-223 treatment and acute adverse events in patients with metastatic castration-resistant prostate cancer. 国際誌

Kazuya Takeda, Yoshihide Kawasaki, Toru Sakayauchi, Chiaki Takahashi, Yu Katagiri, Takaya Tanabe, Yojiro Ishikawa, Keisuke Fujimoto, Masaki Kubozono, Maiko Kozumi, Keiko Abe, Kakutaro Narazaki, Shun Tasaka, Rei Umezawa, Takaya Yamamoto, Noriyoshi Takahashi, Yu Suzuki, Keita Kishida, So Omata, Akihiro Ito, Keiichi Jingu

Asia Oceania journal of nuclear medicine & biology　11　(1)　13-22　2023年

DOI： 10.22038/AOJNMB.2022.67136.1468 　

詳細を見る詳細を閉じる

OBJECTIVES: In the treatment of castration-resistant prostate cancer (CRPC) with bone metastases, radium-223 dichloride (Ra-223) is the only bone-targeted drug that shows survival benefits. Completing six courses of Ra-223 treatment is thought to be associated with better patient survival, but this treatment has a relatively high rate of acute adverse events. METHODS: This retrospective study included 85 patients from 12 institutions in Japan to investigate the clinical significance of the completion of Ra-223 treatment and acute adverse events in CRPC patients. RESULTS: Six courses of Ra-223 treatment were completed in 65.9% of the patients. Grade 3 or higher acute adverse events were observed in 27.1% of patients. The prostate specific antigen and alkaline phosphatase declined at 26.9% and 87.9%, respectively. The overall survival rates at 12 and 24 months were 80.7% and 63.2%, respectively. Both completion of six courses of Ra-223 treatment and absence of grade 3 or higher acute adverse events were associated with longer overall survival. In univariate analysis, factors related to the history of treatment (five or more hormone therapy agents and cytotoxic chemotherapy) and hematological parameters (Prostate specific antigen (PSA) doubling time, alkaline phosphatase, hemoglobin, albumin, and serum calcium) were associated with completing six courses of Ra-223 treatment without experiencing grade 3 or higher acute adverse events. Multivariate analysis showed that a history of chemotherapy, PSA doubling time, hemoglobin, and serum calcium showed statistical significance. We built a predictive score by these four factors. Patients with lower scores showed higher rates of treatment success (p<0.001) and longer overall survival (p<0.001) with statistical significance. CONCLUSIONS: Accomplishing six courses of Ra-223 treatment without grade 3 or higher acute adverse events was a prognostic factor in patients with mCRPC treated with Ra-223. We built a predictive score of treatment success and need future external validation.
Radiation pneumonitis prediction model with integrating multiple dose-function features on 4DCT ventilation images

Yoshiyuki Katsuta, Noriyuki Kadoya, Tomohiro Kajikawa, Shina Mouri, Tomoki Kimura, Kazuya Takeda, Takaya Yamamoto, Nobuki Imano, Shohei Tanaka, Kengo Ito, Takayuki Kanai, Yujiro Nakajima, Keiichi Jingu

Physica Medica　105　102505-102505　2023年1月
出版者・発行元： Elsevier BV
DOI： 10.1016/j.ejmp.2022.11.009 　

ISSN：1120-1797
The efficacy profiles of concurrent chemoradiotherapy with intensity-modulated radiotherapy followed by durvalumab in patients with unresectable stage III non-small cell lung cancer: A multicenter retrospective cohort study. 国際誌

Yuichiro Takeda, Yusaku Kusaba, Yoko Tsukita, Yukari Uemura, Eisaku Miyauchi, Takaya Yamamoto, Hiroshi Mayahara, Akito Hata, Hidetsugu Nakayama, Satoshi Tanaka, Junji Uchida, Kazuhiro Usui, Tatsuya Toyoda, Motohiro Tamiya, Masahiro Morimoto, Yuko Oya, Takeshi Kodaira, Keiichi Jingu, Hisatoshi Sugiura

Clinical and translational radiation oncology　37　57-63　2022年11月

DOI： 10.1016/j.ctro.2022.08.010 　

詳細を見る詳細を閉じる

Purpose: Intensity-modulated radiotherapy (IMRT) is currently used more commonly than 3-dimensional conformal radiation for definitive thoracic radiation. We examined the efficacy profiles of concurrent chemoradiotherapy (CCRT) with IMRT after durvalumab became clinically available. Methods: We reviewed the clinical records of patients with stage III non-small cell lung cancer (NSCLC) treated with CCRT and IMRT at seven centers in Japan and investigated relapse and survival from May 2018 to December 2019. The primary endpoint of this report was progression-free survival (PFS). Results: Among 107 patients enrolled in the study, 87 were sequentially administered durvalumab. From CCRT commencement, patients were followed up for a median period of 29.7 months. The median PFS at the end of the CCRT was 20.7 months. Among the 87 patients, 58 experienced disease relapses, of whom 36 (62.1 %) had distant metastases. Multivariate Cox regression analysis revealed that a favorable response to CCRT, a radiation dose ≥ 62 Gy, and stage IIIA NSCLC were associated with prolonged PFS (all P = 0.04). Multivariate logistic regression by landmark analysis revealed that mortality risk factors were durvalumab treatment duration ≤ 11.7 months, a lower maximum grade of immune-related adverse events, FEV1 < 2805 mL, and radiation dose < 62 Gy (P = 0.01, 0.01, 0.03, and 0.04, respectively). Conclusions: In patients with NSCLC receiving CCRT using IMRT, long PFS was associated with a better response to CCRT, stage IIIA NSCLC, and an increased radiation dose. The duration of durvalumab consolidation also played an essential role in the survival of patients receiving CCRT with IMRT. (250 words).
Favorable response after radiation therapy for intraductal papillary mucinous neoplasms manifesting as acute recurrent pancreatitis: A case report. 国際誌

Ayaka Harigai, Kiyoshi Kume, Noriyoshi Takahashi, So Omata, Rei Umezawa, Keiichi Jingu, Atsushi Masamune

World journal of clinical cases　10　(30)　11116-11121　2022年10月26日

DOI： 10.12998/wjcc.v10.i30.11116 　

詳細を見る詳細を閉じる

BACKGROUND: There has been an increasing number of elderly patients with intraductal papillary mucinous neoplasm (IPMN), who are surgically intolerant and require less invasive treatment options, which are limited. In the present study, we report a case of IPMN presenting with acute recurrent pancreatitis (ARP), in which radiation therapy effectively prevented further attacks of ARP and reduced tumor volume. CASE SUMMARY: An 83-year-old man was referred to our hospital with an asymptomatic incidental pancreatic cyst. Endoscopic ultrasound imaging and magnetic resonance cholangiopancreatography revealed a multiloculated tumor in the head of the pancreas, with dilated pancreatic ducts and mural nodules. The patient was diagnosed with mixed-type IPMN, and five years later, he developed ARP. Several endoscopic pancreatic ductal balloon dilatations failed to prevent further ARP attacks. Surgery was considered clinically inappropriate because of his old age and comorbidities. He was referred to our department for radiation therapy targeted at those lesions causing intraductal hypertension and radiation was administered at a dose of 50 Gy. An magnetic resonance imaging scan taken ten weeks after treatment revealed a decrease in tumor size and improvement of pancreatic duct dilatation. Fourteen months later, he remains symptom-free from ARP. CONCLUSION: This case highlights the important role of radiation therapy in mitigating the signs and symptoms of ARP in patients with inoperable IPMN.
Nicaraven induces programmed cell death by distinct mechanisms according to the expression levels of Bcl-2 and poly (ADP-ribose) glycohydrolase in cancer cells. 国際誌

Lina Abdelghany, Tsuyoshi Kawabata, Shinji Goto, Keiichi Jingu, Tao-Sheng Li

Translational oncology　26　101548-101548　2022年10月4日

DOI： 10.1016/j.tranon.2022.101548 　

詳細を見る詳細を閉じる

The PARP-1 expression level and poly (ADP-ribosyl)ation activity in cancer markedly affect the therapeutic outcome. Nicaraven, a free radical scavenger has been found to inhibit PARP, but the effect on cancer cells is still unclear. In this study, we investigated the potential role and molecular mechanism of nicaraven on cancer cells. Using U937 lymphoma cells and HCT-8 colorectal cancer cells, we found that nicaraven moderately reduced the cell viability of both cells in a dose-dependent manner. Interestingly, nicaraven significantly induced apoptosis of U937 cells that are dominantly expressing Bcl-2 but induced PAR-dependent cell death (parthanatos) of HCT-8 cells that are highly expressing poly (ADP-ribose) glycohydrolase (PARG). Based on our data, nicaraven seems to induce programmed cell death through distinct mechanisms, according to the expression levels of Bcl-2 and PARG in cancer cells.
Chronic expanding hematoma of the left erector spinae muscle after stereotactic body radiotherapy for renal cell carcinoma: a case report. 国際誌

Yojiro Ishikawa, Takaya Yamamoto, Rei Umezawa, Noriyoshi Takahashi, Kazuya Takeda, Yu Suzuki, Keiichi Jingu

Journal of medical case reports　16　(1)　353-353　2022年10月3日

DOI： 10.1186/s13256-022-03612-3 　

詳細を見る詳細を閉じる

BACKGROUND: Hematomas that slowly increase in size for more than 1 month after the initial hemorrhage are referred to as chronic expanding hematomas. Chronic expanding hematoma can also occur after radiosurgery; however, there have been no reports about chronic expanding hematoma in the trunk after stereotactic body radiotherapy. We report a case of chronic expanding hematoma of the left erector spinae muscle after stereotactic body radiotherapy for renal cell carcinoma. CASE PRESENTATION: A 74-year-old Japanese male complained of back pain 7 years after stereotactic body radiotherapy for renal cell carcinoma of the left kidney. There was no history of surgery or trauma to his back. After stereotactic body radiotherapy, there was no acute or late complication of more than grade 2. The renal cell carcinoma did not show shrinkage or progression, and he was diagnosed with stable disease on computed tomography. The patient remains in a stable disease condition 7 years after treatment without surgery or chemotherapy; however, he came to the hospital with gradually worsening back pain for several months. Computed tomography revealed the left erector spinae muscle to be swollen compared with the contralateral side at the third lumbar level. Ultrasonography showed a tumor of 30 mm in size without blood flow in the left paraspinal muscle. Positron emission tomography-computed tomography revealed uptake in the left paraspinal muscle. Pathological examination showed radiation-induced chronic expanding hematoma. CONCLUSIONS: We present the first case report of chronic expanding hematoma of the left erector spinae muscle after stereotactic body radiotherapy for renal cell carcinoma. Usually, stereotactic body radiotherapy for renal cell carcinoma would be considered unlikely to cause chronic expanding hematoma, but the introduction of dialysis and antiplatelet drugs may have increased the risk.
Practical guidelines of online MR-guided adaptive radiotherapy. 国際誌

Hiroyuki Okamoto, Hiroshi Igaki, Takahito Chiba, Keiko Shibuya, Tatsuya Sakasai, Keiichi Jingu, Koji Inaba, Kagayaki Kuroda, Shigeki Aoki, Daisaku Tatsumi, Mitsuhiro Nakamura, Noriyuki Kadoya, Yoshinobu Furuyama, Yu Kumazaki, Naoki Tohyama, Masato Tsuneda, Shie Nishioka, Jun Itami, Hiroshi Onishi, Naoyuki Shigematsu, Takashi Uno

Journal of radiation research　63　(5)　730-740　2022年9月21日

DOI： 10.1093/jrr/rrac048 　

詳細を見る詳細を閉じる

The first magnetic resonance (MR)-guided radiotherapy system in Japan was installed in May 2017. Implementation of online MR-guided adaptive radiotherapy (MRgART) began in February 2018. Online MRgART offers greater treatment accuracy owing to the high soft-tissue contrast in MR-images (MRI), compared to that in X-ray imaging. The Japanese Society for Magnetic Resonance in Medicine (JSMRM), Japan Society of Medical Physics (JSMP), Japan Radiological Society (JRS), Japanese Society of Radiological Technology (JSRT), and Japanese Society for Radiation Oncology (JASTRO) jointly established the comprehensive practical guidelines for online MRgART. These guidelines propose the essential requirements for clinical implementation of online MRgART with respect to equipment, personnel, institutional environment, practice guidance, and quality assurance/quality control (QA/QC). The minimum requirements for related equipment and QA/QC tools, recommendations for safe operation of MRI system, and the implementation system are described. The accuracy of monitor chamber and detector in dose measurements should be confirmed because of the presence of magnetic field. The ionization chamber should be MR-compatible. Non-MR-compatible devices should be used in an area that is not affected by the static magnetic field (outside the five Gauss line), and their operation should be checked to ensure that they do not affect the MR image quality. Dose verification should be performed using an independent dose verification system that has been confirmed to be reliable through commissioning. This guideline proposes the checklists to ensure the safety of online MRgART. Successful clinical implementation of online MRgART requires close collaboration between physician, radiological technologist, nurse, and medical physicist.
[Evaluation of Accuracy of Deformable Image Registration with Newly Developed Treatment Planning Support Software for Thoracic Images].

Haruna Takahashi, Noriyuki Kadoya, Yoshiyuki Katsuta, Shohei Tanaka, Kazuhiro Arai, Takaya Yamamoto, Rei Umezawa, Keiichi Jingu

Nihon Hoshasen Gijutsu Gakkai zasshi　78　(10)　1187-1193　2022年8月24日

DOI： 10.6009/jjrt.2022-1308 　

詳細を見る詳細を閉じる

This study evaluated accuracy of deformable image registration (DIR) with twelve parameter settings for thoracic images. We used peak-inhale and peak-exhale images for ten patients provided by DIR-lab. We used a prototype version of iCView software (ITEM Corporation) with DIR to perform intensity, structure, and hybrid-based DIR with the twelve parameter settings. DIR accuracy was evaluated by a target registration error (TRE) using 300 bronchial bifurcations and the Dice similarity coefficient (DSC) of the lungs. For twelve parameter settings, TRE ranged from 2.83 mm to 5.27 mm, whereas DSC ranged from 0.96 to 0.98. These results demonstrated that DIR accuracy differed among parameter settings and show that appropriate parameter settings are required for clinical practice.
Comparison of acute gastrointestinal toxicities between 3-dimensional conformal radiotherapy and intensity-modulated radiotherapy including prophylactic regions in chemoradiotherapy with S-1 for pancreatic cancer-importance of dose volume histogram parameters in the stomach as the predictive factors. 国際誌

Rei Umezawa, Kei Nakagawa, Masamichi Mizuma, Yoshiyuki Katsuta, Shohei Tanaka, Noriyuki Kadoya, Yu Suzuki, Kazuya Takeda, Noriyoshi Takahashi, Takaya Yamamoto, Michiaki Unno, Keiichi Jingu

Journal of radiation research　63　(6)　856-865　2022年8月20日

DOI： 10.1093/jrr/rrac049 　

詳細を見る詳細を閉じる

The purpose of this study was to compare acute gastrointestinal (GI) toxicities in patients who underwent 3-dimensional conformal radiotherapy (3DCRT) and intensity-modulated radiotherapy (IMRT) in chemoradiotherapy (CRT) with S-1 including prophylactic regions for pancreatic cancer. We also investigated the predictive factor of acute GI toxicities in dose volume histogram (DVH) parameters. Patients who received CRT with S-1 for pancreatic cancer between January 2014 and March 2021 were included. Radiotherapy (RT) with a total dose of 50-54 Gy was delivered. We examined the differences in the frequencies of acute GI toxicity of grade 2 or higher and DVH parameters of the stomach (ST) and duodenum (DU) between the 3DCRT group and the IMRT group. The RT-related predictive factors of acute GI toxicities were investigated by univariate and multivariate analyses. There were 25 patients in the 3DCRT group and 31 patients in the IMRT group. The frequencies of acute GI toxicity of G2 or higher were 36% in the 3DCRT group and 9.7% in the IMRT group (p = 0.035). ST V50 was the most predictive factor (p = 0.001), and the incidences of acute GI toxicity of G2 or higher in ST V50 ≥ 4.1 cc and < 4.1cc were 43.7% and 7.7%, respectively. ST V40 was also a significant predictive factor of acute GI toxicity (p = 0.002). IMRT could reduce acute GI toxicities in CRT with S-1 including prophylactic regions for pancreatic cancer. Acute GI toxicities may be affected by moderate to high doses to the ST.
Stereotactic Radiosurgery for Lung Cancer with a Risk-Adapted Strategy Using the Volumetric Modulated Arc Therapy Technique: A Single Arm Phase II Study

Takaya Yamamoto, Yu Katagiri, Yoko Tsukita, Haruo Matsushita, Rei Umezawa, Yoshiyuki Katsuta, Noriyuki Kadoya, Noriyoshi Takahashi, Yu Suzuki, Kazuya Takeda, Keita Kishida, So Omata, Eisaku Miyauchi, Ryota Saito, Keiichi Jingu

Cancers　14　(16)　3993-3993　2022年8月18日
出版者・発行元： MDPI AG
DOI： 10.3390/cancers14163993 　

eISSN：2072-6694

詳細を見る詳細を閉じる

Purpose: A phase II study carried out to assess the efficacy of a risk-adapted strategy of stereotactic radiosurgery (SRS) for lung cancer. The primary endpoint was 3-year local recurrence, and the secondary endpoints were overall survival (OS), disease-free survival (DFS), rate of start of systemic therapy or best supportive care (SST-BSC), and toxicity. Materials and Methods: Eligible patients fulfilled the following criteria: performance status of 2 or less, forced expiratory volume in 1 s of 700 mL or more, and tumor not located in central or attached to the chest wall. Twenty-eight Gy was prescribed for primary lung cancers with diameters of 3 cm or less and 30 Gy was prescribed for primary lung cancers with diameters of 3.1–5.0 cm or solitary metastatic lung cancer diameters of 5 cm or less. Results: Twenty-one patients were analyzed. The patients included 7 patients with adenocarcinoma, 2 patients with squamous cell carcinoma, 1 patient with metastasis, and 11 patients with clinical diagnosis. The median tumor diameter was 1.9 cm. SRS was prescribed at 28 Gy for 18 tumors and 30 Gy for 3 tumors. During the median follow-up period of 38.9 months for survivors, 1 patient had local recurrence, 7 patients had regional or distant metastasis, and 5 patients died. The 3-year local recurrence, SST-BSC, DFS, and OS rates were 5.3% (95% confidence interval [CI]: 0.3–22.2%), 20.1% (95% CI: 6.0–40.2%), 59.2% (95% CI: 34.4–77.3%), and 78.2% (95% CI: 51.4–91.3%), respectively. The 95% CI upper value of local recurrence was lower than the null local recurrence probability. There was no severe toxicity, and grade 2 radiation pneumonitis occurred in 1 patient. Conclusions: Patients who received SRS for lung cancer had a low rate of 3-year local recurrence and tolerable toxicity.
A case of COVID-19 vaccination during radiotherapy for breast cancer. 国際誌

Noriyoshi Takahashi, Kazuya Takeda, Yu Suzuki, Keita Kishida, Satoshi Teramura, Keiichi Jingu

Journal of the Egyptian National Cancer Institute　34　(1)　34-34　2022年8月15日

DOI： 10.1186/s43046-022-00134-3 　

詳細を見る詳細を閉じる

BACKGROUND: The coronavirus disease 19 (COVID-19) vaccination has been progressing. The safety of vaccination during radiotherapy is not clear. CASE PRESENTATION: We experienced a patient who received a COVID-19 vaccine during radiotherapy. A 60-year-old woman with breast cancer underwent postoperative radiotherapy. She received two vaccine doses and she suffered from severe vertigo. Her radiotherapy was suspended for several days and the radiotherapy schedule needed to be changed. CONCLUSIONS: The association between vertigo and vaccination during radiotherapy is not clear. However, if the general condition of patients worsens, suspension of treatment might be necessary. Therefore, attention should be given to COVID-19 vaccination during radiotherapy.
An Asian multi-national, multi-institutional, retrospective study on image-guided brachytherapy in cervical adenocarcinoma and adenosquamous carcinoma. 国際誌

Noriyuki Okonogi, Naoya Murakami, Ken Ando, Masumi Murata, Kazutoshi Murata, Tomomi Aoshika, Shingo Kato, Anneyuko I Saito, Joo-Young Kim, Yasuo Yoshioka, Shuhei Sekii, Kayoko Tsujino, Chairat Lowanichkiattikul, Poompis Pattaranutaporn, Yuko Kaneyasu, Tomio Nakagawa, Miho Watanabe, Takashi Uno, Rei Umezawa, Keiichi Jingu, Ayae Kanemoto, Masaru Wakatsuki, Katsuyuki Shirai, Hiroshi Igaki, Tatsuya Ohno, Jun Itami

Journal of contemporary brachytherapy　14　(4)　311-320　2022年8月

DOI： 10.5114/jcb.2022.119451 　

詳細を見る詳細を閉じる

Purpose: There are limited reports on outcomes of three-dimensional image-guided brachytherapy (3D-IGBT) for cervical adenocarcinoma in Asia. In a multi-institutional retrospective study, we assessed the clinical outcomes of three-dimensional image-guided brachytherapy for cervical adenocarcinoma or adenosquamous carcinoma (CA/CAC) in Asian countries. Material and methods: Patients who had undergone definitive radiation therapy/concurrent chemoradiotherapy for untreated cervical cancer between 2000 and 2016 were registered. Those who had undergone 3D-IGBT for histologically proven CA/CAC were included. Data on patients' characteristics and treatment were collected, including tumor reduction rate (defined as a percentage of reduction in tumor size before brachytherapy compared with that at diagnosis) and high-risk clinical target volume D90. Overall survival (OS), local control (LC), and progression-free survival (PFS) rates were calculated using Kaplan-Meier method. Late toxicities were assessed using common terminology criteria for adverse events version 4.0. Results: Anonymized data of 498 patients were collected. Of the 498 patients, 36 patients met inclusion criteria. The median follow-up period was 39 months. The 3-year OS, LC, and PFS rates were 68.4%, 68.5%, and 44.4%, respectively. After treatment, five patients had tumor re-growth without complete disappearance of the tumor. Two patients developed grade 3 vaginal toxicity or grade 4 rectal toxicity; none developed other severe late toxicities. A tumor reduction rate of > 26.3% was the only significant factor in multivariate analyses, and was associated with significantly better OS (p = 0.018), LC (p = 0.022), and PFS (p = 0.013). There were no significant trends in local control or dose to high-risk clinical target volume D90. Conclusions: LC rate of CA/CAC was insufficient despite 3D-IGBT. Meanwhile, tumor reduction rate was associated with LC, OS, and PFS rates. Therefore, CA/CAC may require a different treatment strategy than that applied in cervical squamous cell carcinoma.
The benefit of concurrent chemotherapy with radiotherapy for esophageal cancer is limited in Asian patients aged 80 years or older: a SEER database analysis.

Keiichi Jingu, Noriyoshi Takahashi, Rei Umezawa, Takaya Yamamoto, Kazuya Takeda, Yu Suzuki, Keita Kishida, So Omata, Yuta Sato, Hinako Harada, Ayaka Harigai

Esophagus : official journal of the Japan Esophageal Society　19　(4)　653-659　2022年7月2日

DOI： 10.1007/s10388-022-00938-1 　

詳細を見る詳細を閉じる

PURPOSE: To evaluate the benefit of concurrent chemotherapy with radiotherapy (RT) for esophageal cancer in Asian patients aged ≥ 80 years using the Surveillance, Epidemiology, and End Results (SEER) database. MATERIALS AND METHODS: Among more than 7000 patients with squamous cell carcinoma or adenocarcinoma who were treated by RT without surgery for esophageal cancer in the SEER database, 2047 patients aged ≥ 80 years were analyzed. Patients who received chemoradiotherapy (CRT group) and patients who received RT alone (RT alone group) were matched with a propensity score. RESULTS: The median observation period for survivors was 57 months. The 3-year and 5-year overall survival rates in all patients were 15.2% and 8.5%, respectively. The 3-year and 5-year cause-specific survival rates in all patients were 20.8% and 14.5%, respectively. After propensity score matching, the overall survival rate in the CRT group was significantly higher than that in the RT alone group (5-year overall survival rates: 11.9% and 3.2%, respectively, p < 0.001). In 108 Asian or Pacific Islander patients, there was no significant difference (5-year overall survival rates: 13.5% and 0%, respectively, p = 0.291), although the overall survival rate in the CRT group was significantly higher than that in the RT alone group in any other race. CONCLUSIONS: It is controversial whether CRT is beneficial for Asian or Pacific Islander patients aged 80 years or older with esophageal cancer based on Analysis of data in SEER database.
Brachytherapy for primary nasal vestibule cancer using Au-198 grains. 国際誌

Hinako Harada, Yojiro Ishikawa, Shohei Tanaka, Keita Kishida, Rei Umezawa, Takaya Yamamoto, Noriyoshi Takahashi, Kazuya Takeda, Yu Suzuki, Keiichi Jingu

International cancer conference journal　11　(3)　184-187　2022年7月

DOI： 10.1007/s13691-022-00546-x 　

詳細を見る詳細を閉じる

Radiation therapy (RT) is one of the definitive treatments for early-stage nasal vestibular carcinoma and has similar local control rates to resection surgery. There are various methods, including external beam RT and brachytherapy. This report describes a case who showed local control for more than 5 years after brachytherapy alone using Au-198 grains for nasal vestibular carcinoma. A 68-year-old Japanese man complained of swelling and pain in his left nasal cavity. He was diagnosed with squamous cell carcinoma (SCC) (cT1N0M0, stage I). An elevated mass of 8 mm in long diameter was found inside the left nasal cavity. Since the patient selected brachytherapy, nine Au-198 grains 185 mBq were permanently injected percutaneously under local anesthesia, and 85 Gy was prescribed. Grade three dermatitis was observed as an acute adverse event. After 2 years, mild telangiectasia of the left nasal skin and epilation of nasal hair in the left nasal cavity was regarded as late adverse events. The patient continues to keep a complete response for 5 years. For small nasal vestibular SCC, brachytherapy with Au-198 grains might be a good option.
Feasibility of Differential Dose-Volume Histogram Features in Multivariate Prediction Model for Radiation Pneumonitis Occurrence. 国際誌

Yoshiyuki Katsuta, Noriyuki Kadoya, Yuto Sugai, Yu Katagiri, Takaya Yamamoto, Kazuya Takeda, Shohei Tanaka, Keiichi Jingu

Diagnostics (Basel, Switzerland)　12　(6)　2022年5月31日

DOI： 10.3390/diagnostics12061354 　

詳細を見る詳細を閉じる

The purpose of this study is to introduce differential dose-volume histogram (dDVH) features into machine learning for radiation pneumonitis (RP) prediction and to demonstrate the predictive performance of the developed model based on integrated cumulative dose-volume histogram (cDVH) and dDVH features. Materials and methods: cDVH and dDVH features were calculated for 153 patients treated for non-small-cell lung cancer with 60-66 Gy and dose bins ranging from 2 to 8 Gy in 2 Gy increments. RP prediction models were developed with the least absolute shrinkage and selection operator (LASSO) through fivefold cross-validation. Results: Among the 152 patients in the patient cohort, 41 presented ≥grade 2 RP. The interdependencies between cDVH features evaluated by Spearman's correlation were significantly resolved by the inclusion of dDVH features. The average area under curve for the RP prediction model using cDVH and dDVH model was 0.73, which was higher than the average area under curve using cDVH model for 0.62 with statistically significance (p < 0.01). An analysis using the entire set of regression coefficients determined by LASSO demonstrated that dDVH features represented four of the top five frequently selected features in the model fitting, regardless of dose bin. Conclusions: We successfully developed an RP prediction model that integrated cDVH and dDVH features. The best RP prediction model was achieved using dDVH (dose bin = 4 Gy) features in the machine learning process.
A deep learning-based radiomics approach to predict head and neck tumor regression for adaptive radiotherapy. 国際誌

Shohei Tanaka, Noriyuki Kadoya, Yuto Sugai, Mariko Umeda, Miyu Ishizawa, Yoshiyuki Katsuta, Kengo Ito, Ken Takeda, Keiichi Jingu

Scientific reports　12　(1)　8899-8899　2022年5月27日

DOI： 10.1038/s41598-022-12170-z 　

詳細を見る詳細を閉じる

Early regression-the regression in tumor volume during the initial phase of radiotherapy (approximately 2 weeks after treatment initiation)-is a common occurrence during radiotherapy. This rapid radiation-induced tumor regression may alter target coordinates, necessitating adaptive radiotherapy (ART). We developed a deep learning-based radiomics (DLR) approach to predict early head and neck tumor regression and thereby facilitate ART. Primary gross tumor volume (GTVp) was monitored in 96 patients and nodal GTV (GTVn) in 79 patients during treatment. All patients underwent two computed tomography (CT) scans: one before the start of radiotherapy for initial planning and one during radiotherapy for boost planning. Patients were assigned to regression and nonregression groups according to their median tumor regression rate (ΔGTV/treatment day from initial to boost CT scan). We input a GTV image into the convolutional neural network model, which was pretrained using natural image datasets, via transfer learning. The deep features were extracted from the last fully connected layer. To clarify the prognostic power of the deep features, machine learning models were trained. The models then predicted the regression and nonregression of GTVp and GTVn and evaluated the predictive performance by 0.632 + bootstrap area under the curve (AUC). Predictive performance for GTVp regression was highest using the InceptionResNetv2 model (mean AUC = 0.75) and that for GTVn was highest using NASNetLarge (mean AUC = 0.73). Both models outperformed the handcrafted radiomics features (mean AUC = 0.63 for GTVp and 0.61 for GTVn) or clinical factors (0.64 and 0.67, respectively). DLR may facilitate ART for improved radiation side-effects and target coverage.
An Asian multi-national multi-institutional retrospective study comparing intracavitary versus the hybrid of intracavitary and interstitial brachytherapy for locally advanced uterine cervical carcinoma. 国際誌

Naoya Murakami, Ken Ando, Masumi Murata, Kazutoshi Murata, Tatsuya Ohno, Tomomi Aoshika, Shingo Kato, Noriyuki Okonogi, Anneyuko I Saito, Joo-Young Kim, Yasuo Yoshioka, Shuhei Sekii, Kayoko Tsujino, Chairat Lowanichkiattikul, Poompis Pattaranutaporn, Yuko Kaneyasu, Tomio Nakagawa, Miho Watanabe, Takashi Uno, Rei Umezawa, Keiichi Jingu, Ayae Kanemoto, Masaru Wakatsuki, Katsuyuki Shirai, Hiroshi Igaki, Jun Itami

Journal of radiation research　63　(3)　412-427　2022年5月18日

DOI： 10.1093/jrr/rrac014 　

詳細を見る詳細を閉じる

This study is an international multi-institutional retrospective study comparing the clinical outcomes between intracavitary brachytherapy (ICBT) and the hybrid of intracavitary and interstitial brachytherapy (HBT) for locally advanced cervical cancer patients treated with definitive radiation therapy. Locally advanced cervical cancer, the initial size of which is larger than 4 cm and treated by concurrent chemoradiotherapy and image-guided adaptive brachytherapy, were eligible for this retrospective study. Patients who received HBT at least once were included in the HBT group, and patients who received only ICBT were included in the ICBT group. Anonymized data from 469 patients from 13 institutions in Japan, one from Korea and one from Thailand, were analyzed. Two hundred eighty and 189 patients were included in the ICBT group and the HBT group, respectively. Patients in the HBT group had more advanced stage, non-Scc histopathology, a higher rate of uterine body involvement, larger tumor at diagnosis, larger tumor before brachytherapy and a lower tumor reduction ratio. With a median follow-up of 51.3 months (2.1-139.9 months), 4-y local control (LC), progression-free survival (PFS) and overall survival (OS) for the entire patient population were 88.2%, 64.2% and 83%, respectively. The HBT group received a higher HR-CTV D90 than that of the ICBT group (68.8 Gy vs 65.6 Gy, P = 0.001). In multivariate analysis, the non-Scc histological subtype, HR-CTV D95 ≤ 60 Gy, reduction ratio ≤ 29% and total treatment time (TTT) ≥ 9 weeks were identified as the independent adverse prognostic factors for LC. Regarding LC, no difference was found between ICBT and HBT (4-y LC 89.3% vs 86.8%, P = 0.314). After adjustment for confounding factors by propensity score matching, no advantage of applying HBT was demonstrated regarding LC, PFS, or OS. Despite the fact that HBT patients had more adverse clinical factors than ICBT patients, HBT delivered a higher dose to HR-CTV and resulted in comparable LC.
Patterns of failure after salvage chemoradiotherapy for postoperative loco-regional recurrent esophageal cancer: 20-year experience in a single institution in Japan.

Keiichi Jingu, Rei Umezawa, Takaya Yamamoto, Noriyoshi Takahashi, Kazuya Takeda, Yu Suzuki, Keita Kishida, So Omata, Yuta Sato, Noriyuki Kadoya

Esophagus : official journal of the Japan Esophageal Society　19　(4)　639-644　2022年5月16日

DOI： 10.1007/s10388-022-00922-9 　

詳細を見る詳細を閉じる

PURPOSE: The purpose of the present study was to evaluate patterns of recurrence after salvage chemoradiotherapy (SCRT) for postoperative loco-regional recurrent esophageal cancer. METHODS: We reviewed records for 114 patients with postoperative loco-regional recurrent esophageal cancer treated by platinum-based chemoradiotherapy between 2000 and 2020, and we evaluated the patterns of failure in patients who had recurrence again or who had been observed for 2 years or more after SCRT at the last observation date. RESULTS: One hundred and three patients were enrolled in this study. The median observation period for survivors was 60 months. Fifty-three patients died of esophageal cancer and nine patients died of other diseases. The 5-year overall survival rate, cause-specific survival rate and disease-control rate were 43.7%, 45.3% and 37.0%, respectively. Sixty-five patients had failure after SCRT. In those patients, 26 patients had only distant organ or non-regional lymph node metastases, 26 patients had only loco-regional failure, and 13 patients had both. Of those 65 patients, 64 patients showed failure within 42 months after SCRT. Of 39 patients with loco-regional failure, failure in the irradiated field was observed in 28 patients. Of those 28 patients, 27 patients showed failure within 24 months and the other patient showed failure at 26.5 months. CONCLUSIONS: The patterns of failure after SCRT for patients with postoperative loco-regional recurrent esophageal cancer were shown. The patterns of failure suggest that follow-up for at least 4 years after SCRT should be performed for those patients.
Palliative radiotherapy for gastric cancer bleeding: a multi-institutional retrospective study. 国際誌

Kazuya Takeda, Toru Sakayauchi, Masaki Kubozono, Yu Katagiri, Rei Umezawa, Takaya Yamamoto, Yojiro Ishikawa, Noriyoshi Takahashi, Yu Suzuki, Keita Kishida, Keiichi Jingu

BMC palliative care　21　(1)　52-52　2022年4月12日

DOI： 10.1186/s12904-022-00943-2 　

詳細を見る詳細を閉じる

BACKGROUND: Palliative radiotherapy for gastric cancer bleeding has been reported to be a safe and effective treatment, but predictive factors for achievement of hemostasis and overall survival have not been established. METHODS: In this retrospective study, 120 courses of palliative radiotherapy for gastric cancer bleeding in 117 patients in 4 institutes in Japan were reviewed with approval of the ethical committee in each institute. The rate of achieving hemostasis was evaluated by 50% or more reduction of red blood cell transfusion before and after the start of radiotherapy, elevation of blood hemoglobin concentration in a period of 4 weeks from the start of radiotherapy or improvement of subjective or objective clinical symptoms in a period of 4 weeks from the start of radiotherapy. Predictive factors for overall survival and achieving hemostasis were investigated with the Cox hazards model. RESULTS: The median overall survival period was 3.7 months. Multivariate analysis showed that absence of metastatic disease, higher biological effective dose, higher serum albumin level, lower blood urea nitrogen level and lower neutrophil-to-lymphocyte ratio (NLR) were associated with longer overall survival. Elevation of hemoglobin concentration in a period of 4 weeks from the start of radiotherapy (mean concentration: 8.2 g/dL vs. 8.9 g/dL, p = 0.006) and decrease in the amount of red cell transfusion from a 4-week period before to a 4-week period after the start of radiotherapy (mean amount: 716 mL vs. 230 mL, p < 0.0001) were observed. The overall rate of achievement of hemostasis was 59.6%. In multivariate analysis, higher biological effective dose was associated with achievement of hemostasis. Grade 2 or higher acute adverse effects related to radiotherapy were observed in 17.5% of cases in 120 treatment courses. Six cases (5.0%) had grade 3 or 4 adverse effects including gastric penetration in 1 patient and anorexia requiring total parental nutrition in 3 patients. No grade 5 adverse effects were observed. CONCLUSIONS: Palliative radiotherapy for gastric cancer bleeding seems to be an effective and safe treatment strategy. Higher treatment dose was associated with longer overall survival and a hemostatic effect. Some hematological parameters may predict overall survival, and they would be helpful for deciding the treatment strategy.
Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice. 国際誌

Takaya Yamamoto, Yoko Tsukita, Yu Katagiri, Haruo Matsushita, Rei Umezawa, Yojiro Ishikawa, Noriyoshi Takahashi, Yu Suzuki, Kazuya Takeda, Eisaku Miyauchi, Ryota Saito, Yoshiyuki Katsuta, Noriyuki Kadoya, Keiichi Jingu

BMC cancer　22　(1)　364-364　2022年4月4日

DOI： 10.1186/s12885-022-09354-1 　

詳細を見る詳細を閉じる

BACKGROUND: In clinical practice, the effect of durvalumab and radiation pneumonitis (RP) on survival after intensity-modulated radiotherapy (IMRT) is not fully understood. The purpose of this retrospective study was to investigate factors related to distant metastasis-free survival (DMFS), progression-free survival (PFS) and overall survival (OS) after IMRT for locally advanced non-small cell lung cancer (LA-NSCLC). METHODS: All patients who were treated with conventional fractionated IMRT for LA-NSCLC between April 2016 and March 2021 were eligible. Time-to-event data were assessed by using the Kaplan-Meier estimator, and the Cox proportional hazards model was used for prognostic factor analyses. Factors that emerged after the start of IMRT, such as durvalumab administration or the development of RP, were analysed as time-dependent covariates. RESULTS: A total of 68 consecutive patients treated with conventional fractionated IMRT for LA-NSCLC were analysed. Sixty-six patients completed radiotherapy, 50 patients received concurrent chemotherapy, and 36 patients received adjuvant durvalumab. During the median follow-up period of 14.3 months, 23 patients died, and tumour progression occurred in 37 patients, including 28 patients with distant metastases. The 1-year DMFS rate, PFS rate and OS rate were 59.9%, 48.7% and 84.2%, respectively. Grade 2 RP occurred in 16 patients, grade 3 in 6 patients and grade 5 in 1 patient. The 1-year cumulative incidences of grade 2 or higher RP and grade 3 or higher RP were 33.8% and 10.3%, respectively. The results of multivariate analyses showed that durvalumab had a significantly lower hazard ratio (HR) for DMFS, PFS and OS (HR 0.31, p < 0.01; HR 0.33, p < 0.01 and HR 0.32, p = 0.02), respectively. Grade 2 or higher RP showed significance for DMFS and a nonsignificant trend for OS (HR 2.28, p = 0.04 and HR 2.12, p = 0.13), respectively, whereas a higher percentage of lung volume receiving 20 Gy or higher was significant for PFS (HR 2.25, p = 0.01). CONCLUSIONS: In clinical practice, durvalumab administration following IMRT with concomitant chemotherapy showed a significant survival benefit. Reducing the risk of grade 2 or higher RP would also be beneficial.
Successful treatment with proton beam therapy for a solitary sternal metastasis of breast cancer: a case report. 国際誌

Yojiro Ishikawa, Motohisa Suzuki, Hisashi Yamaguchi, Ichiro Seto, Masanori Machida, Yoshiaki Takagawa, Keiichi Jingu, Yasuyuki Kikuchi, Masao Murakami

Journal of medical case reports　16　(1)　111-111　2022年3月20日

DOI： 10.1186/s13256-022-03335-5 　

詳細を見る詳細を閉じる

BACKGROUND: Breast cancer infrequently metastasizes to the sternum as solitary metastasis. We experienced successful treatment with proton beam therapy for a case of sternal metastasis of breast cancer. This case demonstrates for the first time the role of proton therapy in the treatment of oligometastatic sternal metastasis with limited tolerance of normal tissue due to previous photon irradiation. CASE PRESENTATION: A 40-year-old Japanese female presented with lumpiness in her left breast. The patient was diagnosed with breast cancer (cT1N0M0, cStage IA) and underwent partial mastectomy with axillary lymph node dissection. After the mastectomy, the patient received radiation therapy with 50 Gy in 25 fractions for initial irradiation of the left breast. After the initial irradiation of 50 Gy, the patient received 10 Gy in five fractions of a sequential boost for the tumor bed to a total dose of 60 Gy. Although the patient was administered tamoxifen after radiation therapy, solitary sternal metastasis occurred 6 months after radiation therapy. She refused chemotherapy and requested proton beam therapy for her sternal metastasis. The daily proton beam therapy fractions were 2.5 relative biological effectiveness, receiving a total dose of 70 Gy relative biological effectiveness. An acute side effect of grade 2 dermatitis according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. occurred during proton beam therapy, but there was no acute or late complication of more than grade 3. At 3 years after proton beam therapy, the patient remains in complete remission without surgery or chemotherapy. DISCUSSION AND CONCLUSION: Proton beam therapy for solitary sternal metastasis of breast cancer is considered to be a therapeutic option.
Nicaraven mitigates radiation-induced lung injury by downregulating the NF-κB and TGF-β/Smad pathways to suppress the inflammatory response. 国際誌

Yong Xu, Da Zhai, Shinji Goto, Xu Zhang, Keiichi Jingu, Tao-Sheng Li

Journal of radiation research　63　(2)　158-165　2022年3月17日

DOI： 10.1093/jrr/rrab112 　

詳細を見る詳細を閉じる

Radiation-induced lung injury (RILI) is commonly observed in patients receiving radiotherapy, and clinical prevention and treatment remain difficult. We investigated the effect and mechanism of nicaraven for mitigating RILI. C57BL/6 N mice (12-week-old) were treated daily with 6 Gy X-ray thoracic radiation for 5 days in sequences (cumulative dose of 30 Gy), and nicaraven (50 mg/kg) or placebo was injected intraperitoneally in 10 min after each radiation exposure. Mice were sacrificed and lung tissues were collected for experimental assessments at the next day (acute phase) or 100 days (chronic phase) after the last radiation exposure. Of the acute phase, immunohistochemical analysis of lung tissues showed that radiation significantly induced DNA damage of the lung cells, increased the number of Sca-1+ stem cells, and induced the recruitment of CD11c+, F4/80+ and CD206+ inflammatory cells. However, all these changes in the irradiated lungs were effectively mitigated by nicaraven administration. Western blot analysis showed that nicaraven administration effectively attenuated the radiation-induced upregulation of NF-κB, TGF-β, and pSmad2 in lungs. Of the chronic phase, nicaraven administration effectively attenuated the radiation-induced enhancement of α-SMA expression and collagen deposition in lungs. In conclusion we find that nicaraven can effectively mitigate RILI by downregulating NF-κB and TGF-β/pSmad2 pathways to suppress the inflammatory response in the irradiated lungs.
Differential abscopal effect in extracranial and intracranial lesions after radiotherapy alone for vertebral bone metastasis of unknown primary: a case report. 国際誌

Yojiro Ishikawa, Rei Umezawa, Takaya Yamamoto, Noriyoshi Takahashi, Kazuya Takeda, Yu Suzuki, Keiichi Jingu

Journal of medical case reports　16　(1)　94-94　2022年3月6日

DOI： 10.1186/s13256-022-03321-x 　

詳細を見る詳細を閉じる

BACKGROUND: The abscopal effect is a phenomenon in which a tumor located far from irradiated lesions regresses. We have experienced a case in which both intracranial and extracranial lesions showed an abscopal effect after radiotherapy for spinal metastases of unknown primary. We report the differential abscopal effect in extracranial and intracranial lesions. CASE PRESENTATION: A 57-year-old Japanese man was diagnosed with multiple lung nodules, bone metastases, and brain metastases. The results of pathological examination at the previous hospital he visited suggested adenocarcinoma of the lung. However, there was a possibility that the biopsy specimen was inadequate. Radiation therapy was performed on the ninth thoracic vertebra for a total dose of 39 Gy in 13 fractions because the lesion in the ninth thoracic vertebra was destructively extending. After thorough examination, the primary lesion could not be identified, and we made diagnosis of cancer of unknown primary. The patient did not want to receive systemic chemotherapy; however, all of the lesions except for the brain metastases had spontaneously shrunk 2 months after radiation therapy. Although the brain metastases had partially shrunk, whole-brain radiotherapy for a total dose of 36 Gy in 12 fractions was performed. Fifteen months after initial radiation therapy, the brain metastasis recurred, and Gamma Knife radiosurgery was additionally performed. The brain metastases disappeared after the radiosurgery. During a period of 30 months after radiation therapy for the ninth vertebra, the lesions of the trunk all maintained their shrinkage without systemic chemotherapy. Right cervical lymph node metastasis and brain metastases occurred 30 months after the initial radiation therapy. A biopsy of the right cervical lymph node led to the diagnosis of clear cell carcinoma. Although we considered additional radiation therapy or chemotherapy, the patient died 3 months after the progression of recurrence lesions. DISCUSSION AND CONCLUSIONS: We report a rare case in which radiotherapy alone for an extracranial metastatic lesion of a vertebra resulted in an abscopal effect on both extracranial and intracranial lesions. Notably, the abscopal effect in the intracranial lesions was weaker than that in the extracranial lesions.
PP6 deficiency in mice with KRAS mutation and Trp53 loss promotes early death by PDAC with cachexia-like features. 国際誌

Katsuya Fukui, Miyuki Nomura, Kazuhiro Kishimoto, Nobuhiro Tanuma, Koreyuki Kurosawa, Kosuke Kanazawa, Hiroyuki Kato, Tomoki Sato, Shinji Miura, Koh Miura, Ikuro Sato, Hiroyuki Tsuji, Yoji Yamashita, Keiichi Tamai, Toshio Watanabe, Jun Yasuda, Takuji Tanaka, Kennichi Satoh, Toru Furukawa, Keiichi Jingu, Hiroshi Shima

Cancer science　2022年3月5日

DOI： 10.1111/cas.15315 　

詳細を見る詳細を閉じる

To examine effects of PP6 gene (Ppp6c) deficiency on pancreatic tumor development, we developed pancreas-specific, tamoxifen-inducible Cre-mediated KP (KRAS(G12D) plus Trp53-deficient) mice (cKP mice) and crossed them with Ppp6cflox / flox mice. cKP mice with the homozygous Ppp6c deletion developed pancreatic tumors, became emaciated and required euthanasia within 150 days of mutation induction, phenotypes that were not seen in heterozygous or wild-type (WT) mice. At 30 days, a comparative analysis of genes commonly altered in homozygous versus WT Ppp6c cKP mice revealed enhanced activation of Erk and NFκB pathways in homozygotes. By 80 days, the number and size of tumors and number of precancerous lesions had significantly increased in the pancreas of Ppp6c homozygous relative to heterozygous or WT cKP mice. Ppp6c-/- tumors were pathologically diagnosed as pancreatic ductal adenocarcinoma (PDAC) undergoing the epithelial-mesenchymal transition (EMT), and cancer cells had invaded surrounding tissues in three out of six cases. Transcriptome and metabolome analyses indicated an enhanced cancer-specific glycolytic metabolism in Ppp6c-deficient cKP mice and the increased expression of inflammatory cytokines. Individual Ppp6c-/- cKP mice showed weight loss, decreased skeletal muscle and adipose tissue, and increased circulating tumor necrosis factor (TNF)-α and IL-6 levels, suggestive of systemic inflammation. Overall, Ppp6c deficiency in the presence of K-ras mutations and Trp53 gene deficiency promoted pancreatic tumorigenesis with generalized cachexia and early death. This study provided the first evidence that Ppp6c suppresses mouse pancreatic carcinogenesis and supports the use of Ppp6c-deficient cKP mice as a model for developing treatments for cachexia associated with pancreatic cancer.
Long-term survival after definitive proton beam therapy for oligorecurrent esophageal squamous cell carcinoma: a case report. 国際誌

Yojiro Ishikawa, Motohisa Suzuki, Hisashi Yamaguchi, Ichiro Seto, Masanori Machida, Yoshiaki Takagawa, Keiichi Jingu, Yasuyuki Kikuchi, Masao Murakami

Journal of medical case reports　16　(1)　68-68　2022年2月14日

DOI： 10.1186/s13256-022-03275-0 　

詳細を見る詳細を閉じる

BACKGROUND: Radical esophagectomy for esophageal squamous cell carcinoma has improved survival, but the rate of recurrence is high. Patients of recurrent esophageal squamous cell carcinoma after failure of chemotherapy have a poor prognosis. We herein report the achievement of long-term survival after definitive proton beam therapy for oligorecurrent esophageal squamous cell carcinoma after failure of chemotherapy. CASE PRESENTATION: A 60-year-old Japanese man was diagnosed as having squamous cell carcinoma of the lower thoracic esophagus (cT2N0M0, stage IIA). He underwent two courses of neoadjuvant chemotherapy with cisplatin and 5-fluorouracil, and esophagectomy with three-field lymphadenectomy was performed. Microscopic findings after resection showed two lymph node metastases (ypT2N1M0, stage IIB). Five months after resection, a computed tomography scan revealed a solitary liver metastasis in the S4 area. He underwent three courses of chemotherapy with cisplatin and 5-fluorouracil; however, positron emission tomography revealed two lymph node metastases. Surgeons recommended second-line chemotherapy, but the patient refused chemotherapy and requested proton beam therapy. We performed proton beam therapy without chemotherapy for the liver metastasis and lymph node metastases, with total doses of 79.2 and 60 Gy relative biological effectiveness, respectively, according to the tumor location. An acute side effect of grade 1 dermatitis occurred after proton beam therapy, but there was no acute or late complication of more than grade 2. The patient remains in complete remission 5 years after treatment without surgery or chemotherapy. DISCUSSION AND CONCLUSIONS: Proton beam therapy exerted a curative effect on oligorecurrent esophageal squamous cell carcinoma. This is the first report on the achievement of long-term survival after definitive proton beam therapy for oligorecurrent esophageal squamous cell carcinoma.
肺癌照射後再発に対して定位照射が著効した1例

佐藤雄太, 松下晴雄, 梅澤玲, 山本貴也, 石川陽二郎, 高橋紀善, 武田一也, 神宮啓一

Japanese Journal of Radiology　40　(Suppl.)　2-2　2022年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
頭頸部がんに対するIMRT後の口腔内QOLの長期的変化 3D-CRTと比較して

神宮啓一, 高橋紀善, 田坂俊, 松下晴雄, 梅澤玲, 山本貴也, 石川陽二郎, 武田一也

Japanese Journal of Radiology　40　(Suppl.)　3-3　2022年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
80歳以上の高齢食道癌患者における放射線治療の予後因子の検討

高橋紀善, 梅澤玲, 岸田桂太, 山本貴也, 石川陽二郎, 武田一也, 鈴木友, 川端広聖, 寺村聡司, 神宮啓一

Japanese Journal of Radiology　40　(Suppl.)　6-6　2022年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
局所型前立腺癌に対する根治的IMRT後の重篤な晩期尿路障害に関連する臨床因子

武田賢, 梅澤玲, 石川陽二郎, 山本貴也, 高橋紀善, 武田一也, 角谷倫之, 松下晴雄, 神宮啓一, 山下慎一, 三塚浩二, 伊藤明宏, 荒井陽一, 高井良尋

Japanese Journal of Radiology　40　(Suppl.)　6-6　2022年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
外来での照射中問診のためのタブレットアプリケーションの開発

武田一也, 神宮啓一, 園部真也, 植田琢也

Japanese Journal of Radiology　40　(Suppl.)　6-6　2022年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
Radiation Therapy for Advanced Mucinous Carcinoma of the Breast With a Malignant Wound: A Case Report. 国際誌

Yojiro Ishikawa, Rei Umezawa, Takaya Yamamoto, Noriyoshi Takahashi, Kazuya Takeda, Yu Suzuki, Keita Kishida, Kengo Ito, Maiko Kozumi, Kaneki Koyama, Keiichi Jingu

Cureus　14　(2)　e22017　2022年2月

DOI： 10.7759/cureus.22017 　

詳細を見る詳細を閉じる

Patients with breast cancer who refuse standard treatment often suffer from malignant wounds due to the growth of local tumors. However, treatment strategies for patients with unresectable locally advanced breast cancer who refuse standard treatment remain unclear. Usually, such cases are treated with palliative irradiation and do not achieve local control by irradiation alone. This is the first case report discussing the role of high-dose local irradiation and the treatment course for a patient with a massive breast tumor (mucinous adenocarcinoma) who refused standard treatment. A 44-year-old female was diagnosed with mucinous carcinoma of the breast in the right breast (cT1N0M0, cStage I). She refused standard treatment for six years. She visited the emergency department because of acute bleeding from the right breast with malignant wounds. Macroscopically, the tumor in the right breast measured over 20 cm in diameter. The tumor was exudative, exhibited ulceration and slight bleeding, and emitted an odor. Imaging findings showed multiple lymph nodes and bone metastases, and the final diagnosis was stage IV breast cancer (cT4bN1M1). Although the surgeon recommended chemotherapy for breast cancer, the patient refused chemotherapy or other therapy due to concerns regarding treatment-related complications. Considering the symptoms of advanced breast cancer with malignant wounds, she finally agreed to receive radiation therapy (RT). We performed RT at 70 Gy in 35 fractions over seven weeks. The tumor-associated symptoms disappeared after RT. Three months after RT, the tumor had almost disappeared. We administered luteinizing hormone-releasing hormone agonists after RT. Two years after RT, she died due to multiple liver metastases and ascites; however, there was no disease progression in the right breast. High-dose RT for locally advanced mucinous carcinoma of the breast with malignant wounds is considered an effective therapeutic option.
Long-Term Survival Following Palliative Chemoradiotherapy in an Elderly Patient With Advanced Squamous Cell Carcinoma in the Right Mandibular Gingiva. 国際誌

Yojiro Ishikawa, Rei Umezawa, Takaya Yamamoto, Kengo Ito, Keiichi Jingu

Cureus　14　(2)　e22142　2022年2月

DOI： 10.7759/cureus.22142 　

詳細を見る詳細を閉じる

Advanced squamous cell carcinoma (SCC) of the mandibular gingiva in elderly patients is difficult to cure. The treatment policy for elderly patients with advanced SCC of the mandibular gingiva has not been clear. We report a case of right mandibular gingival carcinoma that was successfully treated by palliative chemoradiotherapy. An 83-year-old female complained of pain and an ulcer in her right mandibular gingiva. Oral examination revealed a lesion of about 20 mm in size in the right mandibular gingiva. A diagnosis of SCC in the right mandibular gingiva was made by histology. Imaging findings revealed some right neck lymph node metastases. Based on these findings, a clinical diagnosis before treatment was SCC in the right mandibular gingiva (cT4aN2bM0, stage IV) by the 7th edition of the Union of International Cancer Control. She refused to receive definitive surgery or chemoradiotherapy due to concerns about the invasiveness of these definitive therapies and requested palliative chemoradiotherapy. We delivered S-1 (a combination of tegafur, gimeracil, and oteracil) and radiation therapy (RT) to the primary tumor alone with 30 Gy in 10 fractions using 4-megavoltage equipment via a multiple leaf collimator by three-dimensional RT. Although we could not complete the delivery of S-1 because of an acute side effect, the palliative chemoradiotherapy resulted in a complete response, and the lymph node metastases also disappeared. The patient remains in complete remission for 5 years without surgery or chemotherapy. Palliative chemoradiotherapy for elderly patients with mandibular gingival carcinoma is considered to be one of the therapeutic options.
Radiation recall phenomenon after administration of the mRNA-1273 SARS-CoV-2 vaccine. 国際誌

Yojiro Ishikawa, Rei Umezawa, Takaya Yamamoto, Noriyoshi Takahashi, Kazuya Takeda, Yu Suzuki, Keiichi Jingu

International cancer conference journal　11　(1)　1-5　2022年1月9日

DOI： 10.1007/s13691-021-00528-5 　

詳細を見る詳細を閉じる

Several types of SARS-CoV-2 vaccine have been developed. However, the relationship between SARS-CoV-2 vaccine and radiation therapy (RT) is unclear. Recently, there have been some reports of radiation recall phenomenon (RRP) caused by a SARS-CoV-2 vaccine. We report a case of RRP after administration of the mRNA-1273 SARS-CoV-2 vaccine. A 51-year-old female was diagnosed with breast cancer (cT4N1M0, cStage IIIB) and underwent breast total mastectomy with axillary lymph node dissection after neoadjuvant chemotherapy. After mastectomy, the patient received RT with 50 Gy in 25 fractions. An acute side effect of grade 2 dermatitis according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. occurred after RT. The patient had not started any new systemic medication after RT; however, the patient received the mRNA-1273 SARS-CoV-2 vaccine (Moderna) 1 month after the end of the initial RT. Seven days after vaccination, the patient had a skin reaction with burning sensation and redness. This skin reaction was induced in an area corresponding to the irradiation field of the chest wall. There was no skin reaction in areas other than that described. The reaction was cured within 1 week with topical hydrocortisone. This report is an interesting case report with a RPP after administration of the mRNA-1273 SARS-CoV-2 vaccine.
Optimization on the dose and time of nicaraven administration for mitigating the side effects of radiotherapy in a preclinical tumor-bearing mouse model. 国際誌

Yong Xu, Lina Abdelghany, Reiko Sekiya, Da Zhai, Keiichi Jingu, Tao-Sheng Li

Therapeutic advances in respiratory disease　16　17534666221137277-17534666221137277　2022年

DOI： 10.1177/17534666221137277 　

詳細を見る詳細を閉じる

OBJECTIVE: Radiation-induced lung injury (RILI) is one of the serious complications of radiotherapy. We have recently demonstrated that nicaraven can effectively mitigate RILI in healthy mice. Here, we further tried to optimize the dose and time of nicaraven administration for alleviating the side effects of radiotherapy in tumor-bearing mice. METHODS AND RESULTS: A subcutaneous tumor model was established in the back of the chest in C57BL/6N mice by injecting Lewis lung cancer cells. Therapeutic thoracic irradiations were done, and placebo or different doses of nicaraven (20, 50, 100 mg/kg) were administrated intraperitoneally pre-irradiation (at almost 5-10 min before irradiation) or post-irradiation (within 5 min after irradiation). Mice that received radiotherapy and nicaraven were sacrificed on the 30th day, but control mice were sacrificed on the 15th day. Serum and lung tissues were collected for evaluation. Nicaraven significantly decreased the level of CCL8, but did not clearly change the levels of 8-OHdG, TGF-β, IL-1β, and IL-6 in serum. Besides these, nicaraven effectively decreased the levels of TGF-β, IL-1β, and SOD2 in the lungs, especially by post-irradiation administration with the dose of 20 mg/kg. Although there was no significant difference, the expression of SOD1, 53BP1, and caspase 3 was detected lower in the lungs of mice received nicaraven post-irradiation than that of pre-irradiation. CONCLUSION: According to our data, the administration of nicaraven at a relatively low dose soon after radiotherapy will be recommended for attenuating the side effects of radiotherapy.
Longitudinal analyses and predictive factors of radiation-induced lung toxicity-related parameters after stereotactic radiotherapy for lung cancer. 国際誌

Takaya Yamamoto, Yoshiyuki Katsuta, Kiyokazu Sato, Yoko Tsukita, Rei Umezawa, Noriyoshi Takahashi, Yu Suzuki, Kazuya Takeda, Keita Kishida, So Omata, Eisaku Miyauchi, Ryota Saito, Noriyuki Kadoya, Keiichi Jingu

PloS one　17　(12)　e0278707　2022年

DOI： 10.1371/journal.pone.0278707 　

詳細を見る詳細を閉じる

BACKGROUND AND PURPOSE: The purpose of this prospective study was to investigate changes in longitudinal parameters after stereotactic radiotherapy for lung cancer and to identify possible pretreatment factors related to radiation-induced lung toxicity and the decline in pulmonary function after radiotherapy. MATERIALS AND METHODS: Protocol-specified examinations, including 4-D CT, laboratory tests, pulmonary function tests (PFTs) and body composition measurements, were performed before SRT and at 1 month, 4 months and 12 months after stereotactic radiotherapy. Longitudinal differences were tested by using repeated-measures analysis of variance. Correlations were examined by using the Pearson product-moment correlation coefficient (r). RESULTS: Sixteen patients were analyzed in this study. During a median follow-up period of 26.6 months, grade 1 and 2 lung toxicity occurred in 11 patients and 1 patient, respectively. The mean Hounsfield units (HU) and standard deviation (SD) of the whole lung, as well as sialylated carbohydrate antigen KL-6 (KL-6) and surfactant protein-D (SP-D), peaked at 4 months after radiotherapy (p = 0.11, p<0.01, p = 0.04 and p<0.01, respectively). At 4 months, lung V20 Gy (%) and V40 Gy (%) were correlated with changes in SP-D, whereas changes in the mean HU of the lung were related to body mass index and lean body mass index (r = 0.54, p = 0.02; r = 0.57, p = 0.01; r = 0.69, p<0.01; and r = 0.69, p<0.01, respectively). The parameters of PFTs gradually declined over time. When regarding the change in PFTs from pretreatment to 12 months, lung V5 Gy (cc) showed significant correlations with diffusion capacity for carbon monoxide (DLCO), DLCO/alveolar volume and the relative change in DLCO (r = -0.72, p<0.01; r = -0.73, p<0.01; and r = -0.63, p = 0.01, respectively). CONCLUSIONS: The results indicated that some parameters peaked at 4 months, but PFTs were the lowest at 12 months. Significant correlations between lung V5 Gy (cc) and changes in DLCO and DLCO/alveolar volume were observed.
A long-term survival case with proton beam therapy for advanced sphenoid sinus cancer with hypopituitarism. 国際誌

Yojiro Ishikawa, Motohisa Suzuki, Hisashi Yamaguchi, Ichiro Seto, Masanori Machida, Yoshiaki Takagawa, Keiichi Jingu, Yasuyuki Kikuchi, Masao Murakami

International cancer conference journal　11　(1)　75-80　2022年1月

DOI： 10.1007/s13691-021-00524-9 　

詳細を見る詳細を閉じる

Sphenoid sinus malignancies are rare diseases. Secondary hypopituitarism associated with sphenoid sinus malignancy is not well known. A 41-year-old male complained of right ptosis. Neurological findings revealed right oculomotor, trochlear and glossopharyngeal nerve palsy. Imaging diagnosis suggested a tumor that had spread bilaterally from the sphenoid sinus to the ethmoid sinus, nasopharynx and posterior pharyngeal space. Biopsy revealed squamous cell carcinoma (SCC). Based on these findings, a clinical diagnosis of SCC of the sphenoid sinus was made. Removal of the tumor without damaging nearby organs would have been difficult because the tumor extended to the bilateral optic nerves, optic chiasma and internal carotid artery, and surgeons, therefore, recommended proton beam therapy (PBT). Before PBT, the hypopituitarism occurred in the patient and we administered hydrocortisone and levothyroxine. During treating for hypopituitarism, we performed PBT with nedaplatin and 5-fluorouracil. The daily PBT fractions were 2.2 relative biological effectiveness (RBE) for the tumor received total dose of 81.4 Gy RBE. The acute side effect of grade 2 dermatitis according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. Occurred after PBT. The patient needs to take hydrocortisone and levothyroxine, but he remains in complete remission 8 years after treatment without surgery or chemotherapy. Visual function is gradually declining, but there is no evidence of severe radiation-induced optic neuropathy.
Evaluation of the electron transport algorithm in magnetic field in EGS5 Monte Carlo code. 国際誌

Kengo Ito, Noriyuki Kadoya, Yoshiyuki Katsuta, Shohei Tanaka, Suguru Dobashi, Ken Takeda, Keiichi Jingu

Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)　93　46-51　2022年1月

DOI： 10.1016/j.ejmp.2021.12.001 　

詳細を見る詳細を閉じる

PURPOSE: To evaluate the accuracy of electron transport in the magnetic field of Electron Gamma Shower version 5 (EGS5) by using the special Fano cavity test. METHODS: To simulate electron transport in the magnetic field, the trajectory of the electron was reconstructed with a short step length to restrict fractional energy loss, and the maximum user step length (mxustep) was set at 0.01 cm or 0.001 cm. For the special Fano cavity test, three-layer slab Fano test geometry was used, and uniform and isotropic per unit mass mono-energetic electrons with 0.01, 0.1, 1.0, and 10 MeV were permitted from the central axis of geometry in 0.35 T and 1.5 T. Furthermore, the magnetic field strength was scaled based on the mass density of the material. The relative difference between the calculated dose to gap and the theoretical value was evaluated. Furthermore, the special Fano cavity test was also performed using EGSnrc with the electron-enhanced electric and magnetic field macros under the same conditions, and the results were compared with those of EGS5. RESULTS: Deviations in 0.35 T were within 0.3% regardless of the parameter settings. In 1.5 T, stable results within 0.3% were obtained using 0.001 cm as the mxustep, except for one at 10 MeV. Further, the accuracy of EGSnrc was within 0.2%, except for 10 MeV for a 0.2-cm gap in 1.5 T. CONCLUSIONS: EGS5 with the appropriate parameter settings enable electron transport in magnetic fields similar with the accuracy of EGSnrc.
The Impact of Histological Subtype on Survival Outcome of Patients with Stage IIB-IVA Cervical Cancer Who Received Definitive Radiotherapy.

Shuko Miyahara, Keita Tsuji, Muneaki Shimada, Yusuke Shibuya, Shogo Shigeta, Tomoyuki Nagai, Rei Umezawa, Hideki Tokunaga, Keiichi Jingu, Nobuo Yaegashi

The Tohoku journal of experimental medicine　255　(4)　303-313　2021年12月

DOI： 10.1620/tjem.255.303 　

詳細を見る詳細を閉じる

The impact of histologic subtype on definitive radiotherapy for patients with locally advanced cervical cancer remains unclear. The aim of this retrospective analysis was to assess clinicopathological findings and clinical outcome by histological type in patients with stage IIB-IVA cervical cancer. Ninety-two patients with stage IIB-IVA [International Federation of Gynecology and Obstetrics (FIGO) 2008] cervical cancer, who underwent definitive radiotherapy between 2013 to 2018, were identified as eligible for this study. The clinical information of the eligible patients was obtained from medical records of our hospital. Seventy-eight patients underwent concurrent chemoradiotherapy, and the remaining 14 patients received radiotherapy alone. Of 92 patients, 83 had squamous cell carcinoma (SCC) and 9 had non-SCC histology. Progression-free survival (PFS) rate of patients with non-SCC was significantly worse than of those with SCC (2-year PFS: 62.0% vs. 12.5%, p = 0.0020), but overall survival (OS) rate did not statistically differ between the two subtypes (2-year OS: 82.4% vs. 62.5%, p = 0.2157). Pelvic failure-free (PFF) rate of patients with non-SCC histology was significantly worse than of those with non-SCC (2-year PFF; 88.2% vs. 25.0%, p < 0.0001). In univariate analysis, non-SCC histology was associated with PFS rate, although there was no association with OS rate. In multivariate analysis, non-SCC histology and lymph node metastasis were independent prognostic factors for shorter PFS. In patients with stage IIB-IVA cervical cancer who underwent definitive radiotherapy, patients with non-SCC showed significantly worse PFS rate than those with SCC.
Hyperfractionated radiotherapy for re-irradiation of recurrent esophageal cancer. 国際誌

Kazuya Takeda, Haruo Matsushita, Rei Umezawa, Takaya Yamamoto, Yojiro Ishikawa, Noriyoshi Takahashi, Yu Suzuki, Keiichi Jingu

Radiation oncology journal　39　(4)　265-269　2021年12月

DOI： 10.3857/roj.2021.00325 　

詳細を見る詳細を閉じる

PURPOSE: Re-irradiation is a treatment option for recurrent esophageal cancer patients with a history of radiotherapy, but there is a risk of severe late adverse effects. This study focused on the efficacy and safety of re-irradiation using hyperfractionated radiotherapy. MATERIALS AND METHODS: Twenty-six patients who underwent re-irradiation by the hyperfraction technique using twice-daily irradiation of 1.2 Gy per fraction for recurrent esophageal cancer were retrospectively included in this study. The overall survival period after the start of secondary radiotherapy and the occurrence of late adverse effects were investigated. RESULTS: Of 26 patients, 21 (81%) received re-irradiation with definitive intention and 21 (81%) underwent concurrent chemotherapy. The median re-irradiation dose was 60 Gy in 50 fractions in 25 treatment days, and the median accumulated irradiation dose in equivalent dose in 2 Gy per fraction was 85.4 Gy with an α/β value of 3. The median interval between two courses of radiotherapy was 21.0 months. The median overall survival period was 15.8 months and the 1-year and 3-year overall survival rates were 64.3% and 28.3%, respectively. Higher dose of re-irradiation and concurrent chemotherapy significantly improved survival (p < 0.001 and p = 0.019, respectively). Severe late adverse effects with the Common Terminology Criteria for Adverse Events grade 3 or higher were observed in 5 (19.2%) patients, and 2 (7.7%) of them developed a grade 5 late adverse effect. CONCLUSION: High-dose re-irradiation using a hyperfractionated schedule with concurrent chemotherapy might be related to good prognosis, while the rate of late severe adverse effects is not high compared with the rates in past reports.
Nicaraven prevents the fast growth of inflamed tumors by an anti-inflammatory mechanism. 国際誌

Lina Abdelghany, Xu Zhang, Tsuyoshi Kawabata, Shinji Goto, Nageh El-Mahdy, Keiichi Jingu, Tao-Sheng Li

Medical oncology (Northwood, London, England)　39　(1)　7-7　2021年11月10日

DOI： 10.1007/s12032-021-01602-x 　

詳細を見る詳細を閉じる

Inflammatory microenvironment is known to accelerate the progression of malignant tumors. We investigated the possible anti-inflammatory effect of nicaraven on slowing tumor growth. Tumor-bearing mice randomly received nicaraven injection (50 mg/kg daily, i.p, n = 8) or placebo treatment (n = 8) for 10 days, and then sacrificed for evaluations. Nicaraven administration effectively inhibited the fast growth of tumor, as a large tumor (> 1.0 g) developed finally in three of the eight mice received placebo treatment. Cytokines/chemokines array indicated that nicaraven reduced the levels of CXCL10 and SDF-1 in the tumor as well as the levels of IL-2 and MIP-2 in serum. Immunofluorescence staining showed that nicaraven significantly reduced the recruitment of macrophages and neutrophils in the tumor. Interestingly, western blot indicated that the expression of CD86, CD206, and NIMP-R14 was especially enhanced in the three large-size tumors, suggesting the potential role of nicaraven in preventing the hyper-inflammatory tumor microenvironment. Moreover, the expression of PARP-1 was downregulated, but the expression of phospho-p38 MAPK, phospho-MKK-3/6, and phospho-MSK-1 was upregulated in the large-size tumors, suggesting the involvement of p38 MAPK pathway in the anti-inflammatory effect of nicaraven. Taken together, our study suggests that nicaraven may effectively prevent the fast growth of inflamed tumors by an anti-inflammatory mechanism.
頭頸部がんに対する根治放射線治療後の口腔関連QOL長期的推移招待有り査読有り

神宮啓一, 高橋紀善, 田坂俊, 梅澤玲, 山本貴也, 石川陽二郎, 武田一也, 鈴木友, 角谷倫之, 松下晴雄

頭頸部癌　47　(3)　290-294　2021年11月

ISSN：1349-5747
Successful treatment with radiation therapy for desmoid-type fibromatosis with unilateral hydronephrosis: a case report. 国際誌

Yojiro Ishikawa, Rei Umezawa, Takaya Yamamoto, Noriyoshi Takahashi, Kazuya Takeda, Yu Suzuki, Keiichi Jingu

Journal of medical case reports　15　(1)　540-540　2021年10月27日

DOI： 10.1186/s13256-021-03088-7 　

詳細を見る詳細を閉じる

BACKGROUND: Desmoid-type fibromatosis is a rare disease that can result in hydronephrosis. Hydronephrosis associated with desmoid-type fibromatosis often requires surgery or ureteral stent insertion. Although radiation therapy is recommended for inoperable cases of desmoid-type fibromatosis, there has been no report of treatment for hydronephrosis associated with desmoid-type fibromatosis by radiation therapy alone. We herein report a case of successful treatment for inoperable recurrence of desmoid-type fibromatosis with unilateral hydronephrosis by radiation therapy alone. CASE PRESENTATION: A 43-year-old Japanese female underwent resection of desmoid-type fibromatosis in the right inguinal region and combined resection of the right external iliac vein 5 years before. Other treatment was not performed because of her pregnancy. Four years after surgery, desmoid-type fibromatosis recurred in the right pelvic wall. Cyclooxygenase-2 selective inhibitor treatment was given for 1 year, but her desmoid-type fibromatosis enlarged to more than 10 cm, and she had swelling of her right leg and hydronephrosis of her right kidney. The patient received 50.4 Gy in 28 fractions of prophylactic irradiation using 10 MV X-ray and 9 Gy in five fractions of a sequential boost for the recurrent desmoid-type fibromatosis. Although there was temporary tumor progression at 1 month after radiation therapy, slow regression of the tumor was seen. At 5 years after radiation therapy, there was no disease progression or severe complications. CONCLUSION: We experienced successful treatment for an inoperable case of desmoid-type fibromatosis with hydronephrosis. Moderate-dose radiation therapy alone is an effective and feasible approach for the management of hydronephrosis associated with desmoid-type fibromatosis.
Prediction of radiation pneumonitis with machine learning using 4D-CT based dose-function features. 国際誌

Yoshiyuki Katsuta, Noriyuki Kadoya, Shina Mouri, Shohei Tanaka, Takayuki Kanai, Kazuya Takeda, Takaya Yamamoto, Kengo Ito, Tomohiro Kajikawa, Yujiro Nakajima, Keiichi Jingu

Journal of radiation research　63　(1)　71-79　2021年10月27日

DOI： 10.1093/jrr/rrab097 　

詳細を見る詳細を閉じる

In this article, we highlight the fundamental importance of the simultaneous use of dose-volume histogram (DVH) and dose-function histogram (DFH) features based on functional images calculated from 4-dimensional computed tomography (4D-CT) and deformable image registration (DIR) in developing a multivariate radiation pneumonitis (RP) prediction model. The patient characteristics, DVH features and DFH features were calculated from functional images by Hounsfield unit (HU) and Jacobian metrics, for an RP grade ≥ 2 multivariate prediction models were computed from 85 non-small cell lung cancer patients. The prediction model is developed using machine learning via a kernel-based support vector machine (SVM) machine. In the patient cohort, 21 of the 85 patients (24.7%) presented with RP grade ≥ 2. The median area under curve (AUC) was 0.58 for the generated 50 prediction models with patient clinical features and DVH features. When HU metric and Jacobian metric DFH features were added, the AUC improved to 0.73 and 0.68, respectively. We conclude that predictive RP models that incorporate DFH features were successfully developed via kernel-based SVM. These results demonstrate that effectiveness of the simultaneous use of DVH features and DFH features calculated from 4D-CT and DIR on functional image-guided radiotherapy.
膵癌に対する予防域を含めた放射線治療における3DCRTとIMRTでの急性期有害事象の比較

梅澤玲, 中川圭, 水間正道, 山本貴也, 石川陽二郎, 海野倫明, 神宮啓一

日本癌治療学会学術集会抄録集　59回　O52-6　2021年10月
出版者・発行元： (一社)日本癌治療学会
Evaluation of performance of pelvic CT-MR deformable image registration using two software programs. 国際誌

Tomoya Ishida, Noriyuki Kadoya, Shunpei Tanabe, Haruna Ohashi, Hikaru Nemoto, Suguru Dobashi, Ken Takeda, Keiichi Jingu

Journal of radiation research　2021年9月9日

DOI： 10.1093/jrr/rrab078 　

詳細を見る詳細を閉じる

We assessed the accuracy of deformable image registration (DIR) accuracy between CT and MR images using an open-source software (Elastix, from Utrecht Medical Center) and a commercial software (Velocity AI Ver. 3.2.0 from Varian Medical Systems, Palo Alto, CA, USA) software. Five male patients' pelvic regions were studied using publicly available CT, T1-weighted (T1w) MR, and T2-weighted (T2w) MR images. In the cost function of the Elastix, we used six DIR parameter settings with different regularization weights (Elastix0, Elastix0.01, Elastix0.1, Elastix1, Elastix10, and Elastix100). We used MR Corrected Deformable algorithm for Velocity AI. The Dice similarity coefficient (DSC) and mean distance to agreement (MDA) for the prostate, bladder, rectum and left and right femoral heads were used to evaluate DIR accuracy. Except for the bladder, most algorithms produced good DSC and MDA results for all organs. In our study, the mean DSCs for the bladder ranged from 0.75 to 0.88 (CT-T1w) and from 0.72 to 0.76 (CT-T2w). Similarly, the mean MDA ranges were 2.4 to 4.9 mm (CT-T1w), 4.6 to 5.3 mm (CT-T2w). For the Elastix, CT-T1w was outperformed CT-T2w for both DSCs and MDAs at Elastix0, Elastix0.01, and Elastix0.1. In the case of Velocity AI, no significant differences in DSC and MDA of all organs were observed. This implied that the DIR accuracy of CT and MR images might differ depending on the sequence used.
Clinical outcomes and prognostic factors for esophageal cancer in patients aged 80 years or older who were treated with definitive radiotherapy and chemoradiotherapy.

Noriyoshi Takahashi, Rei Umezawa, Keita Kishida, Takaya Yamamoto, Yojiro Ishikawa, Kazuya Takeda, Yu Suzuki, Kousei Kawabata, Satoshi Teramura, Keiichi Jingu

Esophagus : official journal of the Japan Esophageal Society　19　(1)　129-136　2021年9月2日

DOI： 10.1007/s10388-021-00876-4 　

詳細を見る詳細を閉じる

OBJECTIVE: Aging of populations has been rapidly increasing worldwide. The aim of this study was to identify prognostic factors of overall survival (OS) and progression-free survival (PFS) in patients aged 80 years or older who had esophageal cancer and received radiotherapy. METHODS: Patients aged 80 years or older who received radiotherapy between 2004 and 2015 were retrospectively reviewed. Pretreatment age, gender, performance status, Charlson comorbidity index score, tumor location, histology, clinical stage, results of blood tests and treatment methods were obtained to determine prognostic factors of OS and PFS. Survival curves were drawn using the Kaplan-Meier method and prognostic factors were analyzed using Cox's hazards model. RESULTS: Ninety-two patients were included. Thirty-five patients were treated with chemo-radiotherapy. The median follow-up period was 19.0 months. The 3-year OS and PFS rates were 44.7% and 28.4%, respectively. In multivariate analysis, clinical stage (hazard ratio [HR] 2.28, 95% confidence interval [CI] 1.40-3.73, p = 0.001) and the geriatric nutritional risk index (GNRI, HR 0.95, 95% CI 0.92-0.97, p < 0.001) were significant prognostic factors of OS. Clinical stage (HR 2.06, 95% CI 1.34-3.18, p = 0.001), tumor location (HR 2.04, 95% CI 1.39-3.01, p < 0.001) and GNRI (HR 0.96, 95% CI 0.94-0.99, p = 0.003) were significant prognostic factors of PFS. CONCLUSION: Clinical stage and GNRI were significant prognostic factors of OS and PFS. Tumor location was a significant prognostic factor of PFS. These prognostic factors might be useful for decision-making for elderly patients with esophageal cancer.
RT 乳癌に対するSyncTraX FX4を用いた深吸気息止めVMATによる心臓/肺放射線障害軽減

神宮啓一, 伊藤謙吾, 佐藤清和

MEDICAL NOW　(89)　30-32　2021年9月
出版者・発行元： (株)島津製作所
ISSN：0916-8745
最先端医療の今早期食道癌に対する心筋線量軽減による心毒性低下を図った高精度放射線治療の検討

梅澤玲, 神宮啓一

Medical Science Digest　47　(10)　541-544　2021年9月
出版者・発行元： (株)ニュー・サイエンス社
ISSN：1347-4340
Clinical predictors of severe late urinary toxicity after curative intensity-modulated radiation therapy for localized prostate cancer. 国際誌

Ken Takeda, Rei Umezawa, Yojiro Ishikawa, Takaya Yamamoto, Noriyoshi Takahashi, Kazuya Takeda, Noriyuki Kadoya, Haruo Matsushita, Yoshihide Kawasaki, Koji Mitsuzuka, Akihiro Ito, Yoichi Arai, Yoshihiro Takai, Keiichi Jingu

Journal of radiation research　2021年8月31日

DOI： 10.1093/jrr/rrab074 　

詳細を見る詳細を閉じる

Intractable late urinary toxicity is a serious complication after radiotherapy for patients with localized prostate cancer (LPC). We assessed clinical factors correlated with severe late urinary toxicity in LPC treated with curative image-guided intensity-modulated radiation therapy (IMRT). A total of 452 patients with LPC treated with IMRT between 2002 and 2016 were retrospectively analyzed. Among them, 432 patients received androgen deprivation therapy (ADT). The median total irradiated doses were 80 (range, 76-80) Gy. Each daily dose was 2 Gy per fraction. The median follow-up was 83 (range, 4-210) months. Late urinary toxicity was scored according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03. Grade 3 late urinary toxicity was observed in 27 patients. No cases with grade ≥ 4 late urinary toxicity were observed. The 5-, 10-, and 12.5-year grade 3 late urinary toxicity-free survival rates were 97%, 91.8% and 88.1%, respectively. Age, risk classification, total irradiated dose, ADT duration, antithrombotic therapy (AT), cardiovascular disease, hypertension (HT), diabetes mellitus (DM), dyslipidemia (DL), prior transurethral resection of the prostate (TURP) and prior high-intensity focused ultrasound (HIFU) were investigated for correlations with grade 3 late urinary toxicity. In univariate analysis, AT and prior HIFU and no other studied factors, were correlated with grade 3 late urinary toxicity. AT and prior HIFU appear to be predictive of grade 3 late urinary toxicity. Patients with LPC with these relevant clinical factors should be carefully followed up by sharing detailed information with the urology department.
Why not de-intensification for uterine cervical cancer? 国際誌

Naoya Murakami, Ken Ando, Masumi Murata, Kazutoshi Murata, Tatsuya Ohno, Tomomi Aoshika, Shingo Kato, Noriyuki Okonogi, Anneyuko I Saito, Joo-Young Kim, Yasuko Kumai, Yasuo Yoshioka, Shuhei Sekii, Kayoko Tsujino, Chairat Lowanichkiattikul, Poompis Pattaranutaporn, Yuko Kaneyasu, Tomio Nakagawa, Miho Watanabe, Takashi Uno, Rei Umezawa, Keiichi Jingu, Ayae Kanemoto, Masaru Wakatsuki, Katsuyuki Shirai, Hiroshi Igaki, Jun Itami

Gynecologic oncology　163　(1)　105-109　2021年7月19日

DOI： 10.1016/j.ygyno.2021.07.021 　

詳細を見る詳細を閉じる

OBJECTIVE: The majority of uterine cervical cancer is known to be related to human papillomavirus (HPV), and HPV-related tumors are known to be radio-sensitive. In the management of HPV-related oropharyngeal cancer, de-intensification of treatment has been attempted; however, no such attempt is performed in the management of cervical cancer. The aim of this study was to identify a group of patients who can safely be treated by de-escalated treatment intensity. METHODS: From the Asian international multi-institutional retrospective study involving 13 Japanese, one Thailand, and one Korean institutions based on 469 patients, squamous cell carcinoma (Scc), tumor reduction ratio ≥29%, tumor size before brachytherapy ≤4 cm, and total treatment time (TTT) <9 weeks were identified as factors having an influence on local control. Based on these findings, low-risk patients having these four factors were extracted, and treatment outcomes categorized in 10 Gy increment of CTVHR D90 were compared. RESULTS: Among 469 patients, 162 patients (34.5%) met the criteria of low-risk group, and 63, 41, 43, and 15 patients were categorized in CTVHR D90 50-60 Gy, 60-70 Gy, 70-80 Gy, and >80 Gy, respectively. While 4-y progression-free survival ranged from 66 to 80%, 4-y local control was consistently over 90% in every dose group. Rectum and bladder D2cc and incidence of late adverse events decreased as CTVHR D90 decreased. CONCLUSIONS: The low-risk patients achieved favorable local control with CTVHR D90 <80 Gy. A personalized treatment strategy based on tumor response could also be adopted for cervical cancer.
IMRT improves local control in patients with nasopharyngeal carcinoma compared with conventional radiotherapy: propensity score-matched analysis. 国際誌

Zichang Ma, Rei Umezawa, Takaya Yamamoto, Yojiro Ishikawa, Noriyoshi Takahashi, Kazuya Takeda, Yu Suzuki, Liuwei Tang, Kengo Ito, Noriyuki Kadoya, Keiichi Jingu

Japanese journal of clinical oncology　51　(9)　1444-1451　2021年7月12日

DOI： 10.1093/jjco/hyab100 　

詳細を見る詳細を閉じる

BACKGROUND: It is still controversial whether intensity-modulated radiotherapy has an obvious advantage over conventional radiotherapy. The purposes of this study were to evaluate prognostic factors in pre-treatment characteristics for nasopharyngeal carcinoma and to compare treatment outcomes in patients who received intensity-modulated radiotherapy and patients who received two-dimensional radiotherapy or three-dimensional radiotherapy. METHODS: We reviewed patients with nasopharyngeal carcinoma who received chemoradiotherapy in our hospital during the period from 2000 to 2017, and we excluded patients who had a history of surgery for nasopharyngeal carcinoma and those who had distant metastases before treatment. A total of 72 patients who were treated by radiotherapy with concurrent chemotherapy were enrolled. All of the patients were irradiated with a total dose of 58-70 Gy. Overall survival, locoregional control and progression-free survival rates were compared in the groups treated by intensity-modulated radiotherapy and two-dimensional/three-dimensional radiotherapy. Propensity score matching was performed to homogenize the two groups. RESULTS: The median follow-up period was 62.5 months. After propensity score matching, in patients treated with intensity-modulated radiotherapy, the 5-year rate of overall survival, locoregional control and progression-free survival were 73.5, 95.2 and 72.7%, respectively. In patients treated with two-dimensional/three-dimensional radiotherapy, the 5-year rate of overall survival, locoregional control and progression-free survival were 69.1, 67.7 and 51.8%, respectively. There was a significant difference between the groups only in locoregional control. Late toxicities of grade 2 or higher were occurred in 38.5 and 24.2% of the patients treated by two-dimensional/three-dimensional radiotherapy and intensity-modulated radiotherapy, respectively. CONCLUSIONS: Our results suggested that intensity-modulated radiotherapy is more effective than two-dimensional/three-dimensional radiotherapy in patients with nasopharyngeal carcinoma, especially in locoregional control.
A Pilot Study of Synchronization of Respiration-Induced Motions in the Duodenum and Stomach for the Primary Tumor in Radiation Therapy for Pancreatic Cancer Using 4-Dimensional Computed Tomography

Rei Umezawa, Akihisa Wakita, Yoshiyuki Katsuta, Yoshinori Ito, Satoshi Nakamura, Hiroyuki Okamoto, Noriyuki Kadoya, Kana Takahashi, Koji Inaba, Naoya Murakami, Hiroshi Igaki, Keiichi Jingu, Jun Itami

ADVANCES IN RADIATION ONCOLOGY　6　(4)　2021年7月

DOI： 10.1016/j.adro.2021.100730 　

eISSN：2452-1094
Intensity-modulated radiation therapy with concurrent chemotherapy followed by durvalumab for stage III non-small cell lung cancer: A multi-center retrospective study. 国際誌

Yoko Tsukita, Takaya Yamamoto, Hiroshi Mayahara, Akito Hata, Yuichiro Takeda, Hidetsugu Nakayama, Satoshi Tanaka, Junji Uchida, Kazuhiro Usui, Tatsuya Toyoda, Motohiro Tamiya, Masahiro Morimoto, Yuko Oya, Takeshi Kodaira, Eisaku Miyauchi, Keiichi Jingu, Hisatoshi Sugiura

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology　160　266-272　2021年7月

DOI： 10.1016/j.radonc.2021.05.016 　

詳細を見る詳細を閉じる

BACKGROUND AND PURPOSE: Intensity-modulated radiation therapy (IMRT) is increasingly applied in concurrent chemoradiotherapy (CCRT) for locally-advanced non-small cell lung cancer (NSCLC), with improvement of target coverage and better sparing of normal tissue. IMRT tends to have a larger low-dose irradiation volume than 3D conformal radiotherapy, but the incidence of and risk factors for pneumonitis remain unclear, especially following the approval of durvalumab. MATERIALS AND METHODS: We retrospectively reviewed the records of NSCLC patients treated by CCRT using IMRT at seven Japanese institutions. Primary outcomes were incidence of symptomatic pneumonitis and progression-free survival (PFS). Multivariate logistic regression analysis was used to identify risk factors for ≥grade 2 pneumonitis. RESULTS: Median follow-up from the start of CCRT was 14.3 months (n = 107 patients; median age 70 years, 29% female). Median lung V5 and V20 was 49.2% and 19.5%, respectively. Durvalumab was administered to 87 patients (81%). Pneumonitis developed in 95 (89%) patients of which 53% had grade 1, 28% grade 2, 6.5% grade 3, and 0.9% grade 4. Durvalumab had been discontinued in 16 patients (18.4%) due to pneumonitis. By multivariate analysis, age ≥70 years, male sex, and V5 ≥58.9% were identified as significantly associated with ≥grade 2 pneumonitis (p = 0.0065, 0.036 and 0.0013 respectively). The median PFS from the start of CCRT was not reached (95% CI, 14.2 months to not reached) in patients receiving durvalumab. CONCLUSION: CCRT using IMRT followed by durvalumab was generally effective and tolerable; V5 <60% would be recommended to avoid symptomatic pneumonitis.
Development of a physical geometric phantom for deformable image registration credentialing of radiotherapy centers for a clinical trial. 国際誌

Noriyuki Kadoya, Siwaporn Sakulsingharoj, Tomas Kron, Adam Yao, Nicholas Hardcastle, Alanah Bergman, Hiroyuki Okamoto, Nobutaka Mukumoto, Yujiro Nakajima, Keiichi Jingu, Mitsuhiro Nakamura

Journal of applied clinical medical physics　22　(7)　255-265　2021年6月22日

DOI： 10.1002/acm2.13319 　

詳細を見る詳細を閉じる

PURPOSE: This study aimed to develop a physical geometric phantom for the deformable image registration (DIR) credentialing of radiotherapy centers for a clinical trial and tested the feasibility of the proposed phantom at multiple domestic and international institutions. METHODS AND MATERIALS: The phantom reproduced tumor shrinkage, rectum shape change, and body shrinkage using several physical phantoms with custom inserts. We tested the feasibility of the proposed phantom using 5 DIR patterns at 17 domestic and 2 international institutions (21 datasets). Eight institutions used the MIM software (MIM Software Inc, Cleveland, OH); seven used Velocity (Varian Medical Systems, Palo Alto, CA), and six used RayStation (RaySearch Laboratories, Stockholm, Sweden). The DIR accuracy was evaluated using the Dice similarity coefficient (DSC) and Hausdorff distance (HD). RESULTS: The mean and one standard deviation (SD) values (range) of DSC were 0.909 ± 0.088 (0.434-0.984) and 0.909 ± 0.048 (0.726-0.972) for tumor and rectum proxies, respectively. The mean and one SD values (range) of the HD value were 5.02 ± 3.32 (1.53-20.35) and 5.79 ± 3.47 (1.22-21.48) (mm) for the tumor and rectum proxies, respectively. In three patterns evaluating the DIR accuracy within the entire phantom, 61.9% of the data had more than a DSC of 0.8 in both tumor and rectum proxies. In two patterns evaluating the DIR accuracy by focusing on tumor and rectum proxies, all data had more than a DSC of 0.8 in both tumor and rectum proxies. CONCLUSIONS: The wide range of DIR performance highlights the importance of optimizing the DIR process. Thus, the proposed method has considerable potential as an evaluation tool for DIR credentialing and quality assurance.
Evaluation of the dosimetric impact of heart function-based volumetric modulated arc therapy planning in patients with esophageal cancer.

Shohei Tanaka, Noriyuki Kadoya, Rei Umezawa, Hikaru Nemoto, Yoshiyuki Katsuta, Kengo Ito, Ken Takeda, Keiichi Jingu

Radiological physics and technology　14　(3)　279-287　2021年6月8日

DOI： 10.1007/s12194-021-00623-5 　

詳細を見る詳細を閉じる

Radiotherapy for esophageal cancer entails high-dose irradiation of the myocardium owing to its close anatomical proximity to the esophagus. This study aimed to evaluate the dosimetric impact of functional avoidance planning for the myocardium with volumetric-modulated arc therapy (VMAT) in patients with esophageal cancer and determine the feasibility of functional planning. Ten patients with early stage esophageal cancer were included in this study. The prescribed dose was 60 Gy administered in 30 fractions. An experienced physician contoured the left ventricle (LV) of the myocardium. For each patient, an anatomical plan (non-LV-sparing plan) and a functional plan (LV-sparing plan) were created using the VMAT. In the functional plan, the mean percentage of LV volume receiving a dose of ≥ 30 and ≥ 40 Gy was 6.0% ± 6.7% and 2.4% ± 2.7%, respectively, whereas in the anatomical plan, they were 11.7% ± 13.1% and 4.9% ± 6.5%, respectively. There were no significant differences with respect to the dose to the hottest 1 cm3 of the planning target volume (PTV) and the minimum dose of the gross tumor volume and the dosimetric parameters of other normal tissues between the anatomical and functional plans. We compared the anatomical and functional plans of patients with esophageal cancer undergoing VMAT. Our results demonstrated that the functional plan reduced the dose to the LV with no significant differences in the organs at risk and PTV, indicating that avoidance planning can be safely performed when administering VMAT in patients with esophageal cancer.
Error detection model developed using a multi-task convolutional neural network in patient-specific quality assurance for volumetric-modulated arc therapy. 国際誌

Yuto Kimura, Noriyuki Kadoya, Yohei Oku, Tomohiro Kajikawa, Seiji Tomori, Keiichi Jingu

Medical physics　48　(9)　4769-4783　2021年6月8日

DOI： 10.1002/mp.15031 　

詳細を見る詳細を閉じる

PURPOSE: In patient-specific quality assurance (QA) for static beam intensity-modulated radiation therapy (IMRT), machine-learning-based dose analysis methods have been developed to identify the cause of an error as an alternative to gamma analysis. Although these new methods have revealed that the cause of the error can be identified by analyzing the dose distribution obtained from the two-dimensional detector, they have not been extended to the analysis of volumetric-modulated arc therapy (VMAT) QA. In this study, we propose a deep learning approach to detect various types of errors in patient-specific VMAT QA. METHODS: A total of 161 beams from 104 prostate VMAT plans were analyzed. All beams were measured using a cylindrical detector (Delta4, ScandiDos, Uppsala, Sweden), and predicted dose distributions in a cylindrical phantom were calculated using a treatment planning system (TPS). In addition to the error-free plan, we simulated 12 types of errors: two types of multileaf collimator positional errors (systematic or random leaf offset of 2 mm), two types of monitor unit (MU) scaling errors (±3%), two types of gantry rotation errors (±2° in clockwise and counterclockwise direction), and six types of phantom setup errors (±1 mm in lateral, longitudinal, and vertical directions). The error-introduced predicted dose distributions were created by editing the calculated dose distributions using a TPS with in-house software. Those 13 types of dose difference maps, consisting of an error-free map and 12 error maps, were created from the measured and predicted dose distributions and were used to train the convolutional neural network (CNN) model. Our model was a multi-task model that individually detected each of the 12 types of errors. Two datasets, test sets 1 and 2, were prepared to evaluate the performance of the model. Test set 1 consisted of 13 types of dose maps used for training, while test set 2 included the dose maps with 25 types of errors in addition to the error-free dose map. The dose map, which introduced 25 types of errors, was generated by combining 2 of the 12 types of simulated errors. For comparison with the performance of our model, gamma analysis was performed for test sets 1 and 2 with the criteria set to 3%/2 mm and 2%/1 mm (dose difference/distance to agreement). RESULTS: For test set 1, the overall accuracy of our CNN model, gamma analysis with the criteria set to 3%/2 mm and gamma analysis with the criteria set to 2%/1 mm was 0.92, 0.19, and 0.81, respectively. Similarly, for test set 2, the overall accuracy was 0.44, 0.42, and 0.95, respectively. Our model outperformed gamma analysis in the classification of dose maps containing a single type error, and the performance of our model was inferior in the classification of dose maps containing compound errors. CONCLUSIONS: A multi-task CNN model for detecting errors in patient-specific VMAT QA using a cylindrical measuring device was constructed, and its performance was evaluated. Our results demonstrate that our model was effective in identifying the error type in the dose map for VMAT QA.
Stereotactic body radiotherapy for pulmonary oligometastases as an initial metastasis‐directed therapy: patterns of relapse and predictive factors for early mortality

Takaya Yamamoto, Yuzuru Niibe, Masahiko Aoki, Hiroshi Onishi, Kazunari Yamada, Takashi Shintani, Hideomi Yamashita, Mitsuru Kobayashi, Ryoong‐Jin Oh, Keiichi Jingu

Precision Radiation Oncology　5　(2)　84-92　2021年6月
出版者・発行元： Wiley
DOI： 10.1002/pro6.1115 　
Differences in patterns of recurrence of squamous cell carcinoma and adenocarcinoma after radiotherapy for stage III non-small cell lung cancer.

Yu Katagiri, Keiichi Jingu, Takaya Yamamoto, Haruo Matsushita, Rei Umezawa, Yojiro Ishikawa, Noriyoshi Takahashi, Kazuya Takeda, Shun Tasaka, Noriyuki Kadoya

Japanese journal of radiology　39　(6)　611-617　2021年6月

DOI： 10.1007/s11604-021-01091-y 　

詳細を見る詳細を閉じる

PURPOSE: To evaluate the differences in patterns of recurrence and treatment results by histology after definitive radiotherapy for stage III non-small cell lung cancer (NSCLC) in Japan. MATERIALS AND METHODS: Patients with stage III NSCLC who underwent definitive radiotherapy between 2000 and 2016 in our institution were included. A total of 217 patients were enrolled. Propensity score matching was used to exclude the following confounding factors: (1) age (≥70 years or <70 years), (2) gender, (3) T factor, (4) N factor, (5) Eastern Cooperative Oncology Group performance status score and (6) smoking status (Brinkman index ≥400 or <400). RESULTS: The median observation period for survivors was 55.1 months. After propensity score matching, the Sqcc and adenocarcinoma groups each included 62 paired patients. There was no significant difference in OS or PFS between the adenocarcinoma and Sqcc groups. However, rates of recurrence in the GTV-primary site (p = 0.009) and GTV-lymph node site (p = 0.037) were significantly higher in patients with Sqcc than in patients with adenocarcinoma. New metastatic recurrence was more frequent in patients with adenocarcinoma than in patients with Sqcc (p = 0.025). CONCLUSION: There were significant differences in patterns of recurrence after definitive (chemo)radiotherapy between patients with Sqcc and patients with adenocarcinoma.
Stereotactic body radiotherapy for kidney cancer: a 10-year experience from a single institute. 国際誌

Takaya Yamamoto, Yoshihide Kawasaki, Rei Umezawa, Noriyuki Kadoya, Haruo Matsushita, Kazuya Takeda, Yojiro Ishikawa, Noriyoshi Takahashi, Yu Suzuki, Ken Takeda, Kousei Kawabata, Akihiro Ito, Keiichi Jingu

Journal of radiation research　62　(3)　533-539　2021年5月12日

DOI： 10.1093/jrr/rrab031 　

詳細を見る詳細を閉じる

The purpose of this retrospective study was to investigate survival outcomes and irradiated tumor control (local control [LC]) and locoregional control (LRC) after stereotactic body radiotherapy (SBRT) for T1 or recurrent T1 (rT1) kidney cancer. Twenty-nine nonconsecutive patients with 30 tumors were included. SBRT doses of 70 Gy, 60 Gy or 50 Gy in 10 fractions were prescribed with a linear accelerator using daily image guidance. The Kaplan-Meier method was used to estimate time-to-event outcomes, and the log-rank test was used to compare survival curves between groups divided by each possible factor. The median follow-up periods for all patients and survivors were 57 months and 69.6 months, respectively. The five-year LC rate, LRC rate, progression-free survival (PFS) rate, disease-specific survival (DSS) rate and overall survival (OS) rate were 94%, 88%, 50%, 96% and 68%, respectively. No significant factor was related to OS and PFS. Three of 24 non-hemodialysis (HD) patients had new-onset-HD because of the progression of underlying kidney disease. Grade 3 or higher toxicities from SBRT did not occur. In conclusion, SBRT for kidney cancer provided a high rate of LC, LRC and DSS with minimal toxicities, but patient selection and indication for SBRT should be done carefully considering the relatively low OS rate.
Impact of feature selection methods and subgroup factors on prognostic analysis with CT-based radiomics in non-small cell lung cancer patients. 国際誌

Yuto Sugai, Noriyuki Kadoya, Shohei Tanaka, Shunpei Tanabe, Mariko Umeda, Takaya Yamamoto, Kazuya Takeda, Suguru Dobashi, Haruna Ohashi, Ken Takeda, Keiichi Jingu

Radiation oncology (London, England)　16　(1)　80-80　2021年4月30日

DOI： 10.1186/s13014-021-01810-9 　

詳細を見る詳細を閉じる

BACKGROUND: Radiomics is a new technology to noninvasively predict survival prognosis with quantitative features extracted from medical images. Most radiomics-based prognostic studies of non-small-cell lung cancer (NSCLC) patients have used mixed datasets of different subgroups. Therefore, we investigated the radiomics-based survival prediction of NSCLC patients by focusing on subgroups with identical characteristics. METHODS: A total of 304 NSCLC (Stages I-IV) patients treated with radiotherapy in our hospital were used. We extracted 107 radiomic features (i.e., 14 shape features, 18 first-order statistical features, and 75 texture features) from the gross tumor volume drawn on the free breathing planning computed tomography image. Three feature selection methods [i.e., test-retest and multiple segmentation (FS1), Pearson's correlation analysis (FS2), and a method that combined FS1 and FS2 (FS3)] were used to clarify how they affect survival prediction performance. Subgroup analysis for each histological subtype and each T stage applied the best selection method for the analysis of All data. We used a least absolute shrinkage and selection operator Cox regression model for all analyses and evaluated prognostic performance using the concordance-index (C-index) and the Kaplan-Meier method. For subgroup analysis, fivefold cross-validation was applied to ensure model reliability. RESULTS: In the analysis of All data, the C-index for the test dataset is 0.62 (FS1), 0.63 (FS2), and 0.62 (FS3). The subgroup analysis indicated that the prediction model based on specific histological subtypes and T stages had a higher C-index for the test dataset than that based on All data (All data, 0.64 vs. SCCall, 060; ADCall, 0.69; T1, 0.68; T2, 0.65; T3, 0.66; T4, 0.70). In addition, the prediction models unified for each T stage in histological subtype showed a different trend in the C-index for the test dataset between ADC-related and SCC-related models (ADCT1-ADCT4, 0.72-0.83; SCCT1-SCCT4, 0.58-0.71). CONCLUSIONS: Our results showed that feature selection methods moderately affected the survival prediction performance. In addition, prediction models based on specific subgroups may improve the prediction performance. These results may prove useful for determining the optimal radiomics-based predication model.
Effect of radiotherapy after breast-conserving surgery in elderly patients with early breast cancer according to the AJCC 8th Edition Breast Cancer Staging System in Japan.

Liuwei Tang, Zichang Ma, Yojiro Ishikawa, Haruo Matsushita, Takanori Ishida, Keiichi Jingu

Breast cancer (Tokyo, Japan)　28　(2)　465-470　2021年3月

DOI： 10.1007/s12282-020-01181-1 　

詳細を見る詳細を閉じる

BACKGROUND: The number of elderly patients in Japan with breast cancer has been gradually increasing. The aim of this study was to determine the efficacy of radiotherapy (RT) after breast-conserving surgery (BCS) for elderly patients with early breast cancer who were restaged according to the 8th Edition Breast Cancer Staging System. METHODS: We reviewed patients age ≥ 65 years who received BCS and adjuvant RT or BCS alone for breast cancer between 2010 and 2015 in our institution and restaged those patients using the AJCC 8th edition pathological prognostic staging system. We compared relapse-free survival (RFS) and overall survival (OS) rates in the RT group and no RT group. RESULTS: A total of 170 patients were eligible for analysis: 94 (55.3%) were treated with RT and 76 (44.7%) were treated without RT. Age (p < 0.01) was associated with the use of RT. Adjuvant RT significantly improved RFS (95.75% vs 84.21%, p = 0.02). There was no significant difference between the OS rates in the two groups. Univariate analysis showed that pathologic T stage and N stage were significantly associated with both RFS and OS and that histologic grade, chemotherapy, HER2, and RT were significantly associated with RFS, but not with OS. RT reduced the risk of recurrence (HR = 0.56, 95% CI = 0.19-0.96, p = 0.04). CONCLUSIONS: RT was associated with significantly improved RFS, but had no significant impact on OS in elderly patients with breast cancer after BCS. Adjuvant RT should be performed even for elderly patients with early breast cancer.
Systematic method for a deep learning-based prediction model for gamma evaluation in patient-specific quality assurance of volumetric modulated arc therapy. 国際誌

Seiji Tomori, Noriyuki Kadoya, Tomohiro Kajikawa, Yuto Kimura, Kakutarou Narazaki, Takahiro Ochi, Keiichi Jingu

Medical physics　48　(3)　1003-1018　2021年3月

DOI： 10.1002/mp.14682 　

詳細を見る詳細を閉じる

PURPOSE: This study aimed to develop and evaluate a novel strategy for establishing a deep learning-based gamma passing rate (GPR) prediction model for volumetric modulated arc therapy (VMAT) using dummy target plan data, one measurement process, and a multicriteria prediction method. METHODS: A total of 147 VMAT plans were used for the training set (two sets of 48 dummy target plans) and test set (51 clinical target plans). The dummy plans were measured using a diode array detector. We developed an original convolutional neural network that accepts coronal and sagittal dose distributions to predict the GPRs of 36 pairs of gamma criteria from 0.5%/0.5 mm to 3%/3 mm. Sixfold cross-validation and model averaging were performed, and the mean training result and mean test result were derived from six trained models that were produced during cross-validation. RESULTS: Strong or moderate correlations were observed between the measured and predicted GPRs in all criteria. The mean absolute errors and root mean squared errors of the test set (clinical target plan) were 0.63 and 1.11 in 3%/3 mm, 1.16 and 1.73 in 3%/2 mm, 1.96 and 2.66 in 2%/2 mm, 5.00 and 6.35 in 1%/1 mm, and 5.42 and 6.78 in 0.5%/1 mm, respectively. The Pearson correlation coefficients were 0.80 in the training set and 0.68 in the test set at the 0.5%/1 mm criterion. CONCLUSION: Our results suggest that the training of the deep learning-based quality assurance model can be performed using a dummy target plan.
Recurrence of Lymph Node Micrometastases After Radiotherapy for Head and Neck Carcinoma: A Propensity Score-matched Study. 国際誌

Y U Suzuki, Keiichi Jingu, Eiichi Ishida, Takaki Murata, Masaki Kubozono

Cancer diagnosis & prognosis　1　(3)　165-172　2021年

DOI： 10.21873/cdp.10022 　

詳細を見る詳細を閉じる

BACKGROUND: The standard irradiation dose to the elective lymph node area (ELNA) in locally patients with advanced head and neck squamous cell carcinoma (LA-HNSCC) to control lymph node micrometastases (LN-MM) has not changed since it was empirically determined in the 1950s. We investigated the optimal irradiation dose for controlling LN-MM in ELNAs. PATIENTS AND METHODS: The pattern of recurrence of LA-HNSCC was retrospectively evaluated in patients who underwent concurrent chemoradiotherapy with cisplatin or radiation therapy alone. RESULTS: In total, 162 patients were enrolled. The median observation period was 34 months. No recurrence was found in ELNAs. After propensity score matching, a cisplatin dose of ≥200 mg/m 2 yielded a significantly higher overall survival rate (p≤0.001) and locoregional control rate (p=0.034) than did a dose of <100 mg/m 2 . CONCLUSION: CCRT with a cisplatin dose of ≥200 mg/m 2 can reduce the irradiation dose to 40-44 Gy at 2 Gy per fraction to control LN-MM.
[The impact of 4DCT-ventilation imaging-guided proton therapy on stereotactic body radiotherapy for lung cancer].

Yoshiro Ieko, Noriyuki Kadoya, Takayuki Kanai, Yujiro Nakajima, Kazuhiro Arai, Takahiro Kato, Kengo Ito, Yuya Miyasaka, Ken Takeda, Takeo Iwai, Kenji Nemoto, Keiichi Jingu

Igaku butsuri : Nihon Igaku Butsuri Gakkai kikanshi = Japanese journal of medical physics : an official journal of Japan Society of Medical Physics　41　(3)　157-157　2021年

DOI： 10.11323/jjmp.41.3_157 　
The Long-Term Recovery of Parotid Glands in Nasopharyngeal Carcinoma Treated by Intensity-Modulated Radiotherapy. 国際誌

Shun Tasaka, Keiichi Jingu, Noriyoshi Takahashi, Rei Umezawa, Takaya Yamamoto, Yojiro Ishikawa, Kazuya Takeda, Yu Suzuki, Noriyuki Kadoya

Frontiers in oncology　11　665837-665837　2021年

DOI： 10.3389/fonc.2021.665837 　

詳細を見る詳細を閉じる

Background: Xerostomia is one of the most common adverse events of radiotherapy in head and neck cancer patients. There have been many reports on functional changes of the parotid gland after radiation therapy, but there have been few reports on the volume of the parotid gland and its relationship with oral quality of life (QOL) and even fewer reports on longitudinal change of the parotid gland volume. The purpose of this study was to evaluate the long-term change of the parotid gland volume after intensity-modulated radiotherapy (IMRT) for nasopharyngeal carcinoma and the relationship between parotid irradiation dose and xerostomia symptoms. Methods: We retrospectively analyzed 26 patients with nasopharyngeal cancer treated by IMRT. Longitudinal changes of parotid gland volumes after IMRT were evaluated on CT images. The parotid gland volumes in each period were converted to the ratio to parotid gland volumes before radiotherapy (relative parotid volume). Dunnett's test was used to evaluate the longitudinal changes in relative parotid volumes at 0-6, 7-18, 19-30, 31-42, 43-54 and 55-66 months after IMRT. We assessed xerostomia 3 years or more after IMRT by measuring the degree of oral moisture using a moisture-checking device (Mucus, Life Co., Ltd.) and oral QOL evaluation by GOHAI (General Oral Health Assessment Index). Results: The relative parotid volumes during radiotherapy and at 0-6, 7-18, 19-30, 31-42, 43-54 and 55-66 months after IMRT were 75.2 ± 14.3%, 67.2 ± 11.4%, 68.5 ± 15.9%, 72.4 ± 14.8%, 73.0 ± 13.8%, 76.2 ± 17.5%, and 77.1% ± 17.3%, respectively. The parotid volume had recovered significantly at 43-54 and 55-66 months after IMRT, especially in parotids receiving less than 40 Gy as the mean dose. The mean irradiated dose for bilateral parotids showed negative correlations with oral QOL score and oral moisture after a long period. Conclusions: The parotid volume recovered gradually but had not reached a plateau even 3 years after radiotherapy, especially in parotids receiving less than 40 Gy as the mean dose.
Comparison of predictive performance for toxicity by accumulative dose of DVH parameter addition and DIR addition for cervical cancer patients. 国際誌

Yuya Miyasaka, Noriyuki Kadoya, Rei Umezawa, Yoshiki Takayama, Kengo Ito, Takaya Yamamoto, Shohei Tanaka, Suguru Dobashi, Ken Takeda, Kenji Nemoto, Takeo Iwai, Keiichi Jingu

Journal of radiation research　62　(1)　155-162　2021年1月1日

DOI： 10.1093/jrr/rraa099 　

詳細を見る詳細を閉じる

We compared predictive performance between dose volume histogram (DVH) parameter addition and deformable image registration (DIR) addition for gastrointestinal (GI) toxicity in cervical cancer patients. A total of 59 patients receiving brachytherapy and external beam radiotherapy were analyzed retrospectively. The accumulative dose was calculated by three methods: conventional DVH parameter addition, full DIR addition and partial DIR addition. ${D}_{2{cm}^3}$, ${D}_{1{cm}^3}$ and ${D}_{0.1{cm}^3}$ (minimum doses to the most exposed 2 cm3, 1cm3 and 0.1 cm3 of tissue, respectively) of the rectum and sigmoid were calculated by each method. V50, V60 and V70 Gy (volume irradiated over 50, 60 and 70 Gy, respectively) were calculated in full DIR addition. The DVH parameters were compared between toxicity (≥grade1) and non-toxicity groups. The area under the curve (AUC) of the receiver operating characteristic (ROC) curves were compared to evaluate the predictive performance of each method. The differences between toxicity and non-toxicity groups in ${D}_{2{cm}^3}$ were 0.2, 5.7 and 3.1 Gy for the DVH parameter addition, full DIR addition and partial DIR addition, respectively. The AUCs of ${D}_{2{cm}^3}$ were 0.51, 0.67 and 0.57 for DVH parameter addition, full DIR addition and partial DIR addition, respectively. In full DIR addition, the difference in dose between toxicity and non-toxicity was the largest and AUC was the highest. AUCs of V50, V60 and V70 Gy were 0.51, 0.63 and 0.62, respectively, and V60 and V70 were high values close to the value of ${D}_{2{cm}^3}$ of the full DIR addition. Our results suggested that the full DIR addition may have the potential to predict toxicity more accurately than the conventional DVH parameter addition, and that it could be more effective to accumulate to all pelvic irradiation by DIR.
乳癌術後の左側胸部照射における深吸気息止め照射

武田一也, 坂谷内徹, 工藤展迪, 吉田龍一, 中川紗紀, 神宮啓一

大崎市民病院誌　24　20-23　2020年12月
出版者・発行元：大崎市民病院
ISSN：1881-6142
Dose distribution correction for the influence of magnetic field using a deep convolutional neural network for online MR-guided adaptive radiotherapy. 国際誌

Tomohiro Kajikawa, Noriyuki Kadoya, Shohei Tanaka, Hikaru Nemoto, Noriyoshi Takahashi, Takahito Chiba, Kengo Ito, Yoshiyuki Katsuta, Suguru Dobashi, Ken Takeda, Kei Yamada, Keiichi Jingu

Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)　80　186-192　2020年12月

DOI： 10.1016/j.ejmp.2020.11.002 　

詳細を見る詳細を閉じる

PURPOSE: This study aimed to develop a deep convolutional neural network (CNN)-based dose distribution conversion approach for the correction of the influence of a magnetic field for online MR-guided adaptive radiotherapy. METHODS: Our model is based on DenseNet and consists of two 2D input channels and one 2D output channel. These three types of data comprise dose distributions without a magnetic field (uncorrected), electron density (ED) maps, and dose distributions with a magnetic field. These data were generated as follows: both types of dose distributions were created using 15-field IMRT in the same conditions except for the presence or absence of a magnetic field with the GPU Monte Carlo dose in Monaco version 5.4; ED maps were acquired with planning CT images using a clinical CT-to-ED table at our institution. Data for 50 prostate cancer patients were used; 30 patients were allocated for training, 10 for validation, and 10 for testing using 4-fold cross-validation based on rectum gas volume. The accuracy of the model was evaluated by comparing 2D gamma-indexes against the dose distributions in each irradiation field with a magnetic field (true). RESULTS: The gamma indexes in the body for CNN-corrected uncorrected dose against the true dose were 94.95% ± 4.69% and 63.19% ± 3.63%, respectively. The gamma indexes with 2%/2-mm criteria were improved by 10% in most test cases (99.36%). CONCLUSIONS: Our results suggest that the CNN-based approach can be used to correct the dose-distribution influences with a magnetic field in prostate cancer treatment.
Analyses of the local control of pulmonary Oligometastases after stereotactic body radiotherapy and the impact of local control on survival. 国際誌

Takaya Yamamoto, Yuzuru Niibe, Masahiko Aoki, Takashi Shintani, Kazunari Yamada, Mitsuru Kobayashi, Hideomi Yamashita, Masatoki Ozaki, Yoshihiko Manabe, Hiroshi Onishi, Katsuya Yahara, Atsushi Nishikawa, Kuniaki Katsui, Ryoong-Jin Oh, Atsuro Terahara, Keiichi Jingu

BMC cancer　20　(1)　997-997　2020年10月14日

DOI： 10.1186/s12885-020-07514-9 　

詳細を見る詳細を閉じる

BACKGROUND: Successful local therapy for oligometastases may lead to longer survival. The purpose of this multicentre retrospective study was to investigate factors affecting the local control (LC) of pulmonary oligometastases treated by stereotactic body radiotherapy (SBRT) and to investigate the impact of LC on survival. METHODS: The inclusion criteria included 1 to 5 metastases, the primary lesion and other extrathoracic metastases were controlled before SBRT, and the biological effective dose (BED10) of the SBRT was 75 Gy or more. The Cox proportional hazards model was used for analyses. RESULTS: Data of 1378 patients with 1547 tumours from 68 institutions were analysed. The median follow-up period was 24.2 months. The one-year, 3-year and 5-year LC rates were 92.1, 81.3 and 78.6%, respectively, and the 1-year, 3-year and 5-year overall survival rates were 90.1, 60.3 and 45.5%, respectively. Multivariate analysis for LC showed that increased maximum tumour diameter (p = 0.011), type A dose calculation algorithm (p = 0.005), shorter overall treatment time of SBRT (p = 0.035) and colorectal primary origin (p < 0.001 excluding oesophagus origin) were significantly associated with a lower LC rate. In the survival analysis, local failure (p < 0.001), worse performance status (1 vs. 0, p = 0.013; 2-3 vs. 0, p < 0.001), oesophageal primary origin (vs. colorectal origin, p = 0.038), squamous cell carcinoma (vs. adenocarcinoma, p = 0.006) and increased maximum tumour diameter (p < 0.001) showed significant relationships with shorter survival. CONCLUSIONS: Several factors of oligometastases and SBRT affected LC. LC of pulmonary oligometastases by SBRT showed a significant survival benefit compared to patients with local failure.
Factors related to primary cancer death and non-primary cancer death in patients treated with stereotactic body radiotherapy for pulmonary oligometastases. 国際誌

Takaya Yamamoto, Yuzuru Niibe, Yasuo Matsumoto, Masahiko Aoki, Ryoong-Jin Oh, Masatoki Ozaki, Mitsuru Kobayashi, Yoshihiko Manabe, Takashi Shintani, Yasuhiro Dekura, Hiroshi Onishi, Hideomi Yamashita, Keiichi Jingu

Cancer medicine　9　(23)　8902-8911　2020年10月6日

DOI： 10.1002/cam4.3508 　

詳細を見る詳細を閉じる

Cancer-specific death (CSD) and non-cancer-specific death (non-CSD) after stereotactic body radiotherapy (SBRT) for pulmonary oligometastases have not been studied in detail. The aim of this study was to determine the cumulative incidences of CSD and non-CSD and to reveal prognostic factors. Data from a large survey of SBRT for pulmonary oligometastases were used for analyses, and patients with unknown cause of death were excluded from current analyses. CSD was primary cancer death and non-CSD was non-primary cancer death including a series of cancer treatment-related deaths. Cumulative incidences were calculated using the Kaplan-Meier method and a stratified Cox regression model was used for multivariate analyses (MVA). Fifty-two patients with an unknown death were excluded and a total of 1326 patients was selected. CSD and non-CSD occurred in 375 and 109 patients, respectively. The median OS period was 53.2 months and the cumulative incidences of 1-, 3-, and 5-year CSD vs. non-CSD rates were 6.5% vs. 2.3%, 29.5% vs. 8.6%, and 41.2% vs. 11.0%, respectively. In MVA, the incidence of CSD was related to performance status (1 vs. 0; p < 0.001, 2-3 vs. 0; p = 0.011), oligometastatic state (sync-oligometastases vs. oligo-recurrence, p = 0.026) and maximum tumor diameter (p = 0.009), and the incidence of non-CSD was related to age (p = 0.001), sex (p = 0.030), performance status (2-3 vs. 0; p = 0.002), and irradiated tumor-located lung lobe (left lower lobe vs. other lobes, p = 0.036). CSD was main cause of death, but non-CSD was not rare after SBRT. Prognostic factors for CSD and non-CSD were different, and an understanding of the factors would help in treatment.
A long-term survival case following salvage stereotactic radiotherapy for local recurrence after definitive chemoradiotherapy for stage III non-small cell lung cancer. 国際誌査読有り

Yuta Sato, Keiichi Jingu, Rei Umezawa, Takaya Yamamoto, Yojiro Ishikawa, Kazuya Takeda, Yu Suzuki, Haruo Matsushita

International cancer conference journal　9　(4)　227-230　2020年10月

DOI： 10.1007/s13691-020-00431-5 　

ISSN：2192-3183
Analyses of local control and survival after stereotactic body radiotherapy for pulmonary oligometastases from colorectal adenocarcinoma. 国際誌査読有り

Takaya Yamamoto, Yuzuru Niibe, Yasuo Matsumoto, Hiroshi Onishi, Masahiko Aoki, Atsushi Nishikawa, Ryoong-Jin Oh, Takashi Shintani, Katsuya Yahara, Masatoki Ozaki, Yoshihiko Manabe, Keiichi Jingu

Journal of radiation research　61　(6)　935-944　2020年9月17日

DOI： 10.1093/jrr/rraa071 　

詳細を見る詳細を閉じる

This study is a subset analysis of a retrospective multicenter study performed in Japan and its purpose was to investigate the effectiveness of stereotactic body radiotherapy (SBRT) for pulmonary oligometastases from colorectal cancer. Local control (LC), freedom from further metastases, relapse-free survival and overall survival (OS) after SBRT were retrospectively analyzed. The Kaplan-Meier method was used to estimate lifetime data and the log-rank test was performed as univariate analyses. The Cox proportional hazards model was applied in multivariate analyses. Data for 330 patients with 371 tumors were used for analyses. The median follow-up period was 25.0 months. The 3-year LC, freedom from further metastases, relapse-free survival and OS rates were 64.9, 34.9, 24.9 and 63.4%, respectively. The results of multivariate analyses showed that a higher LC rate was associated with no history of local therapy for oligometastases (P = 0.01), SBRT without concurrent chemotherapy (P < 0.01), type B calculation algorithm (P < 0.01) and higher biological effective radiation doses (≥115 Gy, P = 0.04). A longer OS was associated with no history of local therapy for oligometastases (P = 0.04), a more recent period of SBRT (2010-15, P = 0.02), tumor located in the upper or middle lobe (P < 0.01) and higher biological effective radiation doses (≥115 Gy, P = 0.01). In conclusion, OS after SBRT was good, but LC rate was relatively low. The use of high biological effective radiation doses can improve both LC and OS outcomes.
The impact of 4DCT-ventilation imaging-guided proton therapy on stereotactic body radiotherapy for lung cancer

Yoshiro Ieko, Noriyuki Kadoya, Takayuki Kanai, Yujiro Nakajima, Kazuhiro Arai, Takahiro Kato, Kengo Ito, Yuya Miyasaka, Ken Takeda, Takeo Iwai, Kenji Nemoto, Keiichi Jingu

Radiological Physics and Technology　13　(3)　230-237　2020年9月
出版者・発行元： Springer Science and Business Media LLC
DOI： 10.1007/s12194-020-00572-5 　

ISSN：1865-0333

eISSN：1865-0341
Development of a dynamic deformable thorax phantom for the quality management of deformable image registration. 国際誌査読有り

Yasuharu Sugawara, Noriyuki Kadoya, Kazuki Kotabe, Yujiro Nakajima, Ryutaro Ikeda, Shunpei Tanabe, Haruna Ohashi, Keiichi Jingu

Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)　77　100-107　2020年9月
出版者・発行元： Elsevier BV
DOI： 10.1016/j.ejmp.2020.08.007 　

ISSN：1120-1797

詳細を見る詳細を閉じる

The purpose of this study was to develop a novel dynamic deformable thorax phantom for deformable image registration (DIR) quality assurance (QA) and to verify as a tool for commissioning and DIR QA. The phantom consists of a base phantom, an inner phantom, and a motor-derived piston. The base phantom is an acrylic cylinder phantom with a diameter of 180 mm. The inner phantom consists of deformable, 20 mm thick disk-shaped sponges. To evaluate the physical characteristics of the phantom, we evaluated its image quality and deformation. DIR accuracies were evaluated using the three types of commercially DIR software (MIM, RayStation, and Velocity AI) to test the feasibility of this phantom. We used different DIR parameters to test the impact of parameters on DIR accuracy in various phantom settings. To evaluate DIR accuracy, a target registration error (TRE) was calculated using the anatomical landmark points. The three locations (i.e., distal, middle, and proximal positions) had different displacement amounts. This result indicated that the inner phantom was not moved but deformed. In cases with different phantom settings and marker settings, the ranges of the average TRE were 0.63-15.60 mm (MIM). In cases with different DIR parameters settings, the ranges of the average TRE were as follows: 0.73-7.10 mm (MIM), 8.25-8.66 mm (RayStation), and 8.26-8.43 mm (Velocity). These results suggest that our phantom could evaluate the detailed DIR behaviors with TRE. Therefore, this is indicative of the potential usefulness of our phantom in DIR commissioning and QA.
Evaluation of four-dimensional cone beam computed tomography ventilation images acquired with two different linear accelerators at various gantry speeds using a deformable lung phantom. 国際誌査読有り

Noriyuki Kadoya, Hikaru Nemoto, Tomohiro Kajikawa, Yujiro Nakajima, Takayuki Kanai, Yoshiro Ieko, Ryutaro Ikeda, Kiyokazu Sato, Suguru Dobashi, Ken Takeda, Keiichi Jingu

Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)　77　75-83　2020年9月

DOI： 10.1016/j.ejmp.2020.07.030 　

詳細を見る詳細を閉じる

We evaluated four-dimensional cone beam computed tomography (4D-CBCT) ventilation images (VICBCT) acquired with two different linear accelerator systems at various gantry speeds using a deformable lung phantom. The 4D-CT and 4D-CBCT scans were performed using a computed tomography (CT) scanner, an X-ray volume imaging system (Elekta XVI) mounted in Versa HD, and an On-Board Imager (OBI) system mounted in TrueBeam. Intensity-based deformable image registration (DIR) was performed between peak-exhale and peak-inhale images. VICBCT- and 4D-CT-based ventilation images (VICT) were derived by DIR using two metrics: one based on the Jacobian determinant and one on changes in the Hounsfield unit (HU). Three different DIR regularization values (λ) were used for VICBCT. Correlations between the VICBCT and VICT values were evaluated using voxel-wise Spearman's rank correlation coefficient (r). In case of both metrics, the Jacobian-based VICBCT with a gantry speed of 0.6 deg/sec in Versa HD showed the highest correlation for all the gantry speeds (e.g., λ = 0.05 and r = 0.68). Thus, the r value of the Jacobian-based VICBCT was greater or equal to that of the HU-based VICBCT. In addition, the ventilation accuracy of VICBCT increased at low gantry speeds. Thus, the image quality of VICBCT was affected by the change in gantry speed in both the imaging systems. Additionally, DIR regularization considerably influenced VICBCT in both the imaging systems. Our results have the potential to assist in designing CBCT protocols, incorporating VICBCT imaging into the functional avoidance planning process.
Dose-dependent Radiation-induced Myocardial Damage in Esophageal Cancer Treated with Chemoradiotherapy: A Prospective Cardiac Magnetic Resonance Imaging Study 査読有り

Rei Umezawa, Noriyuki Kadoya, Hideki Ota, Yujiro Nakajima, Masahide Saito, Hidenobu Takagi, Kentaro Takanami, Noriyoshi Takahashi, Yojiro Ishikawa, Takaya Yamamoto, Haruo Matsushita, Ken Takeda, Kei Takase, Keiichi Jingu

Advances in Radiation Oncology　5　(6)　1170-1178　2020年8月
出版者・発行元： Elsevier BV
DOI： 10.1016/j.adro.2020.07.012 　

ISSN：2452-1094
What motivated medical students and residents to become radiation oncologists in Japan?-Questionnaire report by the radiotherapy promotion committee of JASTRO. 国際誌査読有り

Yuji Murakami, Shin-Ei Noda, Yoshiomi Hatayama, Toshiya Maebayashi, Keiichi Jingu, Yasushi Nagata, Takashi Mizowaki

Journal of radiation research　61　(5)　727-732　2020年7月22日

DOI： 10.1093/jrr/rraa051 　

詳細を見る詳細を閉じる

This study aimed to clarify the motivations and timing of the decision to become radiation oncologists. MATERIALS AND METHODS: We conducted an online survey for new members of the Japanese Society for Radiation Oncology (JASTRO). RESULTS: The response rate was 43.3%. Data of the 79 respondents who wanted to obtain a board-certification of JASTRO were analysed. We divided the respondents into two groups: Group A, those who entered a single radiation oncology department, and Group B, those who joined a radiology department in which the radiation oncology department and diagnostic radiology department were integrated. The most common period when respondents were most attracted to radiation oncology was "5th year of university" in Group A and "2nd year of junior residency" and "senior residency" in Group B. Furthermore, 79.5% of Group A and 40% of Group B chose periods before graduation from a university with a significant difference. The most common period when respondents made up their minds to become radiation oncologists was "2nd year of junior residency" in both groups. Internal medicine was the most common department to consider if they did not join the radiation oncology or radiology department. CONCLUSION: To increase the radiation oncologists, it is crucial to enhance clinical training in the fifth year of university for Group A and to continue an active approach to maintain interest in radiation oncology until the end of junior residency. In Group B facilities, it is desirable to provide undergraduates more opportunities to come in contact with radiation oncology.
Risk factors for severe gastrointestinal toxicity in patients receiving palliative radiotherapy for metastatic bone tumors: association with the use of molecular-targeted agents. 国際誌査読有り

Yuji Murakami, Masahiro Kenjo, Kazuki Ishikawa, Toru Sakayauchi, Satoshi Itasaka, Yoshiharu Negoro, Keiichi Jingu, Yasumasa Nishimura, Yasushi Nagata, Kazuhiko Ogawa

Journal of radiation research　61　(4)　629-634　2020年6月22日

DOI： 10.1093/jrr/rraa035 　

詳細を見る詳細を閉じる

This study aimed to investigate whether the use of molecular-targeted agents could affect gastrointestinal (GI) toxicity in palliative radiotherapy (RT) for metastatic bone tumors in the abdominopelvic region. We collected data of patients who received palliative RT for bone metastases in the abdominopelvic region between 2013 and 2014 from six institutions. Data of 395 patients were collected and184 patients received molecularly targeted therapy, of whom 80 received vascular endothelial growth factor (VEGF)-targeted agents. For 556 lesions, 410 sessions of irradiation were undergone. GI toxicity of ≥G3 was observed in 3.8% of patients. The incidence rates of ≥G3 GI toxicity in patients without targeted agents use, in those using VEGF-targeted agents and in those using non-VEGF-targeted agents were 3.8, 7.5 and 1.0%, respectively. Regarding risk factors of the occurrence of ≥G3 GI toxicity, univariate analysis in all patients showed that a history of abdominopelvic surgery was a significant risk factor (P = 0.01), and the use of VEGF-targeted agents showed a trend of high incidence (P = 0.06). In patients using VEGF-targeted agents, both univariate and multivariate analysis showed that combined anticoagulant use (P = 0.03 and 0.01) and agent use between 1 week before and after RT (P = 0.046 and 0.03) were significant risk factors. In conclusion, the history of abdominopelvic surgery was associated with ≥G3 GI toxicity and the use of VEGF-targeted agents showed a trend for high incidence. When using VEGF-targeted agents, caution should be exercised in the combined use of anticoagulants and in the agent use between 1 week before and after RT.
Significant reduction of oncologic pulmonary death by local control for pulmonary oligometastases treated with stereotactic body radiotherapy. 国際誌査読有り

Takaya Yamamoto, Yuzuru Niibe, Kazunari Yamada, Masahiko Aoki, Hiroshi Onishi, Kuniaki Katsui, Yasuhiro Dekura, Atsushi Nishikawa, Yoshihiko Manabe, Hideomi Yamashita, Keiichi Jingu

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology　147　86-91　2020年6月

DOI： 10.1016/j.radonc.2020.03.019 　

詳細を見る詳細を閉じる

BACKGROUND AND PURPOSE: The rate of oncologic pulmonary death after stereotactic body radiotherapy for pulmonary oligometastases has never been reported. The purpose of current study was to investigate the rate of freedom from oncologic pulmonary death (FOPD) and to analyze factors affecting for FOPD. MATERIALS AND METHODS: The inclusion criteria for this retrospective study were that SBRT was performed between 2004 and 2015, the number of metastases was 5 or less, the primary lesion and extrathoracic metastases needed to be controlled before SBRT and a biological effective dose (BED10) of 75 Gy or more was needed. The Kaplan-Meier estimator and the log-rank test were used to calculate and compare the stratified rates of FOPD. The Cox proportional hazards model was used for multivariate analyses (MVA). Primary disease death from a non-oncologic pulmonary cause was censored in model 1 and was excluded in model 2. RESULTS: A total of 1172 patients with 1315 tumors were enrolled. During a median follow-up period of 24.5 months, oncologic pulmonary deaths accounted for 101 of 221 primary disease deaths. The 1-year, 3-year and 5-year FOPD rates in model 1 were 98.2%, 89.4% and 84.0%, respectively. MVA for FOPD revealed that local failure of the irradiated tumor, squamous cell carcinoma pathology, and chemotherapy after SBRT had significant relationships with lower FOPD rates in both model 1 and model 2. CONCLUSIONS: Successful local control of pulmonary oligometastases by SBRT contributed to a higher FOPD rate.
Clinical experience of pelvic radiotherapy or chemoradiotherapy for postoperative uterine cervical cancer using intensity-modulated radiation therapy. 国際誌査読有り

Takaya Yamamoto, Rei Umezawa, Hideki Tokunaga, Masaki Kubozono, Maiko Kozumi, Noriyoshi Takahashi, Haruo Matsushita, Noriyuki Kadoya, Kengo Ito, Kiyokazu Sato, Keita Tsuji, Muneaki Shimada, Keiichi Jingu

Journal of radiation research　61　(3)　470-478　2020年5月22日

DOI： 10.1093/jrr/rraa004 　

詳細を見る詳細を閉じる

The purpose of this study was to reveal treatment outcomes and toxicity after pelvic intensity-modulated radiotherapy (IMRT) for postoperative uterine cervical cancer of Japanese patients. Consecutive patients who were treated with pelvic IMRT for postoperative cervical cancer in our institute were retrospectively analyzed. Relapse-free survival (RFS) and overall survival (OS) were calculated using the Kaplan-Meier estimator, and log-rank tests were used to compare differences. From the database, 62 patients were identified. The pathology was squamous cell carcinoma in 44 patients and other pathology in 18 patients. Of the 62 patients, 35 had high-risk prognostic factors and 27 patients had intermediate-risk prognostic factors. The prescribed radiation doses were 50 Gy in 25 fractions for 58 patients and 50.4 Gy in 28 fractions for 4 patients. One patient received a vaginal cuff boost. Chemotherapy was administered in 36 patients. During the median follow-up period of 50.9 months, there was no locoregional failure. Six patients in the high-risk group relapsed, but none of the patients in the intermediate-risk group relapsed (P = 0.02). The 3-year OS and RFS rates were 98.2% and 90.9%, respectively. Significant factors related to RFS were squamous cell carcinoma pathology (P = 0.02), pathological T stage (P = 0.04), surgical margin status (P < 0.01) and multiple lymph nodes metastases (P < 0.01). Grade 3 or more toxicity occurred in 6 patients. Four patients had obstruction of the intestine, and 2 patients had stenosis of the urinary tract. In clinical practice, the use of pelvic IMRT for postoperative cervical cancer of Japanese patients showed a low rate of toxicity without decreasing the efficacy.
How Much Was the Elective Lymph Node Region Covered in Involved-Field Radiation Therapy for Locally Advanced Pancreatic Cancer? Evaluation of Overlap Between Gross Target Volume and Celiac Artery-Superior Mesenteric Artery Lymph Node Regions

Rei Umezawa, Yoshinori Ito, Akihisa Wakita, Satoshi Nakamura, Hiroyuki Okamoto, Kana Takahashi, Koji Inaba, Naoya Murakami, Hiroshi Igaki, Keiichi Jingu, Jun Itami

ADVANCES IN RADIATION ONCOLOGY　5　(3)　377-387　2020年5月

DOI： 10.1016/j.adro.2019.08.014 　

eISSN：2452-1094
Error detection using a convolutional neural network with dose difference maps in patient-specific quality assurance for volumetric modulated arc therapy. 国際誌査読有り

Yuto Kimura, Noriyuki Kadoya, Seiji Tomori, Yohei Oku, Keiichi Jingu

Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)　73　57-64　2020年5月

DOI： 10.1016/j.ejmp.2020.03.022 　

詳細を見る詳細を閉じる

The aim of this study was to evaluate the use of dose difference maps with a convolutional neural network (CNN) to detect multi-leaf collimator (MLC) positional errors in patient-specific quality assurance for volumetric modulated radiation therapy (VMAT). A cylindrical three-dimensional detector (Delta4, ScandiDos, Uppsala, Sweden) was used to measure 161 beams from 104 clinical prostate VMAT plans. For the simulation used error-free plans plus plans with two types of MLC error were introduced: systematic error and random error. A total of 483 dose distributions in a virtual cylindrical phantom were calculated with a treatment planning system. Dose difference maps were created from two planar dose distributions from the measured and calculated dose distributions, and these were used as the input for the CNN, with 375 datasets assigned for training and 108 datasets assigned for testing. The CNN model had three convolution layers and was trained with five-fold cross-validation. The CNN model classified the error types of the plans as "error-free," "systematic error," or "random error," with an overall accuracy of 0.944. The sensitivity values for the "error-free," "systematic error," and "random error" classifications were 0.889, 1.000, and 0.944, respectively, and the specificity values were 0.986, 0.986, and 0.944, respectively. This approach was superior to those based on gamma analysis. Using dose difference maps with a CNN model may provide an effective solution for detecting MLC errors for patient-specific VMAT quality assurance.
Prognostic value of the AJCC 8th edition staging system for Japanese patients treated with surgery followed by radiotherapy for breast cancer. 査読有り

Liuwei Tang, Yojiro Ishikawa, Haruo Matsushita, Keiichi Jingu

International journal of clinical oncology　25　(8)　1499-1505　2020年4月30日

DOI： 10.1007/s10147-020-01686-x 　

詳細を見る詳細を閉じる

BACKGROUND: American Joint Committee on Cancer (AJCC) 8th Edition Breast Cancer Staging System, biological information in addition to anatomical information was added as a basis for prognosis evaluation, but its prognostic impact in Japanese patients treated with postoperative radiotherapy has not been discussed. To determine the applicability of the updated prognostic staging system, we evaluated the prognostic value and confirmed the effectiveness of this system in patients in whom postoperative radiotherapy was performed. MATERIALS AND METHODS: Patients who were treated with postoperative radiotherapy for breast cancer in our institution between January 2011 and December 2015 were restaged by the AJCC 8th pathological prognosis staging system, and then overall survival (OS), disease-free survival (DFS) rates and hazard ratios (HR) were analyzed to compare the predictive fit of the two staging systems. RESULTS: Five hundred and seven patients who in whom postoperative radiotherapy was performed for breast cancer were enrolled in this study. 36.1% patients were downstaged and 5.3% patients were upstaged from the 7th to 8th editions staging system classification. Kaplan-Meier curves and HRs showed differences in OS and DFS rates between the 7th edition and 8th edition staging systems. The AJCC 8th edition prognostic stage system has a better prognostic prediction of OS and DFS than does the 7th edition anatomic stage system. CONCLUSIONS: Compared with the 7th edition in breast cancer, AJCC 8th edition prognostic stage system has more precise stratification and superior prognostic value, providing a more accurate reference for the choice of radiotherapy for patients with breast cancer.
Quantitative analysis of intra-fractional variation in CT-based image guided brachytherapy for cervical cancer patients. 国際誌査読有り

Yuya Miyasaka, Noriyuki Kadoya, Kengo Ito, Rei Umezawa, Masaki Kubozono, Takaya Yamamoto, Yujiro Nakajima, Masahide Saito, Yoshiki Takayama, Kenji Nemoto, Takeo Iwai, Keiichi Jingu

Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)　73　164-172　2020年4月30日

DOI： 10.1016/j.ejmp.2020.04.009 　

詳細を見る詳細を閉じる

We quantified intra-fractional dose variation and organ movement during CT-based 3D-image guided brachytherapy (3D-IGBT) in cervical cancer patients. Fifteen patients who underwent CT-based 3D-IGBT were studied. For all patients, pre-delivery CT for treatment planning after applicator insertion and post-delivery CT after dose delivery without changing the applicator position were acquired. Pre- and post-delivery CT were rigidly fused by matching the inserted applicator and planned dose on pre-delivery CT (pre-delivery dose) was mapped on post-delivery CT (post-delivery dose). D2, D1, and D0.1 cm3 of the rectum and bladder were compared between pre- and post-delivery doses with contours on each CT image. Organ movement and deformation was evaluated using deformation vector fields calculated by deformable image registration between pre- and post-delivery CT. We also evaluated dose variation and DVF between with and without a catheter to control filling. Differences in all DVH parameters were <±3% in physical dose and ± 5% in EQD2. However, a > 15% dose difference was found in 13.8% of the fractions in rectum D2 cm3 and in 11.1% of those in bladder D2 cm3. The mean value of DVF for bladder was larger than that of rectum, especially for the superior-inferior (S-I) direction. Insertion catheters in bladder reduced mean dose and DVF variation compared with that of without catheters. In fraction groups with large dose increasing, DVF in the S-I direction was significantly larger than that of other fraction groups. Our results indicated that preparation is needed to reduce changes in the S-I direction affect dose variation.
Comparison of the effects of radiotherapy doses of 50.4 Gy and 60 Gy on outcomes of chemoradiotherapy for thoracic esophageal cancer: subgroup analysis based on the Comprehensive Registry of Esophageal Cancer in Japan from 2009 to 2011 by the Japan Esophageal Society 査読有り

Kenji Nemoto, Shohei Kawashiro, Yasushi Toh, Hodaka Numasaki, Yuji Tachimori, Takashi Uno, Keiichi Jingu, Hisahiro Matsubara

Esophagus　17　(2)　122-126　2020年4月
出版者・発行元： Springer Science and Business Media LLC
DOI： 10.1007/s10388-019-00711-x 　

ISSN：1612-9059

eISSN：1612-9067
Stereotactic Body Radiotherapy for Pulmonary Oligometastases from Esophageal Cancer: Results and Prognostic Factors. 国際誌査読有り

Takaya Yamamoto, Yuzuru Niibe, Yasuo Matsumoto, Yasuhiro Dekura, Ryoong-Jin Oh, Hideomi Yamashita, Hisao Kakuhara, Masahiko Aoki, Keiichi Jingu

Anticancer research　40　(4)　2065-2072　2020年4月

DOI： 10.21873/anticanres.14164 　

詳細を見る詳細を閉じる

BACKGROUND/AIM: The aim of this multi-center retrospective study was to investigate the results of stereotactic body radiotherapy (SBRT) for pulmonary oligometastases from esophageal cancer. PATIENTS AND METHODS: Oligometastases from the esophagus were identified from a dataset of a Japanese survey. The Kaplan-Meier method and Cox regression were applied to perform analyses. RESULTS: A total of 114 patients with 132 pulmonary oligometastases were collected. The 3-year local control rate, freedom from further metastasis (FFFM) rate and overall survival (OS) rate were 70.2%, 25.3% and 37.5%, respectively. Performance status (PS) (PS 1 vs. PS 0, p<0.01), disease-free interval (p=0.03) and history of local therapy for metastasis (p=0.01) had significant relationships with FFFM and only PS was an independent prognostic factor for OS (PS 1 vs. PS 0, p=0.02; PS 2-3 vs. PS 0, p=0.04). CONCLUSION: SBRT for pulmonary oligometastases from esophageal cancer provided good local control and survival.
Multi-atlas-based auto-segmentation for prostatic urethra using novel prediction of deformable image registration accuracy. 国際誌査読有り

Hisamichi Takagi, Noriyuki Kadoya, Tomohiro Kajikawa, Shohei Tanaka, Yoshiki Takayama, Takahito Chiba, Kengo Ito, Suguru Dobashi, Ken Takeda, Keiichi Jingu

Medical physics　47　(7)　3023-3031　2020年3月22日

DOI： 10.1002/mp.14154 　

詳細を見る詳細を閉じる

PURPOSE: Accurate identification of the prostatic urethra and bladder can help determine dosing and evaluate urinary toxicity during intensity-modulated radiation therapy (IMRT) planning in patients with localized prostate cancer. However, it is challenging to locate the prostatic urethra in planning computed tomography (pCT). In the present study, we developed a multiatlas-based auto-segmentation method for prostatic urethra identification using deformable image registration accuracy prediction with machine learning (ML) and assessed its feasibility. METHODS: We examined 120 patients with prostate cancer treated with IMRT. All patients underwent temporary urinary catheter placement for identification and contouring of the prostatic urethra in pCT images (ground truth). Our method comprises the following three steps: (a) select four atlas datasets from the atlas datasets using the deformable image registration (DIR) accuracy prediction model, (b) deform them by structure-based DIR, (3) and propagate urethra contour using displacement vector field calculated by the DIR. In (a), for identifying suitable datasets, we used the trained support vector machine regression (SVR) model and five feature descriptors (e.g., prostate volume) to increase DIR accuracy. This method was trained/validated using 100 patients and performance was evaluated within an independent test set of 20 patients. Fivefold cross-validation was used to optimize the hype parameters of the DIR accuracy prediction model. We assessed the accuracy of our method by comparing it with those of two others: Acostas method-based patient selection (previous study method, by Acosta et al.), and the Waterman's method (defines the prostatic urethra based on the center of the prostate, by Waterman et al.). We used the centerlines distance (CLD) between the ground truth and the predicted prostatic urethra as the evaluation index. RESULTS: The CLD in the entire prostatic urethra was 2.09 ± 0.89 mm (our proposed method), 2.77 ± 0.99 mm (Acosta et al., P = 0.022), and 3.47 ± 1.19 mm (Waterman et al., P < 0.001); our proposed method showed the highest accuracy. In segmented CLD, CLD in the top 1/3 segment was highly improved from that of Waterman et.al. and was slightly improved from that of Acosta et.al., with results of 2.49 ± 1.78 mm (our proposed method), 2.95 ± 1.75 mm (Acosta et al., P = 0.42), and 5.76 ± 3.09 mm (Waterman et al., P < 0.001). CONCLUSIONS: We developed a DIR accuracy prediction model-based multiatlas-based auto-segmentation method for prostatic urethra identification. Our method identified prostatic urethra with mean error of 2.09 mm, likely due to combined effects of SVR model employment in patient selection, modified atlas dataset characteristics and DIR algorithm. Our method has potential utility in prostate cancer IMRT and can replace use of temporary indwelling urinary catheters.
Variations between dose-ventilation and dose-perfusion metrics in radiotherapy planning for lung cancer 査読有り

Nakajima Y, Kadoya N, Kimura T, Hioki K, Jingu K, Yamamoto T

Advances in Radiation Oncology　2020年3月20日
The effects of a transverse magnetic field on the dose enhancement of nanoparticles in a proton beam: a Monte Carlo simulation. 国際誌査読有り

Mohammadreza Parishan, Reza Faghihi, Noriyuki Kadoya, Keiichi Jingu

Physics in medicine and biology　65　(8)　085002-085002　2020年2月26日

DOI： 10.1088/1361-6560/ab7a70 　

詳細を見る詳細を閉じる

High-Z nanoparticles (NP) as radiosensitization agents provide the feasibility of dose localization within the tumor in radiotherapy. Dose enhancement of NPs in the presence of a magnetic field (MF) could be challenged when magnetic resonance imaging (MRI) systems are used as an image-guided system. The MF can influence dose enhancement of NPs at their interfaces and surrounding medium and affect their dose deposition behavior. In the TOPAS Monte Carlo code, gold nanoparticle (GNP) and superparamagnetic iron oxide nanoparticle (SPION) were irradiated using 70 and 150 MeV proton beams, in presence of transverse MF strengths with 0, 1, 3, and 7 T. The changes in the liberated secondary electrons from NPs and their dose enhancement ratio (DER), magnetic dose enhancement ratio (MDER), and angular dose distribution in 10 nm shell thicknesses up to 500 nanometers from their centers were measured. The central plane of NPs was considered as a scorer that its thickness was 2 nm and divided to 6-degree sectors with 10 nm radial length. The dose deposition in this voxelated scorer was calculated. The values of the deposited doses around NPs decrease rapidly while the DERs resulted from the secondary electrons are increased. MDERs are changed within ±5% and ±7% for 20 and 50 nm radius NPs, respectively. The variation in the angular dose distribution around a singular NP was not considerable with different applied MF strengths. The dose values in the voxelated central plane show very similar results for the same NPs types in the different MF strengths. The typically used MF in the MRI systems, could not cause an electron return effect (ERE) at the interfaces of NPs and water. The DERs of NPs in a water medium resulted from emerged secondary electrons, experience a low degree of perturbation in the presence of an MF. The results of this study show that the NPs as dose enhancement agents can be used also in an MF without pronounced modification in their efficacy caused by electron return effect.
Homology-based radiomic features for prediction of the prognosis of lung cancer based on CT-based radiomics. 国際誌査読有り

Noriyuki Kadoya, Shohei Tanaka, Tomohiro Kajikawa, Shunpei Tanabe, Kota Abe, Yujiro Nakajima, Takaya Yamamoto, Noriyoshi Takahashi, Kazuya Takeda, Suguru Dobashi, Ken Takeda, Kazuaki Nakane, Keiichi Jingu

Medical physics　47　(5)　2197-2205　2020年2月25日

DOI： 10.1002/mp.14104 　

詳細を見る詳細を閉じる

PURPOSE: Radiomics is a new technique that enables noninvasive prognostic prediction by extracting features from medical images. Homology is a concept used in many branches of algebra and topology that can quantify the contact degree. In the present study, we developed homology-based radiomic features to predict the prognosis of non-small-cell lung cancer (NSCLC) patients and then evaluated the accuracy of this prediction method. METHODS: Four data sets were used: two to provide training and test data and two for the selection of robust radiomic features. All the data sets were downloaded from The Cancer Imaging Archive (TCIA). In two-dimensional cases, the Betti numbers consist of two values: b0 (zero-dimensional Betti number), which is the number of isolated components, and b1 (one-dimensional Betti number), which is the number of one-dimensional or "circular" holes. For homology-based evaluation, CT images must be converted to binarized images in which each pixel has two possible values: 0 or 1. All CT slices of the gross tumor volume were used for calculating the homology histogram. First, by changing the threshold of the CT value (range: -150 to 300 HU) for all its slices, we developed homology-based histograms for b0 , b1 , and b1 /b0 using binarized images All histograms were then summed, and the summed histogram was normalized by the number of slices. 144 homology-based radiomic features were defined from the histogram. To compare the standard radiomic features, 107 radiomic features were calculated using the standard radiomics technique. To clarify the prognostic power, the relationship between the values of the homology-based radiomic features and overall survival was evaluated using LASSO Cox regression model and the Kaplan-Meier method. The retained features with non-zero coefficients calculated by the LASSO Cox regression model were used for fitting the regression model. Moreover, these features were then integrated into a radiomics signature. An individualized rad score was calculated from a linear combination of the selected features, which were weighted by their respective coefficients. RESULTS: When the patients in the training and test data sets were stratified into high-risk and low-risk groups according to the rad scores, the overall survival of the groups was significantly different. The C-index values for the homology-based features (rad score), standard features (rad score), and tumor size were 0.625, 0.603, and 0.607, respectively, for the training data sets and 0.689, 0.668, and 0.667 for the test data sets. This result showed that homology-based radiomic features had slightly higher prediction power than the standard radiomic features. CONCLUSIONS: Prediction performance using homology-based radiomic features had a comparable or slightly higher prediction power than standard radiomic features. These findings suggest that homology-based radiomic features may have great potential for improving the prognostic prediction accuracy of CT-based radiomics. In this result, it is noteworthy that there are some limitations.
Chemoradiotherapy and radiotherapy alone in patients with esophageal cancer aged 80 years or older based on the Comprehensive Registry of Esophageal Cancer in Japan. 査読有り

Keiichi Jingu, Hodaka Numasaki, Yasushi Toh, Kenji Nemoto, Takashi Uno, Yuichiro Doki, Hisahiro Matsubara

Esophagus : official journal of the Japan Esophageal Society　2020年2月22日

DOI： 10.1007/s10388-020-00725-w 　

詳細を見る詳細を閉じる

BACKGROUND: There has been no definitive evidence of chemoradiotherapy being superior to radiotherapy alone in patients aged 80 years or older. The purpose of the present study was to evaluate the results of radiotherapy and chemoradiotherapy in patients aged 80 years or older with esophageal cancer in the Japanese Nationwide Cancer Database. METHODS: A total of 358 patients aged 80 years or older who were treated with radiotherapy alone or with chemoradiotherapy for esophageal cancer between 2009 and 2011 were enrolled. RESULTS: The 5-year overall survival (OS) rates in patients with cStages 0-I, II, III and IV were 40.9%, 24.7%, 12.2% and 4.9%, respectively. The 5-year cause-specific survival (CSS) rates in patients aged 80 years or older with cStages 0-I, cStage II, cStage III and cStage IV were 73.5%, 41.4%, 25.3% and 7.4%, respectively. In patients treated with radiotherapy alone, the 5-year OS rates for patients with cStages 0-I, II, III and IV were 36.5%, 12.0%, 5.4% and 0%, respectively. In patients treated with chemoradiotherapy, the 5-year OS rates for patients with cStages 0-I, II, III and IV were 45.0%, 36.1%, 16.4% and 7.1%, respectively. In multivariate analysis, chemoradiotherapy, early stage and squamous cell carcinoma were significantly favorable prognostic factors for OS in patients aged 80 years or older (p < 0.001, p < 0.001 and p = 0.0323, respectively). We were unable to evaluate toxicities, because of lack of information in the registry. CONCLUSION: Concurrent chemotherapy with radiotherapy for esophageal cancer in patients aged 80 years or older is a significantly favorable prognostic factor for OS. However, chemoradiotherapy should be carefully selected in elderly patients.
モンテカルロ線量計算のためのリニアック構造内光子輸送に基づく関数線源モデル

石澤儀樹, 土橋卓, 武田賢, 角谷倫之, 伊藤謙吾, 千葉貴仁, 高山佳樹, 佐藤清和, 神宮啓一

Japanese Journal of Radiology　38　(Suppl.)　9-9　2020年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
Evaluation of the effect of user-guided deformable image registration of thoracic images on registration accuracy among users. 国際誌査読有り

Yujiro Nakajima, Noriyuki Kadoya, Takayuki Kanai, Masahide Saito, Satoshi Kito, Shimpei Hashimoto, Katsuyuki Karasawa, Keiichi Jingu

Medical dosimetry : official journal of the American Association of Medical Dosimetrists　2020年1月31日

DOI： 10.1016/j.meddos.2019.12.004 　

詳細を見る詳細を閉じる

User-guided deformable image registration (DIR) has allowed users to actively participate in the DIR process and is expected to improve DIR accuracy. The purpose of this study was to evaluate the time required for and effect of user-guided DIR on registration accuracy for thoracic images among users. In this study, 4-dimensional computed tomographic images of 10 thoracic cancer patients were used. The dataset for these patients was provided by DIR-Lab (www.dir-lab.com) and included a coordinate list of anatomical landmarks (300 bronchial bifurcations). Four medical physicists from different institutions performed DIR between peak-inhale and peak-exhale images with/without the user-guided DIR tool, Reg Refine, implemented in MIM Maestro (MIM software, Cleveland, OH). DIR accuracy was quantified by using target registration errors (TREs) for 300 anatomical landmarks in each patient. The average TREs with user-guided DIR in the 10 images by the 4 medical physicists were 1.48, 1.80, 3.46, and 3.55 mm, respectively, whereas the TREs without user-guided DIR were 3.28, 3.45, 3.56, and 3.28 mm, respectively. The average times taken by the 4 physicists to use the user-guided DIR were 10.0, 6.7, 7.1, and 8.0 min, respectively. This study demonstrated that user-guided DIR can improve DIR accuracy and requires only a moderate amount of time (<10 min). However, 2 of the 4 users did not show much improvement in DIR accuracy, which indicated the necessity of training prior to use of user-guided DIR.
A case report and review of the literature: cardiotoxicities after radiotherapy for breast cancer patients with high-risk factors of cardiovascular disease. 国際誌

Liuwei Tang, Haruo Matsushita, Yojiro Ishikawa, Takanori Ishida, Keiichi Jingu

International cancer conference journal　9　(1)　41-44　2020年1月

DOI： 10.1007/s13691-019-00390-6 　

詳細を見る詳細を閉じる

Cardiovascular disease (CVD) is an important adverse effect of radiotherapy and is responsible for increased morbidity and mortality in long-term survivors with breast cancer. Patients may have pre-existing cardiovascular risk factors before treatment of breast cancer, and the effects of pre-existing cardiovascular risk factors can be compounded by radiotherapy. We report a case of left breast cancer in a 63-year-old female with a high risk of CVD who was suspected of having radiation-induced myocardium injury 1 year after postoperative adjuvant therapy. Radiation oncologists should not only reduce the adverse effects by perfecting radiotherapy technology but also consider reducing other high-risk factors for CVD.
IMRTの患者QAにおける3Dプリンタで作成した頭頚部患者模擬ファントムの評価

角谷倫之, 阿部幸太, 根本光, 佐藤清和, 家子義朗, 伊藤謙吾, 土橋卓, 武田賢, 神宮啓一

医学物理　40　(3)　109-109　2020年
出版者・発行元：公益社団法人日本医学物理学会
DOI： 10.11323/jjmp.40.3_109 　

ISSN：1345-5354
Pulmonary Oligometastases Treated by Stereotactic Body Radiation Therapy: A Nationwide Survey of 1,378 Patients. 国際誌

Yuzuru Niibe, Takaya Yamamoto, Hiroshi Onishi, Hideomi Yamashita, Kuniaki Katsui, Yasuo Matsumoto, Ryoong-Jin Oh, Masahiko Aoki, Takashi Shintani, Kazunari Yamada, Mitsuru Kobayashi, Masatoki Ozaki, Yoshihiko Manabe, Katsuya Yahara, Atsushi Nishikawa, Hisao Kakuhara, Kentaro Yamamoto, Tetsuya Inoue, Y U Takada, Kenji Nagata, Osamu Suzuki, Atsuro Terahara, Keiichi Jingu

Anticancer research　40　(1)　393-399　2020年1月

DOI： 10.21873/anticanres.13965 　

詳細を見る詳細を閉じる

AIM: This study was performed to confirm the superior overall survival (OS) after pulmonary oligo-recurrence compared to pulmonary sync-oligometastases in a large nationwide study. PATIENTS AND METHODS: Patients that met the following criteria were included: 1 to 5 lung-only metastases at the beginning of stereotactic body radiation therapy (SBRT) was performed between January 2004 and June 2015, and the biological effective dose (BED) of SBRT was 75 Gy or more. The parameters included in the analyses were age, gender, ECOG PS, primary lesion, pathology, oligoetastatic state, SBRT date, chemotherapy before SBRT, chemotherapy concurrent SBRT, chemotherapy after SBRT, maximum tumor diameter, number of metastases, field coplanarity, dose prescription, BED10, OTT of SBRT. RESULTS: In total, 1,378 patients with 1,547 tumors were enrolled. Oligo-recurrence occurred in 1,016 patients, sync-oligometastases in 118, and unclassified oligometastases in 121. The three-year OS was 64.0% for oligo-recurrence and 47.5% for sync-oligometastasis (p<0.001). In the multivariate analysis, the hazard ratio (HR) for sync-oligometastases versus oligo-recurrence was 1.601 (p=0.014). Adverse events of Grade 5 were occurred in 3 patients. CONCLUSION: This is the first nationwide to indicate that the OS of patients with pulmonary oligo-recurrence is better than that of patients with sync-oligometastases.
DNA-PKcs is activated under nutrient starvation and activates Akt, MST1, FoxO3a, and NDR1. 査読有り

Shiga S, Murata Y, Hashimoto T, Urushihara Y, Fujishima Y, Kudo K, Sonohara Y, Kurusu M, Takeda K, Jingu K, Hosoi Y

Biochemical and biophysical research communications　2019年11月

DOI： 10.1016/j.bbrc.2019.10.133 　

ISSN：0006-291X
A convolutional neural network approach for IMRT dose distribution prediction in prostate cancer patients. 国際誌査読有り

Tomohiro Kajikawa, Noriyuki Kadoya, Kengo Ito, Yoshiki Takayama, Takahito Chiba, Seiji Tomori, Hikaru Nemoto, Suguru Dobashi, Ken Takeda, Keiichi Jingu

Journal of radiation research　60　(5)　685-693　2019年10月23日

DOI： 10.1093/jrr/rrz051 　

ISSN：0449-3060

詳細を見る詳細を閉じる

The purpose of the study was to compare a 3D convolutional neural network (CNN) with the conventional machine learning method for predicting intensity-modulated radiation therapy (IMRT) dose distribution using only contours in prostate cancer. In this study, which included 95 IMRT-treated prostate cancer patients with available dose distributions and contours for planning target volume (PTVs) and organs at risk (OARs), a supervised-learning approach was used for training, where the dose for a voxel set in the dataset was defined as the label. The adaptive moment estimation algorithm was employed for optimizing a 3D U-net similar network. Eighty cases were used for the training and validation set in 5-fold cross-validation, and the remaining 15 cases were used as the test set. The predicted dose distributions were compared with the clinical dose distributions, and the model performance was evaluated by comparison with RapidPlan™. Dose-volume histogram (DVH) parameters were calculated for each contour as evaluation indexes. The mean absolute errors (MAE) with one standard deviation (1SD) between the clinical and CNN-predicted doses were 1.10% ± 0.64%, 2.50% ± 1.17%, 2.04% ± 1.40%, and 2.08% ± 1.99% for D2, D98 in PTV-1 and V65 in rectum and V65 in bladder, respectively, whereas the MAEs with 1SD between the clinical and the RapidPlan™-generated doses were 1.01% ± 0.66%, 2.15% ± 1.25%, 5.34% ± 2.13% and 3.04% ± 1.79%, respectively. Our CNN model could predict dose distributions that were superior or comparable with that generated by RapidPlan™, suggesting the potential of CNN in dose distribution prediction.
Evaluation of a 3D-printed heterogeneous anthropomorphic head and neck phantom for patient-specific quality assurance in intensity-modulated radiation therapy. 査読有り

Noriyuki Kadoya, Kota Abe, Hikaru Nemoto, Kiyokazu Sato, Yoshiro Ieko, Kengo Ito, Suguru Dobashi, Ken Takeda, Keiichi Jingu

Radiological physics and technology　12　(3)　351-356　2019年9月

DOI： 10.1007/s12194-019-00527-5 　

ISSN：1865-0333

詳細を見る詳細を閉じる

We evaluated an anthropomorphic head and neck phantom with tissue heterogeneity, produced using a personal 3D printer, with quality assurance (QA), specific to patients undergoing intensity-modulated radiation therapy (IMRT). Using semi-automatic segmentation, 3D models of bone, soft tissue, and an air-filled cavity were created based on computed tomography (CT) images from patients with head and neck cancer treated with IMRT. For the 3D printer settings, polylactide was used for soft tissue with 100% infill. Bone was reproduced by pouring plaster into the cavity created by the 3D printer. The average CT values for soft tissue and bone were 13.0 ± 144.3 HU and 439.5 ± 137.0 HU, respectively, for the phantom and 12.1 ± 124.5 HU and 771.5 ± 405.3 HU, respectively, for the patient. The gamma passing rate (3%/3 mm) was 96.1% for a nine-field IMRT plan. Thus, this phantom may be used instead of a standard shape phantom for patient-specific QA in IMRT.
Current status of radiotherapy for patients with thoracic esophageal cancer in Japan, based on the Comprehensive Registry of Esophageal Cancer in Japan from 2009 to 2011 by the Japan Esophageal Society. 査読有り

Toh Y, Numasaki H, Tachimori Y, Uno T, Jingu K, Nemoto K, Matsubara H

Esophagus : official journal of the Japan Esophageal Society　2019年8月

DOI： 10.1007/s10388-019-00690-z 　

ISSN：1612-9059
Is Concurrent Chemotherapy With Radiotherapy for Esophageal Cancer Beneficial in Patients Aged 80 Years or Older? 国際誌査読有り

Keiichi Jingu, Noriyoshi Takahashi, Yuji Murakami, Kazuki Ishikawa, Satoshi Itasaka, Takeo Takahashi, Fumiaki Isohashi, Toru Sakayauchi, Kazuhiko Ogawa

Anticancer research　39　(8)　4279-4283　2019年8月

DOI： 10.21873/anticanres.13592 　

ISSN：0250-7005

詳細を見る詳細を閉じる

BACKGROUND/AIM: To determine whether concurrent chemotherapy with radiotherapy should be performed in elderly patients with esophageal cancer. PATIENTS AND METHODS: A total of 185 patients aged 80 years or older who were treated with definitive radiotherapy alone or combined with chemoradiotherapy for esophageal cancer at seven institutions were enrolled. In order to compare survival rates of patients treated with chemoradiotherapy with those of patients treated with radiotherapy alone, propensity score matching was performed to homogenize the two populations. RESULTS: For the whole patient cohort, the 3-year overall survival (OS) rate was 52.6% and the median survival was 42.5 months. After propensity score matching, the 3-year OS rate for the chemoradiotherapy group was not significantly better than that for the group treated with radiotherapy alone (53.7% vs. 59.9%, p=0.876). CONCLUSION: Concurrent chemotherapy with radiotherapy for esophageal cancer in patients aged 80 years or older did not have significant OS benefit over radiotherapy alone.
FDG-PET might not contribute to improving survival in patients with locally advanced inoperable esophageal cancer. 査読有り

Keiichi Jingu, Rei Umezawa, Takaya Yamamoto, Kazuya Takeda, Yojiro Ishikawa, Noriyoshi Takahashi, Noriyuki Kadoya, Haruo Matsushita

International journal of clinical oncology　24　(8)　927-933　2019年8月

DOI： 10.1007/s10147-019-01428-8 　

ISSN：1341-9625

詳細を見る詳細を閉じる

BACKGROUND: In Japan, positron emission tomography using 18F-fluorodeoxyglucose (FDG-PET) has been covered by the national health insurance for esophageal cancer since 2006. FDG-PET is commonly performed in advanced esophageal cancer. The aim of this study was to determine the effect of FDG-PET on survival in patients with locally advanced inoperable esophageal cancer. METHODS: We retrospectively reviewed all patients with cT4 and without M1 esophageal cancer on CT in our institution between 2000 and 2014, and data for 78 patients who meet the eligibility criteria described below were used for analysis in this study. The eligibility criteria included (1) cT4 esophageal cancer without distant metastases or M1 lymph node metastasis (UICC 2002), (2) histologically proven squamous cell carcinoma, (3) 20-79 years of age, (4) having undergone at least 1 cycle of concomitant chemotherapy, (5) having been irradiated with 50 Gy or more, and (6) no other active malignant tumor during treatment. RESULTS: Two patients were excluded because abdominal lymph node metastases or neck lymph node metastases were detected by FDG-PET. In 78 eligible patients, FDG-PET was not performed before treatment in 41 of the 78 patients and was performed in the other patients. The median observation period was 68 months. The 3-year and 5-year overall survival rates in 78 patients were 36.9% and 30.8%, respectively. There was no significant difference in overall survival or progression-free survival between patients in whom FDG-PET was performed and those in whom FDG-PET was not performed (12.0 months vs. 11.0 months, p = 0.920 and 6.0 months vs. 6.0 months, p = 0.844, respectively). CONCLUSIONS: Compared with only CT, additional information from FDG-PET is not associated with improving survival in patients with locally advanced esophageal cancer. Our results suggest that FDG-PET might not have much meaning for survival in locally advanced esophageal cancer.
Improvement of the MRI and clinical features of Asian Graves' ophthalmopathy by radiation therapy with steroids. 査読有り

Ma Z, Ozaki H, Ishikawa Y, Jingu K

Japanese journal of radiology　37　(8)　612-618　2019年6月

DOI： 10.1007/s11604-019-00846-y 　

ISSN：1867-1071
EP-1523 Predictors of severe late urinary toxicity after curative radiotherapy for localised prostatecancer 査読有り

K. Takeda, Y. Takayama, N. Kadoya, H. Takagi, K. Ito, T. Chiba, K. Sato, S. Dobashi, R. Umezawa, T. Yamamoto, Y. Ishikawa, K. Takeda, H. Matsushita, Y. Kawasaki, K. Mitsuduka, K. Jingu

Radiotherapy and Oncology　133　S823-S824　2019年4月
出版者・発行元： Elsevier BV
DOI： 10.1016/s0167-8140(19)31943-7 　

ISSN：0167-8140
Organ-preserving approach via radiotherapy for small cell carcinoma of the bladder: an analysis based on the Japanese Radiation Oncology Study Group (JROSG) survey. 国際誌査読有り

Akamatsu H, Nakamura K, Ebara T, Inaba K, Itasaka S, Jingu K, Kosaka Y, Murai T, Nagata K, Soejima T, Takahashi S, Toyoda T, Toyoshima S, Nemoto K, Akimoto T

Journal of radiation research　60　(4)　509-516　2019年4月

DOI： 10.1093/jrr/rrz018 　

ISSN：0449-3060
Dose escalation of external beam radiotherapy for high-risk prostate cancer-Impact of multiple high-risk factor. 国際誌査読有り

Rei Umezawa, Koji Inaba, Satoshi Nakamura, Akihisa Wakita, Hiroyuki Okamoto, Keisuke Tsuchida, Tairo Kashihara, Kazuma Kobayashi, Ken Harada, Kana Takahashi, Naoya Murakami, Yoshinori Ito, Hiroshi Igaki, Keiichi Jingu, Jun Itami

Asian journal of urology　6　(2)　192-199　2019年4月

DOI： 10.1016/j.ajur.2017.07.002 　

ISSN：2214-3882

詳細を見る詳細を閉じる

Objective: To retrospectively investigate the treatment outcomes of external beam radiotherapy with androgen deprivation therapy (ADT) in high-risk prostate cancer in three radiotherapy dose groups. Methods: Between 1998 and 2013, patients with high-risk prostate cancer underwent three-dimensional conformal radiotherapy or intensity-modulated radiotherapy of 66 Gy, 72 Gy, or 78 Gy with ADT. Prostate-specific antigen (PSA) relapse was defined using the Phoenix definition. PSA relapse-free survival (PRFS) was evaluated in each radiotherapy dose group. Moreover, high-risk patients were divided into H-1 (patients with multiple high-risk factors) and H-2 (patients with a single high-risk factor) as risk subgroups. Results: Two hundred and eighty-nine patients with a median follow-up period of 77.3 months were analyzed in this study. The median duration of ADT was 10.1 months. Age, Gleason score, T stage, and radiotherapy dose influenced PRFS with statistical significance both in univariate and multivariate analyses. The 4-year PRFS rates in Group-66 Gy, Group-72 Gy and Group-78 Gy were 72.7%, 81.6% and 90.3%, respectively. PRFS rates in the H-1 subgroup differed with statistical significance with an increasing radiotherapy dose having a more favorable PRFS, while PRFS rates in H-2 subgroup did not differ with increase in radiotherapy dose. Conclusion: Dose escalation for high-risk prostate cancer in combination with ADT improved PRFS. PRFS for patients in the H-1 subgroup was poor, but dose escalation in those patients was beneficial, while dose escalation in the H-2 subgroup was not proven to be effective for improving PRFS.
舌がん以外の頭頸部がんに対する低線量率密封小線源治療

岸田桂太, 神宮啓一, 松下晴雄, 梅澤玲, 山本貴也, 石川陽二郎, 高橋紀善, 片桐佑, 田坂俊, 武田一也, 福井勝哉, 鈴木友, 川端広聖, 寺村聡司, 伊藤謙吾, 角谷倫之, 千葉貴仁, 高山佳樹

Japanese Journal of Radiology　37　(Suppl.)　4-4　2019年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
食道癌放射線治療後晩期有害事象としての胸水(心嚢液)貯留重症例の検討

松下晴雄, 梅澤玲, 山本貴也, 石川陽二郎, 高橋紀善, 片桐佑, 田坂俊, 武田一也, 福井勝哉, 鈴木友, 川端広聖, 寺村聡司, 岸田桂太, 神宮啓一, 角谷倫之, 伊藤謙吾, 千葉貴仁, 高山佳樹

Japanese Journal of Radiology　37　(Suppl.)　6-6　2019年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
I期食道癌に対する放射線化学療法後の再発形式

寺村聡司, 高橋紀善, 梅澤玲, 松下晴雄, 山本貴也, 石川陽二郎, 片桐佑, 武田一也, 田坂俊, 福井勝哉, 鈴木友, 岸田桂太, 川端広聖, 神宮啓一

Japanese Journal of Radiology　37　(Suppl.)　12-12　2019年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
A comparative analysis of clinicopathological factors between esophageal small cell and basaloid squamous cell carcinoma. 査読有り

Ishida H, Kasajima A, Onodera Y, Konno T, Maruyama S, Okamoto H, Sato C, Heishi T, Sakurai T, Taniyama Y, Takahashi M, Fujishima F, Jingu K, Ishioka C, Sasano H, Kamei T

Medicine　98　(8)　e14363-e14363　2019年2月
出版者・発行元：
DOI： 10.1097/MD.0000000000014363 　

ISSN：0025-7974
Investigation of thoracic four-dimensional CT-based dimension reduction technique for extracting the robust radiomic features. 国際誌査読有り

Shohei Tanaka, Noriyuki Kadoya, Tomohiro Kajikawa, Shohei Matsuda, Suguru Dobashi, Ken Takeda, Keiichi Jingu

Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)　58　141-148　2019年2月

DOI： 10.1016/j.ejmp.2019.02.009 　

ISSN：1120-1797

詳細を見る詳細を閉じる

Robust feature selection in radiomic analysis is often implemented using the RIDER test-retest datasets. However, the CT Protocol between the facility and test-retest datasets are different. Therefore, we investigated possibility to select robust features using thoracic four-dimensional CT (4D-CT) scans that are available from patients receiving radiation therapy. In 4D-CT datasets of 14 lung cancer patients who underwent stereotactic body radiotherapy (SBRT) and 14 test-retest datasets of non-small cell lung cancer (NSCLC), 1170 radiomic features (shape: n = 16, statistics: n = 32, texture: n = 1122) were extracted. A concordance correlation coefficient (CCC) > 0.85 was used to select robust features. We compared the robust features in various 4D-CT group with those in test-retest. The total number of robust features was a range between 846/1170 (72%) and 970/1170 (83%) in all 4D-CT groups with three breathing phases (40%-60%); however, that was a range between 44/1170 (4%) and 476/1170 (41%) in all 4D-CT groups with 10 breathing phases. In test-retest, the total number of robust features was 967/1170 (83%); thus, the number of robust features in 4D-CT was almost equal to that in test-retest by using 40-60% breathing phases. In 4D-CT, respiratory motion is a factor that greatly affects the robustness of features, thus by using only 40-60% breathing phases, excessive dimension reduction will be able to be prevented in any 4D-CT datasets, and select robust features suitable for CT protocol of your own facility.
Automated noncoplanar treatment planning strategy in stereotactic radiosurgery of multiple cranial metastases: HyperArc and CyberKnife dose distributions. 査読有り

Kadoya N, Abe Y, Kajikawa T, Ito K, Yamamoto T, Umezawa R, Chiba T, Katsuta Y, Takayama Y, Kato T, Kikuchi Y, Jingu K

Medical dosimetry : official journal of the American Association of Medical Dosimetrists　2019年2月

DOI： 10.1016/j.meddos.2019.02.004 　

ISSN：0958-3947
Hypofractionated Radiotherapy for Anaplastic Thyroid Carcinoma: 15 Years of Experience in a Single Institution. 国際誌査読有り

Noriyoshi Takahashi, Haruo Matsushita, Rei Umezawa, Takaya Yamamoto, Yojiro Ishikawa, Yu Katagiri, Shun Tasaka, Kazuya Takeda, Katsuya Fukui, Noriyuki Kadoya, Kengo Ito, Keiichi Jingu

European thyroid journal　8　(1)　24-30　2019年1月

DOI： 10.1159/000493315 　

ISSN：2235-0640

詳細を見る詳細を閉じる

Background: Anaplastic thyroid carcinoma (ATC) is a rare cancer and has a poor prognosis. Several radiation protocols have been reported, but the results were not satisfactory. Objective: The aim of this study was to determine the effect of hypofractionated radiotherapy. Methods: Thirty-three patients who received radiotherapy for ATC between January 2000 and December 2014 were retrospectively included. We defined hypofractionated radiotherapy as a single dose ≥5 Gy. Results: Nineteen patients were treated with hypofractionated radiotherapy. Twenty-eight patients died, and 27 of those patients died from ATC. Sixteen patients died from distant metastasis and 6 from local recurrence. In the hypofractionated radiotherapy group, local recurrence occurred in 5 patients and 1 of them died from active bleeding from a local tumor. There was local recurrence in 7 patients who received the other protocol, and 5 of them died from asphyxiation, active bleeding, or uncontrollable growth of a local tumor on the neck. The median overall survival (OS) was 5 months. In multivariate analysis, patients who received an equivalent dose in 2-Gy fractions (EQD2) ≥50 Gy had significantly better OS (p = 0.016). In univariate analysis, patients who received hypofractionated radiotherapy did not have significantly better OS (p = 0.872) or local control (p = 0.090). The χ2 test showed that significantly fewer patients died from local recurrence in the hypofractionated radiotherapy group (p = 0.025). Conclusions: Multivariate analysis showed that an EQD2 ≥50 Gy resulted in better OS, and hypofractionated radiotherapy decreased the rate of mortality from local recurrence.
局所型前立腺がんに対する三次元原体照射における日々のCBCT画像から算出したDVHに基づく照射野形状最適化の有効性の検討

木村祐利, 土橋卓, 石澤儀樹, 角谷倫之, 伊藤謙吾, 千葉貴仁, 高山佳樹, 佐藤清和, 松下晴雄, 神宮啓一, 武田賢

日本放射線技術学会雑誌　74　(12)　1396-1405　2018年12月
出版者・発行元： (公社)日本放射線技術学会
ISSN：0369-4305

eISSN：1881-4883
FDG-PETは局所進行食道癌における生命予後を改善せず

神宮啓一, 松下晴雄, 梅澤玲, 山本貴也, 石川陽二郎, 高橋紀善, 角谷倫之, 高浪健太郎

核医学　55　(1)　41-41　2018年12月
出版者・発行元： (一社)日本核医学会
ISSN：0022-7854

eISSN：2189-9932
当院における塩化ラジウム(223Ra)の初期経験

太田瑛梨, 鎌田裕基, 外山由貴, 齋藤美穂子, 高浪健太郎, 高瀬圭, 高橋紀善, 石川陽二郎, 山本貴也, 梅澤玲, 松下晴雄, 神宮啓一

核医学　55　(1)　37-37　2018年12月
出版者・発行元： (一社)日本核医学会
ISSN：0022-7854

eISSN：2189-9932
[Field Shape Optimization Technique Based on Dose Volume Histogram Using Daily Cone-beam Computed Tomography in Three-dimensional Conformal Radiation Therapy for Localized Prostate Cancer: Develop and Evaluation]. 査読有り

Yuto Kimura, Suguru Dobashi, Yoshiki Ishizawa, Noriyuki Kadoya, Kengo Ito, Takahito Chiba, Yoshiki Takayama, Kiyokazu Sato, Haruo Matsushita, Keiichi Jingu, Ken Takeda

Nihon Hoshasen Gijutsu Gakkai zasshi　74　(12)　1396-1405　2018年12月

DOI： 10.6009/jjrt.2018_JSRT_74.12.1396 　

ISSN：0369-4305

詳細を見る詳細を閉じる

This study aimed to develop and evaluate field shape optimization technique based on dose calculation using daily cone-beam computed tomography (CBCT) to compensate for interfractional anatomic changes in three-dimensional conformal radiation therapy (3D-CRT) for prostate cancer. For each of 10 patients, 9-10 CBCT images were obtained throughout the treatment course. The prostate, seminal vesicles, and rectum were manually contoured in all CBCT images. Subsequently, plan adaptation was performed with a program developed in-house. This program calculates dose distributions on CBCT images and optimizes field shape to minimize rectal dose while keeping the target at the optimal dose coverage (the planning target volume D95% receives 95% of the prescription dose). To evaluate the adaptive planning approach, we re-calculated dose distributions on CBCT images based on the conventional and adaptive plans. For the entire cohort, plan adaptation improved rectal V50 Gy, V60 Gy, V65 Gy, and V70 Gy by -7.71±8.43%, -8.30±8.90%, -7.91±8.51% and -7.03±7.70% on average (±SD), respectively. Our results demonstrate that adaptive planning approach is superior to the conventional planning approach for optimizing dose distribution, and this adaptive approach can optimize field shape in 3 min. The proposed approach can be an effective solution for the problem of interfractional anatomic changes in 3D-CRT for prostate cancer.
Whole-body total lesion glycolysis is an independent predictor in patients with esophageal cancer treated with definitive chemoradiotherapy

Noriyoshi Takahashi, Rei Umezawa, Kentaro Takanami, Takaya Yamamoto, Youjirou Ishikawa, Maiko Kozumi, Kazuya Takeda, Noriyuki Kadoya, Keiichi Jingu

Radiotherapy and Oncology　129　(1)　161-165　2018年10月

DOI： 10.1016/j.radonc.2017.10.019 　

ISSN：0167-8140

eISSN：1879-0887
Stereotactic Radiotherapy for Oligometastases in Lymph Nodes-A Review 国際誌査読有り

Haruo Matsushita, Keiichi Jingu, Rei Umezawa, Takaya Yamamoto, Yojiro Ishikawa, Noriyoshi Takahashi, Yu Katagiri, Noriyuki Kadoya

TECHNOLOGY IN CANCER RESEARCH & TREATMENT　17　1533033818803597-1533033818803597　2018年10月

DOI： 10.1177/1533033818803597 　

ISSN：1533-0346

eISSN：1533-0338
Controversial issues in radiotherapy after breast-conserving surgery for early breast cancer in older patients: a systematic review. 査読有り

Tang L, Matsushita H, Jingu K

Journal of radiation research　2018年10月

DOI： 10.1093/jrr/rry071 　

ISSN：0449-3060
舌癌に対する198Au粒子での小線源治療における周術期口腔管理の器具として設計したスペーサー(Design of the spacer for brachytherapy using 198Au grain for carcinoma of the tongue as a tool of perioperative oral management) 査読有り

Suenaga Hanako, Tamahara Toru, Dodo Mina, Murakami Toshimitsu, Sasaki Satoshi, Ito Kengo, Jingu Keiichi, Koseki Takeyoshi, Sasaki Keiichi

Journal of Prosthodontic Research　62　(4)　518-521　2018年10月
出版者・発行元： (公社)日本補綴歯科学会
DOI： 10.1016/j.jpor.2018.07.002 　

ISSN：1883-1958

eISSN：1883-9207
Automated prediction of dosimetric eligibility of patients with prostate cancer undergoing intensity-modulated radiation therapy using a convolutional neural network. 査読有り

Tomohiro Kajikawa, Noriyuki Kadoya, Kengo Ito, Yoshiki Takayama, Takahito Chiba, Seiji Tomori, Ken Takeda, Keiichi Jingu

Radiological physics and technology　11　(3)　320-327　2018年9月

DOI： 10.1007/s12194-018-0472-3 　

ISSN：1865-0333

詳細を見る詳細を閉じる

The quality of radiotherapy has greatly improved due to the high precision achieved by intensity-modulated radiation therapy (IMRT). Studies have been conducted to increase the quality of planning and reduce the costs associated with planning through automated planning method; however, few studies have used the deep learning method for optimization of planning. The purpose of this study was to propose an automated method based on a convolutional neural network (CNN) for predicting the dosimetric eligibility of patients with prostate cancer undergoing IMRT. Sixty patients with prostate cancer who underwent IMRT were included in the study. Treatment strategy involved division of the patients into two groups, namely, meeting all dose constraints and not meeting all dose constraints, by experienced medical physicists. We used AlexNet (i.e., one of common CNN architectures) for CNN-based methods to predict the two groups. An AlexNet CNN pre-trained on ImageNet was fine-tuned. Two dataset formats were used as input data: planning computed tomography (CT) images and structure labels. Five-fold cross-validation was used, and performance metrics included sensitivity, specificity, and prediction accuracy. Class activation mapping was used to visualize the internal representation learned by the CNN. Prediction accuracies of the model with the planning CT image dataset and that with the structure label dataset were 56.7 ± 9.7% and 70.0 ± 11.3%, respectively. Moreover, the model with structure labels focused on areas associated with dose constraints. These results revealed the potential applicability of deep learning to the treatment planning of patients with prostate cancer undergoing IMRT.
Stereotactic Radiotherapy for Pulmonary Oligometastases From Colorectal Cancer: A Systematic Review and Meta-Analysis 査読有り

Keiichi Jingu, Haruo Matsushita, Takaya Yamamoto, Rei Umezawa, Yojiro Ishikawa, Noriyoshi Takahashi, Yu Katagiri, Kazuya Takeda, Noriyuki Kadoya

TECHNOLOGY IN CANCER RESEARCH & TREATMENT　17　1533033818794936　2018年8月

DOI： 10.1177/1533033818794936 　

ISSN：1533-0346

eISSN：1533-0338
Impact of change in serum albumin level during and after chemoradiotherapy in patients with locally advanced esophageal cancer 査読有り

Kazuya Takeda, Rei Umezawa, Noriyoshi Takahashi, Haruo Matsushita, Maiko Kozumi, Yojiro Ishikawa, Takaya Yamamoto, Ken Takeda, Keiichi Jingu

ESOPHAGUS　15　(3)　190-197　2018年7月

DOI： 10.1007/s10388-018-0612-1 　

ISSN：1612-9059

eISSN：1612-9067
Left Ventricular T1 Mapping during Chemotherapy-Radiation Therapy: Serial Assessment of Participants with Esophageal Cancer. 国際誌査読有り

Takagi H, Ota H, Umezawa R, Kimura T, Kadoya N, Higuchi S, Sun W, Nakajima Y, Saito M, Komori Y, Jingu K, Takase K

Radiology　289　(2)　172076-354　2018年7月

DOI： 10.1148/radiol.2018172076 　

ISSN：0033-8419
A deep learning-based prediction model for gamma evaluation in patient-specific quality assurance. 国際誌査読有り

Tomori S, Kadoya N, Takayama Y, Kajikawa T, Shima K, Narazaki K, Jingu K

Medical physics　2018年7月

DOI： 10.1002/mp.13112 　

ISSN：0094-2405
Oesophageal squamous cell carcinoma: histogram-derived ADC parameters are not predictive of tumour response to chemoradiotherapy 査読有り

Maiko Kozumi, Hideki Ota, Takaya Yamamoto, Rei Umezawa, Haruo Matsushita, Yojiro Ishikawa, Noriyoshi Takahashi, Tomonori Matsuura, Kei Takase, Keiichi Jingu

European Radiology　1-10　2018年5月3日
出版者・発行元： Springer Verlag
DOI： 10.1007/s00330-018-5439-6 　

ISSN：1432-1084 0938-7994
Evaluation of functionally weighted dose-volume parameters for thoracic stereotactic ablative radiotherapy (SABR) using CT ventilation 査読有り

Takayuki Kanai, Noriyuki Kadoya, Yujiro Nakajima, Yuya Miyasaka, Yoshiro Ieko, Tomohiro Kajikawa, Kengo Ito, Takaya Yamamoto, Suguru Dobashi, Ken Takeda, Kenji Nemoto, Keiichi Jingu

Physica Medica　49　47-51　2018年5月1日
出版者・発行元： Associazione Italiana di Fisica Medica
DOI： 10.1016/j.ejmp.2018.05.001 　

ISSN：1724-191X 1120-1797

eISSN：1724-191X
Oligo-recurrence and Sync-oligometastases 査読有り

Yuzuru Niibe, Keiichi Jingu, Hiroshi Onishi

Journal of Thoracic Oncology　13　(4)　e59-e60　2018年4月1日
出版者・発行元： Elsevier Inc
DOI： 10.1016/j.jtho.2017.11.115 　

ISSN：1556-1380 1556-0864
Long-term Results of External Beam Radiotherapy for Prostate Cancer with Prostate-specific Antigen of More Than 50 ng/ml and Without Evidence of Lymph Node or Distant Metastasis. 国際誌査読有り

Rei Umezawa, Koji Inaba, Satoshi Nakamura, Akihisa Wakita, Hiroyuki Okamoto, Satoshi Shima, Keisuke Tsuchida, Tairo Kashihara, Kazuma Kobayashi, Ken Harada, Kana Takahashi, Naoya Murakami, Yoshinori Ito, Hiroshi Igaki, Keiichi Jingu, Jun Itami

Anticancer research　38　(4)　2303-2309　2018年4月

DOI： 10.21873/anticanres.12475 　

ISSN：0250-7005

eISSN：1791-7530

詳細を見る詳細を閉じる

BACKGROUND/AIM: To evaluate long-term treatment outcomes of external beam radiotherapy for prostate cancer with a pretreatment prostate-specific antigen (PSA) level of more than 50 ng/ml and without evidence of lymph node or distant metastasis. PATIENTS AND METHODS: Definitive radiotherapy of 66 Gy or 72 Gy in combination with androgen deprivation therapy (ADT) was performed. PSA relapse-free survival (PRFS), distant metastasis-free survival (DMFS), cause-specific survival (CSS), and overall survival (OS) were evaluated. The impact of prognostic factors on PRFS, DMFS, CSS, and OS was analyzed in univariate and multivariate analyses. RESULTS: One hundred twenty patients with a median follow-up period of 92.6 months were analyzed in this study. The median duration of ADT was 11.0 months. The 5- and 8-year PRFS rates in all patients were 65.1% and 48.5%, respectively. The 8-year DMFS, CSS, and OS rates in all patients were 84.0%, 93.4%, and 81.6%, respectively. Both in univariate and multivariate analyses, Gleason score (GS) and radiotherapy dose were significant prognostic factors (p=0.015 and 0.001). There was no significant difference between each prognostic factor in DMFS, CSS, and OS. CONCLUSION: We might have indicated the significance of definitive radiotherapy even for prostate cancer with PSA of more than 50 ng/ml and without evidence of metastasis.
Log file-based patient dose calculations of double-arc VMAT for head-and-neck radiotherapy 査読有り

Yoshiyuki Katsuta, Noriyuki Kadoya, Yukio Fujita, Eiji Shimizu, Kazuhiro Majima, Haruo Matsushita, Ken Takeda, Keiichi Jingu

Physica Medica　48　6-10　2018年4月1日
出版者・発行元： Associazione Italiana di Fisica Medica
DOI： 10.1016/j.ejmp.2018.03.006 　

ISSN：1724-191X 1120-1797
Image-guided interstitial high-dose-rate brachytherapy for locally recurrent uterine cervical cancer: A single-institution study 査読有り

Rei Umezawa, Naoya Murakami, Satoshi Nakamura, Akihisa Wakita, Hiroyuki Okamoto, Keisuke Tsuchida, Tairo Kashihara, Kazuma Kobayashi, Ken Harada, Kana Takahashi, Koji Inaba, Yoshinori Ito, Hiroshi Igaki, Koji Masui, Ken Yoshida, Keiichi Jingu, Nikolaos Tselis, Jun Itami

Brachytherapy　17　(2)　368-376　2018年3月1日
出版者・発行元： Elsevier Inc.
DOI： 10.1016/j.brachy.2017.11.011 　

ISSN：1873-1449 1538-4721
Impact of a commercially available model-based dose calculation algorithm on treatment planning of high-dose-rate brachytherapy in patients with cervical cancer. 国際誌査読有り

Kota Abe, Noriyuki Kadoya, Shinya Sato, Shimpei Hashimoto, Yujiro Nakajima, Yuya Miyasaka, Kengo Ito, Rei Umezawa, Takaya Yamamoto, Noriyoshi Takahashi, Ken Takeda, Keiichi Jingu

Journal of radiation research　59　(2)　198-206　2018年3月1日

DOI： 10.1093/jrr/rrx081 　

ISSN：0449-3060

詳細を見る詳細を閉じる

We evaluated the impact of model-based dose calculation algorithms (MBDCAs) on high-dose-rate brachytherapy (HDR-BT) treatment planning for patients with cervical cancer. Seven patients with cervical cancer treated using HDR-BT were studied. Tandem and ovoid applicators were used in four patients, a vaginal cylinder in one, and interstitial needles in the remaining two patients. MBDCAs were applied to the Advanced Collapsed cone Engine (ACE; Elekta, Stockholm, Sweden). All plans, which were originally calculated using TG-43, were re-calculated using both ACE and Monte Carlo (MC) simulations. Air was used as the rectal material. The mean difference in the rectum D2cm3 between ACErec-air and MCrec-air was 8.60 ± 4.64%, whereas that in the bladder D2cm3 was -2.80 ± 1.21%. Conversely, in the small group analysis (n = 4) using water instead of air as the rectal material, the mean difference in the rectum D2cm3 between TG-43 and ACErec-air was 11.87 ± 2.65%, whereas that between TG-43 and ACErec-water was 0.81 ± 2.04%, indicating that the use of water as the rectal material reduced the difference in D2cm3 between TG-43 and ACE. Our results suggested that the differences in the dose-volume histogram (DVH) parameters of TG-43 and ACE were large for the rectum when considerable air (gas) volume was present in it, and that this difference was reduced when the air (gas) volume was reduced. Also, ACE exhibited better dose calculation accuracy than that of TG-43 in this situation. Thus, ACE may be able to calculate the dose more accurately than TG-43 for HDR-BT in treating cervical cancers, particularly for patients with considerable air (gas) volume in the rectum.
頭頸部原発骨肉腫の6例査読有り

嵯峨井俊, 小川武則, 臼渕肇, 小嶋郁穂, 村田隆紀, 高橋昌宏, 西條憲, 加藤健吾, 中目亜矢子, 大越明, 東賢二郎, 石井亮, 香取幸夫

頭頸部外科　27　(3)　379-385　2018年2月
出版者・発行元：特定非営利活動法人日本頭頸部外科学会
DOI： 10.5106/jjshns.27.379 　

ISSN：1349-581X

eISSN：1884-474X
当院における頭頸部メルケル細胞癌の放射線治療成績

山本貴也, 松下晴雄, 久保園正樹, 田邊隆哉, 石川陽二郎, 古積麻衣子, 高橋紀善, 片桐佑, 武田一也, 田坂俊, 福井勝哉, 鈴木友, 角谷倫之, 伊藤謙吾, 千葉瑞己, 神宮啓一, 土橋卓, 武田賢

Japanese Journal of Radiology　36　(Suppl.)　4-4　2018年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
II・III期食道癌CRTにおける血液検査データと予後との関連

武田一也, 松下晴雄, 久保園正樹, 田邊隆哉, 石川陽二郎, 山本貴也, 古積麻衣子, 高橋紀善, 片桐佑, 田坂俊, 福井勝哉, 鈴木友, 角谷倫之, 伊藤謙吾, 千葉瑞己, 神宮啓一, 武田賢, 土橋卓, 梅澤玲

Japanese Journal of Radiology　36　(Suppl.)　5-5　2018年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
pT3前立腺癌術後PSA再発に対する救済照射症例に関する検討

福井勝哉, 松下晴雄, 久保園正樹, 田邊隆哉, 石川陽二郎, 山本貴也, 古積麻衣子, 高橋紀善, 片桐佑, 武田一也, 田坂俊, 鈴木友, 角谷倫之, 伊藤謙吾, 千葉瑞己, 神宮啓一

Japanese Journal of Radiology　36　(Suppl.)　8-8　2018年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
進行頭頸部癌に対するQuad Shot(1回3.5Gy、BID、1コース14Gy4分割)での治療経験

松下晴雄, 久保園正樹, 田邊隆哉, 石川陽二郎, 山本貴也, 古積麻衣子, 高橋紀善, 片桐佑, 武田一也, 田坂俊, 福井勝哉, 鈴木友, 角谷倫之, 伊藤謙吾, 千葉瑞己, 神宮啓一, 武田賢, 土橋卓

Japanese Journal of Radiology　36　(Suppl.)　10-10　2018年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
Native T1値と細胞外容積分画を用いた放射線心筋傷害の評価

高木英誠, 大田英揮, 高瀬圭, 梅沢玲, 神宮啓一

Japanese Journal of Radiology　36　(Suppl.)　2-2　2018年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
Dosimetric evaluation of MLC-based dynamic tumor tracking radiotherapy using digital phantom: Desired setup margin for tracking radiotherapy 査読有り

Noriyuki Kadoya, Kei Ichiji, Tomoya Uchida, Yujiro Nakajima, Ryutaro Ikeda, Yosuke Uozumi, Xiaoyong Zhang, Ivo Bukovsky, Takaya Yamamoto, Ken Takeda, Yoshihiro Takai, Keiichi Jingu, Noriyasu Homma

Medical Dosimetry　43　(1)　74-81　2018年2月1日
出版者・発行元： Elsevier Inc.
DOI： 10.1016/j.meddos.2017.08.005 　

ISSN：1873-4022 0958-3947
Knockdown of AMPKα decreases ATM expression and increases radiosensitivity under hypoxia and nutrient starvation in an SV40-transformed human fibroblast cell line, LM217. 査読有り

Murata Y, Hashimoto T, Urushihara Y, Shiga S, Takeda K, Jingu K, Hosoi Y

Biochemical and biophysical research communications　495　(4)　2566-2572　2018年1月22日
出版者・発行元：
DOI： 10.1016/j.bbrc.2017.12.141 　

ISSN：1090-2104 0006-291X
Prognostic Value of Radiation Pneumonitis After Stereotactic Body Radiotherapy: Effect of Pulmonary Emphysema Quantitated Using CT Images 査読有り

Takaya Yamamoto, Noriyuki Kadoya, Yoshinao Sato, Haruo Matsushita, Rei Umezawa, Masaki Kubozono, Yojiro Ishikawa, Maiko Kozumi, Noriyoshi Takahashi, Yohei Morishita, Yu Katagiri, Kiyokazu Sato, Kengo Ito, Ken Takeda, Keiichi Jingu

Clinical Lung Cancer　19　(1)　e85-e90　2018年1月1日
出版者・発行元： Elsevier Inc.
DOI： 10.1016/j.cllc.2017.05.022 　

ISSN：1938-0690 1525-7304

eISSN：1938-0690
Quantifying the performance of two different types of commercial software programs for 3D patient dose reconstruction for prostate cancer patients: Machine log files vs. machine log files with EPID images. 国際誌査読有り

Noriyuki Kadoya, Yoshio Kon, Yoshiki Takayama, Takuya Matsumoto, Naoki Hayashi, Yoshiyuki Katsuta, Kengo Ito, Takahito Chiba, Suguru Dobashi, Ken Takeda, Keiichi Jingu

Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)　45　170-176　2018年1月

DOI： 10.1016/j.ejmp.2017.12.018 　

ISSN：1120-1797

詳細を見る詳細を閉じる

We clarified the reconstructed 3D dose difference between two different commercial software programs (Mobius3D v2.0 and PerFRACTION v1.6.4). Five prostate cancer patients treated with IMRT (74 Gy/37 Fr) were studied. Log files and cine EPID images were acquired for each fraction. 3D patient dose was reconstructed using log files (Mobius3D) or log files with EPID imaging (PerFRACTION). The treatment planning dose was re-calculated on homogeneous and heterogeneous phantoms, and log files and cine EPID images were acquired. Measured doses were compared with the reconstructed point doses in the phantom. Next, we compared dosimetric metrics (mean dose for PTV, rectum, and bladder) calculated by Mobius3D and PerFRACTION for all fractions from five patients. Dose difference at isocenter between measurement and reconstructed dose for two software programs was within 3.0% in both homogeneous and heterogeneous phantoms. Moreover, the dose difference was larger using skip arc plan than that using full arc plan, especially for PerFRACTION (e.g., dose difference at isocenter for PerFRACTION: 0.34% for full arc plan vs. -4.50% for skip arc plan in patient 1). For patients, differences in dosimetric parameters were within 1% for almost all fractions. PerFRACTION had wider range of dose difference between first fraction and the other fractions than Mobius3D (e.g., maximum difference: 0.50% for Mobius3D vs. 1.85% for PerFRACTION), possibly because EPID may detect some types of MLC positioning errors such as miscalibration errors or mechanical backlash which cannot be detected by log files, or that EPID data might include image acquisition failure and image noise.
Assessment and agreement of the CT appearance pattern and its severity grading of radiation-induced lung injury after stereotactic body radiotherapy for lung cancer. 国際誌査読有り

Takaya Yamamoto, Noriyuki Kadoya, Yohei Morishita, Yoshinao Sato, Haruo Matsushita, Rei Umezawa, Yojiro Ishikawa, Noriyoshi Takahashi, Yu Katagiri, Ken Takeda, Keiichi Jingu

PloS one　13　(10)　e0204734　2018年

DOI： 10.1371/journal.pone.0204734 　

詳細を見る詳細を閉じる

PURPOSE: Radiographic severity of radiation-induced lung injury (RILI) has not been well-studied. The goal of this study was to assess the CT appearance pattern and severity of RILI without consideration of the clinical presentation. MATERIAL AND METHODS: A total of 49 patients, 41 with primary lung cancer and 8 with metastatic lung cancer, were treated by 4-fraction stereotactic body radiotherapy (SBRT). RILI after SBRT was separately assessed by two observers. The early and late CT appearance patterns and CT-based severity grading were explored. RESULTS: The median follow-up period was 39.0 months. In the early CT findings of observers 1 and 2, there was diffuse consolidation in 15 and 8, diffuse ground glass opacity (GGO) in 0 and 0, patchy consolidation and GGO in 17 and 20, patchy GGO in 3 and 3, and no changes in 10 and 14, respectively (kappa = 0.61). In late CT findings of observer 1 and 2, there were modified conventional pattern in 28 and 24, mass-like pattern in 8 and 11, scar-like pattern in 12 and 12, and no changes in 1 and 2, respectively (kappa = 0.63). In the results of the CT-based grading by observers 1 and 2, there were grade 0 in 1 and 2, grade 1 in 10 and 14, grade 2 in 31 and 29, grade 3 in 7 and 4, and none of grade 4 or more, respectively (kappa = 0.66). According to multivariate analyses (MVA), the significant predicting factors of grade 2 or more CT-based RILI were age (p = 0.01), oxygen dependence (p = 0.03) and interstitial shadow (p = 0.03). CONCLUSIONS: The agreement of the CT appearance and CT-based grading between two observers was good. These indicators may be able to provide us with more objective information and a better understanding of RILI.
Patient-Specific Quality Assurance Using Monte Carlo Dose Calculation and Elekta Log Files for Prostate Volumetric-Modulated Arc Therapy 査読有り

Yoshiyuki Katsuta, Noriyuki Kadoya, Yukio Fujita, Eiji Shimizu, Kenichi Matsunaga, Kinya Sawada, Haruo Matsushita, Kazuhiro Majima, Keiichi Jingu

TECHNOLOGY IN CANCER RESEARCH & TREATMENT　16　(6)　1220-1225　2017年12月

DOI： 10.1177/1533034617745250 　

ISSN：1533-0346

eISSN：1533-0338
CT画像から作成する肺機能画像の臨床利用に向けて最適なCT撮影法の検討

中島祐二朗, 木藤哲史, 唐澤克之, 角谷倫之, 神宮啓一

東京都福祉保健医療学会抄録　13回　28-29　2017年11月
出版者・発行元： (公財)東京都福祉保健財団人材養成部職員研修室
Long-Term Outcome of Surgery or Stereotactic Radiotherapy for Lung Oligo-recurrence 査読有り

Yuzuru Niibe, Keiichi Jingu, Hiroshi Onishi

Journal of Thoracic Oncology　12　(11)　e191　2017年11月1日
出版者・発行元： Elsevier Inc
DOI： 10.1016/j.jtho.2017.07.035 　

ISSN：1556-1380 1556-0864
Clinical utility of texture analysis of 18F-FDG PET/CT in patients with Stage I lung cancer treated with stereotactic body radiotherapy 査読有り

Kazuya Takeda, Kentaro Takanami, Yuko Shirata, Takaya Yamamoto, Noriyoshi Takahashi, Kengo Ito, Kei Takase, Keiichi Jingu

JOURNAL OF RADIATION RESEARCH　58　(6)　862-869　2017年11月

DOI： 10.1093/jrr/rrx050 　

ISSN：0449-3060

eISSN：1349-9157
Clinical impact of dosimetric changes for volumetric modulated arc therapy in log file-based patient dose calculations 査読有り

Yoshiyuki Katsuta, Noriyuki Kadoya, Yukio Fujita, Eiji Shimizu, Kenichi Matsunaga, Haruo Matsushita, Kazuhiro Majima, Keiichi Jingu

PHYSICA MEDICA-EUROPEAN JOURNAL OF MEDICAL PHYSICS　42　1-6　2017年10月

DOI： 10.1016/j.ejmp.2017.08.004 　

ISSN：1120-1797

eISSN：1724-191X
Re-irradiation for oligo-recurrence from esophageal cancer with radiotherapy history: a multi-institutional study 査読有り

Keiichi Jingu, Yuzuru Niibe, Hideomi Yamashita, Kuniaki Katsui, Toshihiko Matsumoto, Tomohiro Nishina, Atsuro Terahara

RADIATION ONCOLOGY　12　(1)　146　2017年9月

DOI： 10.1186/s13014-017-0882-0 　

ISSN：1748-717X
Evaluation of rectum and bladder dose accumulation from external beam radiotherapy and brachytherapy for cervical cancer using two different deformable image registration techniques 査読有り

Noriyuki Kadoya, YuYa Miyasaka, Takaya Yamamoto, Yoshihiro Kuroda, Kengo Ito, Mizuki Chiba, Yujiro Nakajima, Noriyoshi Takahashi, Masaki Kubozono, Rei Umezawa, Suguru Dobashi, Ken Takeda, Keiichi Jingu

JOURNAL OF RADIATION RESEARCH　58　(5)　720-728　2017年9月

DOI： 10.1093/jrr/rrx028 　

ISSN：0449-3060

eISSN：1349-9157
Comparison of DVH-based plan verification methods for VMAT: ArcCHECK-3DVH system and dynalog-based dose reconstruction 査読有り

Masahide Saito, Noriyuki Kadoya, Kiyokazu Sato, Kengo Ito, Suguru Dobashi, Ken Takeda, Hiroshi Onishi, Keiichi Jingu

Journal of Applied Clinical Medical Physics　18　(4)　206-214　2017年7月1日
出版者・発行元： John Wiley and Sons Ltd
DOI： 10.1002/acm2.12123 　

ISSN：1526-9914
Effect of DIR uncertainty on prostate passive-scattering proton therapy dose accumulation 査読有り

Yoshitomo Abe, Noriyuki Kadoya, Kazuhiro Arai, Yoshiki Takayama, Takahiro Kato, Kanako Kimura, Takashi Ono, Tatsuya Nakamura, Hitoshi Wada, Yasuhiro Kikuchi, Keiichi Jingu

PHYSICA MEDICA-EUROPEAN JOURNAL OF MEDICAL PHYSICS　39　113-120　2017年7月

DOI： 10.1016/j.ejmp.2017.06.005 　

ISSN：1120-1797

eISSN：1724-191X
Evaluation of the performance of deformable image registration between planning CT and CBCT images for the pelvic region: comparison between hybrid and intensity-based DIR 査読有り

Yoshiki Takayama, Noriyuki Kadoya, Takaya Yamamoto, Kengo Ito, Mizuki Chiba, Kousei Fujiwara, Yuya Miyasaka, Suguru Dobashi, Kiyokazu Sato, Ken Takeda, Keiichi Jingu

JOURNAL OF RADIATION RESEARCH　58　(4)　567-571　2017年7月

DOI： 10.1093/jrr/rrw123 　

ISSN：0449-3060

eISSN：1349-9157
Feasibility of a Direct-Conversion Method from Magnetic Susceptibility to Relative Electron Density for Radiation Therapy Treatment Planning 査読有り

Kengo Ito, Noriyuki Kadoya, Yujiro Nakajima, Masahide Saito, Kiyokazu Sato, Tatsuo Nagasaka, Kazuomi Yamanaka, Suguru Dobashi, Ken Takeda, Haruo Matsushita, Keiichi Jingu

Int J Med Phys Clin Eng Radiat Oncol　(6)　252-265　2017年7月
Radiation-induced heart disease after treatment for esophageal cancer 査読有り

Keiichi Jingu, Rei Umezawa, Katsuya Fukui

ESOPHAGUS　14　(3)　215-220　2017年7月

DOI： 10.1007/s10388-017-0569-5 　

ISSN：1612-9059

eISSN：1612-9067
Successful corticosteroid treatment for pleural effusion due to radiation-induced pleuritis after chemoradiotherapy in a patient with esophageal cancer 査読有り

Kumagai Takuro, Nakano Toru, Matsushita Haruo, Jingu Keiichi, Ohuchi Noriaki, Kamei Takashi

INTERNATIONAL CANCER CONFERENCE JOURNAL　6　(3)　138-143　2017年7月

DOI： 10.1007/s13691-017-0293-y 　

ISSN：2192-3183
心臓MRI検査を用いた食道癌化学放射線療法後の心筋障害に対する前向き研究

梅澤玲, 角谷倫之, 大田英揮, 高橋紀善, 高瀬圭, 神宮啓一

日本食道学会学術集会プログラム・抄録集　71回　P27-7　2017年6月
出版者・発行元： (NPO)日本食道学会
Minimal impact of postmastectomy radiation therapy on locoregional recurrence for breast cancer patients with 1 to 3 positive lymph nodes in the modern treatment era 査読有り

Minoru Miyashita, Hiroshi Tada, Akihiko Suzuki, Gou Watanabe, Hisashi Hirakawa, Masakazu Amari, Yoichiro Kakugawa, Masaaki Kawai, Akihiko Furuta, Kaoru Sato, Ryuichi Yoshida, Akiko Ebata, Hironobu Sasano, Keiichi Jingu, Noriaki Ohuchi, Takanori Ishida

SURGICAL ONCOLOGY-OXFORD　26　(2)　163-170　2017年6月

DOI： 10.1016/j.suronc.2017.03.003 　

ISSN：0960-7404

eISSN：1879-3320
Dose Escalation Improves Outcome in Stereotactic Body Radiotherapy for Pulmonary Oligometastases from Colorectal Cancer 査読有り

Keiichi Jingu, Yukinori Matsuo, Hiroshi Onishi, Takaya Yamamoto, Masahiko Aoki, Yuji Murakami, Hideomi Yamashita, Hisao Kakuhara, Kenji Nemoto, Toru Sakayauchi, Masahiko Okamoto, Yuzuru Niibe, Yasushi Nagata, Kazuhiko Ogawa

ANTICANCER RESEARCH　37　(5)　2709-2713　2017年5月

DOI： 10.21873/anticanres.11621 　

ISSN：0250-7005

eISSN：1791-7530
Feasibility of a Direct-Conversion Method from Magnetic Susceptibility to Relative Electron Density for Radiation Therapy Treatment Planning 査読有り

Ito K, Kaodya N, Nakajima Y, Saito M, Sato K, Nagasaka T, Yamanaka K, Dobashi S, Takeda K, Matsushita H, Jingu K

International Journal of Medical Physics, Clinical Engineering and Radiation Oncology　6　(2)　111-123　2017年5月

DOI： 10.4236/ijmpcero.2017.63023 　

ISSN：2168-5444
Definitive carbon-ion radiotherapy for locally advanced parotid gland carcinomas 査読有り

Masashi Koto, Azusa Hasegawa, Ryo Takagi, Hiroaki Ikawa, Kensuke Naganawa, Jun-etsu Mizoe, Keiichi Jingu, Hirohiko Tsujii, Hiroshi Tsuji, Tadashi Kamada, Yoshitaka Okamoto

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK　39　(4)　724-729　2017年4月

DOI： 10.1002/hed.24671 　

ISSN：1043-3074

eISSN：1097-0347
Prognostic factors associated with the accuracy of deformable image registration in lung cancer patients treated with stereotactic body radiotherapy 査読有り

Yasuharu Sugawara, Hidenobu Tachibana, Noriyuki Kadoya, Nozomi Kitamura, Amit Sawant, Keiichi Jingu

Medical Dosimetry　42　(4)　326-333　2017年2月4日
出版者・発行元： Elsevier Inc.
DOI： 10.1016/j.meddos.2017.07.004 　

ISSN：1873-4022 0958-3947
眼球NK-T細胞リンパ腫に対する放射線治療経過報告

田坂俊, 松下晴雄, 久保園正樹, 白田佑子, 田邊隆哉, 石川陽二郎, 古積麻衣子, 高橋紀善, 片桐佑, 福井勝哉, 武田一也, 角谷倫之, 伊藤謙吾, 千葉瑞己, 神宮啓一, 武田賢, 土橋卓

Japanese Journal of Radiology　35　(Suppl.)　9-9　2017年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
化学放射線療法が著効した肺原発Pleomorphic carcinomaの1例

武田一也, 松下晴雄, 久保園正樹, 白田佑子, 田邊隆哉, 石川陽二郎, 古積麻衣子, 高橋紀善, 片桐佑, 田坂俊, 福井勝哉, 角谷倫之, 伊藤謙吾, 千葉瑞己, 神宮啓一, 武田賢, 土橋卓, 藤島史喜

Japanese Journal of Radiology　35　(Suppl.)　9-9　2017年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
肝腫瘍への定位照射を目的としたCTガイド下金マーカー留置術における合併症の検討

高橋祐輝, 松浦智徳, 榊原宏幸, 森下陽平, 加賀谷由里子, 野村脩子, 木下知, 長谷川哲也, 佐藤嘉尚, 嶋内亜希子, 森菜緒子, 大田英揮, 常陸真, 北見昌広, 冨永循哉, 清治和将, 高瀬圭, 神宮啓一, 小川芳弘

Japanese Journal of Radiology　35　(Suppl.)　2-2　2017年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
4D-CTを用いた肺機能画像の生理学的評価

金井貴幸, 根本建二, 角谷倫之, 伊藤謙吾, 岸和馬, 松下晴雄, 神宮啓一, 武田賢

Japanese Journal of Radiology　35　(Suppl.)　4-4　2017年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
Definitive salvage radiation therapy and chemoradiation therapy for lymph node oligo-recurrence of esophageal cancer: a Japanese multi-institutional study of 237 patients 査読有り

Hideomi Yamashita, Keiichi Jingu, Yuzuru Niibe, Kuniaki Katsui, Toshihiko Matsumoto, Tomohiro Nishina, Atsuro Terahara

RADIATION ONCOLOGY　12　(1)　38　2017年2月

DOI： 10.1186/s13014-017-0780-5 　

ISSN：1748-717X
Evaluation of deformable image registration between external beam radiotherapy and HDR brachytherapy for cervical cancer with a 3D-printed deformable pelvis phantom. 査読有り

Kadoya N, Miyasaka Y, Nakajima Y, Kuroda Y, Ito K, Chiba M, Sato K, Dobashi S, Yamamoto T, Takahashi N, Kubozono M, Takeda K, Jingu K

Med Phys　44　(4)　1445-1455　2017年2月
CBCTを用いた適応放射線治療

千葉瑞己, 角谷倫之, 伊藤謙吾, 岸和馬, 佐藤清和, 松下晴雄, 神宮啓一, 武田賢, 土橋卓

Japanese Journal of Radiology　35　9-9　2017年2月
Elective nodal irradiation is not necessary in chemoradiotherapy for postoperative loco-regional recurrent esophageal cancer 査読有り

Keiichi Jingu, Rei Umezawa, Takaya Yamamoto, Haruo Matsushita, Youjirou Ishikawa, Maiko Kozumi, Masaki Kubozono, Noriyoshi Takahashi, Noriyuki Kadoya, Ken Takeda

Japanese Journal of Clinical Oncology　47　(3)　200-205　2017年
出版者・発行元： Oxford University Press
DOI： 10.1093/jjco/hyw195 　

ISSN：1465-3621 0368-2811
Feasibility of CBCT-based proton dose calculation using a histogram-matching algorithm in proton beam therapy 査読有り

Kazuhiro Arai, Noriyuki Kadoya, Takahiro Kato, Hiromitsu Endo, Shinya Komori, Yoshitomo Abe, Tatsuya Nakamura, Hitoshi Wada, Yasuhiro Kikuchi, Yoshihiro Takai, Keiichi Jingu

PHYSICA MEDICA-EUROPEAN JOURNAL OF MEDICAL PHYSICS　33　68-76　2017年1月

DOI： 10.1016/j.ejmp.2016.12.006 　

ISSN：1120-1797

eISSN：1724-191X
3D プリンタで作製した頭頚部放射線治療補助固定具の検討～従来固定具との固定精度および線量特性比較調査～

佐藤清和, 武田賢, 土橋卓, 角谷倫之, 伊藤謙吾, 千葉瑞己, 岸和馬, 梁川功, 神宮啓一

日放技学誌　73　(1)　57-65　2017年
出版者・発行元：公益社団法人日本放射線技術学会
DOI： 10.6009/jjrt.2017_JSRT_73.1.57 　

ISSN：0369-4305

詳細を見る詳細を閉じる

<p>Our aim was to investigate the feasibility of a three-dimensional (3D) -printed head-and-neck (HN) immobilization device by comparing its positional accuracy and dosimetric properties with those of a conventional immobilization device (CID). We prepared a 3D-printed immobilization device (3DID) consisting of a mask and headrest with acrylonitrile-butadiene-styrene resin developed from the computed tomography data obtained by imaging a HN phantom. For comparison, a CID comprising a thermoplastic mask and headrest was prepared using the same HN phantom. We measured the setup error using the ExacTrac X-ray image system. Furthermore, using the ionization chamber and the water-equivalent phantom, we measured the changes in the dose due to the difference in the immobilization device material from the photon of 4 MV and 6 MV. The positional accuracy of the two devices were almost similar in each direction except in the vertical, lateral, and pitch directions (t-test, p<0.0001), and the maximum difference was 1 mm, and 1°. The standard deviations were not statistically different in each direction except in the longitudinal (F-test, p=0.034) and roll directions (F-test, p<0.0001). When the thickness was the same, the dose difference was almost similar at a 50 mm depth. At a 1 mm depth, the 3DID-plate had a 2.9–4.2% lower dose than the CID-plate. This study suggested that the positional accuracy and dosimetric properties of 3DID were almost similar to those of CID.</p>
頭頸部メルケル細胞癌の放射線治療経験査読有り

山本貴也, 角谷倫之, 松下晴雄, 藤村卓, 片桐佑, 福井勝哉, 中島祐二朗, 久保園正樹, 佐藤清和, 武田賢, 相場節也, 神宮啓一

臨床放射線　61　(13)　1781-1786　2016年12月
出版者・発行元：金原出版(株)
ISSN：0009-9252
Metabolic tumor volume on FDG-PET/CT is a possible prognostic factor for Stage I lung cancer patients treated with stereotactic body radiation therapy: a retrospective clinical study 査読有り

Noriyoshi Takahashi, Takaya Yamamoto, Haruo Matsushita, Toshiyuki Sugawara, Masaki Kubozono, Rei Umezawa, Yojiro Ishikawa, Maiko Kozumi, Yu Katagiri, Syun Tasaka, Kazuya Takeda, Ken Takeda, Suguru Dobashi, Keiichi Jingu

JOURNAL OF RADIATION RESEARCH　57　(6)　655-661　2016年11月

DOI： 10.1093/jrr/rrw048 　

ISSN：0449-3060

eISSN：1349-9157
Multi-institutional Validation Study of Commercially Available Deformable Image Registration Software for Thoracic Images 査読有り

Noriyuki Kadoya, Yujiro Nakajima, Masahide Saito, Yuki Miyabe, Masahiko Kurooka, Satoshi Kito, Yukio Fujita, Motoharu Sasaki, Kazuhiro Arai, Kensuke Tani, Masashi Yagi, Akihisa Wakita, Naoki Tohyama, Keiichi Jingu

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS　96　(2)　422-431　2016年10月

DOI： 10.1016/j.ijrobp.2016.05.012 　

ISSN：0360-3016

eISSN：1879-355X
Oligo-recurrence predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy: A multi-institutional study of 61 subjects 査読有り

Yuzuru Niibe, Tetsuo Nishimura, Tetsuya Inoue, Katsuyuki Karasawa, Yoshiyuki Shioyama, Keiichi Jingu, Hiroki Shirato

BMC Cancer　16　(1)　2016年8月19日
出版者・発行元： BioMed Central Ltd.
DOI： 10.1186/s12885-016-2680-8 　

ISSN：1471-2407
Borderline resectable膵癌と術前化学放射線療法招待有り

中川圭, 元井冬彦, 水間正道, 中村聡明, 片寄友, 神宮啓一, 海野倫明

コンセンサス癌治療　14　(2)　107-110　2016年7月
Lung stereotactic radiotherapy for oligometastases: comparison of oligo-recurrence and sync-oligometastases 査読有り

Hideomi Yamashita, Yuzuru Niibe, Takaya Yamamoto, Kuniaki Katsui, Keiichi Jingu, Susumu Kanazawa, Atsuro Terahara, Keiichi Nakagawa

JAPANESE JOURNAL OF CLINICAL ONCOLOGY　46　(7)　687-691　2016年7月

DOI： 10.1093/jjco/hyw047 　

ISSN：0368-2811

eISSN：1465-3621
Comparison of visual biofeedback system with a guiding waveform and abdomen-chest motion self-control system for respiratory motion management 査読有り

Yujiro Nakajima, Noriyuki Kadoya, Takayuki Kanai, Kengo Ito, Kiyokazu Sato, Suguru Dobashi, Takaya Yamamoto, Yojiro Ishikawa, Haruo Matsushita, Ken Takeda, Keiichi Jingu

JOURNAL OF RADIATION RESEARCH　57　(4)　387-392　2016年7月

DOI： 10.1093/jrr/rrv106 　

ISSN：0449-3060

eISSN：1349-9157
Evaluation of four-dimensional computed tomography (4D-CT)-based pulmonary ventilation: The high correlation between 4D-CT ventilation and Kr-81m-planar images was found 査読有り

Takayuki Kanai, Noriyuki Kadoya, Kengo Ito, Kazuma Kishi, Suguru Dobashi, Takaya Yamamoto, Rei Umezawa, Haruo Matsushita, Ken Takeda, Keiichi Jingu

RADIOTHERAPY AND ONCOLOGY　119　(3)　444-448　2016年6月

DOI： 10.1016/j.radonc.2016.04.030 　

ISSN：0167-8140
Quantification of residual dose estimation error on log file-based patient dose calculation 査読有り

Yoshiyuki Katsuta, Noriyuki Kadoya, Yukio Fujita, Eiji Shimizu, Kenichi Matsunaga, Haruo Matsushita, Kazuhiro Majima, Keiichi Jingu

PHYSICA MEDICA-EUROPEAN JOURNAL OF MEDICAL PHYSICS　32　(5)　701-705　2016年5月

DOI： 10.1016/j.ejmp.2016.04.015 　

ISSN：1120-1797

eISSN：1724-191X
Impact of postmastectomy radiation therapy on locoregional recurrence for breast cancer patients with 1 to 3 positive lymph nodes in the modern treatment era. 査読有り

Minoru Miyashita, Takanori Ishida, Akihiko Suzuki, Hiroshi Tada, Gou Watanabe, Narumi Harada-shoji, Akiko Sato-Tadano, Hisashi Hirakawa, Masakazu Amari, Kentaro Tamaki, Hironobu Sasano, Keiichi Jingu, Noriaki Ohuchi

JOURNAL OF CLINICAL ONCOLOGY　34　(15)　2016年5月

DOI： 10.1200/JCO.2016.34.15_suppl.1046 　

ISSN：0732-183X

eISSN：1527-7755
Renal atrophy after stereotactic body radiotherapy for renal cell carcinoma 査読有り

Takaya Yamamoto, Noriyuki Kadoya, Ken Takeda, Haruo Matsushita, Rei Umezawa, Kiyokazu Sato, Masaki Kubozono, Kengo Ito, Yojiro Ishikawa, Maiko Kozumi, Noriyoshi Takahashi, Yu Katagiri, Hiroshi Onishi, Keiichi Jingu

RADIATION ONCOLOGY　11　(1)　72　2016年5月

DOI： 10.1186/s13014-016-0651-5 　

ISSN：1748-717X
OC-0271: Positional accuracy valuation of a three dimensional printed device for head and neck immobilisation 査読有り

K. Sato, K. Takeda, S. Dobashi, K. Kishi, N. Kadoya, K. Ito, M. Chiba, K. Jingu

Radiotherapy and Oncology　119　S126-S127　2016年4月
出版者・発行元： Elsevier BV
DOI： 10.1016/s0167-8140(16)31520-1 　

ISSN：0167-8140
Dosemetric Parameters Predictive of Rib Fractures after Proton Beam Therapy for Early-Stage Lung Cancer 査読有り

Yojiro Ishikawa, Tatsuya Nakamura, Takahiro Kato, Noriyuki Kadoya, Motohisa Suzuki, Yusuke Azami, Masato Hareyama, Yasuhiro Kikuchi, Keiichi Jingu

TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE　238　(4)　339-345　2016年4月

DOI： 10.1620/tjem.238.339 　

ISSN：0040-8727

eISSN：1349-3329
Evaluation of the safety and efficacy of carbon ion radiotherapy for locally advanced adenoid cystic carcinoma of the tongue base 査読有り

Masashi Koto, Azusa Hasegawa, Ryo Takagi, Hiroaki Ikawa, Kensuke Naganawa, Jun-etsu Mizoe, Keiichi Jingu, Hirohiko Tsujii, Hiroshi Tsuji, Tadashi Kamada, Yoshitaka Okamoto

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK　38　E2122-E2126　2016年4月

DOI： 10.1002/hed.24397 　

ISSN：1043-3074

eISSN：1097-0347
Association between radiation dose to the heart and myocardial fatty acid metabolic impairment due to chemoradiation-therapy: Prospective study using I-123 BMIPP SPECT/CT 査読有り

Kentaro Takanami, Akira Arai, Rei Umezawa, Takashi Takeuchi, Noriynki Kadoya, Yasuyuki Taki, Keiichi Jingu, Kei Takase

RADIOTHERAPY AND ONCOLOGY　119　(1)　77-83　2016年4月

DOI： 10.1016/j.radonc.2016.01.024 　

ISSN：0167-8140
Clinical and volumetric prognostic factors in external beam radiotherapy for head and neck cancer 査読有り

K. Takeda, H. Matsushita, T. Ogawa, S. Dobashi, Y. Ishizawa, K. Chida, N. Kadoya, K. Ito, M. Chiba, M. Kubozono, R. Umezawa, Y. Shirata, Y. Ishikawa, T. Yamamoto, M. Kozumi, T. Tanabe, N. Takahashi, Y. Katagiri, S. Tazaka, K. Takeda, K. Sato, Y. Katori, K. Jingu

Radiother Oncol　119　(1)　504-505　2016年4月
Carbon ion radiotherapy for locally advanced squamous cell carcinoma of the external auditory canal and middle ear

Masashi Koto, Azusa Hasegawa, Ryo Takagi, Go Sasahara, Hiroaki Ikawa, Jun-etsu Mizoe, Keiichi Jingu, Hirohiko Tsujii, Tadashi Kamada, Yoshitaka Okamoto

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK　38　(4)　512-516　2016年4月

DOI： 10.1002/hed.23905 　

ISSN：1043-3074

eISSN：1097-0347
Chemoradiotherapy for T4 and/or M1 lymph node esophageal cancer: experience since 2000 at a high-volume center in Japan

Keiichi Jingu, Rei Umezawa, Haruo Matsushita, Toshiyuki Sugawara, Masaki Kubozono, Takaya Yamamoto, Youjirou Ishikawa, Maiko Kozumi, Noriyoshi Takahashi, Yu Katagiri, Noriyuki Kadoya, Ken Takeda

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY　21　(2)　276-282　2016年4月

DOI： 10.1007/s10147-015-0896-2 　

ISSN：1341-9625

eISSN：1437-7772
前立腺癌74Gy照射の治療成績

石川陽二郎, 松下晴雄, 菅原俊幸, 梅澤玲, 久保園正樹, 山本貴也, 片桐佑, 古積麻衣子, 高橋紀善, 角谷倫之, 木田智士, 伊藤謙吾, 神宮啓一, 武田賢, 土橋卓

Japanese Journal of Radiology　34　(Suppl.)　5-5　2016年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
胸部食道癌II/III期に対する根治的化学放射線治療成績予後因子の検討

梅澤玲, 松下晴雄, 菅原俊幸, 久保園正樹, 山本貴也, 石川陽二郎, 片桐佑, 古積麻衣子, 高橋紀善, 角谷倫之, 木田智士, 伊藤謙吾, 神宮啓一, 武田賢, 土橋卓

Japanese Journal of Radiology　34　(Suppl.)　9-9　2016年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
縦隔へ40Gy以上照射された根治的放射線治療後、異時性肺癌に対する定位放射線治療成績の検討

山本貴也, 松下晴雄, 菅原俊幸, 梅澤玲, 久保園正樹, 石川陽二郎, 古積麻衣子, 片桐佑, 高橋紀善, 角谷倫之, 伊藤謙吾, 木田智士, 神宮啓一, 土橋卓, 武田賢

Japanese Journal of Radiology　34　(Suppl.)　9-9　2016年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
FDG-PET/CTでのMetabolic tumor volumeを用いた肺定位放射線治療に対する予後予測の検討

高橋紀善, 松下晴雄, 菅原俊幸, 梅澤玲, 久保園正樹, 石川陽二郎, 山本貴也, 片桐佑, 古積麻衣子, 角谷倫之, 木田智士, 伊藤謙吾, 神宮啓一, 土橋卓, 武田賢

Japanese Journal of Radiology　34　(Suppl.)　9-9　2016年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
3D-IGBTにおける独立線量計算の有効性の検討

伊藤謙吾, 角谷倫之, 木田智士, 高橋紀善, 古積麻衣子, 山本貴也, 石川陽二郎, 梅澤玲, 久保園正樹, 菅原俊幸, 松下晴雄, 神宮啓一, 武田賢, 土橋卓

Japanese Journal of Radiology　34　(Suppl.)　10-10　2016年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
手術不適応非小細胞肺癌III期に対する放射線治療成績東北大学病院200例超の解析結果

片桐佑, 松下晴雄, 菅原俊幸, 梅澤玲, 久保園正樹, 山本貴也, 石川陽二郎, 古積麻衣子, 高橋紀善, 角谷倫之, 木田智士, 伊藤謙吾, 神宮啓一, 土橋卓, 武田賢

Japanese Journal of Radiology　34　(Suppl.)　11-11　2016年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
縦隔放射線療法と関連した心筋代謝疾患の評価パイロットスタディ(Assessment of Myocardial Metabolic Disorder Associated with Mediastinal Radiotherapy: a pilot study)

梅澤玲, 高浪健太郎, 松下晴雄, 菅原俊幸, 久保園正樹, 山本貴也, 石川陽二郎, 片桐佑, 古積麻衣子, 高橋紀善, 角谷倫之, 木田智士, 伊藤謙吾, 神宮啓一, 武田賢, 土橋卓

Japanese Journal of Radiology　34　(Suppl.)　4-4　2016年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
Clinical outcomes of radiotherapy for esophageal cancer between 2004 and 2008: the second survey of the Japanese Radiation Oncology Study Group (JROSG)

Yasumasa Nishimura, Keiichi Jingu, Satoshi Itasaka, Yoshiharu Negoro, Yuji Murakami, Katsuyuki Karasawa, Gen Kawaguchi, Fumiaki Isohashi, Masao Kobayashi, Yoshiyuki Itoh, Takuro Ariga

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY　21　(1)　88-94　2016年2月

DOI： 10.1007/s10147-015-0872-x 　

ISSN：1341-9625

eISSN：1437-7772
Definitive Chemoradiotherapy for Advanced Pulmonary Sarcomatoid Carcinoma 査読有り

Kazuya Takeda, Haruo Matsushita, Masaki Kubozono, Takaya Tanabe, Yojiro Ishikawa, Takaya Yamamoto, Maiko Kozumi, Noriyoshi Takahashi, Yu Katagiri, Shun Tasaka, Katsuya Fukui, Ken Takeda, Fumiyoshi Fujishima, Masakazu Ichinose, Keiichi Jingu

INTERNAL MEDICINE　55　(22)　3325-3330　2016年

DOI： 10.2169/internalmedicine.55.6990 　

ISSN：0918-2918

eISSN：1349-7235
Radiation Therapy Is a Reasonable Option for Improving the Prognosis in Hepatocellular Carcinoma

Yasuteru Kondo, Osamu Kimura, Takayuki Kogure, Masashi Ninomiya, Rei Umezawa, Toshiyuki Sugawara, Haruo Matsushita, Keiichi Jingu, Yu Nakagome, Tomoaki Iwata, Tatsuki Morosawa, Yasuyuki Fujisaka, Takao Iwasaki, Tooru Shimosegawa

TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE　237　(4)　249-257　2015年12月

DOI： 10.1620/tjem.237.249 　

ISSN：0040-8727

eISSN：1349-3329
Metabolic Tumor Volume and Total Lesion Glycolysis on FDG-PET/CT Are Possible Prognostic Factors for Stage I Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy 査読有り

N. Takahashi, T. Yamamoto, K. Jingu, H. Matsushita, T. Sugawara, M. Kubozono, R. Umezawa, Y. Ishikawa, M. Kozumi, Y. Katagiri, K. Takeda

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS　93　(3)　E426-E426　2015年11月

ISSN：0360-3016

eISSN：1879-355X
Evaluation of Prognostic Factors in Clinical Blood Examinations in Patients Undergoing Chemoradiation Therapy for Stage II-III Thoracic Esophageal Cancer 査読有り

R. Umezawa, H. Matsushita, T. Sugawara, M. Kubozono, T. Yamamoto, Y. Ishikawa, M. Kozumi, N. Takahashi, Y. Katagiri, N. Kadoya, K. Takeda, K. Jingu

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS　93　(3)　E152-E153　2015年11月

ISSN：0360-3016

eISSN：1879-355X
食道癌化学放射線療法における心臓照射線量と心筋脂肪酸代謝障害の関連 BMIPP SPECT/CTによる経時的評価

高浪健太郎, 荒井晃, 梅澤玲, 角谷倫之, 竹内孝至, 神宮啓一, 高瀬圭

日独医報　60　(2)　240-240　2015年11月
出版者・発行元：バイエル薬品(株)
ISSN：0912-0351
A comparative study of the extent of cerebral microvascular injury following whole-brain irradiation versus reduced-field irradiation in long-term survivors of intracranial germ cell tumors

Li Li, Shunji Mugikura, Toshihiro Kumabe, Takaki Murata, Etsuro Mori, Kei Takase, Keiichi Jingu, Shoki Takahashi

RADIOTHERAPY AND ONCOLOGY　117　(2)　302-307　2015年11月

DOI： 10.1016/j.radonc.2015.09.017 　

ISSN：0167-8140
Investigation of the clinicopathological features of squamous cell carcinoma of the vulva: a retrospective survey of the Tohoku Gynecologic Cancer Unit

Masayuki Futagami, Yoshihito Yokoyama, Kaori Iino, Masahiko Aoki, Tadahiro Shoji, Toru Sugiyama, Hisanori Ariga, Hideki Tokunaga, Tadao Takano, Yoh Watanabe, Nobuo Yaegashi, Keiichi Jingu, Naoki Sato, Yukihiro Terada, Akira Anbai, Tsuyoshi Ohta, Hirohisa Kurachi, Yuuki Kuroda, Hiroshi Nishiyama, Keiya Fujimori, Takafumi Watanabe, Hisashi Sato, Toru Tase, Hitoshi Wada, Hideki Mizunuma

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY　20　(5)　1005-1011　2015年10月

DOI： 10.1007/s10147-015-0803-x 　

ISSN：1341-9625

eISSN：1437-7772
Formula corrected maximal standardized uptake value in FDG-PET for partial volume effect and motion artifact is not a prognostic factor in stage I non-small cell lung cancer treated with stereotactic body radiotherapy

Takaya Yamamoto, Noriyuki Kadoya, Yuko Shirata, Tomohiro Kaneta, Masashi Koto, Rei Umezawa, Youjirou Ishikawa, Masaki Kubozono, Toshiyuki Sugawara, Haruo Matsushita, Keiko Abe, Ken Takeda, Keiichi Jingu

ANNALS OF NUCLEAR MEDICINE　29　(8)　666-673　2015年10月

DOI： 10.1007/s12149-015-0991-5 　

ISSN：0914-7187

eISSN：1864-6433
Long-term results of chemoradiotherapy for stage II-III thoracic esophageal cancer in a single institution after 2000-with a focus on comparison of three protocols-

Rei Umezawa, Keiichi Jingu, Haruo Matsushita, Toshiyuki Sugawara, Masaki Kubozono, Takaya Yamamoto, Yojiro Ishikawa, Maiko Kozumi, Noriyoshi Takahashi, Yu Katagiri, Noriyuki Kadoya, Ken Takeda, Hisanori Ariga, Kenji Nemoto, Shogo Yamada

BMC CANCER　15　2015年10月

DOI： 10.1186/s12885-015-1836-2 　

ISSN：1471-2407
みかけの拡散係数パラメータによる進行食道扁平上皮癌における化学放射線療法の治療効果予測に関する研究

古積麻衣子, 大田英揮, 山本貴也, 松下晴雄, 久保園正樹, 白田佑子, 石川陽二郎, 神宮啓一

日本医学放射線学会秋季臨床大会抄録集　51回　S507-S508　2015年9月
出版者・発行元： (公社)日本医学放射線学会
ISSN：0048-0428

eISSN：1347-7951
Dosimetric impact of 4-dimensional computed tomography ventilation imaging-based functional treatment planning for stereotactic body radiation therapy with 3-dimensional conformal radiation therapy

Noriyuki Kadoya, Sang Yong Cho, Takayuki Kanai, Yusuke Onozato, Kengo Ito, Suguru Dobashi, Takaya Yamamoto, Rei Umezawa, Haruo Matsushita, Ken Takeda, Keiichi Jingu

Practical Radiation Oncology　5　(5)　e505-e512　2015年9月1日
出版者・発行元： Elsevier Inc.
DOI： 10.1016/j.prro.2015.03.001 　

ISSN：1879-8500
食道癌に対する(化学)放射線療法の施設別治療成績 2004〜2008年

西村恭昌, 神宮啓一, 板坂聡, 根来慶春, 村上祐司, 唐澤克之, 川口弦, 礒橋文明, 小林雅夫, 伊藤善之

日本食道学会学術集会プログラム・抄録集　69回　156-156　2015年7月
出版者・発行元： (NPO)日本食道学会
Comparative Effect of Different Respiratory Motion Management Systems 査読有り

Y. Nakajima, N. Kadoya, S. Kida, K. Ito, T. Kanai, K. Kishi, K. Sato, S. Dobashi, K. Takeda, K. Jingu

MEDICAL PHYSICS　42　(6)　3309-3309　2015年6月

ISSN：0094-2405
Evaluation of Patient DVH-Based QA Metrics for Prostate VMAT: Correlation Between Accuracy of Estimated 3D Patient Dose and MLC Position Error 査読有り

N. Kadoya, M. Saito, Y. Fujita, M. Ogasawara, K. Ito, K. Sato, K. Kishi, S. Dobashi, K. Takeda, K. Jingu

MEDICAL PHYSICS　42　(6)　3629-3629　2015年6月

ISSN：0094-2405
縦隔へ照射既往のある異時性第二肺癌に対する定位放射線治療成績の検討

山本貴也, 角谷倫之, 久保園正樹, 佐藤清和, 片桐佑, 松下晴雄, 菅原俊幸, 梅澤玲, 岸和馬, 伊藤謙吾, 武田賢, 神宮啓一

臨床放射線　60　(4)　556-563　2015年4月10日

ISSN：0009-9252
続発性ヘモクロマトーシスを背景とした肝細胞癌門脈腫瘍栓再発に対し放射線治療が著効した1例(続報) 査読有り

井上亨悦, 水間正道, 大塚英郎, 中川圭, 林洋毅, 岡田恭穂, 吉田寛, 元井冬彦, 内藤剛, 片寄友, 神宮啓一, 海野倫明

肝臓　56　(4)　150-156　2015年4月

DOI： 10.2957/kanzo.41.823 　
Assessment of myocardial metabolic disorder associated with mediastinal radiotherapy for esophageal cancer -a pilot study-

Rei Umezawa, Kentaro Takanami, Noriyuki Kadoya, Yujiro Nakajima, Masahide Saito, Hideki Ota, Haruo Matsushita, Toshiyuki Sugawara, Masaki Kubozono, Takaya Yamamoto, Yojiro Ishikawa, Ken Takeda, Yasuyuki Taki, Kei Takase, Keiichi Jingu

RADIATION ONCOLOGY　10　2015年4月

DOI： 10.1186/s13014-015-0410-z 　

ISSN：1748-717X
Impact of tumor attachment to the pleura measured by a pretreatment CT image on outcome of stage I NSCLC treated with stereotactic body radiotherapy

Takaya Yamamoto, Noriyuki Kadoya, Yuko Shirata, Masashi Koto, Kiyokazu Sato, Haruo Matsushita, Toshiyuki Sugawara, Rei Umezawa, Masaki Kubozono, Yojiro Ishikawa, Maiko Kozumi, Noriyoshi Takahashi, Kengo Ito, Yu Katagiri, Ken Takeda, Keiichi Jingu

RADIATION ONCOLOGY　10　2015年2月

DOI： 10.1186/s13014-015-0343-6 　

ISSN：1748-717X
Evaluation of patient DVH-based QA metrics for prostate VMAT: correlation between accuracy of estimated 3D patient dose and magnitude of MLC misalignment

Noriyuki Kadoya, Masahide Saito, Makoto Ogasawara, Yukio Fujita, Kengo Ito, Kiyokazu Sato, Kazuma Kishi, Suguru Dobashi, Ken Takeda, Keiichi Jingu

JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS　16　(3)　179-189　2015年

DOI： 10.1120/jacmp.v16i3.5251 　

ISSN：1526-9914
MRI findings of-radiation-induced myocardial damage in patients with oesophageal cancer 査読有り

R. Umezawa, H. Ota, K. Takanami, A. Ichinose, H. Matsushita, H. Saito, K. Takase, K. Jingu

CLINICAL RADIOLOGY　69　(12)　1273-1279　2014年12月

DOI： 10.1016/j.crad.2014.08.010 　

ISSN：0009-9260

eISSN：1365-229X
Clinical Factors Relating to Cervical Body Volume Reduction during Curative External Beam Radiation Therapy for Head and Neck Cancer 査読有り

Takeda K, Dobashi S, Komori S, Chida K, Kadoya N, Kida S, Ito K, Sugawara T, Kubozono M, Umezawa R, Ishikawa Y, Yamamoto T, Kozumi M, Takahashi N, Katagiri Y, Onozato Y, Kanai T, Sato K, Kishi K, Matsushita H, Ogawa T, Katori Y, Jingu K

J Nucl Med Radiat Ther　(6)　203　2014年12月
4D CTによる肺機能画像を用いた生理機能学的な線量最適化の試み

木田智士, 角谷倫之, 金井貴幸, 伊藤謙吾, 小野里侑祐, 神宮啓一

日本放射線技術学会雑誌　70　(11)　1353-1359　2014年11月
出版者・発行元： (公社)日本放射線技術学会
DOI： 10.6009/jjrt.2014_JSRT_70.11.1353 　

ISSN：0369-4305

eISSN：1881-4883
Evaluation of accuracy of B-spline transformation-based deformable image registration with different parameter settings for thoracic images

Takayuki Kanai, Noriyuki Kadoya, Kengo Ito, Yusuke Onozato, Sang Yong Cho, Kazuma Kishi, Suguru Dobashi, Rei Umezawa, Haruo Matsushita, Ken Takeda, Keiichi Jingu

JOURNAL OF RADIATION RESEARCH　55　(6)　1163-1170　2014年11月

DOI： 10.1093/jrr/rru062 　

ISSN：0449-3060

eISSN：1349-9157
Feasibility of carbon ion radiotherapy for locally advanced sinonasal adenocarcinoma

Masashi Koto, Azusa Hasegawa, Ryo Takagi, Go Sasahara, Hiroaki Ikawa, Jun-etsu Mizoe, Keiichi Jingu, Hirohiko Tsujii, Tadashi Kamada, Yoshitaka Okamoto

RADIOTHERAPY AND ONCOLOGY　113　(1)　60-65　2014年10月

DOI： 10.1016/j.radonc.2014.09.009 　

ISSN：0167-8140

eISSN：1879-0887
Impact of Tumor Attachment to the Pleura Measured by a Pretreatment CT Image on Outcome of Stage I NSCLC Treated With Stereotactic Body Radiation Therapy 査読有り

T. Yamamoto, N. Kadoya, N. Takahashi, H. Matsushita, Y. Shirata, T. Sugawara, M. Kubozono, R. Umezawa, K. Abe, S. Fujimoto, Y. Ishikawa, M. Kozumi, K. Takeda, K. Jingu

International Journal of Radiation Oncology*Biology*Physics　90　(1)　S614-S615　2014年9月
出版者・発行元： Elsevier BV
DOI： 10.1016/j.ijrobp.2014.05.1834 　

ISSN：0360-3016
Clinical Factors With Respect to Cervical Body Volume Reduction During Definitive External Beam Radiation Therapy for Oropharyngeal Squamous Cell Carcinoma 査読有り

K. Takeda, S. Dobashi, S. Komori, K. Chida, N. Kadoya, K. Itoh, T. Sugawara, M. Kubozono, R. Umezawa, Y. Ishikawa, T. Yamamoto, T. Fujimoto, M. Kozumi, Y. Onozato, T. Suzuki, H. Matsushita, K. Jingu

International Journal of Radiation Oncology*Biology*Physics　90　(1)　S511-S511　2014年9月
出版者・発行元： Elsevier BV
DOI： 10.1016/j.ijrobp.2014.05.1567 　

ISSN：0360-3016
Even Local Control of Metastatic Lung Tumors Is Worse Than That of Primary Lung Cancer in Patients Treated With Stereotactic Body Radiation Therapy 査読有り

N. Takahashi, T. Yamamoto, Y. Shirata, H. Matsushita, T. Sugawara, M. Kubozono, R. Umezawa, S. Fujimoto, Y. Ishikawa, M. Kozumi, K. Abe, K. Takeda, K. Jingu

International Journal of Radiation Oncology*Biology*Physics　90　(1)　S617-S617　2014年9月
出版者・発行元： Elsevier BV
DOI： 10.1016/j.ijrobp.2014.05.1840 　

ISSN：0360-3016
Long-Term Results of Chemoradiation Therapy for Stage II-III Thoracic Esophageal Cancer: Comparison of 3 Protocols 査読有り

R. Umezawa, K. Jingu, T. Sugawara, M. Kubozono, K. Abe, T. Fujimoto, T. Yamamoto, Y. Ishikawa, M. Kozumi, N. Kadoya, K. Takeda, H. Matsushita

International Journal of Radiation Oncology*Biology*Physics　90　(1)　S340-S340　2014年9月
出版者・発行元： Elsevier BV
DOI： 10.1016/j.ijrobp.2014.05.1113 　

ISSN：0360-3016
Dosimetric Impact of 4D-CT Ventilation Imaging-Based Functional Treatment Planning for Stereotactic Body Radiation Therapy 査読有り

N. Kadoya, S. Cho, T. Kanai, K. Ito, Y. Onozato, K. Kishi, S. Dobashi, T. Yamamoto, R. Umezawa, K. Takeda, K. Jingu

International Journal of Radiation Oncology*Biology*Physics　90　(1)　S145-S145　2014年9月
出版者・発行元： Elsevier BV
DOI： 10.1016/j.ijrobp.2014.05.613 　

ISSN：0360-3016
Assessment of Myocardial Metabolic Disorder Associated With Mediastinal Radiation Therapy for Esophageal Cancer 査読有り

R. Umezawa, K. Takanami, H. Ota, T. Kaneta, N. Kadoya, Y. Fujita, A. Arai, K. Arai, H. Matsushita, K. Takase, K. Jingu

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS　90　S205-S205　2014年9月

DOI： 10.1016/j.ijrobp.2014.05.762 　

ISSN：0360-3016

eISSN：1879-355X
頭頸部癌を対象とした198Au密封小線源治療の線量計算

伊藤謙吾, 角谷倫之, 藤田幸男, 岸和馬, 佐藤清和, 武田賢, 土橋卓, 梅澤玲, 久保園正樹, 松下晴雄, 神宮啓一

臨床放射線　59　(9)　1219-1225　2014年9月
出版者・発行元：金原出版(株)
ISSN：0009-9252
Hyperosmolar hyperglycemic nonketotic coma after chemoradiotherapy for esophageal cancer

Toni Nakano, Go Miyata, Ko Onodera, Hirofumi Ichikawa, Takashi Kamei, Tohru Hoshida, Hiroshi Kikuchi, Keiichi Jingu, Noriaki Ohuchi

ESOPHAGUS　11　(4)　273-276　2014年9月

DOI： 10.1007/s10388-013-0405-5 　

ISSN：1612-9059

eISSN：1612-9067
Designing protective stents for electron release from dental restorations in external radiotherapy using monte carlo simulation

Masahide Saito, Noriyuki Kadoya, Suguru Dobashi, Keiichi Jingu

Proc of the 21st EGS Users' Meeting in Japan, KEK Proc 2014-6　2014年8月
Dose–Volume Constraints in Rectum in Patients with Prostate Cancer after 74-Gy 3-Dimensional Conformal Radiotherapy. 査読有り

Ishikawa Y, Kadoya N, Matsushita H, Sugawara T, Kubozono M, Umezawa R, Yamamoto T, Kozumi M, Takeda K, Jingu K

J Radiol Radiat Ther　2014年7月
Future Direction of Image-Guided Radiotherapy for Localized Prostate Cancer for more Precise and Conformal Treatment Delivery

Ken Takeda, Rei Umezawa, Yohjiro Ishikawa, Noriyuki Kadoya, Kengo Ito, Toshiyuki Sugawara, Masaki Kubozono, Takaya Yamamoto, Maiko Kozumi, Suguru Dobashi, Koichi Chida, Haruo Matsushita, Keichi Jingu

J Radiol Radiat Ther　2014年7月1日
出版者・発行元： SciMedCentral
Evaluation of On-Board kV Cone Beam Computed Tomographye-Based Dose Calculation With Deformable Image Registration Using Hounsfield Unit Modifications

Yusuke Onozato, Noriyuki Kadoya, Yukio Fujita, Kazuhiro Arai, Suguru Dobashi, Ken Takeda, Kazuma Kishi, Rei Umezawa, Haruo Matsushita, Keiichi Jingu

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS　89　(2)　416-423　2014年6月

DOI： 10.1016/j.ijrobp.2014.02.007 　

ISSN：0360-3016

eISSN：1879-355X
Outcomes after stereotactic body radiotherapy for lung tumors, with emphasis on comparison of primary lung cancer and metastatic lung tumors

Takaya Yamamoto, Keiichi Jingu, Yuko Shirata, Masashi Koto, Haruo Matsushita, Toshiyuki Sugawara, Masaki Kubozono, Rei Umezawa, Keiko Abe, Noriyuki Kadoya, Youjirou Ishikawa, Maiko Kozumi, Noriyoshi Takahashi, Ken Takeda, Yoshihiro Takai

BMC CANCER　14　2014年6月

DOI： 10.1186/1471-2407-14-464 　

ISSN：1471-2407
頭頸部癌に対する適応放射線治療の基礎研究－頭頸部外部放射線治療期間中の頸部体積減少について－査読有り

小森慎也, 武田賢, 土橋卓, 角谷倫之, 藤田幸男, 伊藤謙吾, 山本貴也, 梅澤玲, 松下晴雄, 神宮啓一, 岸和馬, 佐藤清和

脳神経・頭頸部update 2014 臨床放射線　59　(05)　733-739　2014年5月
Adjuvant radiotherapy after prostatectomy for prostate cancer in Japan: a multi-institutional survey study of the JROSG

Manabu Aoki, Takashi Mizowaki, Tetsuo Akimoto, Katsumasa Nakamura, Yasuo Ejima, Keiichi Jingu, Yoshifumi Tamai, Nobuaki Nakajima, Shinya Takemoto, Masaki Kokubo, Hiroyuki Katoh

JOURNAL OF RADIATION RESEARCH　55　(3)　533-540　2014年5月

DOI： 10.1093/jrr/rrt137 　

ISSN：0449-3060

eISSN：1349-9157
北日本放射線治療施設における子宮頸癌術後腟断端再発に関する治療方針北日本放射線腫瘍学研究会アンケート調査結果

神宮啓一, 久保園正樹, 松下晴雄, 菅原俊幸, 梅澤玲, 阿部恵子, 藤本俊裕, 山本貴也, 石川陽二郎, 田邊隆哉, 古積麻衣子, 高橋紀善

臨床放射線　59　(4)　574-578　2014年4月
出版者・発行元：金原出版(株)
ISSN：0009-9252
Risk factors for brain injury after carbon ion radiotherapy for skull base tumors

Masashi Koto, Azusa Hasegawa, Ryo Takagi, Akira Fujikawa, Takamichi Morikawa, Riwa Kishimoto, Keiichi Jingu, Hirohiko Tsujii, Tadashi Kamada

RADIOTHERAPY AND ONCOLOGY　111　(1)　25-29　2014年4月

DOI： 10.1016/j.radonc.2013.11.005 　

ISSN：0167-8140
食道悪性黒色腫の2例

木下知, 松下晴雄, 菅原俊幸, 久保園正樹, 梅澤玲, 阿部恵子, 角谷倫之, 藤田幸男, 白田佑子, 田邊隆哉, 山本貴也, 神宮啓一, 武田賢, 土橋卓

Japanese Journal of Radiology　32　(Suppl.)　12-12　2014年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
I期非小細胞肺癌定位照射の予後因子

白田佑子, 久保園正樹, 菅原俊幸, 松下晴雄, 阿部恵子, 梅澤玲, 角谷倫之, 藤田幸男, 田邊隆哉, 山本貴也, 土橋卓, 神宮啓一, 武田賢, 小藤昌志

Japanese Journal of Radiology　32　6-6　2014年2月
B-splineを用いたdeformable image registrationの高精度化の検討

金井貴幸, 曹翔永, 土橋卓, 武田賢, 角谷倫之, 藤田幸男, 伊藤謙吾, 神宮啓一, 岸和馬

日本放射線技術学会東北部会雑誌　(23)　187-187　2014年1月
出版者・発行元： (公社)日本放射線技術学会-東北支部
Clinical factors relevant to regional body volume changes during radical external radiotherapy for head and neck cancer

S. Komori, K. Takeda, S. Dobashi, N. Kadoya, Y. Fujita, K. Ito, T. Yamamoto, R. Umezawa, H. Matsushita, K. Jingu, K. Kishi, K. Sato

Japanese Journal of Clinical Radiology　59　733-739　2014年1月1日

ISSN：0009-9252
Methods for treatment of postoperative recurrence of uterine cervical cancer in the vaginal stump: Results of a survey by NJRTOG

Keiichi Jingu, M. Kubozono, H. Matsushita, T. Sugawara, R. Umezawa, K. Abe, T. Fujimoto, T. Yamamoto, Y. Ishikawa, T. Tanabe, M. Kozumi, N. Takahashi

Japanese Journal of Clinical Radiology　59　574-578　2014年1月1日

ISSN：0009-9252
Evaluation of various deformable image registration algorithms for thoracic images 査読有り

Noriyuki Kadoya, Yukio Fujita, Yoshiyuki Katsuta, Suguru Dobashi, Ken Takeda, Kazuma Kishi, Masaki Kubozono, Rei Umezawa, Toshiyuki Sugawara, Haruo Matsushita, Keiichi Jingu

JOURNAL OF RADIATION RESEARCH　55　(1)　175-182　2014年1月

DOI： 10.1093/jrr/rrt093 　

ISSN：0449-3060

eISSN：1349-9157
Radiotherapy of six fractions per a week for T1 glottic carcinoma

T. Akai, S. Nomoto, K. Hayashi, Y. Kuwabara, K. Yoshimitsu, T. Sueta, T. Nakagawa, Y. Akita, K. Jingu, K. Nakamura

Japanese Journal of Clinical Radiology　58　(10)　1347-1353　2013年10月

ISSN：0009-9252
Reassessing the Prognostic Value of the Maximum Standardized Uptake Value (SUVmax) in FDG-PET by Correcting for the Partial Volume Effect and Respiratory Motion Blur in Stage I Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy 査読有り

T. Yamamoto, N. Kadoya, Y. Shirata, R. Umezawa, M. Kubozono, T. Sugawara, T. Kaneta, H. Matsushita, K. Takeda, K. Jingu

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS　87　(2)　S523-S523　2013年10月

ISSN：0360-3016

eISSN：1879-355X
Magnetic Resonance Imaging Findings of Radiation-Induced Myocardial Damage in Patients With Esophageal Cancer 査読有り

R. Umezawa, K. Jingu, K. Takase, H. Ota, K. Takanami, T. Kaneta, K. Takeda, H. Matsushita, S. Takahashi

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS　87　(2)　S291-S292　2013年10月

ISSN：0360-3016

eISSN：1879-355X
Comparison of Cumulative Dose in the Spinal Cord Using Rigid Registration and Nonrigid Registration for 2-Step Adaptive Intensity Modulated Radiation Therapy for Head-and-Neck Cancer 査読有り

K. Arai, N. Kadoya, Y. Fujita, K. Kishi, K. Sato, K. Takeda, S. Dobashi, H. Matsushita, K. Jingu

Int J Radiat Oncol Biol Phys　87　(2)　S710-S711　2013年10月
Investigation of correction method of recovery effect and motion blur for SUV quantification in FDG PET/CT in patients with early lung cancer 査読有り

Noriyuki Kadoya, Yukio Fujita, Kengo Ito, Suguru DObashi, Ken Takeda, Kazuma Kishi, Takaya Yamamoto, Rei Umezawa, Toshiyuki Sugawara, Tomohiro Kaneta, Haruo Matsushita, Keiichi Jingu

J Nucl Med Radiat Ther　4　(4)　2013年9月

DOI： 10.4172/2155-9619.1000162 　
Evaluation of radiation-induced myocardial damage using iodine-123 β-methyl-iodophenyl pentadecanoic acid scintigraphy. 査読有り

Umezawa R, Takase K, Jingu K, Takanami K, Ota H, Kaneta T, Takeda K, Matsushita H, Ariga H, Takahashi S, Yamada S

Journal of radiation research　54　(5)　880-889　2013年9月

DOI： 10.1093/jrr/rrt011 　

ISSN：0449-3060
Results of chemoradiotherapy for stage I esophageal cancer in medically inoperable patients compared with results in operable patients

K. Jingu, H. Matsushita, K. Takeda, K. Narazaki, H. Ariga, R. Umezawa, T. Sugawara, G. Miyata, K. Onodera, K. Nemoto, S. Yamada

DISEASES OF THE ESOPHAGUS　26　(5)　522-527　2013年7月

DOI： 10.1111/j.1442-2050.2012.01396.x 　

ISSN：1120-8694

eISSN：1442-2050
前立腺癌74Gy照射による直腸障害の検討

石川陽二郎, 角谷倫之, 藤田幸男, 神宮啓一, 松下晴雄, 菅原俊幸, 久保園正樹, 梅沢玲, 清水栄二, 阿部恵子, 白田佑子, 古積麻衣子, 山田章吾, 武田賢, 有賀久哲

Japanese Journal of Radiology　31　(Suppl.I)　3-3　2013年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
術後食道癌孤立性リンパ節転移再発に対する放射線化学療法治療長期成績

神宮啓一, 松下晴雄, 菅原俊幸, 久保園正樹, 清水栄二, 梅澤玲, 阿部恵子, 白田佑子, 石川陽二郎, 山本貴也, 古積麻衣子, 山田章吾, 武田賢, 有賀久哲, 根本建二

Japanese Journal of Radiology　31　(Suppl.I)　11-11　2013年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
二次発がんを生じた後に不幸な経過をたどった若年性上咽頭癌の1例

古積麻衣子, 松下晴雄, 菅原俊幸, 神宮啓一, 清水栄二, 梅澤玲, 阿部恵子, 白田佑子, 石川陽二郎, 山本貴也, 角谷倫之, 藤田幸男, 武田賢, 土橋卓, 久保園正樹, 有賀久哲, 山田章吾

Japanese Journal of Radiology　31　(Suppl.I)　12-12　2013年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
頭頸部癌術後予防照射の検討

松下晴雄, 菅原俊幸, 神宮啓一, 清水栄二, 梅澤玲, 阿部恵子, 白田佑子, 石川陽二郎, 山本貴也, 古積麻衣子, 角谷倫之, 藤田幸男, 武田賢, 土橋卓, 久保園正樹, 有賀久哲, 山田章吾

Japanese Journal of Radiology　31　(Suppl.I)　10-10　2013年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
stage I食道癌に対する放射線化学療法手術可能と不可症例の長期成績比較

神宮啓一, 松下晴雄, 菅原俊幸, 久保園正樹, 梅澤玲, 清水栄二, 阿部恵子, 白田佑子, 石川陽二郎, 山本貴也, 古積麻衣子, 武田賢, 山田章吾, 根本建二, 有賀久哲

Japanese Journal of Radiology　31　(Suppl.I)　2-2　2013年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
Long-term results of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II study 査読有り

Keiichi Jingu, Haruo Matsushita, Ken Takeda, Rei Umezawa, Chiaki Takahashi, Toshiyuki Sugawara, Masaki Kubozono, Keiko Abe, Takaya Tanabe, Yuko Shirata, Takaya Yamamoto, Youjirou Ishikawa, Kenji Nemoto

BMC CANCER　12　542　2012年11月

DOI： 10.1186/1471-2407-12-542 　

ISSN：1471-2407
Dosimetric properties of radiophotoluminescent glass detector in low-energy photon beams 査読有り

Noriyuki Kadoya, Kouhei Shimomura, Satoshi Kitou, Yasuo Shiota, Yukio Fujita, Suguru Dobashi, Ken Takeda, Keiichi Jingu, Haruo Matsushita, Yoshihito Namito, Syuichi Ban, Syuji Koyama, Katsuyoshi Tabushi

MEDICAL PHYSICS　39　(10)　5910-5916　2012年10月

DOI： 10.1118/1.4747261 　

ISSN：0094-2405
Prognostic factors for local control of stage I non-small cell lung cancer in stereotactic radiotherapy: a retrospective analysis 査読有り

Yuko Shirata, Keiichi Jingu, Masashi Koto, Masaki Kubozono, Ken Takeda, Toshiyuki Sugawara, Noriyuki Kadoya, Haruo Matsushita

RADIATION ONCOLOGY　7　182　2012年10月

DOI： 10.1186/1748-717X-7-182 　

ISSN：1748-717X
Intraoperative Radiotherapy for Pancreatic Cancer: 30-Year Experience in a Single Institution in Japan 査読有り

Keiichi Jingu, Takaya Tanabe, Kenji Nemoto, Hisanori Ariga, Rei Umezawa, Yoshihiro Ogawa, Ken Takeda, Masashi Koto, Toshiyuki Sugawara, Masaki Kubozono, Eiji Shimizu, Keiko Abe, Shogo Yamada

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS　83　(4)　E507-E511　2012年7月

DOI： 10.1016/j.ijrobp.2012.01.024 　

ISSN：0360-3016
Treatment outcome of high-dose image-guided intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer at a single institute in Japan 査読有り

Ken Takeda, Yoshihiro Takai, Kakutaro Narazaki, Masatoshi Mitsuya, Rei Umezawa, Noriyuki Kadoya, Yukio Fujita, Toshiyuki Sugawara, Masaki Kubozono, Eiji Shimizu, Keiko Abe, Yuko Shirata, Yohjiro Ishikawa, Takaya Yamamoto, Maiko Kozumi, Suguru Dobashi, Haruo Matsushita, Koichi Chida, Shigeto Ishidoya, Yoichi Arai, Keiichi Jingu, Shogo Yamada

RADIATION ONCOLOGY　7　105　2012年7月

DOI： 10.1186/1748-717X-7-105 　

ISSN：1748-717X
Radiotherapy for esophageal cancer in Japan 査読有り

Shogo Yamada, Kenji Nemoto, Hisanori Ariga, Keiichi Jingu

ESOPHAGUS　9　(2)　66-74　2012年6月

DOI： 10.1007/s10388-012-0321-0 　

ISSN：1612-9059
PD-0329 EVALUATION OF VARIOUS DEFORMABLE IMAGE REGISTRATION ALGORITHMS USING THORACIC IMAGES 査読有り

N. Kadoya, Y. Fujita, Y. Katsuta, Y. Onozato, S. Dobashi, K. Takeda, K. Kishi, T. Yamamoto, K. Jingu, H. Matsushita

Radiotherapy and Oncology　103　S131-S131　2012年5月
出版者・発行元： Elsevier BV
DOI： 10.1016/s0167-8140(12)70668-0 　

ISSN：0167-8140
Long-Term Results of Radiochemotherapy for Solitary Lymph Node Metastasis After Curative Resection of Esophageal Cancer 査読有り

Keiichi Jingu, Hisanori Ariga, Kenji Nemoto, Kakutaro Narazaki, Rei Umezawa, Ken Takeda, Masashi Koto, Toshiyuki Sugawara, Masaki Kubozono, Go Miyata, Ko Onodera, Shogo Yamada

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS　83　(1)　172-177　2012年5月

DOI： 10.1016/j.ijrobp.2011.06.1978 　

ISSN：0360-3016
Experience With Carbon Ion Radiotherapy for WHO Grade 2 Diffuse Astrocytomas 査読有り

Azusa Hasegawa, Jun-Etsu Mizoe, Hirohiko Tsujii, Tadashi Kamada, Keiichi Jingu, Yasuo Iwadate, Youichi Nakazato, Masao Matsutani, Kintomo Takakura

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS　83　(1)　100-106　2012年5月

DOI： 10.1016/j.ijrobp.2011.06.1952 　

ISSN：0360-3016
CARBON ION RADIATION THERAPY IMPROVES THE PROGNOSIS OF UNRESECTABLE ADULT BONE AND SOFT-TISSUE SARCOMA OF THE HEAD AND NECK 査読有り

Keiichi Jingu, Hirohiko Tsujii, Jun-Etsu Mizoe, Azusa Hasegawa, Hiroki Bessho, Ryo Takagi, Takamichi Morikawa, Morio Tonogi, Hiroshi Tsuji, Tadashi Kamada, Shogo Yamada

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS　82　(5)　2125-2131　2012年4月

DOI： 10.1016/j.ijrobp.2010.08.043 　

ISSN：0360-3016
Results of carbon ion radiotherapy for head and neck cancer 査読有り

Jun-etsu Mizoe, Azusa Hasegawa, Keiichi Jingu, Ryo Takagi, Hiroki Bessyo, Takamichi Morikawa, Mono Tonoki, Hiroshi Tsuji, Tadashi Kamada, Hirohiko Tsujii, Yoshitaka Okamoto

RADIOTHERAPY AND ONCOLOGY　103　(1)　32-37　2012年4月

DOI： 10.1016/j.radonc.2011.12.013 　

ISSN：0167-8140
放射線誘発性髄膜腫に対し過分割放射線治療を行った1例

山本貴也, 神宮啓一, 有賀久哲, 武田賢, 菅原俊幸, 久保園正樹, 梅澤玲, 清水栄二, 阿部恵子, 白田佑子, 田邊隆哉, 石川陽二郎, 山田章吾

Japanese Journal of Radiology　30　(Suppl.I)　14-14　2012年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
前立腺癌に対する外照射(non-IMRT)による高線量処方時の直腸線量制限

石川陽二郎, 角谷倫之, 藤田幸男, 神宮啓一, 松下晴雄, 菅原俊幸, 梅澤玲, 阿部恵子, 山田章吾, 武田賢

日本医学放射線学会学術集会抄録集　71回　S286-S287　2012年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：0048-0428

eISSN：1347-7951
Impact of pathological tumor stage for salvage radiotherapy after radical prostatectomy in patients with prostate-specific antigen < 1.0 ng/ml 査読有り

Rei Umezawa, Hisanori Ariga, Yoshihiro Ogawa, Keiichi Jingu, Haruo Matsushita, Ken Takeda, Keisuke Fujimoto, Toru Sakayauchi, Toshiyuki Sugawara, Masaki Kubozono, Kakutaro Narazaki, Eiji Shimizu, Yoshihiro Takai, Shogo Yamada

RADIATION ONCOLOGY　6　150　2011年11月

DOI： 10.1186/1748-717X-6-150 　

ISSN：1748-717X
INTRAOPERATIVE RADIOTHERAPY FOR UNRESECTABLE PANCREATIC CANCER: A MULTI-INSTITUTIONAL RETROSPECTIVE ANALYSIS OF 144 PATIENTS 査読有り

Kazuhiko Ogawa, Katsuyuki Karasawa, Yoshinori Ito, Yoshihiro Ogawa, Keiichi Jingu, Hiroshi Onishi, Shinichi Aoki, Hitoshi Wada, Masaki Kokubo, Etsuyo Ogo, Hidehiro Etoh, Tomoko Kazumoto, Makoto Takayama, Kenji Nemoto, Yasumasa Nishimura

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS　80　(1)　111-118　2011年5月

DOI： 10.1016/j.ijrobp.2010.01.065 　

ISSN：0360-3016
1期肺癌定位照射の治療成績に及ぼす各種因子の影響

白田佑子, 神宮啓一, 有賀久哲, 武田賢, 小藤昌志, 坂谷内徹, 久保園正樹, 清水栄二, 小川芳弘, 山田章吾

日本医学放射線学会学術集会抄録集　267-267　2011年2月
Long-term Results of Chemoradiotherapy for Solitary Lymph Node Metastasis after Curative Resection of Esophageal Cancer 査読有り

K. Jingu, H. Ariga, K. Nemoto, R. Umezawa, K. Takeda, S. Yamada

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS　81　(2)　S319-S319　2011年

ISSN：0360-3016
縦隔・肺門リンパ節転移に対して重粒子線治療を施行した腎細胞癌の一剖検例

廣瀬勝己, 川口英夫, 畑山佳臣, 青木昌彦, 掛端伸也, 清野浩子, 澁谷剛一, 長畑守雄, 三浦弘行, 小野修一, 溝江純悦, 神宮啓一

Japanese Journal of Radiology　29　(Suppl.I)　5-5　2011年1月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
Malignant mucosal melanoma treated with carbon ion radiotherapy with concurrent chemotherapy: Prognostic value of pretreatment apparent diffusion coefficient (ADC) 査読有り

Keiichi Jingu, Riwa Kishimoto, Jun-Etsu Mizoe, Azusa Hasegawa, Hiroki Bessho, Hiroshi Tsuji, Tadashi Kamada, Shogo Yamada, Hirohiko Tsujii

RADIOTHERAPY AND ONCOLOGY　98　(1)　68-73　2011年1月

DOI： 10.1016/j.radonc.2010.09.017 　

ISSN：0167-8140
Predicting the Severity of Acute Urinary Toxicity after Brachytherapy with Iodine-125 for Localized Prostate Cancer

Ken Takeda, Keichi Jingu, Masashi Koto, Keisuke Fujimoto, Kakutaro Narazaki, Masaki Kubozono, Hideo Saito, Shigeyuki Yamada, Kohji Mitsuduka, Shigeto Ishidoya, Hisanori Ariga, Yoichi Arai, Shogo Yamada

TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE　223　(1)　55-60　2011年1月

DOI： 10.1620/tjem.223.55 　

ISSN：0040-8727

eISSN：1349-3329
Carbon ion radiotherapy for basal cell adenocarcinoma of the head and neck: preliminary report of six cases and review of the literature 査読有り

Keiichi Jingu, Azusa Hasegawa, Jun-Etsu Mizo, Hiroki Bessho, Takamichi Morikawa, Hiroshi Tsuji, Hirohiko Tsujii, Tadashi Kamada

RADIATION ONCOLOGY　5　89　2010年10月

DOI： 10.1186/1748-717X-5-89 　

ISSN：1748-717X
INTRAOPERATIVE RADIOTHERAPY FOR RESECTED PANCREATIC CANCER: A MULTI-INSTITUTIONAL RETROSPECTIVE ANALYSIS OF 210 PATIENTS 査読有り

Kazuhiko Ogawa, Katsuyuki Karasawa, Yoshinori Ito, Yoshihiro Ogawa, Keiichi Jingu, Hiroshi Onishi, Shinichi Aoki, Hitoshi Wada, Masaki Kokubo, Hidehiro Etoh, Tomoko Kazumoto, Makoto Takayama, Yoshiharu Negoro, Kenji Nemoto, Yasumasa Nishimura

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS　77　(3)　734-742　2010年7月

DOI： 10.1016/j.ijrobp.2009.09.010 　

ISSN：0360-3016
Carbon Ion Radiotherapy: Clinical Experiences at National Institute of Radiological Science (NIRS)

Tohru Okada, Tadashi Kamada, Hiroshi Tsuji, Jun-etsu Mizoe, Masayuki Baba, Shingo Kato, Shigeru Yamada, Shinji Sugahara, Shigeo Yasuda, Naoyoshi Yamamoto, Reiko Imai, Azusa Hasegawa, Hiroshi Imada, Hiroki Kiyohara, Kenichi Jingu, Makoto Shinoto, Hirohiko Tsujii

JOURNAL OF RADIATION RESEARCH　51　(4)　355-364　2010年7月

DOI： 10.1269/jrr.10016 　

ISSN：0449-3060
F-18-fluorodeoxyglucose positron emission tomography immediately after chemoradiotherapy predicts prognosis in patients with locoregional postoperative recurrent esophageal cancer 査読有り

Keiichi Jingu, Tomohiro Kaneta, Kenji Nemoto, Ken Takeda, Yoshihiro Ogawa, Hisanori Ariga, Masashi Koto, Toru Sakayauchi, Yoshihiro Takai, Shoki Takahashi, Shogo Yamada

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY　15　(2)　184-190　2010年4月

DOI： 10.1007/s10147-010-0044-y 　

ISSN：1341-9625
Focal dose escalation using FDG-PET-guided intensity-modulated radiation therapy boost for postoperative local recurrent rectal cancer: a planning study with comparison of DVH and NTCP 査読有り

Keiichi Jingu, Hisanori Ariga, Tomohiro Kaneta, Yoshihiro Takai, Ken Takeda, Lindel Katja, Kakutaro Narazaki, Takahiro Metoki, Keisuke Fujimoto, Rei Umezawa, Yoshihiro Ogawa, Kenji Nemoto, Masashi Koto, Masatoshi Mitsuya, Naruhiro Matsufuji, Shoki Takahashi, Shogo Yamada

BMC CANCER　10　127　2010年4月

DOI： 10.1186/1471-2407-10-127 　

ISSN：1471-2407
Results of Intraoperative Radiotherapy for Pancreatic Cancer in the Last Decade: Comparing with Historical Results 査読有り

K. Jingu, H. Ariga, Y. Ogawa, R. Umezawa, M. Koto, K. Takeda, S. Yamada

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS　78　(3)　S311-S311　2010年

ISSN：0360-3016
PROSPECTIVE COMPARISON OF SURGERY ALONE AND CHEMORADIOTHERAPY WITH SELECTIVE SURGERY IN RESECTABLE SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS 査読有り

Hisanori Ariga, Kenji Nemoto, Shukichi Miyazaki, Takashi Yoshioka, Yohishiro Ogawa, Toru Sakayauchi, Keiichi Jingu, Go Miyata, Ko Onodera, Hirofumi Ichikawa, Takashi Kamei, Shunsuke Kato, Chikashi Ishioka, Susumu Satomi, Shogo Yamada

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS　75　(2)　348-356　2009年10月

DOI： 10.1016/j.ijrobp.2009.02.086 　

ISSN：0360-3016
肺癌に対する定位放射線治療後の局所再発症例に対する再照射

小藤昌志, 小川芳弘, 有賀久哲, 武田賢, 藤本圭介, 坂谷内徹, 神宮啓一, 目時隆博, 奈良崎覚太朗, 山田章吾, 仲田栄子, 高井良尋

Japanese Journal of Radiology　27　(Suppl.)　6-6　2009年4月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
イメージガイド下前立腺IMRTの治療成績

奈良崎覚太朗, 小川芳弘, 有賀久哲, 武田賢, 小藤昌志, 藤本圭介, 坂谷内徹, 神宮啓一, 目時隆博, 山田章吾, 仲田栄子, 高井良尋

Japanese Journal of Radiology　27　(Suppl.)　6-6　2009年4月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
膠原病患者への放射線治療後の検討

目時隆博, 小川芳弘, 有賀久哲, 武田賢, 小藤昌志, 藤本圭介, 坂谷内徹, 神宮啓一, 奈良崎覚太朗, 山田章吾, 仲田栄子, 高井良尋

Japanese Journal of Radiology　27　(Suppl.)　6-6　2009年4月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
過去25年間の放射線治療患者14000例の検討

小川芳弘, 有賀久哲, 武田賢, 小藤昌志, 藤本圭介, 坂谷内徹, 神宮啓一, 目時隆博, 奈良崎覚太朗, 山田章吾, 仲田栄子, 高井良尋

Japanese Journal of Radiology　27　(Suppl.)　6-6　2009年4月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
骨転移を伴った甲状腺濾胞癌に対し、I-131内照射により長期生存を得た症例

坂谷内徹, 小川芳弘, 有賀久哲, 武田賢, 小藤昌志, 藤本圭介, 神宮啓一, 奈良崎覚太朗, 目時隆博, 山田章吾, 仲田栄子, 高井良尋, 丸岡伸, 中村護

Japanese Journal of Radiology　27　(Suppl.)　13-13　2009年4月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
食道小細胞癌の放射線治療

吉田さやか, 小川芳弘, 有賀久哲, 小藤昌志, 藤本圭介, 坂谷内徹, 神宮啓一, 奈良崎覚太郎, 目時隆博, 山田章吾, 高井良尋, 仲田栄子, 根本建二

Japanese Journal of Radiology　27　(Suppl.)　15-15　2009年4月
出版者・発行元： (公社)日本医学放射線学会
ISSN：1867-1071

eISSN：1867-108X
食道小細胞癌の放射線治療

吉田さやか, 小川芳弘, 有賀久哲, 小藤昌志, 藤本圭介, 坂谷内徹, 神宮啓一, 奈良崎覚太郎, 目時隆博, 山田章吾, 高井良尋, 仲田栄子, 根本建二

核医学　45　(2)　144-144　2008年5月
出版者・発行元： (一社)日本核医学会
ISSN：0022-7854

eISSN：2189-9932
頭頸部癌術後照射の検討非照射症例との比較

有賀久哲, 小川芳弘, 武田賢, 坂谷内徹, 藤本圭介, 奈良崎覚太朗, 神宮啓一, 松本世津, 山田章吾, 高井義尋, 仲田栄子, 角藤芳久

Radiation Medicine　26　(Suppl.I)　4-4　2008年4月
出版者・発行元： (公社)日本医学放射線学会
ISSN：0288-2043

eISSN：1862-5274
縦隔照射後のBNP経時的変化

神宮啓一, 小川芳弘, 有賀久哲, 武田賢, 坂谷内徹, 藤本圭介, 奈良崎覚太朗, 松本世津, 山田章吾, 高井良尋, 仲田栄子

Radiation Medicine　26　(Suppl.I)　5-5　2008年4月
出版者・発行元： (公社)日本医学放射線学会
ISSN：0288-2043

eISSN：1862-5274
膀胱癌の放射線治療

小川芳弘, 有賀久哲, 武田賢, 坂谷内徹, 藤本圭介, 奈良崎覚太朗, 神宮啓一, 松本世津, 山田章吾, 高井良尋, 仲田栄子

Radiation Medicine　26　(Suppl.I)　6-6　2008年4月
出版者・発行元： (公社)日本医学放射線学会
ISSN：0288-2043

eISSN：1862-5274
化学放射線療法を施行した食道癌のFDG-PET

武田賢, 小川芳弘, 有賀久哲, 坂谷内徹, 藤本圭介, 奈良崎覚太朗, 神宮啓一, 目時隆博, 山田章吾, 金田朋洋, 高井良尋, 仲田栄子

Radiation Medicine　26　(Suppl.I)　12-12　2008年4月
出版者・発行元： (公社)日本医学放射線学会
ISSN：0288-2043

eISSN：1862-5274
直腸癌術後-局所再発症例に対する放射線治療

藤本圭介, 小川芳弘, 有賀久哲, 武田賢, 坂谷内徹, 奈良崎覚太朗, 神宮啓一, 目時隆博, 山田章吾, 高井良尋, 仲田栄子

Radiation Medicine　26　(Suppl.I)　12-12　2008年4月
出版者・発行元： (公社)日本医学放射線学会
ISSN：0288-2043

eISSN：1862-5274
前立腺癌術後PSA再発に対する放射線治療

小川芳弘, 有賀久哲, 武田賢, 坂谷内徹, 藤本圭介, 奈良崎覚太朗, 神宮啓一, 目時隆博, 山田章吾, 根本建二, 高井良尋, 仲田栄子

Radiation Medicine　26　(Suppl.I)　12-12　2008年4月
出版者・発行元： (公社)日本医学放射線学会
ISSN：0288-2043

eISSN：1862-5274
放射線シンチレータを用いた体内埋め込み型リアルタイム式マイクロ線量計の開発

仲田栄子, 大石幹雄, 小川芳弘, 有賀久哲, 武田賢, 坂谷内徹, 藤本圭介, 奈良崎覚太郎, 神宮啓一, 目時隆博, 山田章吾, 神崎壽夫, 四竈樹男, 永田晋二, 藤健太郎, 渡邊暁, 岸和馬, 白鳥和敏, 中村大介, 三津谷正俊

Radiation Medicine　26　(Suppl.I)　12-12　2008年4月
出版者・発行元： (公社)日本医学放射線学会
ISSN：0288-2043

eISSN：1862-5274
Gimeracil(CDHP)の放射線増感作用査読有り

仲田栄子, 福島正和, 高井良尋, 根本建二, 小川芳弘, 有賀久哲, 武田賢, 坂谷内徹, 藤本圭介, 奈良崎覚太朗, 神宮啓一, 松本世津, 山田章吾

Radiation Medicine　26　(1)　6-6　2008年4月
出版者・発行元： (公社)日本医学放射線学会
ISSN：0288-2043

eISSN：1862-5274
Predictive factors for late rectal bleeding after external radiotherapy for prostate cancer 査読有り

K. Takeda, Y. Ogawa, H. Ariga, M. Koloh, T. Sakayauchi, K. Fujimoto, K. Jingu, K. Narazaki, Y. Takai, S. Yamada

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS　72　(1)　S349-S349　2008年

ISSN：0360-3016
Radiation therapy for elderly patients over 80 years old with esophageal cancer 査読有り

K. Fujimoto, K. Nemoto, Y. Ogawa, H. Ariga, K. Takeda, T. Sakayauchi, M. Koto, K. Jingu, Y. Takai, S. Yamada

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS　72　(1)　S280-S280　2008年

ISSN：0360-3016
Radiation therapy for limited-stage small-cell esophageal cancer 査読有り

S. Yoshida, H. Ariga, K. Nemoto, Y. Ogawa, K. Fujimoto, K. Jingu, C. Takahashi, M. Kubozono, K. Takeda, S. Yamada

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS　72　(1)　S262-S262　2008年

ISSN：0360-3016
直腸癌術後再発に対するPET/CT planningに関する初期研究～GTVとBTVの相違～

神宮啓一, 三津谷正俊, 渡邉暁, 武田賢, 目時隆博, 小川芳弘, 有賀久哲, 山田章吾, 高井良尋, 細貝良行, 金田朋洋

日本放射線腫瘍学会誌　20　(3)　127-131　2008年
出版者・発行元：一般社団法人日本放射線腫瘍学会
DOI： 10.11182/jastro.20.127 　

ISSN：1040-9564

詳細を見る詳細を閉じる

【目的】CTによるgross tumor volume（GTV）とFDG-PET/CTによるbiological target volume（BTV）の間及び放射線腫瘍医間の標的体積に差があるか，明らかにする．【方法】術後局所再発直腸癌 7 症例で，独立した放射線腫瘍医 3 人が，それぞれCT上とPET/CT上でtargetを囲い，GTVとBTVの平均体積を，二元配置分散分析法を用いて比較した．放射線治療時と同姿勢でFDG-PET/CTを撮像し，CT画像とPET画像をDICOMデータにて，それぞれ放射線治療計画装置に送り，DICOM情報によるfusionを行った．GTVはCT上で異常陰影を標的体積として囲い，FDGの異常集積範囲は主にtumor/muscle比を参考に，各放射線腫瘍医が肉眼的に標的体積を設定した．【結果】この 7 症例の標的体積の平均が，GTV; 77.2±53.6cm³，BTV; 58.0±48.0cm³となり，BTVがGTVより統計学的に有意な低値となった（p<0.001）．GTVとBTVの間には強い相関を認めた（r=0.952, p<0.001）．直腸癌局所再発症例では，放射線腫瘍医間の標的体積には明らかな差は認めなかった（F（2, 18）=0.654, MSe=5220.046, p=0.532）．modalityに有意な主効果が見られた（F（1, 18）=28.252, MSe=137.496, p<0.001）．【結論】直腸癌の局所再発症例でも，機能画像（PET/CT）によるtarget volumeと形態画像（CT）による標的体積で有意な差を認めた．
過去26年間における放射線治療患者13,526例の予後

小川芳弘, 有賀久哲, 武田賢, 小藤昌志, 坂谷内徹, 藤本圭介, 目時隆博, 神宮啓一, 奈良崎覚太朗, 高井良尋, 山田章吾

The Journal of JASTRO = 日本放射線腫瘍学会誌　19　(4)　289-295　2007年12月25日

DOI： 10.11182/jastro.19.289 　

ISSN：1040-9564
Radiation therapy for biochemical failure after radical prostatectomy

Yoshihiro Ogawa, H. Ariga, K. Takeda, T. Sakayauchi, M. Koto, K. Fujimoto, T. Meji, K. Jingu, K. Narasaki, S. Yamada, K. Nemoto, T. Ujiie

Japanese Journal of Clinical Radiology　52　1795-1801　2007年12月1日

ISSN：0009-9252
Temporal change in brain natriuretic peptide after radiotherapy for thoracic esophageal cancer 査読有り

Keiichi Jingu, Kenji Nemoto, Tomohiro Kaneta, Minako Oikawa, Yoshihiro Ogawa, Hisanori Ariga, Ken Takeda, Toru Sakayauchi, Keisuke Fujimoto, Kakutaro Narazaki, Yoshihiro Takai, Eiko Nakato, Hiroshi Fukuda, Shoki Takahashi, Shogo Yamada

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS　69　(5)　1417-1423　2007年12月

DOI： 10.1016/j.ijrobp.2007.05.054 　

ISSN：0360-3016
A phase II study on stereotactic body radiotherapy for stage I non-small cell lung cancer

Masashi Koto, Yoshihiro Takai, Yoshihiro Ogawa, Haruo Matsushita, Ken Takeda, Chiaki Takahashi, Keith R. Britton, Kei-ichi Jingu, Kenji Takai, Masatoshi Mitsuya, Kenji Nemoto, Shogo Yamada

RADIOTHERAPY AND ONCOLOGY　85　(3)　429-434　2007年12月

DOI： 10.1016/j.radonc.2007.10.017 　

ISSN：0167-8140
前立腺癌根治手術後PSA再発に対する放射線治療査読有り

小川芳弘, 根本建二, 有賀久哲, 武田賢, 坂谷内徹, 小藤昌志, 藤本圭介, 目時隆博, 神宮啓一, 奈良崎覚太朗, 氏家隆, 山田章吾

臨床放射線　52　(13)　1795-1801　2007年10月1日
Long-term results of the phase II study on radiotherapy combined with nedaplatin and 5-FU for postoperative locoregional recurrent esophagealcancer 査読有り

K. Jingu, K. Nemoto, H. Matsushita, C. Takahashi, Y. Ogawa, H. Ariga, K. Takeda, M. Koto, Y. Takai, S. Yamada

EJC SUPPLEMENTS　5　(4)　273-273　2007年9月

ISSN：1359-6349
The efficacy of early F-18-fluorodeoxyglucose positron emission tomography following completion of definitive chemoradiotherapy in patients with esophageal carcinoma 査読有り

K. Takeda, K. Jingu, H. Ariga, M. Kotoh, T. Sakayauchi, K. Fujimoto, T. Metoki, K. Narazaki, Y. Ogawa, S. Yamada

EJC SUPPLEMENTS　5　(4)　275-276　2007年9月

ISSN：1359-6349
原発性孤立性非小細胞肺癌に対する多門照射を用いた加速過分割照射の肺反応の検討

菅原俊幸, 小藤昌志, 小川芳弘, 高井憲司, 坂谷内徹, 奈良崎覚太朗, 神宮啓一, 仲田栄子, 根本建二, 高井良尋, 山田章吾

Radiation Medicine　25　(Suppl.I)　17-17　2007年4月
出版者・発行元： (公社)日本医学放射線学会
ISSN：0288-2043

eISSN：1862-5274
ヒト大腸癌細胞株DLD-1に対するCapecitabineと2-ME2を用いたin vivoでの化学放射線療法の検討

仲田栄子, 根本建二, 小川芳弘, 高井憲司, 坂谷内徹, 神宮啓一, 菅原俊幸, 奈良崎覚太郎, 高井良尋, 山田章吾

Radiation Medicine　25　(Suppl.I)　18-18　2007年4月
出版者・発行元： (公社)日本医学放射線学会
ISSN：0288-2043

eISSN：1862-5274
転移性ヒト大腸癌細胞株HT-29-lucに対するS-1(TS-1(R),Taiho,Co),Capecitabine(Xeloda(R),Chugai/Rosh),2-ME2(Panzem(R),Entremed,Inc),UFT/LV(Taiho,Co)を用いたin vivoにおける転移抑制効果の比較試験

仲田栄子, 根本建二, 小川芳弘, 高井憲司, 坂谷内徹, 神宮啓一, 菅原俊幸, 奈良崎覚太郎, 山田章吾, 高井良尋

Radiation Medicine　25　(Suppl.I)　18-18　2007年4月
出版者・発行元： (公社)日本医学放射線学会
ISSN：0288-2043

eISSN：1862-5274
Initial evaluation of dynamic human imaging using F-18-FRP170 as a new PET tracer for imaging hypoxia 査読有り

Tomohiro Kaneta, Yoshihiro Takai, Ren Iwata, Takashi Hakamatsuka, Hiroyasu Yasuda, Katsutoshi Nakayama, Yoichi Ishikawa, Shoichi Watanuki, Shozo Furumoto, Yoshihito Funaki, Eiko Nakata, Keiichi Jingu, Michihiko Tsujitani, Masatoshi Ito, Hiroshi Fukuda, Shoki Takahashi, Shogo Yamada

ANNALS OF NUCLEAR MEDICINE　21　(2)　101-107　2007年2月

DOI： 10.1007/BF03033987 　

ISSN：0914-7187
The utility of F-18-fluorodeoxyglucose positron emission tomography for early diagnosis of radiation-induced myocardial damage 査読有り

Keiichi Jingu, Tomohiro Kaneta, Kenji Nemoto, Azusa Ichinose, Minako Oikawa, Yoshihiro Takai, Yoshihiro Ogawa, Eiko Nakata, Toru Sakayauchi, Kenji Takai, Toshiyuki Sugawara, Kakutaro Narazaki, Hiroshi Fukuda, Shoki Takahashi, Shogo Yamada

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS　66　(3)　845-851　2006年11月

DOI： 10.1016/j.ijrobp.2006.06.007 　

ISSN：0360-3016
Current status and future perspectives of chemoradiation therapy for esophageal cancer

Kenji Nemoto, Y. Ogawa, K. Takai, T. Sakayauchi, T. Sugawara, K. Jingu, K. Narasaki, S. Yamada, E. Nakata, Y. Takai

Japanese Journal of Clinical Radiology　51　337-342　2006年4月18日

ISSN：0009-9252
Construction of remote radiotherapy planning system using remote disk mount technique

Yoshihiro Ogawa, Kenji Nemoto, Kenji Takai, Toru Sakayauchi, Toshiyuki Sugawara, Kakutaro Narazaki, Keiichi Jingu, Hideo Miyachi, Yoshihiro Takai, Shogo Yamada, Yu Rong

Journal of JASTRO　18　(1)　39-42　2006年3月1日
出版者・発行元：一般社団法人日本放射線腫瘍学会
DOI： 10.11182/jastro.18.39 　

ISSN：1040-9564
Results of radiation therapy combined with nedaplatin (cis-diammine-glycoplatinum) and 5-Fluorouracil for postoperative locoregional recurrent esophageal cancer 査読有り

K Jingu, K Nemoto, H Matsushita, C Takahashi, Y Ogawa, T Sugawara, E Nakata, Y Takai, S Yamada

BMC CANCER　6　50　2006年3月

DOI： 10.1186/1471-2407-6-50 　

ISSN：1471-2407
術後再発食道癌に対するNedaplatin及び5-FUを併用した放射線化学療法第2相試験

神宮啓一, 根本建二, 松下晴雄, 高橋ちあき, 小川芳弘, 高井良尋, 仲田栄子, 山田章吾

日本医学放射線学会学術集会抄録集　65回　S219-S219　2006年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN：0048-0428

eISSN：1347-7951
PET検査用新規低酸素マーカー18F-FRP170の臨床応用

金田朋洋, 袴塚崇, 高橋昭喜, 神宮啓一, 菅原俊幸, 山田章吾, 高井良尋, 丸岡伸, 岩田錬, 石川洋一, 船木善仁, 工藤幸司, 仲田栄子, 古本祥三, 福田寛

核医学　42　(4)　414-414　2005年12月
出版者・発行元： (一社)日本核医学会
ISSN：0022-7854

eISSN：2189-9932
Salvage radiation therapy for residual superficial esophageal cancer after endoscopic mucosal resection

K Nemoto, K Takai, Y Ogawa, T Sakayauchi, T Sugawara, K Jingu, H Wada, Y Takai, S Yamada

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS　63　(5)　1290-1294　2005年12月

DOI： 10.1016/j.ijrobp.2005.05.011 　

ISSN：0360-3016
ヒト大腸癌細胞株DLD-1/FU(5-FU抵抗性株)に対するS-1/Oxaliplatinの化学放射線療法でのin vivoにおける治療効果

仲田栄子, 根本建二, 高井良尋, 小川芳弘, 高井憲司, 坂谷内徹, 神宮啓一, 菅原俊幸, 奈良崎覚太郎, 野宮琢磨, 山田章吾

日本癌治療学会誌　40　(2)　489-489　2005年9月
出版者・発行元： (一社)日本癌治療学会
ISSN：0021-4671
Current status and future perspectives of chemoradiation therapy for esophageal cancer

Kenji Nemoto, Y. Ogawa, K. Takai, T. Sakayauchi, T. Sugawara, K. Jingu, Y. Takai, S. Yamada, H. Onodera, S. Miyazaki, S. Satomi, T. Yoshioka

Japanese Journal of Clinical Radiology　50　947-953　2005年9月1日

ISSN：0009-9252
A case of high FDG-uptake into the myocardium after radiotherapy for esophageal cancer 査読有り

Keiichi Jingu, Kenji Nemoto, Tomohiro Kaneta, Yoshihiro Takai, Azusa Ichinose, Yoshihiro Ogawa, Shogo Yamada

Nippon Acta Radiologica　65　(3)　266-269　2005年7月25日
出版者・発行元： 3
ISSN：0048-0428 1347-7951
ヒト大腸癌細胞DLD-1株に対するTS-1を用いての化学放射線療法におけるin vivo系でのPreclinical Experiment

仲田栄子, 高井良尋, 根本建二, 小川芳弘, 高橋ちあき, 小藤昌志, 野宮琢磨, 藤本圭介, キース・ブリトン, 目時隆博, 神宮啓一, 山田章吾, 福島正和

日本医学放射線学会雑誌　64　(8)　576-577　2004年11月
出版者・発行元： (公社)日本医学放射線学会
ISSN：0048-0428

eISSN：1347-7951
Reirradiation with brachytherapy for recurrent tongue cancer after initial brachytherapy

N. Kunitake, K. Nakamura, M. Kimura, T. Watanabe, T. Sasaki, H. Terashima, K. Jingu, K. Masuda

Nihon Igaku Hōshasen Gakkai zasshi. Nippon acta radiologica　61　(8)　427-430　2001年

ISSN：0048-0428

︎全件表示 ︎最初の5件までを表示

MISC 152

頸部食道癌に対するSIB-IMRTでの化学放射線療法多施設第II相臨床試験(JROSG12-1)

板坂聡, 坂中克幸, 伊藤芳紀, 神宮啓一, 石川一樹, 太田陽介, 村上裕司, 室谷健太, 小川和彦, 西村恭昌

日本食道学会学術集会抄録集(CD-ROM)　78th　2024年
【IGRT今後の展開】エレクタUnityの装置導入と1年半の臨床経験

角谷倫之, 田中祥平, 佐藤清和, 新井一弘, 高橋紀善, 梅澤玲, 神宮啓一

Rad Fan　21　(13)　48-52　2023年11月
出版者・発行元： (株)メディカルアイ
ISSN： 1348-3498
この機会にしっかり評価、最適な放射線治療モダリティ即時適応放射線治療

神宮啓一

日本癌治療学会学術集会抄録集　61回　OWS3-4　2023年10月
出版者・発行元： (一社)日本癌治療学会
1.5T MR-linacにおける深層学習を使用した新たな患者QAシステムの開発

戸塚凌太, 角谷倫之, 新井一弘, 佐藤清和, 神宮啓一

日本放射線技術学会雑誌　79　(9)　1021-1022　2023年9月
出版者・発行元： (公社)日本放射線技術学会
ISSN： 0369-4305

eISSN： 1881-4883
Oligometastasisに対する新規治療戦略頭頸部癌由来の肺oligometastasesに対する定位放射線治療の有効性と安全性

神宮啓一, 山本貴也, 新部譲

頭頸部癌　49　(2)　74-74　2023年5月
出版者・発行元： (一社)日本頭頸部癌学会
ISSN： 1349-5747

eISSN： 1881-8382
医学物理における放射線科学の革新臨床医から見た医学物理における放射線治療技術の発展

神宮啓一

日本放射線技術学会総会学術大会予稿集　79回　99-99　2023年3月
出版者・発行元： (公社)日本放射線技術学会
ISSN： 1884-7846
放射線治療を受けた椎体転移患者における予後予測因子の検討

武田一也, 武田一也, 梅澤玲, 山本貴也, 高橋紀善, 鈴木友, 岸田桂太, 尾股聡, 神宮啓一

日本癌治療学会学術集会(Web)　61st　2023年
MR画像誘導放射線治療の日本における展望

神宮啓一, 高橋紀善, 角谷倫之

医用画像情報学会雑誌　39　(4)　68-69　2022年12月
出版者・発行元：医用画像情報学会
ISSN： 0910-1543

eISSN： 1880-4977
MR画像誘導放射線治療の日本における展望

神宮啓一, 高橋紀善, 角谷倫之

医用画像情報学会雑誌　39　(4)　68-69　2022年12月
出版者・発行元：医用画像情報学会
ISSN： 0910-1543

eISSN： 1880-4977
がん治療における放射線治療の最前線 MRI誘導オンライン適応放射線治療

神宮啓一, 高橋紀善, 角谷倫之

日本癌治療学会学術集会抄録集　60回　SSY8-1　2022年10月
出版者・発行元： (一社)日本癌治療学会
胸部領域における新規開発した治療計画支援ソフトウェアの非剛体レジストレーションの精度評価

高橋春奈, 角谷倫之, 勝田義之, 田中祥平, 新井一弘, 山本貴也, 梅澤玲, 神宮啓一

日本放射線技術学会雑誌　78　(10)　1187-1193　2022年10月
出版者・発行元： (公社)日本放射線技術学会
ISSN： 0369-4305

eISSN： 1881-4883
がん治療における放射線治療の最前線 MRI誘導オンライン適応放射線治療

神宮啓一, 高橋紀善, 角谷倫之

日本癌治療学会学術集会抄録集　60回　SSY8-1　2022年10月
出版者・発行元： (一社)日本癌治療学会
80歳以上の食道癌でも放射線治療に化学療法併用は必要か? SEER分析

神宮啓一, 高橋紀善, 梅澤玲, 山本貴也, 武田一也, 鈴木友, 岸田桂太, 尾股聡

日本食道学会学術集会プログラム・抄録集　76回　153-153　2022年9月
出版者・発行元： (NPO)日本食道学会
機能画像の放射線治療応用

神宮啓一

日本医学放射線学会秋季臨床大会抄録集　58回　S383-S384　2022年8月
出版者・発行元： (公社)日本医学放射線学会
ISSN： 0048-0428

eISSN： 1347-7951
放射線治療における膵臓変位推定の為の2D断層画像駆動型複数臓器接触シミュレーション

原裕貴, 角谷倫之, 三目直登, 家永直人, 梅澤玲, 神宮啓一, 黒田嘉宏

日本医用画像工学会大会予稿集　41回　86-87　2022年7月
出版者・発行元： (一社)日本医用画像工学会
MRリニアックの新たなる可能性～未来への潮流を探る～より良い放射線治療を目指して無駄な鉄砲はうたない

神宮啓一

日本放射線技術学会総会学術大会予稿集　78回　86-86　2022年3月
出版者・発行元： (公社)日本放射線技術学会
ISSN： 1884-7846
非小細胞肺がんに対する肺換気画像とレディオミクスによる機械学習ベース放射線肺臓炎予測モデルの開発

毛利詩菜, 角谷倫之, 勝田義之, 田中祥平, 武田一也, 山本貴也, 金井貴幸, 中島祐二朗, 武田賢, 神宮啓一

日本放射線腫瘍学会高精度放射線外部照射部会学術大会プログラム・抄録集　35th　2022年
東北からはじまる世界最先端のがん治療「MRI一体型放射線治療装置の導入と東北大学病院の取り組み」

神宮啓一

日本放射線技術学会東北支部雑誌　(31)　np35-np37　2022年1月
出版者・発行元： (公社)日本放射線技術学会-東北支部
高齢食道癌患者における放射線治療の治療効果と予後因子の研究

高橋紀善, 梅澤玲, 神宮啓一

日本食道学会学術集会プログラム・抄録集　75回　295-295　2021年9月
出版者・発行元： (NPO)日本食道学会
【皮膚悪性腫瘍(第2版)下-基礎と臨床の最新研究動向-】乳房外パジェット病治療放射線療法

白田佑子, 松下晴雄, 小川芳弘, 神宮啓一

日本臨床　79　(増刊3 皮膚悪性腫瘍(下))　292-297　2021年7月
出版者・発行元： (株)日本臨床社
ISSN： 0047-1852
放射線治療

神宮啓一, 梅澤玲, 山本貴也, 石川陽二郎, 高橋紀善, 武田一也, 鈴木友, 寺村聡司, 尾股聡

日本気管食道科学会会報　72　(2)　84-87　2021年4月
出版者・発行元： (NPO)日本気管食道科学会
ISSN： 0029-0645

eISSN： 1880-6848
膵癌に対する予防域を含めた放射線治療における3DCRTとIMRTでの急性期有害事象の比較

梅澤玲, 中川圭, 水間正道, 山本貴也, 石川陽二郎, 海野倫明, 神宮啓一

日本癌治療学会学術集会(Web)　59th　2021年
Report of AAPM Task Group 275~レポートの詳細と実臨床における放射線治療計画のダブルチェックの実施~

角谷倫之, 伊藤謙吾, 勝田義之, 田中祥平, 田邊俊平, 大橋陽奈, 石田知也, 梅田真梨子, 菅井裕斗, 毛利詩菜, 武田賢, 神宮啓一

日本医学物理学会学術大会教育講演資料　121st　2021年

ISSN： 1345-5362
前立腺癌放射線治療後に発生した恥骨radiation-induced sarcomaの1例

尾股聡, 梅澤玲, 綿貫宗則, 佐藤聡子, 田邊隆哉, 神宮啓一

臨床放射線　66　(6)　2021年

ISSN： 0009-9252
乳癌術後の左側胸部照射における深吸気息止め照射

武田一也, 坂谷内徹, 工藤展迪, 吉田龍一, 中川紗紀, 神宮啓一

大崎市民病院誌　24　20-23　2020年12月
出版者・発行元：大崎市民病院
ISSN： 1881-6142
食道癌術後の孤立性の遠隔転移の治療食道癌肺転移への定位放射線治療成績多施設共同研究

神宮啓一, 山本貴也, 新部譲

日本食道学会学術集会プログラム・抄録集　74回　77-77　2020年12月
出版者・発行元： (NPO)日本食道学会
外来放射線治療におけるタブレット問診票の導入

園部真也, 武田一也, 佐々木恵利奈, 中村直毅, 植田琢也, 神宮啓一, 中山雅晴

医療情報学連合大会論文集　40回　855-856　2020年11月
出版者・発行元： (一社)日本医療情報学会
ISSN： 1347-8508

eISSN： 2433-698X
外来放射線治療でのタブレット問診システム

園部真也, 武田一也, 佐々木恵利奈, 中村直毅, 植田琢也, 神宮啓一, 中山雅晴

医療の質・安全学会誌　15　(Suppl.)　237-237　2020年11月
出版者・発行元： (一社)医療の質・安全学会
ISSN： 1881-3658

eISSN： 1882-3254
Oligometastases: History and future vision of breast cancer

Yuzuru Niibe, Keiichi Jingu, Hiroshi Onishi

Translational Cancer Research　9　(8)　5028-5031　2020年8月1日
出版者・発行元： AME Publishing Company
DOI： 10.21037/tcr-20-325 　

ISSN： 2219-6803 2218-676X
【Q&Aでまとめる! 予後予測・治療効果予測の画像検査】消化管・肝・胆・膵胸部食道癌に対する根治的放射線化学療法の治療効果を予測する画像検査方法は何か?

高橋紀善, 梅澤玲, 古積麻衣子, 山本貴也, 武田一也, 松下晴雄, 石川陽二郎, 鈴木友, 角谷倫之, 勝田義之, 伊藤謙吾, 神宮啓一

臨床放射線　65　(8)　881-885　2020年8月
出版者・発行元：金原出版(株)
ISSN： 0009-9252
頭頸部がんに対する放射線治療後の口腔内QOLの長期的変化(3D-CRT vs. IMRT)

神宮啓一, 高橋紀善, 田坂俊, 梅澤玲, 山本貴也, 石川陽二郎, 武田一也, 鈴木友, 松下晴雄

頭頸部癌　46　(2)　160-160　2020年7月
出版者・発行元： (一社)日本頭頸部癌学会
ISSN： 1349-5747

eISSN： 1881-8382
局所進行頭頸部扁平上皮癌における予防的リンパ節照射線量の検討プロペンシティスコア・マッチング解析

鈴木友, 神宮啓一, 松下晴雄, 梅澤玲, 久保園正樹, 山本貴也, 石川陽二郎, 武田一也, 川端広聖, 岸田桂太, 寺村聡司, 尾股聡, 佐藤雄太, 石田英一, 村田隆紀

頭頸部癌　46　(2)　184-184　2020年7月
出版者・発行元： (一社)日本頭頸部癌学会
ISSN： 1349-5747

eISSN： 1881-8382
最新医用画像技術 AIと放射線治療

角谷倫之, 松田匠平, 竹内孝至, 梶川智博, 田中祥平, 田邊俊平, 勝田義之, 伊藤謙吾, 神宮啓一

臨床放射線　65　(2)　163-171　2020年2月
出版者・発行元：金原出版(株)
ISSN： 0009-9252
局所型前立腺癌の強度変調放射線治療におけるフルエンスマップに基づく照射野修正法の有効性の検討

山本大晃, 土橋卓, 角谷倫之, 伊藤謙吾, 千葉貴仁, 勝田義之, 佐藤清和, 松下晴雄, 神宮啓一, 武田賢

日本放射線腫瘍学会高精度放射線外部照射部会学術大会プログラム・抄録集　33rd　2020年
外来放射線治療におけるタブレット問診票の導入

園部真也, 武田一也, 佐々木恵利奈, 中村直毅, 植田琢也, 神宮啓一, 中山雅晴

医療情報学連合大会論文集(CD-ROM)　40th　2020年

ISSN： 2433-698X
Precision medicineに向けたRadiomicsの試み-放射線治療医の立場から-

高橋紀善, 梅澤玲, 山本貴也, 武田一也, 松下晴雄, 石川陽二郎, 田坂俊, 鈴木友, 角谷典之, 神宮啓一

日本放射線腫瘍学会高精度放射線外部照射部会学術大会プログラム・抄録集　33rd　2020年
心臓原発血管肉腫に対して化学放射線治療を施行した1例査読有り

山本貴也, 城田英和, 井上千裕, 松下晴雄, 梅澤玲, 石川陽二郎, 石岡千加史, 神宮啓一

臨床放射線　64　(11)　1369-1374　2019年10月
出版者・発行元：金原出版(株)
ISSN： 0009-9252
【循環器症候群(第3版)-その他の循環器疾患を含めて-】心筋疾患放射線照射による心筋障害

神宮啓一, 梅澤玲

日本臨床　別冊　(循環器症候群I)　263-265　2019年9月
出版者・発行元： (株)日本臨床社
ISSN： 0047-1852
命と機能を守る頭頸部がん診療【頭頸部がんの最新診療】最新の頭頸部がんの放射線治療

神宮啓一

日本医師会雑誌　148　(6)　1099‐1102　2019年9月1日

ISSN： 0021-4493
Evaluation of Factors That Affect 4D Cone Beam CT-Ventilation Images for Adaptive Functional Avoidance Radiotherapy

H Nemoto, N Kadoya, T Kajikawa, Y Nakajima, T Kanai, Y Ieko, K, Takeda, K Jingu

Medical Physics　46　(6)　e378-e378　2019年6月
出版者・発行元： Wiley
DOI： 10.1002/mp.13589 　
The Feasibility of MVCT-Based Radiomics for Delta-Radiomics in Head and Neck Cancer

K Abe, N Kadoya, S Tanaka, Y Nakajima, S Hashimoto, T Kajikawa, K Karasawa, K Jingu

Medical Physics　46　(6)　e142-e142　2019年6月
出版者・発行元： Wiley
DOI： 10.1002/mp.13589 　

ISSN： 0094-2405

eISSN： 2473-4209
全国登録データを用いた食道癌に対する根治的放射線治療の全国の実態把握査読有り

日月裕司, 藤也寸志, 沼崎穂高, 神宮啓一, 宇野隆, 根本建二, 松原久裕

日本食道学会学術集会プログラム・抄録集　73回　18-18　2019年6月
出版者・発行元： (NPO)日本食道学会
前立腺癌におけるIMRTに対する畳み込みニューラルネットワークに基づく線量分布予測法の評価

梶川智博, 角谷倫之, 高山佳樹, 戸森聖治, 伊藤謙吾, 千葉貴仁, 土橋卓, 武田賢, 神宮啓一

日本放射線腫瘍学会高精度放射線外部照射部会学術大会プログラム・抄録集　32nd　2019年
膵臓癌における原発巣に対するリスク臓器・リンパ節領域の呼吸変動による位置変化に関する検討

梅澤玲, 梅澤玲, 脇田明尚, 伊藤芳紀, 中村哲志, 岡本裕之, 高橋加奈, 稲葉浩二, 村上直也, 井垣浩, 神宮啓一, 伊丹純

日本放射線腫瘍学会高精度放射線外部照射部会学術大会プログラム・抄録集　32nd　2019年
食道癌の治療化学放射線療法術前補助化学放射線療法

神宮啓一, 梅澤玲, 山本貴也, 高橋紀善, 武田一也

日本臨床　76　389‐391　2018年10月31日

ISSN： 0047-1852
転移・再発腫瘍に対する放射線治療/転移性脊椎腫瘍の治療のアプローチ転移・再発腫瘍に対する高精度放射線治療

神宮啓一, 山本貴也, 松下晴雄, 梅澤玲

日本癌治療学会学術集会抄録集　56回　PD4-1　2018年10月
出版者・発行元： (一社)日本癌治療学会
特集核医学の放射線治療への新規応用はじめに

神宮啓一, 山本哲哉

臨床放射線　63　(9)　959-959　2018年9月10日
出版者・発行元：金原出版
DOI： 10.18888/rp.0000000543 　

ISSN： 0009-9252
【核医学の放射線治療への新規応用】FDG-PET/CTを用いた放射線治療の予後予測

高橋紀善, 梅澤玲, 高浪健太郎, 山本貴也, 武田一也, 松下晴雄, 石川陽二郎, 片桐佑, 神宮啓一

臨床放射線　63　(9)　969-978　2018年9月
出版者・発行元：金原出版(株)
ISSN： 0009-9252
胸部領域のCT-based Radiomicsにおける施設毎のロバストなRadiomic特徴量の新たな絞り込み法の開発

田中祥平, 角谷倫之, 佐藤慎哉, 梶川智博, 松田匠平, 土橋卓, 武田賢, 神宮啓一

日本放射線技術学会雑誌　74　(9)　985-986　2018年9月
出版者・発行元： (公社)日本放射線技術学会
ISSN： 0369-4305

eISSN： 1881-4883
4DCBCTを用いた経時的な肺機能変化に基づく放射線治療法の開発に向けた初期検討

根本光, 角谷倫之, 梶川智博, 中島祐二朗, 家子義朗, 武田賢, 神宮啓一

日本放射線技術学会雑誌　74　(9)　1004-1004　2018年9月
出版者・発行元： (公社)日本放射線技術学会
ISSN： 0369-4305

eISSN： 1881-4883
放射線治療におけるイノベーション

神宮啓一

日本医学放射線学会秋季臨床大会抄録集　54回　S438-S438　2018年9月
出版者・発行元： (公社)日本医学放射線学会
ISSN： 0048-0428

eISSN： 1347-7951
食道癌に対する放射線治療の変遷と将来

神宮啓一, 梅澤玲, 高橋紀善, 山田章吾

日本食道学会学術集会プログラム・抄録集　72回　12-12　2018年6月
出版者・発行元： (NPO)日本食道学会
肺癌SRT症例の治療前PETにおけるテクスチャ解析の有用性

武田一也, 松下晴雄, 久保園正樹, 田邊隆哉, 石川陽二郎, 山本貴也, 古積麻衣子, 高橋紀善, 片桐佑, 田坂俊, 福井勝哉, 鈴木友, 角谷倫之, 伊藤謙吾, 千葉瑞己, 神宮啓一, 武田賢, 土橋卓, 高浪健太郎, 高瀬圭, 瀧靖之

Japanese Journal of Radiology　36　(Suppl.)　11-11　2018年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN： 1867-1071

eISSN： 1867-108X
根治的放射線化学療法を施行した胸部食道癌におけるFDG-PET/CTを用いた予後予測検討

高橋紀善, 伊藤謙吾, 神宮啓一

Japanese Journal of Radiology　36　(Suppl.)　11-11　2018年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN： 1867-1071

eISSN： 1867-108X
長期CRが得られた喉頭形質細胞腫の1例

鈴木友, 松下晴雄, 久保園正樹, 田邊隆哉, 石川陽二郎, 山本貴也, 古積麻衣子, 高橋紀善, 武田一也, 田坂俊, 福井勝哉, 角谷倫之, 伊藤謙吾, 千葉瑞己, 神宮啓一, 武田賢, 土橋卓

Japanese Journal of Radiology　36　(Suppl.)　12-12　2018年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN： 1867-1071

eISSN： 1867-108X
前立腺癌に対する3D-CRTにおけるon-line adaptive radiation therapyの有効性の初期検討

木村祐利, 土橋卓, 石澤儀樹, 角谷倫之, 伊藤謙吾, 千葉貴仁, 高山佳樹, 佐藤清和, 松下晴雄, 神宮啓一, 武田賢

日本放射線腫瘍学会高精度放射線外部照射部会学術大会プログラム・抄録集　31st (CD-ROM)　2018年
IMRT前立腺がん患者に対するEPIDに基づいたin vivo線量測定に対する直腸ガスの影響

MATSUMOTO Takuya, KADOYA Noriyuki, KON Yoshio, TAKAYAMA Yoshiki, SATO Kiyokazu, ITO Kengo, CHIBA Takahito, DOBASHI Suguru, TAKEDA Ken, JINGU Keiichi

医学物理 Supplement　38　(1)　2018年

ISSN： 1345-5362
II・III期食道癌CRTにおける血液検査データと予後との関連

武田一也, 松下晴雄, 久保園正樹, 田邊隆哉, 石川陽二郎, 山本貴也, 古積麻衣子, 高橋紀善, 片桐佑, 田坂俊, 福井勝哉, 鈴木友, 角谷倫之, 伊藤謙吾, 千葉瑞己, 神宮啓一, 武田賢, 土橋卓, 梅澤玲

Japanese Journal of Radiology　36　(Supplement)　2018年

ISSN： 1867-1071
FDG-PETは局所進行食道癌における生命予後を改善せず

神宮啓一, 松下晴雄, 梅澤玲, 山本貴也, 石川陽二郎, 高橋紀善, 角谷倫之, 高浪健太郎

核医学(Web)　55　(1)　2018年

ISSN： 2189-9932
当院における塩化ラジウム(²²³Ra)の初期経験

太田瑛梨, 鎌田裕基, 外山由貴, 齋藤美穂子, 高浪健太郎, 高瀬圭, 高橋紀善, 石川陽二郎, 山本貴也, 梅澤玲, 松下晴雄, 神宮啓一

核医学(Web)　55　(1)　2018年

ISSN： 2189-9932
肺SBRT患者におけるCT-based radiomicsを用いた予後予測の有用性の検討

佐藤慎哉, 角谷倫之, 武田一也, 梶川智博, 山本貴也, 武田賢, 神宮啓一

日本放射線腫瘍学会高精度放射線外部照射部会学術大会プログラム・抄録集　31st (CD-ROM)　2018年
胸部悪性腫瘍に対する化学放射線療法に伴う心臓合併症の画像所見 (特集胸部の最新画像情報2018)

高浪健太郎, 梅澤玲, 神宮啓一, 高瀬圭

臨床放射線　63　(1)　53-60　2018年1月
出版者・発行元：金原出版
DOI： 10.18888/rp.0000000308 　

ISSN： 0009-9252
心臓MRI検査を用いた食道癌化学放射線療法後の心筋障害に対する前向き研究

梅澤玲, 角谷倫之, 大田英揮, 中島祐二朗, 齋藤正英, 高橋紀善, 高瀬圭, 神宮啓一

日本癌治療学会学術集会抄録集　55回　P127-3　2017年10月
出版者・発行元： (一社)日本癌治療学会
食道癌 (特集腫瘍に対する放射線治療 : 高度化・個別化治療へ) -- (先端放射線治療)

神宮啓一, 梅澤玲, 山本貴也, 高橋紀善, 武田一也

日本臨床 = Japanese journal of clinical medicine　75　(8)　1229-1233　2017年8月
出版者・発行元：日本臨床社
ISSN： 0047-1852
Impact of 4D-CT Ventilation Image-Based Proton Radiotherapy for Stereotactic Body Radiotherapy

Y Ieko, N Kadoya, T Kanai, Y Nakajima, K Arai, T Kato, K Ito, Y Miyasaka, K Takeda, K Jingu

Medical Physics　44　(6)　3040-3040　2017年6月
出版者・発行元： Wiley
DOI： 10.1002/mp.12304 　
Impact of Optimal Weighting for Functional Lung Avoidance Using CT Ventilation

T Kanai, N Kadoya, Y Nakajima, Y Miyasaka, Y Ieko, T Kajikawa, K Ito, T Yamamoto, S Dobashi, K Takeda, K Nemoto, K Jingu

Medical Physics　44　(6)　2811-2812　2017年6月
出版者・発行元： Wiley
DOI： 10.1002/mp.12304 　
Feasibility of a Novel Evaluation Method for Deformable Image Registration-Based Dose Accumulation for HDR Brachytherapy with a 3D-Printed Deformable Phantom

K Abe, N Kadoya, S Hashimoto, Y Miyasaka, Y Nakajima, K Ito K Sato, K Takeda, K Jingu

Medical Physics　44　(6)　2778-2778　2017年6月
出版者・発行元： Wiley
DOI： 10.1002/mp.12304 　
非小細胞肺癌oligometastases : 副腎oligometastasesを中心に

新部譲, 神宮啓一, 寺原敦朗

臨床放射線　62　(4)　601-604　2017年4月
出版者・発行元：金原出版
DOI： 10.18888/J01565.2017221592 　

ISSN： 0009-9252
次の25年の放射線治療の進歩を期待して (特集次の25年の放射線医療の進歩を見据えて)

神宮啓一

臨床放射線　62　(2)　253-256　2017年2月
出版者・発行元：金原出版
DOI： 10.18888/J01565.2017145733 　

ISSN： 0009-9252
CTから作成する肺機能画像の治療計画への利用に向けて:4D-CT vs 息止めCT

中島祐二朗, 角谷倫之, 木藤哲史, 岡野智之, 神宮啓一, 二瓶圭二, 唐澤克之

日本放射線腫瘍学会高精度放射線外部照射部会学術大会プログラム・抄録集　30th　2017年
Native T1値と細胞外容積分画を用いた放射線心筋障害の評価

高木英誠, 高木英誠, 大田英揮, 梅沢玲, 梅沢玲, 神宮啓一, 高瀬圭

日獨医報　62　(1)　2017年

ISSN： 0912-0351
頭蓋底浸潤鼻副鼻腔悪性腫瘍に対する治療戦略

小川武則, 小嶋郁穂, 村田隆紀, 阪本真弥, 岸田佳太, 高橋紀善, 松下晴雄, 荒川一弥, 野村和弘, 中目亜矢子, 大越明, 東賢二郎, 石井亮, 嵯峨井俊, 神宮啓一, 香取幸夫

頭頸部癌　43　(4)　409-414　2017年
出版者・発行元：日本頭頸部癌学会
DOI： 10.5981/jjhnc.43.409 　

ISSN： 1349-5747

eISSN： 1881-8382
胸部領域におけるユーザーガイド非剛体位置合わせの有効性検討

中島祐二朗, 木藤哲史, 唐澤克之, 角谷倫之, 神宮啓一, 金井貴幸, 齋藤正英

東京都福祉保健医療学会抄録　12th　218‐219　2016年11月
Oligometastasesに対する放射線治療 (第1土曜特集がん放射線療法Update 2016) -- (疾患別治療成績 : ここまで治るようになった! 機能温存と生存率向上)

神宮啓一, 新部譲

医学のあゆみ　257　(1)　123-126　2016年4月2日
出版者・発行元：医歯薬出版
ISSN： 0039-2359
CBCTとDeformable image registrationを用いた前立腺癌IMRTの臓器変動を考慮した合算線量の評価

高山佳樹, 角谷倫之, 伊藤謙吾, 千葉瑞己, 藤原康生, 宮坂友侑也, 土橋卓, 佐藤清和, 武田賢, 神宮啓一

日本放射線腫瘍学会高精度放射線外部照射部会学術大会プログラム・抄録集　29th　2016年
食道小細胞癌におけるp16発現と治療法に関する後ろ向き研究

石田裕嵩, 中野徹, 藤島史喜, 谷山裕亮, 櫻井直, 佐藤千晃, 小澤洋平, 高橋雅信, 神宮啓一, 亀井尚

日本食道学会学術集会抄録集(CD-ROM)　70th　2016年
Stereotactic body radiotherapy for pulmonary oligometastases with emphasis on the difference in oligometastatic state

Yuzuru Niibe, Hideomi Yamashita, Takaya Yamamoto, Kuniaki Katsui, Keiichi Nakagawa, Susumu Kanazawa, Jiro Kawamori, Wataru Takahashi, Atsuro Terahara, Keiichi Jingu

ANNALS OF ONCOLOGY　26　99-99　2015年11月

ISSN： 0923-7534

eISSN： 1569-8041
有害事象をいかに防止するか?放射線心筋障害の機序と対策

神宮啓一, 梅澤玲, 松下晴雄, 久保園正樹, 角谷倫之, 白田佑子, 山本貴也, 石川陽二郎, 古積麻衣子, 高橋紀善, 片桐佑

臨床放射線　60　(10)　1221-1224　2015年10月10日
出版者・発行元：金原出版(株)
ISSN： 0009-9252
Association between radiation dosimetry of the heart and the myocardial fatty acid metabolic impairment due to chemoradiation-therapy : Prospective study using I-123 BMIPP SPECT/CT

K. Takanami, R. Umezawa, N. Kadoya, A. Arai, K. Jingu, K. Takase

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING　42　S284-S285　2015年10月

ISSN： 1619-7070

eISSN： 1619-7089
【有害事象をいかに防止するか?】放射線心筋障害の機序と対策

神宮啓一, 梅澤玲, 松下晴雄, 久保園正樹, 角谷倫之, 白田佑子, 山本貴也, 石川陽二郎, 古積麻衣子, 高橋紀善, 片桐佑

臨床放射線　60　(10)　1221-1224　2015年10月
出版者・発行元：金原出版(株)
ISSN： 0009-9252
甲状腺癌の治療戦略甲状腺がんに対する放射線治療

神宮啓一, 丸岡伸, 梅澤玲, 高橋紀善

癌と化学療法　42　(6)　666-669　2015年6月15日

ISSN： 0385-0684
Re: MRI findings of radiation-induced myocardial damage in patients with oesophageal cancer. A reply

R. Umezawa, H. Ota, K. Jingu

CLINICAL RADIOLOGY　70　(6)　677-678　2015年6月

DOI： 10.1016/j.crad.2015.02.008 　

ISSN： 0009-9260

eISSN： 1365-229X
Radiotherapy for thyroid cancer

Keiichi Jingu, Shin Maruoka, Rei Umezawa, Noriyoshi Takahashi

Japanese Journal of Cancer and Chemotherapy　42　(6)　666-669　2015年6月1日
出版者・発行元： Japanese Journal of Cancer and Chemotherapy Publishers Inc.
ISSN： 0385-0684
Intensity‐modulated radiotherapy(IMRT)後のPSA failure症例からみたハイリスク前立腺癌への治療戦略

川崎芳英, 三塚浩二, 神宮啓一, 武田賢, 荒井陽一

泌尿器外科　28　627-630　2015年5月15日

ISSN： 0914-6180
放射線治療の合併症と対策 (特集がん放射線治療の最前線)

神宮啓一, 松下晴雄, 梅澤玲

日本医師会雑誌　144　(2)　269-271　2015年5月
出版者・発行元：日本医師会
ISSN： 0021-4493
がん放射線治療の最前線放射線治療の合併症と対策

神宮啓一, 松下晴雄, 梅澤玲

日本医師会雑誌　144　(2)　269-271　2015年5月1日
出版者・発行元：日本医師会
ISSN： 0021-4493
前立腺癌の内分泌療法―気になる最新の動向放射線外照射に併用する内分泌療法の現状と課題

三塚浩二, 川崎芳英, 荒井陽一, 神宮啓一

臨床泌尿器科　69　(5)　360-366　2015年4月20日

DOI： 10.11477/mf.1413205323 　

ISSN： 0385-2393
胆道癌 II.各論腺癌胆嚢癌治療胆嚢癌放射線治療の現状と展望

神宮啓一, 梅澤玲

日本臨床　73　590-594　2015年3月20日

ISSN： 0047-1852
頭頸部癌に対する強度変調放射線治療(IMRT:Intensity‐modulated radiotherapy)の歴史と今後の展望

神宮啓一

日本耳鼻咽喉科学会会報　118　(3)　248-251　2015年3月20日
出版者・発行元：一般社団法人日本耳鼻咽喉科学会
DOI： 10.3950/jibiinkoka.118.248 　

ISSN： 0030-6622
Current status and prospects of radiotherapy for gallbladder cancer

Keiichi Jingu, Rei Umezawa

Nihon rinsho. Japanese journal of clinical medicine　73　590-594　2015年3月1日

ISSN： 0047-1852
History and future of treatment for head and neck cancer using IMRT

Kei ichi Jingu

Nihon Jibiinkoka Gakkai kaiho　118　248-251　2015年3月1日

ISSN： 0030-6622
pT3前立腺癌術後PSA failureに対する放射線単独局所治療成績

神宮啓一, 梅澤玲, 松下晴雄, 菅原俊幸, 久保園正樹, 阿部恵子, 藤本俊裕, 山本貴也, 石川陽二郎, 古積麻衣子, 高橋紀善, 角谷倫之, 藤田幸男, 伊藤謙吾

Japanese Journal of Radiology　33　(Suppl.)　11-11　2015年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN： 1867-1071

eISSN： 1867-108X
モンテカルロ法を用いた四次元線量分布計算コードの開発

藤田幸男, 角谷倫之, 伊藤謙吾, 高橋紀善, 古積麻衣子, 山本貴也, 阿部恵子, 梅澤玲, 久保園正樹, 菅原俊幸, 松下晴雄, 神宮啓一, 武田賢, 土橋卓

Japanese Journal of Radiology　33　(Suppl.)　3-3　2015年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN： 1867-1071
みかけの拡散係数パラメータによる進行食道扁平上皮癌における化学放射線療法の治療効果予測に関する研究

古積麻衣子, 大田英揮, 山本貴也, 松下晴雄, 久保園正樹, 白田佑子, 石川陽二郎, 神宮啓一

日本医学放射線学会秋季臨床大会抄録集　51st　2015年

ISSN： 0048-0428
モンテカルロシミュレーションを用いた眼窩領域の電子線治療における水晶体防護物質の検討

中島祐二朗, 角谷倫之, 伊藤謙吾, 土橋卓, 武田賢, 神宮啓一, 岸和馬, 佐藤清和

日本放射線技術学会東北部会雑誌　(24)　113-113　2015年1月
出版者・発行元： (公社)日本放射線技術学会-東北支部
治療計画支援ソフトウェアiVASの精度検証

齋藤正英, 角谷倫之, 木田智士, 伊藤謙吾, 金井貴幸, 土橋卓, 武田賢, 神宮啓一, 岸和馬

日本放射線技術学会東北部会雑誌　(24)　114-114　2015年1月
出版者・発行元： (公社)日本放射線技術学会-東北支部
A case of successful treatment with radiotherapy of hepatocellular carcinoma with portal vein tumor thrombus in secondary hemochromatosis due to myelodysplastic syndrome (2nd report)

Koetsu Inoue, Masamichi Mizuma, Hideo Ohtsuka, Kei Nakagawa, Hiroki Hayashi, Takaho Okada, Hiroshi Yoshida, Fuyuhiko Motoi, Takeshi Naito, Yu Katayose, Keiichi Jingu, Michiaki Unno

Acta Hepatologica Japonica　56　(4)　150-156　2015年
出版者・発行元： Japan Society of Hepatology
DOI： 10.2957/kanzo.56.150 　

ISSN： 1881-3593 0451-4203
Current status and problems of androgen deprivation therapy concurrent with external radiation beam therapy

Koji Mitsuzuka, Yoshihide Kawasaki, Yoichi Arai, Keiichi Jingu

Japanese Journal of Clinical Urology　69　360-366　2015年1月1日

ISSN： 0385-2393
Mechanism of development and countermeasure for radiation-induced myocardial disorder

Keiichi Jingu

Japanese Journal of Clinical Radiology　60　1221-1224　2015年1月1日

ISSN： 0009-9252
The impact of audio-visual biofeedback with a patient-specific guiding waveform on respiratory motion management: Comparison of two different respiratory management systems

Y. Nakajima, N. Kadoya, S. Kida, K. Ito, T. Kanai, K. Kishi, K. Sato, S. Dobashi, K. Takeda, H. Matsushita, K. Jingu

WORLD CONGRESS ON MEDICAL PHYSICS AND BIOMEDICAL ENGINEERING, 2015, VOLS 1 AND 2　51　587-590　2015年

DOI： 10.1007/978-3-319-19387-8_144 　

ISSN： 1680-0737
現場で知っておきたい放射線治療法の適応と選択強度変調放射線治療(IMRT)の適応と問題点(Basics of Radiation Therapy)

神宮啓一

日本医学放射線学会秋季臨床大会抄録集　50回　S652-S652　2014年9月
出版者・発行元： (公社)日本医学放射線学会
ISSN： 0048-0428
心臓MRI検査を用いた放射線治療後の心筋変化の検出

梅澤玲, 高瀬圭, 大田英揮, 高浪健太郎, 金田朋洋, 神宮啓一, 高橋昭喜

日独医報　59　(1)　114-114　2014年6月
出版者・発行元：バイエル薬品(株)
ISSN： 0912-0351
放射線診断と治療の進歩強度変調放射線治療(IMRT:Intensity-modulated radiotherapy)

神宮啓一

耳鼻咽喉科臨床補冊　(補冊139)　44-44　2014年6月
出版者・発行元：耳鼻咽喉科臨床学会
ISSN： 0912-1870
頭蓋内胚細胞性腫瘍長期生存例のT2*強調像MRI所見全脳照射vs全脳室照射

李麗, 麦倉俊司, 村田隆紀, 高橋昭喜, 神宮啓一, 隈部俊宏, 藤井俊勝, 森悦郎

Japanese Journal of Radiology　32　(Suppl.)　9-9　2014年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN： 1867-1071
低血糖脳症の重症度判定に関してMRI所見が有用であったと考えられた1症例

岡村将史, 麦倉俊司, 坂本拓矢, 千田美穂, 奈古一宏, 玉手英一, 神宮啓一, 小川晋, 伊藤貞嘉

糖尿病　57　(2)　142-142　2014年2月
出版者・発行元： (一社)日本糖尿病学会
ISSN： 0021-437X
【前立腺癌局所治療後再発の診断、治療】前立腺癌局所治療後再発の治療前立腺全摘後再発に対する救済放射線療法の適応と課題

三塚浩二, 梅澤玲, 神宮啓一, 荒井陽一

泌尿器外科　27　(2)　165-172　2014年2月
出版者・発行元：医学図書出版(株)
ISSN： 0914-6180
頭頸部癌に対する適応放射線治療の基礎研究頭頸部外部放射線治療期間中の頸部体積減少の傾向

小森慎也, 武田賢, 土橋卓, 角谷倫之, 藤田幸男, 伊藤謙吾, 神宮啓一, 岸和馬

日本放射線技術学会東北部会雑誌　(23)　102-102　2014年1月
出版者・発行元： (公社)日本放射線技術学会-東北支部
骨盤領域におけるdeformable image registrationを用いた自動輪郭抽出の精度評価

阿部良知, 新井一弘, 武田賢, 土橋卓, 角谷倫之, 藤田幸男, 神宮啓一, 岸和馬, 梁川功

日本放射線技術学会東北部会雑誌　(23)　185-185　2014年1月
出版者・発行元： (公社)日本放射線技術学会-東北支部
Deformable Image Registrationを用いたDose-warpingに生じる線量誤差の検討

伊藤謙吾, 角谷倫之, 藤田幸男, 松下晴雄, 神宮啓一, 新井一弘, 武田賢, 土橋卓, 岸和馬

日本放射線技術学会東北部会雑誌　(23)　186-186　2014年1月
出版者・発行元： (公社)日本放射線技術学会-東北支部
複数のアルゴリズムを用いた頭頸部領域における自動輪郭抽出の精度評価

千葉瑞己, 新井一弘, 土橋卓, 武田賢, 角谷倫之, 藤田幸男, 伊藤謙吾, 神宮啓一, 岸和馬

日本放射線技術学会東北部会雑誌　(23)　188-188　2014年1月
出版者・発行元： (公社)日本放射線技術学会-東北支部
3DVHを用いたVMAT線量検証手法の精度検証とその有用性の検討

小笠原誠, 土橋卓, 武田賢, 岸和馬, 佐藤清和, 角谷倫之, 藤田幸男, 松下晴雄, 神宮啓一

日本放射線技術学会東北部会雑誌　(23)　131-131　2014年1月
出版者・発行元： (公社)日本放射線技術学会-東北支部
【食道胃接合部癌の診断と治療】治療放射線治療

神宮啓一

消化器外科　36　(11)　1637-1641　2013年10月
出版者・発行元： (株)へるす出版
ISSN： 0387-2645
【明日への提言2013〜放射線医学教育のかたち】放射線治療医の教育に対する理想と現実と希望

神宮啓一

映像情報Medical　45　(10)　752-753　2013年9月
出版者・発行元：産業開発機構(株)
ISSN： 1346-1354
Evaluation of dose calculation accuracy of modified CBCT using multi -level-threshold algorithm

Yusuke Onozato, Noriyuki Kadoya, Yukio Fujita, Yoshiyuki Katsuta, Suguru Dobashi, Ken Takeda, Kazuma Kishi, Kiyokazu Satou, Keiko Abe, Rei Umezawa, Eiji Shimizu, Toshiyuki Sugawara, Keiichi Jingu, Haruo Matsushita

IFMBE Proceedings　39 IFMBE　1799-1802　2013年4月16日

DOI： 10.1007/978-3-642-29305-4_473 　

ISSN： 1680-0737
新しい治療戦略シリーズ泌尿器科領域における放射線治療最先端前立腺癌におけるIMRTの成績とQOL

並木俊一, 武田賢, 石戸谷滋人, 高井良尋, 奈良崎覚太朗, 梅澤玲, 山田章吾, 神宮啓一, 荒井陽一

日本泌尿器科学会雑誌　104　(2)　120-120　2013年3月
出版者・発行元： (一社)日本泌尿器科学会
ISSN： 0021-5287
発展し続けるがん放射線治療

神宮啓一

宮城県医師会報　(806)　166-168　2013年3月
出版者・発行元： (公社)宮城県医師会
放射線治療における機能画像の応用

神宮啓一

東北医学雑誌　124　(2)　196(1)-196(2),197-198　2012年12月25日

ISSN： 0040-8700
上咽頭癌に対する強度変調放射線治療において局所再発が増えるか?(第1報)

神宮啓一, 阿部恵子, 小藤昌志, 松下晴雄, 藤本圭介, 菅原俊幸, 清水栄二, 梅澤玲, 武田賢, 山田章吾

頭頸部癌　38　(2)　195-195　2012年5月
出版者・発行元：日本頭頸部癌学会
ISSN： 1349-5747
EP-1403 EVALUATION OF ON-BOARD KV CONE BEAM CT-BASED DOSE CALCULATION FOR PELVIC ADAPTIVE RADIOTHERAPY 査読有り

Y. Onozato, N. Kadoya, Y. Fujita, Y. Katsuta, S. Dobashi, K. Takeda, K. Kishi, K. Satou, K. Jingu, H. Matsushita

Radiotherapy and Oncology　103　S533-S533　2012年5月
出版者・発行元： Elsevier BV
DOI： 10.1016/s0167-8140(12)71736-x 　

ISSN： 0167-8140
EP-1160 DOES IMRT INCREASE LOCO-REGIONAL FAILURE IN PATIENTS WITH NASOPHARYNGEAL CANCER? A FIRST REPORT 査読有り

K. Jingu, K. Abe, M. Koto, K. Fujimoto, H. Matsushita, T. Sugawara, R. Umezawa, N. Kadoya, K. Takeda, S. Yamada

Radiotherapy and Oncology　103　S447-S448　2012年5月
出版者・発行元： Elsevier BV
DOI： 10.1016/s0167-8140(12)71493-7 　

ISSN： 0167-8140
限局性前立腺癌に対する小線源療法(LDR)後の急性期尿路障害

武田賢, 神宮啓一, 久保園正樹, 菅原俊幸, 清水栄二, 白田佑子, 阿部恵子, 田邊隆哉, 有賀久哲, 山田章吾

Japanese Journal of Radiology　30　(Suppl.I)　13-13　2012年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN： 1867-1071
放射線誘発性髄膜腫に対し過分割放射線治療を行った1例

山本貴也, 神宮啓一, 有賀久哲, 武田賢, 菅原俊幸, 久保園正樹, 梅澤玲, 清水栄二, 阿部恵子, 白田佑子, 田邊隆哉, 石川陽二郎, 山田章吾

Japanese Journal of Radiology　30　(Supplement 1)　2012年

ISSN： 1867-1071
前立腺癌に対する外照射(non-IMRT)による高線量処方時の直腸線量制限

石川陽二郎, 角谷倫之, 藤田幸男, 神宮啓一, 松下晴雄, 菅原俊幸, 梅澤玲, 阿部恵子, 山田章吾, 武田賢

日本医学放射線学会総会抄録集　71st　2012年

ISSN： 0048-0428
ステージI食道癌の治療戦略手術可能と不可stage I食道癌に対する放射線化学療法 2つの前向き試験長期成績比較

神宮啓一, 有賀久哲, 奈良崎覚太朗, 武田賢, 梅澤玲, 菅原俊幸, 山田章吾, 宮田剛, 小野寺浩, 根本建二

日本食道学会学術集会プログラム・抄録集 65回　97-97　2011年9月
局所型前立腺癌に対する3次元原体照射後の晩期消化管障害に関連する臨床因子(Clinical Predictors of Late Gastrointestinal Toxicity after Three-dimensional Conformal Radiotherapy for Localized Prostate Cancer)

武田賢, 有賀久哲, 神宮啓一, 久保園正樹, 菅原俊幸, 梅澤玲, 清水栄二, 土橋卓, 角谷倫之, 藤田幸男, 根本建二, 山田章吾

東北大学医学部保健学科紀要　20　(2)　103-108　2011年7月
出版者・発行元：東北大学医学部保健学科
ISSN： 1348-8899
鼻副鼻腔腫瘍治療戦略の新しい可能性を探る鼻副鼻腔腫瘍に対する炭素イオン線治療

長谷川安都佐, 溝江純悦, 神宮啓一, 高木亮, 森川貴迪, 鎌田正, 辻井博彦

日本鼻科学会会誌　50　(1)　96-98　2011年4月
出版者・発行元： (一社)日本鼻科学会
ISSN： 0910-9153
F-18 FDG・I-123 BMIPP・心臓MRIで放射線心筋障害が疑われた3症例

梅澤玲, 高瀬圭, 高浪健太郎, 神宮啓一, 有賀久哲, 金田朋洋, 大田英揮, 高橋昭喜, 山田章吾

日本医学放射線学会学術集会抄録集　70回　S209-S209　2011年2月
出版者・発行元： (公社)日本医学放射線学会
ISSN： 0048-0428

eISSN： 1347-7951
鼻副鼻腔腫瘍に対する炭素イオン線治療

長谷川安都佐, 溝江純悦, 神宮啓一, 高木亮, 森川貴迪, 鎌田正, 辻井博彦

日本鼻科学会会誌　50　(1)　96-98　2011年
出版者・発行元：日本鼻科学会
局所型前立腺癌に対する3次元原体照射後の晩期消化管障害に関連する臨床因子

武田賢, 有賀久哲, 神宮啓一

東北大学医学部保健学科紀要　20　(2)　103-108　2011年
出版者・発行元：東北大学医学部保健学科
ISSN： 1348-8899

詳細を見る詳細を閉じる

Original Paper
頭頸部悪性腫瘍に対する炭素イオン線治療後の腐骨形成に関するリスクファクター

恩田健志, 高木亮, 別所央城, 高野伸夫, 柴原孝彦, 神宮啓一, 長谷川安都佐, 溝江純悦, 鎌田正

日本口腔科学会雑誌　60　(1)　127-127　2011年1月
出版者・発行元： (NPO)日本口腔科学会
ISSN： 0029-0297
脳腫瘍の放射線療法重粒子線治療 (新時代の脳腫瘍学--診断・治療の最前線) -- (脳腫瘍の治療)

長谷川安都佐, 溝江純悦, 神宮啓一

日本臨床　68　(0)　416-420　2010年12月
出版者・発行元：日本臨床社
ISSN： 0047-1852
【新時代の脳腫瘍学診断・治療の最前線】脳腫瘍の治療脳腫瘍の放射線療法重粒子線治療

長谷川安都佐, 溝江純悦, 神宮啓一, 鎌田正, 辻井博彦

日本臨床　68　(増刊10 新時代の脳腫瘍学)　416-420　2010年12月
出版者・発行元： (株)日本臨床社
ISSN： 0047-1852
頭頸部癌(頭蓋底を含む)に対する重粒子線治療 (AYUMI 重粒子線治療--最新治療エビデンス)

長谷川安都佐, 神宮啓一

医学のあゆみ　235　(4)　289-292　2010年10月23日
出版者・発行元：医歯薬出版
ISSN： 0039-2359
鼻副鼻腔腫瘍治療戦略の新しい可能性を探る鼻副鼻腔腫瘍に対する炭素イオン線治療

長谷川安都佐, 溝江純悦, 神宮啓一, 高木亮, 森川貴迪, 鎌田正, 辻井博彦

日本鼻科学会会誌　49　(3)　328-328　2010年7月
出版者・発行元： (一社)日本鼻科学会
ISSN： 0910-9153
頭頸部粘膜悪性黒色腫に対する化学療法併用重粒子線治療と重粒子線単独療法の治療成績比較

神宮啓一, 長谷川安都佐, 溝江純悦, 別所央城, 森川貴迪, 辻比呂志, 鎌田正, 辻井博彦

頭頸部癌　36　(2)　172-172　2010年5月
出版者・発行元：日本頭頸部癌学会
ISSN： 1349-5747
手術非適応腺様嚢胞癌に対する炭素イオン線治療

長谷川安都佐, 溝江純悦, 神宮啓一, 別所央城, 森川貴迪, 鎌田正, 辻井博彦

頭頸部癌　36　(2)　177-177　2010年5月
出版者・発行元：日本頭頸部癌学会
ISSN： 1349-5747
【頭頸部腫瘍診療における論点耳鼻口腔咽頭編】聴器癌に対する治療法の選択は? 炭素イオン線治療の立場から

溝江純悦, 長谷川安都佐, 別所央城, 神宮啓一

JOHNS　25　(10)　1463-1466　2009年10月
出版者・発行元： (株)東京医学社
ISSN： 0910-6820
重粒子線がん治療 : 頭頸部悪性腫瘍を中心に (特集放医研第15回公開講座 : 放射隷･人の心･重粒子線がん治療を知る)

神宮啓一, 溝江純悦, 長谷川安都佐

放射線科学　52　(9)　10-13　2009年9月
出版者・発行元：放射線医学総合研究所
ISSN： 0441-2540
頭頸部腺様嚢胞癌における炭素線治療後の辺縁再発とDVH解析

神宮啓一, 溝江純悦, 長谷川安都佐, 別所央城, 辻比呂志, 鎌田正, 辻井博彦, 浅倉裕史

日本放射線腫よう学会誌　21　(Supplement 1)　141　2009年8月19日

ISSN： 1040-9564
頭蓋底浸潤を認める頭頸部悪性腫瘍に対する重粒子線治療

長谷川安都佐, 溝江純悦, 神宮啓一

耳鼻咽喉科展望　52　(3)　176-181　2009年6月1日
出版者・発行元：耳鼻咽喉科展望会
DOI： 10.11453/orltokyo.52.176 　

ISSN： 0386-9687
【機能温存をめざした頭頸部癌治療update】重粒子線治療

長谷川安都佐, 溝江純悦, 神宮啓一, 別所央城, 柿本吉堂

ENTONI　(103)　40-45　2009年6月
出版者・発行元： (株)全日本病院出版会
ISSN： 1346-2067
重粒子線治療標準化のための画像診断 MRI

神宮啓一, 溝江純悦

重粒子医科学センターシンポジウム　8回　76-83　2009年3月
出版者・発行元： (独)放射線医学総合研究所
頭頚部非扁平上皮癌における重粒子線照射後の腐骨形成に関する解析

柿本吉堂, 長谷川安都佐, 溝江純悦, 神宮啓一, 別所央城, 浅倉裕史

日本放射線腫よう学会誌　20　(Supplement 1)　2008年

ISSN： 1040-9564
術後再発食道癌における放射線化学療法前後のFDG-PET所見による予後予測

神宮啓一, 金田朋洋, 根本建二, 小川芳弘, 有賀久哲, 高井良尋, 武田賢, 高橋昭喜, 福田寛, 井上健太郎, 山田章吾

核医学　44　(3)　290-290　2007年10月
出版者・発行元： (一社)日本核医学会
ISSN： 0022-7854
放射線治療の晩期有害事象に対する高気圧酸素療法についての検討

松下晴雄, 根本建二, 小川芳弘, 有賀久哲, 武田賢, 坂谷内徹, 藤本圭介, 奈良崎覚太朗, 神宮啓一, 高井良尋, 山田章吾

The Journal of JASTRO = 日本放射線腫瘍学会誌　19　(3)　147-155　2007年9月25日

ISSN： 1040-9564
食道癌放射線治療に伴う心臓障害の先行指標

神宮啓一, 小川芳弘, 有賀久哲

放射線生物研究　41　(4)　343-354　2006年12月
出版者・発行元：放射線生物研究会
ISSN： 0441-747X

eISSN： 2186-9766
2293: Image-Guided IMRT Reducing Urethral Dose for Prostate Cancer - An Evaluation of Acute Adverse Events 査読有り

Y. Takai, M. Mitsuya, K. Narazaki, T. Sakayauchi, K.R. Britton, Y. Ogawa, H. Ariga, K. Takeda, K. Jingu, S. Yamada

Int J Radiat Oncol Biol Phys　66　(3)　S373-S374　2006年11月
【IVR医と放射線治療医に必要な基礎的知識消化器癌に対する化学放射線療法】食道癌に対する化学放射線療法

根本建二, 小川芳弘, 高井憲司, 坂谷内徹, 菅原俊幸, 神宮啓一, 奈良崎覚太郎, 仲田栄子, 高井良尋, 山田章吾

臨床放射線　51　(3)　337-342　2006年
出版者・発行元：金原出版(株)
ISSN： 0009-9252
Stereo-tactic body radiotherapy using dual KV-XRAY on-board imaging system for stage I non-small cell lung cancer

M Koto, Y Takai, K Jingu, K Nemoto, Y Ogawa, K Takai, S Yamada

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS　63　(2)　S408-S409　2005年

ISSN： 0360-3016
【化学放射線療法にどこまで期待できるか現状と展望】食道癌に対する化学放射線療法の現状と展望 (臨床放射線)

根本建二, 小川芳弘, 高井憲司, 坂谷内徹, 菅原俊幸, 神宮啓一, 小野寺浩, 宮崎修吉, 里見進, 吉岡孝, 高井良尋, 山田章吾

臨床放射線　50　(8)　947-953　2005年
当科におけるT2喉頭癌の治療成績

野宮琢磨, 高井良尋, 根本建二, 小川芳弘, 有賀久哲, 武田賢, 後藤卓美, 小藤昌志, 藤本圭介, 加藤裕美子, キース・ブリトン, 久保園正樹, 奈良崎覚太朗, 川住祐介, 神宮啓一, 山田章吾

日本医学放射線学会雑誌　63　(9)　605-605　2003年11月
根治照射後5年以上経過して再発した子宮頸癌の検討

加藤裕美子, 高井良尋, 根本建二, 小川芳弘, 有賀久哲, 武田賢, 後藤卓美, 小藤昌志, 野宮琢磨, 藤本圭介, キース・ブリトン, 久保園正樹, 奈良崎覚太朗, 川住祐介, 神宮啓一, 山田章吾

日本医学放射線学会雑誌　63　(9)　606-607　2003年11月

︎全件表示 ︎最初の5件までを表示

講演・口頭発表等 91

膵癌に対する予防域を含めた放射線治療における3DCRTとIMRTでの急性期有害事象の比較

梅澤玲, 中川圭, 水間正道, 山本貴也, 石川陽二郎, 海野倫明, 神宮啓一

日本癌治療学会学術集会(Web)　2021年
心臓原発血管肉腫に対して放射線治療を施行した1例

山本貴也, 松下晴雄, 梅澤玲, 石川陽二郎, 片桐佑, 武田一也, 田坂俊, 福井勝哉, 鈴木友, 寺村聡司, 川端広聖, 岸田圭太, 尾股聡, 神宮啓一, 城田英和

Japanese Journal of Radiology　2021年
肺癌局所再発例にサルベージ照射が著効した1例

佐藤雄太, 松下晴雄, 梅澤玲, 山本貴也, 石川陽二郎, 武田一也, 田坂俊, 鈴木友, 川端広聖, 尾股聡, 神宮啓一

Japanese Journal of Radiology　2021年
MRI画像を用いたJacobian解析による全脳照射後の脳萎縮評価

石川陽二郎, 角谷倫之, 根本光, 細谷祐里, 松下晴雄, 梅澤玲, 山本貴也, 片桐佑, 武田一也, 田坂俊, 鈴木友, 尾股聡, 佐藤雄太, 伊藤謙吾, 千葉貴仁, 神宮啓一

Japanese Journal of Radiology　2021年
食道癌照射後再発に対する過分割照射の有効性と安全性

武田一也, 松下晴雄, 梅澤玲, 山本貴也, 石川陽二郎, 片桐佑, 田坂俊, 鈴木友, 寺村聡司, 川端広聖, 尾股聡, 佐藤雄太, 角谷倫之, 伊藤謙吾, 千葉貴仁, 神宮啓一

Japanese Journal of Radiology　2021年
小型肺癌に対する定位手術的放射線治療の初期経験

山本貴也, 松下晴雄, 角谷倫之, 伊藤謙吾, 千葉貴仁, 梅澤玲, 石川陽二郎, 片桐佑, 武田一也, 田坂俊, 鈴木友, 神宮啓一

Japanese Journal of Radiology　2021年
東北大学病院における子宮頸癌術後照射の検討

山本貴也, 梅澤玲, 久保園正樹, 松下晴雄, 石川陽二郎, 片桐佑, 武田一也, 田坂俊, 鈴木友, 神宮啓一, 徳永英樹, 八重樫伸生

Japanese Journal of Radiology　2021年
高リスク前立腺癌MRI画像の定量解析による予後予測の検討

川端広聖, 武田一也, 松下晴雄, 梅澤玲, 山本貴也, 石川陽二郎, 片桐佑, 田坂俊, 鈴木友, 寺村聡司, 尾股聡, 佐藤雄太, 角谷倫之, 武田賢, 神宮啓一, 大田英揮

Japanese Journal of Radiology　2021年
食道癌術後の孤立性の遠隔転移の治療食道癌肺転移への定位放射線治療成績多施設共同研究

神宮啓一, 山本貴也, 新部譲

日本食道学会学術集会プログラム・抄録集　2020年12月
外来放射線治療でのタブレット問診システム

園部真也, 武田一也, 佐々木恵利奈, 中村直毅, 植田琢也, 神宮啓一, 中山雅晴

医療の質・安全学会誌　2020年11月
外来放射線治療におけるタブレット問診票の導入

園部真也, 武田一也, 佐々木恵利奈, 中村直毅, 植田琢也, 神宮啓一, 中山雅晴

医療情報学連合大会論文集　2020年11月
肺定位放射線治療後の放射線誘発肺障害に対するCT画像評価の検討

山本貴也, 角谷倫之, 松下晴雄, 梅澤玲, 石川陽二郎, 高橋紀善, 片桐佑, 神宮啓一, 森下陽平, 佐藤嘉尚, 武田賢

Japanese Journal of Radiology　2020年2月
日本の多施設研究を基にした、体幹部定位放射線治療(SBRT)を行った肺癌oligometastasisの局所制御に関する分析(Local control analyses of pulmonary oligometastases treated by Stereotactic Body Radiation Therapy(SBRT) from a multi-institutional survey in Japan)

山本貴也, 神宮啓一, 新部譲, 青木昌彦

Japanese Journal of Radiology　2020年2月
中期経過観察された食道癌化学放射線療法後における心事故と心臓MRI所見の関連性

梅澤玲, 角谷倫之, 松下晴雄, 山本貴也, 石川陽二郎, 片桐佑, 武田一也, 福井勝哉, 田坂俊, 鈴木友, 川端広聖, 岸田桂太, 寺村聡司, 尾股聡, 伊藤謙吾, 高山佳樹, 千葉貴仁, 神宮啓一, 大田英揮, 高瀬圭

Japanese Journal of Radiology　2020年2月
80歳を超える後期高齢者食道癌放射線治療に化学療法併用は必要か

神宮啓一, 高橋紀善, 松下晴雄, 梅澤玲, 山本貴也, 石川陽二郎, 武田一也, 片桐佑, 田坂俊, 福井勝哉, 鈴木友, 川端広聖, 岸田桂太, 寺村聡司, 尾股聡

Japanese Journal of Radiology　2020年2月
Sturge-Weber症候群に合併したびまん性脈絡膜血管腫に放射線治療を行なった1例

石川陽二郎, 松下晴雄, 梅澤玲, 山本貴也, 武田一也, 片桐佑, 田坂俊, 福井勝哉, 鈴木友, 川端広聖, 岸田桂太, 寺村聡司, 尾股聡, 神宮啓一

Japanese Journal of Radiology　2020年2月
治療計画用CT装置Siemens SOMATOM Definition AS+の初期使用経験

武田一也, 山本貴也, 伊藤謙吾, 神宮啓一, 佐藤清和, 小関健由

Japanese Journal of Radiology　2020年2月
CT画像における肺癌患者の予後予測解析ホモロジーによる新たな挑戦

田中祥平, 角谷倫之, 梶川智博, 松田匠平, 土橋卓, 武田賢, 神宮啓一, 中根和昭

Japanese Journal of Radiology　2020年2月
体幹部定位放射線治療における視認下能動的呼吸停止システム基盤の開発研究

石川陽二郎, 角谷倫之, 梶川智博, 田中祥平, 松下晴雄, 梅澤玲, 山本貴也, 武田一也, 片桐佑, 田坂俊, 福井勝哉, 鈴木友, 川端広聖, 岸田桂太, 寺村聡司, 尾股聡, 神宮啓一

Japanese Journal of Radiology　2020年2月
炎症性腸疾患症例における急性期・晩期放射線障害の後方視的検討

鈴木友, 松下晴雄, 梅澤玲, 山本貴也, 石川陽二郎, 高橋紀善, 片桐佑, 福井勝哉, 武田一也, 田坂俊, 川端広聖, 岸田桂太, 寺村聡司, 神宮啓一

Japanese Journal of Radiology　2019年2月
FDG-PET/CTでのTexture解析を用いた胸部食道癌に対する放射線化学療法の予後予測検討

高橋紀善, 梅澤玲, 武田一也, 松下晴雄, 山本貴也, 石川陽二郎, 片桐佑, 田坂俊, 岸田桂太, 寺村聡司, 神宮啓一, 高浪健太郎

Japanese Journal of Radiology　2019年2月
長期CRが得られた喉頭形質細胞腫の1例

鈴木友, 松下晴雄, 久保園正樹, 田邊隆哉, 石川陽二郎, 山本貴也, 古積麻衣子, 高橋紀善, 武田一也, 田坂俊, 福井勝哉, 角谷倫之, 伊藤謙吾, 千葉瑞己, 神宮啓一, 武田賢, 土橋卓

Japanese Journal of Radiology　2018年2月
根治的放射線化学療法を施行した胸部食道癌におけるFDG-PET/CTを用いた予後予測検討

高橋紀善, 伊藤謙吾, 神宮啓一

Japanese Journal of Radiology　2018年2月
肺癌SRT症例の治療前PETにおけるテクスチャ解析の有用性

武田一也, 松下晴雄, 久保園正樹, 田邊隆哉, 石川陽二郎, 山本貴也, 古積麻衣子, 高橋紀善, 片桐佑, 田坂俊, 福井勝哉, 鈴木友, 角谷倫之, 伊藤謙吾, 千葉瑞己, 神宮啓一, 武田賢, 土橋卓, 高浪健太郎, 高瀬圭, 瀧靖之

Japanese Journal of Radiology　2018年2月
当院における塩化ラジウム(²²³Ra)の初期経験

太田瑛梨, 鎌田裕基, 外山由貴, 齋藤美穂子, 高浪健太郎, 高瀬圭, 高橋紀善, 石川陽二郎, 山本貴也, 梅澤玲, 松下晴雄, 神宮啓一

核医学(Web)　2018年
FDG-PETは局所進行食道癌における生命予後を改善せず

神宮啓一, 松下晴雄, 梅澤玲, 山本貴也, 石川陽二郎, 高橋紀善, 角谷倫之, 高浪健太郎

核医学(Web)　2018年
II・III期食道癌CRTにおける血液検査データと予後との関連

武田一也, 松下晴雄, 久保園正樹, 田邊隆哉, 石川陽二郎, 山本貴也, 古積麻衣子, 高橋紀善, 片桐佑, 田坂俊, 福井勝哉, 鈴木友, 角谷倫之, 伊藤謙吾, 千葉瑞己, 神宮啓一, 武田賢, 土橋卓, 梅澤玲

Japanese Journal of Radiology　2018年
MRI-LINACにおける磁場不均一の有無による肺線量分布の変化

伊藤謙吾, 角谷倫之, 中島祐二朗, 中島祐二朗, 高山佳樹, 宮坂友侑也, 土橋卓, 武田賢, 松下晴雄, 神宮啓一

日本放射線腫瘍学会高精度放射線外部照射部会学術大会プログラム・抄録集　2017年
4DCT換気能を用いた放射線肺臓炎の予測

金井貴幸, 角谷倫之, 中島祐二朗, 中島祐二朗, 宮坂友侑也, 家子義朗, 伊藤謙吾, 山本貴也, 土橋卓, 武田賢, 根本建二, 神宮啓一

日本放射線腫瘍学会高精度放射線外部照射部会学術大会プログラム・抄録集　2017年
みかけの拡散係数パラメータによる進行食道扁平上皮癌における化学放射線療法の治療効果予測に関する研究

古積麻衣子, 大田英揮, 山本貴也, 松下晴雄, 久保園正樹, 白田佑子, 石川陽二郎, 神宮啓一

日本医学放射線学会秋季臨床大会抄録集　2015年9月11日
A Quality Assurance Procedure for VMAT Delivery Technique with Multiple Verification Metric Using TG-119 Protocol

Y. Katsuta, N. Kadoya, E. Shimizu, K. Matsunaga, M. Inoue, K. Majima, K. Jingu

MEDICAL PHYSICS　2015年6月
The Impact of the Tumor Location to Deformable Image Registration

Y. Sugawara, H. Tachibana, N. Kadoya, N. Kitamura, K. Jingu

MEDICAL PHYSICS　2015年6月
乳癌上腕骨転移照射後の上腕浮腫,末梢神経障害に対し200回超の高気圧酸素療法(HBO)を施行,奏功している症例

松下晴雄, 菅原俊幸, 梅澤玲, 久保園正樹, 阿部恵子, 山本貴也, 古積麻衣子, 高橋紀善, 角谷倫之, 藤田幸男, 伊藤謙吾, 神宮啓一, 武田賢, 土橋卓

Jpn J Radiol　2015年2月25日
pT3前立腺癌術後PSA failureに対する放射線単独局所治療成績

神宮啓一, 梅澤玲, 松下晴雄, 菅原俊幸, 久保園正樹, 阿部恵子, 藤本俊裕, 山本貴也, 石川陽二郎, 古積麻衣子, 高橋紀善, 角谷倫之, 藤田幸男, 伊藤謙吾

Japanese Journal of Radiology　2015年2月
骨軟部悪性腫瘍に対する放射線治療成績

古積麻衣子, 松下晴雄, 菅原俊幸, 久保園正樹, 梅澤玲, 阿部恵子, 山本貴也, 角谷倫之, 藤田幸男, 伊藤謙吾, 高橋紀善, 神宮啓一, 武田賢, 土橋卓

Japanese Journal of Radiology　2015年2月
VariSeedを用いたAu-198密封小線源治療の線量分布計算

伊藤謙吾, 角谷倫之, 藤田幸男, 高橋紀善, 古積麻衣子, 山本貴也, 阿部恵子, 梅澤玲, 久保園正樹, 菅原俊幸, 松下晴雄, 神宮啓一, 武田賢, 土橋卓

Japanese Journal of Radiology　2015年2月
東北大学病院における食道腺癌に対する放射線治療経験

高橋紀善, 松下晴雄, 菅原俊幸, 梅澤玲, 久保園正樹, 阿部恵子, 山本貴也, 古積麻衣子, 角谷倫之, 藤田幸男, 伊藤謙吾, 神宮啓一, 武田賢, 土橋卓

Japanese Journal of Radiology　2015年2月
甲状腺MALTリンパ腫に対し放射線治療を行い長期経過観察中の症例

平塚裕介, 松下晴雄, 菅原俊幸, 梅澤玲, 久保園正樹, 阿部恵子, 山本貴也, 古積麻衣子, 高橋紀善, 角谷倫之, 藤田幸男, 伊藤謙吾, 神宮啓一, 武田賢, 土橋卓

Japanese Journal of Radiology　2015年2月
モンテカルロ法を用いた四次元線量分布計算コードの開発

藤田幸男, 角谷倫之, 伊藤謙吾, 高橋紀善, 古積麻衣子, 山本貴也, 阿部恵子, 梅澤玲, 久保園正樹, 菅原俊幸, 松下晴雄, 神宮啓一, 武田賢, 土橋卓

Japanese Journal of Radiology　2015年2月
治療計画支援ソフトウェアiVASの精度検証

齋藤正英, 角谷倫之, 木田智士, 伊藤謙吾, 金井貴幸, 土橋卓, 武田賢, 神宮啓一, 岸和馬

日本放射線技術学会東北部会雑誌　2015年1月
モンテカルロシミュレーションを用いた眼窩領域の電子線治療における水晶体防護物質の検討

中島祐二朗, 角谷倫之, 伊藤謙吾, 土橋卓, 武田賢, 神宮啓一, 岸和馬, 佐藤清和

日本放射線技術学会東北部会雑誌　2015年1月
4D CTによる肺機能画像を用いた生理機能学的な線量最適化の試み

木田智士, 角谷倫之, 金井貴幸, 伊藤謙吾, 小野里侑祐, 神宮啓一

日本放射線技術学会雑誌　2014年11月
Clinical Outcome of Radiation Therapy for Esophageal Cancer Between 2004 and 2008: Second Survey

Y. Nishimura, K. Jingu, S. Itasaka, Y. Negoro, Y. Murakami, K. Karasawa, G. Kawaguchi, F. Isohashi, M. Kobayashi, Y. Itoh, T. Ariga

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS　2014年9月
Impact of Tumor Attachment to the Pleura Measured by a Pretreatment CT Image on Outcome of Stage I NSCLC Treated With Stereotactic Body Radiation Therapy

T. Yamamoto, N. Kadoya, N. Takahashi, H. Matsushita, Y. Shirata, T. Sugawara, M. Kubozono, R. Umezawa, K. Abe, S. Fujimoto, Y. Ishikawa, M. Kozumi, K. Takeda, K. Jingu

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS　2014年9月
低血糖脳症の重症度判定に関してMRI所見が有用であったと考えられた1症例

岡村将史, 麦倉俊司, 坂本拓矢, 千田美穂, 奈古一宏, 玉手英一, 神宮啓一, 小川晋, 伊藤貞嘉

糖尿病　2014年2月28日
食道癌術後再発に対する放射線化学療法予後因子―多変量解析結果―

神宮啓一, 松下晴雄, 菅原俊幸, 久保園正樹, 梅澤玲, 阿部恵子, 角谷倫之, 藤田幸男, 田邊隆之, 白田佑子, 山本貴也, 武田賢, 土橋卓, 根本建二

Jpn J Radiol　2014年2月25日
低血糖脳症の重症度判定に関してMRI所見が有用であったと考えられた1症例

岡村将史, 麦倉俊司, 坂本拓矢, 千田美穂, 奈古一宏, 玉手英一, 神宮啓一, 小川晋, 伊藤貞嘉

糖尿病　2014年2月
食道癌術後再発に対する放射線化学療法予後因子多変量解析結果

神宮啓一, 松下晴雄, 菅原俊幸, 久保園正樹, 梅澤玲, 阿部恵子, 角谷倫之, 藤田幸男, 田邊隆之, 白田佑子, 山本貴也, 武田賢, 土橋卓, 根本建二

Japanese Journal of Radiology　2014年2月
食道悪性黒色腫の2例

木下知, 松下晴雄, 菅原俊幸, 久保園正樹, 梅澤玲, 阿部恵子, 角谷倫之, 藤田幸男, 白田佑子, 田邊隆哉, 山本貴也, 神宮啓一, 武田賢, 土橋卓

Japanese Journal of Radiology　2014年2月
呼吸性移動によるSUVmaxの減弱に対する補正法の検討

角谷倫之, 藤田幸男, 山本貴也, 白田佑子, 阿部恵子, 梅澤玲, 久保園正樹, 菅原俊幸, 松下晴雄, 神宮啓一, 土橋卓, 武田賢, 金田朋洋

Japanese Journal of Radiology　2014年2月
頭蓋内胚細胞性腫瘍長期生存例のT2*強調像MRI所見全脳照射vs全脳室照射

李麗, 麦倉俊司, 村田隆紀, 高橋昭喜, 神宮啓一, 隈部俊宏, 藤井俊勝, 森悦郎

Japanese Journal of Radiology　2014年2月
複数のアルゴリズムを用いた頭頸部領域における自動輪郭抽出の精度評価

千葉瑞己, 新井一弘, 土橋卓, 武田賢, 角谷倫之, 藤田幸男, 伊藤謙吾, 神宮啓一, 岸和馬

日本放射線技術学会東北部会雑誌　2014年1月
B-splineを用いたdeformable image registrationの高精度化の検討

金井貴幸, 曹翔永, 土橋卓, 武田賢, 角谷倫之, 藤田幸男, 伊藤謙吾, 神宮啓一, 岸和馬

日本放射線技術学会東北部会雑誌　2014年1月
Deformable Image Registrationを用いたDose-warpingに生じる線量誤差の検討

伊藤謙吾, 角谷倫之, 藤田幸男, 松下晴雄, 神宮啓一, 新井一弘, 武田賢, 土橋卓, 岸和馬

日本放射線技術学会東北部会雑誌　2014年1月
骨盤領域におけるdeformable image registrationを用いた自動輪郭抽出の精度評価

阿部良知, 新井一弘, 武田賢, 土橋卓, 角谷倫之, 藤田幸男, 神宮啓一, 岸和馬, 梁川功

日本放射線技術学会東北部会雑誌　2014年1月
3DVHを用いたVMAT線量検証手法の精度検証とその有用性の検討

小笠原誠, 土橋卓, 武田賢, 岸和馬, 佐藤清和, 角谷倫之, 藤田幸男, 松下晴雄, 神宮啓一

日本放射線技術学会東北部会雑誌　2014年1月
頭頸部癌に対する適応放射線治療の基礎研究頭頸部外部放射線治療期間中の頸部体積減少の傾向

小森慎也, 武田賢, 土橋卓, 角谷倫之, 藤田幸男, 伊藤謙吾, 神宮啓一, 岸和馬

日本放射線技術学会東北部会雑誌　2014年1月
Evaluation of On-Board kV Cone Beam CT-Based Dose Calculation Using Deformable Image Registration and Modification of HU Values

Y. Onozato, N. Kadoya, Y. Fujita, K. Arai, S. Dobashi, K. Takeda, K. Kishi, K. Satou, Y. Kumazaki, K. Jingu

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS　2013年10月
Evaluation of dose calculation accuracy of modified CBCT using multi -level-threshold algorithm

Yusuke Onozato, Noriyuki Kadoya, Yukio Fujita, Yoshiyuki Katsuta, Suguru Dobashi, Ken Takeda, Kazuma Kishi, Kiyokazu Satou, Keiko Abe, Rei Umezawa, Eiji Shimizu, Toshiyuki Sugawara, Keiichi Jingu, Haruo Matsushita

IFMBE Proceedings　2013年4月16日

詳細を見る詳細を閉じる

We evaluated dose calculation accuracy for modi- fied Cone-Beam computed tomography (CBCT) images using Multi -level-threshold algorithm, and compared it with un- modified CBCT images. Inhomogeneous pelvis phantom imag- es and three prostate cancer patient images were acquired from both planning CT (PCT) and CBCT. The Hounsfield Units (HUs) were measured for air, tissue, bone. Using in- house software, three different tissue types were differentiated in both imaging modalities. The HUs of CBCT images were replaced by the mean HUs of the same tissue type of the PCT. An intensity modulated radiation therapy (IMRT) plan was created on PCT and copied to the modified CBCT. To evaluate the dosimetric accuracy, dose distributions based on CBCT images were compared it with PCT for four datasets (one inhomogeneous phantom, three prostate cancer patients ). HU- ED calibration acquired with PCT was used in both images. In the inhomogeneous pelvis phantom, differences in dose param- eter were seen. Regarding PTV, Rectum, and Bladder, differ- ences in mean dose between PCT and CBCT were 0.4%, 0.4%, and 0.1%, respectively, whereas those between PCT and modi- fied CBCT were 0.2%, 0.1%, and 0%, respectively. In the patient study, the average dose difference of PTV, Rectum, and Bladder between PCT and CBCT were 1.0%, 0.2%, and 0.6%, respectively, compared to PCT and modified CBCT, 0.5%, 0.1%, and 0.2%, respectively. We found that the dose difference in the plans based on PCT and CBCT were de- creased after this modification. The uncertainty in patient positioning between PCT and CBCT may cause additional discrepancies in the calculated results compared to the results in the phantom study. An accurate dose calculation based on CBCT images is possible when density distributions are cor- rected. This method does not need to acquire HU-ED calibra- tion for CBCT, and may be able to remove scatter. © 2013 Springer-Verlag.
Assessment of a commercially available automatic deformable image registration

Yoshiyuki Katsuta, Noriyuki Kadoya, Yukio Fujita, Yusuke Onozato, Kengo Ito, Tokihiro Yamamoto, Suguru Dobashi, Ken Takeda, Kazuma Kishi, Kiyokazu Satou, Youjiro Ishikawa, Takaya Yamamoto, Maiko Kozumi, Keiichi Jingu, Haruo Matsushita

IFMBE Proceedings　2013年4月16日

詳細を見る詳細を閉じる

Ventilation imaging can be performed using thoracic four dimensional computed tomography (4D-CT) images (max inhale phase and max exhale phase) and deformable image registration (DIR). If this method was administered in multi institution, some institution would use commercially available automatic DIR software. But, there are not many reports about commercially available automatic DIR. In this study, we evaluated the accuracy of a commercially available automatic deformable image registration (DIR) algorithm using 4D-CT images. For evaluating the accuracy of DIR, registration error was calculated by difference between manual displacement and automatic calculated displacement (DIR outputs). A B-spline DIR algorithm implemented in a Velocity AI ver. 2.7.0 software (Velocity Medial, GA, USA) was evaluated. 4D-CT images including 300 landmarks /case, throughout the lung, provided by DIR-lab (www.dir-lab.com). In this study, five patients were studied. The goal of DIR was to find a point to point correspondence between inhale image and exhale image. First, manual displacement was calculated by land mark points between max inhale phase and max exhale phase. Next, DIR outputs were calculated by a Velocity AI. After that, registration error was calculated by difference between manual displacement and DIR outputs. The mean 3D registration error (standard deviation) for the five cases was 2.70 (2.24) mm. Fewer large errors were seen, but the frequent histogram had a peak at 1.5mm of 3D error, and the frequencies decline as one moves away from the peak. The average 3D registration errors for case1 were 0.94 mm for 1.5 mm motion distance magnitude, 1.96 mm for 6.0 mm and 3.70 mm for 9.0 mm, respectively. Our result clearly shows that the accuracy of DIR in Velocity AI was within 3.0 mm. Therefore commercially available automatic DIR may be useful for image-guided radiation therapy, adaptive radiation therapy and ventilation imaging. © 2013 Springer-Verlag.
二次発がんを生じた後に不幸な経過をたどった若年性上咽頭癌の1例

古積麻衣子, 松下晴雄, 菅原俊幸, 神宮啓一, 清水栄二, 梅澤玲, 阿部恵子, 白田佑子, 石川陽二郎, 山本貴也, 角谷倫之, 藤田幸男, 武田賢, 土橋卓, 久保園正樹, 有賀久哲, 山田章吾

Japanese Journal of Radiology　2013年2月
術後食道癌孤立性リンパ節転移再発に対する放射線化学療法治療長期成績

神宮啓一, 松下晴雄, 菅原俊幸, 久保園正樹, 清水栄二, 梅澤玲, 阿部恵子, 白田佑子, 石川陽二郎, 山本貴也, 古積麻衣子, 山田章吾, 武田賢, 有賀久哲, 根本建二

Japanese Journal of Radiology　2013年2月
21世紀の子宮頸癌I期、II期放射線治療

久保園正樹, 松下晴雄, 菅原俊幸, 神宮啓一, 清水栄二, 梅澤玲, 阿部恵子, 白田佑子, 石川陽二郎, 山本貴也, 古積麻衣子, 有賀久哲, 小川芳弘, 山田章吾

Japanese Journal of Radiology　2013年2月
原発不明頭頸部扁平上皮癌の検討

菅原俊幸, 松下晴雄, 神宮啓一, 清水栄二, 阿部恵子, 梅沢玲, 山本貴也, 石川陽二郎, 古積麻衣子, 角谷倫之, 藤田幸男, 武田賢, 土橋卓, 久保園正樹, 小川芳弘, 山田章吾

Japanese Journal of Radiology　2013年2月
Kasabach-Merritt症候群を合併し、集学的治療を要したKaposiform hemangioendotheliomaの年長児例

及川善嗣, 南條由佳, 佐藤篤, 今泉益栄, 武山淳二, 入江正寛, 神宮啓一, 牛尾茂子

日本小児血液・がん学会学術集会・日本小児がん看護学会・公益財団法人がんの子どもを守る会公開シンポジウムプログラム総会号　2012年11月
早期肺がんにおける3D‐PETと4D‐PETによるSUVmaxの相違

神宮啓一, YAMAMOTO Tokihiro, YANG Jaewon, LOO BW. Jr

核医学　2012年8月31日
上咽頭癌に対する強度変調放射線治療において局所再発が増えるか?(第1報)

神宮啓一, 阿部恵子, 小藤昌志, 松下晴雄, 藤本圭介, 菅原俊幸, 清水栄二, 梅澤玲, 武田賢, 山田章吾

頭頸部癌　2012年5月
限局性前立腺癌に対する小線源療法(LDR)後の急性期尿路障害

武田賢, 神宮啓一, 久保園正樹, 菅原俊幸, 清水栄二, 白田佑子, 阿部恵子, 田邊隆哉, 有賀久哲, 山田章吾

Japanese Journal of Radiology　2012年2月
集学的治療の有用性が示唆された難治性Kasabach-Merritt症候群の一例

片山紗乙莉, 入江正寛, 大内芽里, 佐藤篤, 今泉益栄, 佐藤智樹, 齊藤潤子, 北見昌広, 島貫義久, 神宮啓一

日本小児科学会雑誌　2012年2月
F-18 FDG・I-123 BMIPP・心臓MRIで放射線心筋障害が疑われた3症例

梅澤玲, 高瀬圭, 高浪健太郎, 神宮啓一, 有賀久哲, 金田朋洋, 大田英揮, 高橋昭喜, 山田章吾

日本医学放射線学会学術集会抄録集　2011年2月
頭頸部悪性腫瘍に対する炭素イオン線治療後の腐骨形成に関するリスクファクター

恩田健志, 高木亮, 別所央城, 高野伸夫, 柴原孝彦, 神宮啓一, 長谷川安都佐, 溝江純悦, 鎌田正

日本口腔科学会雑誌　2011年1月
基底細胞腺癌に対する炭素線治療-6例報告-

神宮啓一, 長谷川安都佐, 溝江純悦, 高木亮, 辻比呂志, 鎌田正辻井博彦

第23回日本放射線腫瘍学会学術大会　2010年11月18日
Results of Intraoperative Radiotherapy for Pancreatic Cancer in the Last Decade: Comparing with Historical Results 国際会議

Keiichi Jingu MD, Hisanori Ariga MD, Yoshihiro Ogawa MD, Rei Umezawa MD, Masashi Koto MD, Ken Takeda MD, Shogo Yamada MD

ASTRO 53rd annual meeting　2010年10月31日
頭頸部粘膜悪性黒色腫に対する化学療法併用重粒子線治療と重粒子線単独療法の治療成績比較

神宮啓一, 長谷川安都佐, 溝江純悦, 高木亮, 森川貴迪, 辻比呂志, 鎌田正辻井博彦

第34回日本頭頚部癌学会学術集会　2010年6月9日
Carbon Ion Radiotherapy for Malignant Tumors of the Head and Neck in NIRS 国際会議

Keiichi Jingu, MD, Azusa Hasegawa, DDS, Jun-Etsu Mizoe, MD, Ryou Takagi, DDS, Takamichi Morikawa, DDS, Hiroshi Tsuji, MD, Tadashi Kamada, MD, Hirohiko Tsujii MD

A Joint Symposium of the Japan National Institute of Radiological Science　2010年5月27日
頭頸部粘膜悪性黒色腫に対する炭素線化学療法後の予後予測

神宮啓一, 岸本理和, 溝江純悦, 長谷川安都佐, 別所央城, 辻, 比呂志, 鎌田, 正辻井博彦

第69回日本医学放射線学会総会　2010年4月8日
Carbon Ion Radiotherapy for Malignant Head-and-Neck Tumors Invading the Skull Base

A. Hasegawa, K. Jingu, J. Mizoe, R. Takagi, T. Morikawa, T. Kamada, H. Tsujii

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS　2010年
頭頸部腺様嚢胞癌における炭素線治療後の辺縁再発とDVH解析

神宮啓一, 溝江純悦, 長谷川安都佐, 別所央城, 辻比呂志, 鎌田正, 辻井博彦, 浅倉裕史

日本放射線腫よう学会誌　2009年8月19日
東北大における前立腺癌小線源療法の初期経験

神宮啓一

Radiat Med　2009年4月25日
食道小細胞癌の放射線治療

吉田さやか, 小川芳弘, 有賀久哲, 小藤昌志, 藤本圭介, 坂谷内徹, 神宮啓一, 奈良崎覚太郎, 目時隆博, 山田章吾, 高井良尋, 仲田栄子, 根本建二

Radiat Med　2009年4月25日
骨転移を伴った甲状腺濾胞癌に対し、I-131内照射により長期生存を得た症例

坂谷内徹, 小川芳弘, 有賀久哲, 武田賢, 小藤昌志, 藤本圭介, 神宮啓一, 奈良崎覚太朗, 目時隆博, 山田章吾, 仲田栄子, 高井良尋, 丸岡伸, 中村護

Japanese Journal of Radiology　2009年4月
術後再発食道癌における放射線化学療法前後のFDG-PET所見による予後予測

神宮啓一, 武田賢, 小川芳弘, 有賀久哲, 山田章吾, 根本建二, 金田朋洋, 高橋昭喜, 福田寛, 高井良尋

第20回日本放射線腫瘍学会総会　2007年12月13日
術後再発食道癌における放射線化学療法前後のFDG-PET所見による予後予測

神宮啓一, 武田賢, 小川芳弘, 有賀久哲, 山田章吾, 根本建二, 金田朋洋, 高橋昭喜, 福田寛, 高井良尋

第45回日本癌治療学会総会　2007年10月24日
Long-term results of the phase II study on radiotherapy combined with nedaplatin and 5-FU for postoperative locoregional recurrent esophageal cancer 国際会議

Keiichi Jingu

ECCO14　2007年9月23日
Prognostic impact of FDG-PET before and after chemoradiotherapy in locoregional postoperative recurrent esophageal cancer 国際会議

Keiichi Jingu

the 5th Japan-US Cancer Therapy Symposium & the 5th S.Takahashi Memorial International Joint Symposium　2007年9月7日
放射線心筋障害における血清BNP濃度の有用性

神宮啓一, 小川芳弘, 有賀久哲, 武田賢, 坂谷内徹, 藤本圭介, 奈良崎覚太朗, 松本世津, 山田章吾, 高井良尋, 仲田栄子

第66回日本放射線医学会総会　2007年4月13日
Clinical Significance of Focal Increased 18F–FDG Uptake in the Basal Myocardium after Radiotherapy for Esophageal Cancer 国際会議

K Jingu, K Nemoto, S Yamada, T Kaneta, S Takahashi

RSNA 92nd annual meeting　2006年11月26日
胸部食道癌根治放射線治療後のBNP経時的変化の検討

神宮啓一, 小川芳弘, 有賀久哲, 武田賢, 坂谷内徹, 藤本圭介, 奈良崎覚太朗, 目時隆博, 松本世津, 山田章吾, 根本建二, 高井良尋, 仲田栄子

第19回日本放射線腫瘍学会総会　2006年11月23日
Result of Radiation Therapy Combined with Nedaplatin (Cis-Diammine-Glycoplatinum) and 5-Fluorouracil for Postoperative locoregional Recurrent Esophageal Cancer 国際会議

Keiichi Jingu, Kenji Nemoto, Haruo Matushita, Chiaki Takahashi, Yoshihiro Ogawa, Toshiyuki Sugawara, Eiko Nakata, Yoshihiro Takai, Shogo Yamada

ASTRO 48th annual meeting　2006年11月5日
術後再発食道癌に対するNedaplatin及び5-FUを併用した放射線化学療法：第2相試験

神宮啓一, 根本建二, 高井良尋, 小川芳弘, 高井憲司, 坂谷内徹, 仲田栄子, 菅原俊幸, 奈良崎覚太郎, 山田章吾, 松下晴雄, 高橋ちあき

第65回日本医学放射線学会総会　2006年4月7日
Stereo-tactic body radiotherapy using dual KV-XRAY on-board imaging system for stage I non-small cell lung cancer

M Koto, Y Takai, K Jingu, K Nemoto, Y Ogawa, K Takai, S Yamada

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS　2005年

︎全件表示 ︎最初の5件までを表示

共同研究・競争的資金等の研究課題 17

多発転移性腎癌におけるニボルマブと放射線治療の相乗効果を検証する無作為比較試験

大西洋, 神宮啓一, 白井克幸, 村上祐司, 淡河悦代, 小岩井慶一郎, 平田岳郎, 佐藤啓, 小島崇宏, 櫻井英幸, 増井浩二, 高橋正幸, 土谷順彦, 青木昌彦, 萬利乃寛, 山下英臣, 室伏景子, 古平毅, 生島仁史, 井垣浩, 三井貴彦

提供機関：Japan Society for the Promotion of Science

制度名：Grants-in-Aid for Scientific Research

研究種目：Grant-in-Aid for Scientific Research (B)

研究機関：University of Yamanashi

2024年4月1日～ 2029年3月31日
中枢神経に対する放射線防護剤の開発研究

神宮啓一, 麦倉俊司

提供機関：Japan Society for the Promotion of Science

制度名：Grants-in-Aid for Scientific Research

研究種目：Grant-in-Aid for Scientific Research (C)

研究機関：Tohoku University

2022年4月1日～ 2025年3月31日
局所進行非小細胞肺癌に対する肺機能画像を用いたオーダーメイド放射線治療法の開発

木村智樹, 神宮啓一, 永田靖, 角谷倫之, 河原大輔, 中島祐二朗, 今野伸樹, 日置一成, 唐澤克之

提供機関：Japan Society for the Promotion of Science

制度名：Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B)

研究種目：Grant-in-Aid for Scientific Research (B)

研究機関：Hiroshima University

2020年4月1日～ 2024年3月31日

詳細を見る詳細を閉じる

本研究は、機能肺(肺機能画像として4次元CTによる肺換気画像と肺血流シンチによる肺血流画像を用いた高肺機能領域)に対する照射線量の低減が放射線肺臓炎の抑制につながるという仮説のもと、強度変調放射線治療（IMRT）により機能肺を選択的に低減させ、実臨床において放射線肺臓炎の低減につながるか否かを前向きに検証する。具体的には多施設共同前向き試験「切除不能局所進行非小細胞肺癌に対する肺機能画像を用いた強度変調放射線治療第II相試験（UMIN000038382）」として、手術不能もしくは拒否かつ根治照射可能な局所進行非小細胞肺癌IIBからIIIC期（UICC第8版）に対し、肺機能画像を用いたIMRTによる選択的な機能肺への照射線量低減が、重篤な放射線肺臓炎（≧Grade 3）の頻度を減少させるか否かを検証する。登録期間は5年で、予定登録数は75例である。広島大学、東北大学、がん・感染症センター都立駒込病院の3施設が参加し、既に全施設で倫理委員会承認済みであり、令和元年10月より、本研究に対し同意を得られた肺癌患者を登録中である。高知大学も参加予定で機器設備が整い次第、倫理委員会での承認を得る予定である。
Radiomics技術を用いてCT画像のみから肺機能画像を作成する手法の開発

角谷倫之, 市地慶, 神宮啓一, 山本貴也

提供機関：Japan Society for the Promotion of Science

制度名：Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)

研究種目：Grant-in-Aid for Scientific Research (C)

研究機関：Tohoku University

2019年4月1日～ 2022年3月31日

詳細を見る詳細を閉じる

我々は肺癌の放射線治療において、患者毎に肺機能に応じた正常肺への線量低減により重篤な副作用を低減する目的で、肺機能画像を用いたオーダーメイド放射線治療法の開発を行ってきた。今までは肺機能画像を取得するために追加検査が必要であり、かつその検査も容易に行う事ができなかった。そこで、我々は放射線治療予後予測研究に既に用いているradiomics技術に注目し、この技術を用いることで肺野内のCT値情報から膨大な高次元画像特徴量を抽出することができ、これまで不可能であったCT画像のみから局所的な換気能力の違いを捉えることができ、高精度な肺機能画像を簡便に作成することが可能ではないかという着想に至った。本研究では、そのradiomics技術とCT画像のみから肺機能画像を作成する手法の開発を行う。昨年度は、肺野内から膨大なradiomics特徴量を抽出できるプラットフォームを用いて、呼吸機能検査値と相関があるradiomics特徴量の探索および機械学習のモデルの最適化を行った。その中で、LASSOモデルを用いることで高い予測精度を達成できることがわかり、高い予測精度となるモデルを構築できた(AUC > 0.8).今年度得られた結果から、複数のradiomics特徴量を組み合わせることで高い精度で肺機能値を予測できることがわかり、radiomicsを使うことで医用画像のみから呼吸機能検査値を十分推定できる可能性を見出すことができた。
IVIMイメージングによる人組織血液酸素飽和度の定量

田村元, 神宮啓一, 麦倉俊司, 大田英揮, 木下俊文

提供機関：Japan Society for the Promotion of Science

制度名：Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)

研究種目：Grant-in-Aid for Scientific Research (C)

研究機関：Tohoku University

2018年4月1日～ 2022年3月31日

詳細を見る詳細を閉じる

2018年度はIVIM-MRIについて基礎的検討を行った。 MRI拡散強調画像は、ランダムに位置を変える(水)分子の集合から得られる信号を捉えることができる。b値と呼ばれるパラメータを大きくするほど、僅かな動きを捉えることができる。生体の分子は、熱運動以外に血流に伴う運動もしている。毛細管など微小血管の向きの分布はほぼ等方的と考えられ、血流に乗った分子の運動はランダムな移動と見なすことができる。血流は速いので、小さなb値でも信号変化が生ずる。一方で熱運動は、より大きなb値で変化が明瞭となる。さらに生体中では、細胞膜などで自由な熱運動が制限され (制限拡散) 位置の変化が小さくなるので、さらに大きなb値を用いると制限拡散による信号変化が明瞭となる。 IVIMは、大小の複数のb値を用いて、血流を含めた分子の運動を捉えようとする方法である。しかし、組織の血液量が小さいと、血流の信号が小さく、ノイズに埋もれて捉えることが難しくなる。さらに、脳では脳脊髄液、腎では尿細管内液からの信号も考慮する必要がある。液体の信号はFLAIRという撮像法を用いて抑制することができると考えられる。これら３成分 (血液、組織水、自由水) を考慮に入れたモデルを作り、様々な条件下でIVIMの信号のシミュレーションをおこない、さらに、その信号から得られるパラメータを評価した。その結果、臨床的撮像条件においては、画素ごとに計算する場合、血液量が10%程度以上あれば、血液酸素飽和度を推定可能であるという結果が得られた。脳では血液量が5％以下であり、画素ごとの解析では困難であり、画素の集合を平均した信号を用いるなどの工夫が必要と考えられた。結果の一部は、2018年国際磁気共鳴医学会と日本磁気共鳴医学会の大会で報告した。
放射線認知障害：Advanced MR による発症機構解明と動物モデルによる検証

麦倉俊司, 神宮啓一, 森悦朗, 高瀬圭, 金森政之, 高橋昭喜, 森菜緒子, 飯塚統

提供機関：Japan Society for the Promotion of Science

制度名：Grants-in-Aid for Scientific Research

研究種目：Grant-in-Aid for Scientific Research (B)

研究機関：Tohoku University

2017年4月1日～ 2021年3月31日

詳細を見る詳細を閉じる

小児がん長期生存者の約50％に放射線認知障害が生じる。放射線認知障害のリスク診断、認知障害を回避した放射線治療法の開発（発症予防）、認知障害の遺伝子治療の開発をめざすには、その発症機構の解明が急務である。一方長期生存者からの病理組織採取は難しい。現在Advanced MRIにより、脳微細構造変化に相当するパタメーターや行動の際の脳活動が非侵襲的に評価できるようになっている。本研究は、小児がん長期生存者を対象に、Advanced MRIを用いて放射線認知障害の発症機構を解明し、照射後認知障害マウスから得られた病理組織で検証する。研究の学術的背景：医療レベルの進歩に伴い小児がん患者の長期予後は著明に改善しているが、頭蓋内照射後の小児がん生存者の約50％に遅発性認知機能障害が生じ、がんが征圧されたにもかかわらず、教育・職業上の障害に直面している。MRIにより非侵襲的に脳微細構造変化や、脳活動の評価が可能である。1. 微小血管損傷を検出できる磁化率強調画像や 2. 神経突起の密度や散乱の程度が評価できる神経突起画像、3. 神経細胞の密度と相関するパラメーターを測定できるMRスペクトロスコピー(MRS)、4. 脳局所血流動態の評価ができる非造影脳灌流画像があり、5. functional MRI（ｆMRI）では実際の行動に対応する脳の活動が描出できる。研究A 小児がん長期生存者においてAdvanced MRにより微細構造変化、脳活動変化を検出した。今後、認知機能障害の有無や程度との関連性を検討し、放射線認知障害の発症機構を解明する。そして研究B.放射線認知障害マウスから得た病理組織と対比、検証する。
Oligometastasesに対する放射線治療の個別化治療戦略の確立

新部譲, 神宮啓一, 島田英昭, 山下英臣

提供機関：Japan Society for the Promotion of Science

制度名：Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)

研究種目：Grant-in-Aid for Scientific Research (C)

研究機関：Toho University

2017年4月1日～ 2021年3月31日

詳細を見る詳細を閉じる

本年は、新倫理指針にともなったプロトコールの作成作業を進めた。予想以上に、多施設共同研究の研究費内での実施が難しく、新倫理指針後のプロトコールを実際に進めるまでには至っていない。一方、研究成果は、昨年までに行った研究の英文論文化を進めたり、サブ解析結果を、放射線腫瘍学分野では、世界一評価の高い第60回米国放射線腫瘍学会 (ASTRO 2018) にて、新部と分担研究者の東北大学神宮啓一教授らで、”Local contorol analyses of pulmonary oliotometastasers treated by stereotactic body radiation therapy (SBRT) from a multi-institutional survey in Japan" のタイトルでOral Presentationを行った。また、国内でも、第56回日本癌治療学会学術集会の指名パネル演者として、Oligometastasesについて、発表および討論を行った。一般演題ではあるが、日本放射線腫瘍学会第31回学術大会にて、"食道癌リンパ節oligo-recurrenceに対する放射線療法：対象群を変更しての再検討" のタイトルで口演発表を行った。なお、Pulmonary Oligometastasesに関しては、英文論文を書き、英文校正後、英文論文を投稿し、次年度中には投稿予定である。
肺・肝以外の諸臓器における定位放射線治療の効果と安全性の評価

大西洋, 神宮啓一, 根本建二, 塩山善之, 芝本雄太, 中村和正, 松下晴雄, 小岩井慶一郎, 佐藤啓, 宇野隆, 鈴木修, 伊丹純, 原田英幸, 石川仁, 山下英臣, 唐澤克之, 松尾幸憲, 馬屋原博, 小久保雅樹, 木村智樹, 高山賢二, 大賀才路, 野宮琢磨, 加藤徳雄, 吉武忠正

提供機関：Japan Society for the Promotion of Science

制度名：Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B)

研究種目：Grant-in-Aid for Scientific Research (B)

研究機関：University of Yamanashi

2016年4月1日～ 2021年3月31日

詳細を見る詳細を閉じる

【会議の開催】第5回全体会議：2019年4月13日、第6回全体会議：2019年11月22日、メール会議随時開催【既存多施設研究の遂行】1.有転移性肺癌患者におけるNivolumabと定位放射線治療の併用の安全性試験（NIVOSTLUC-I)、2.保険外臓器腫瘍に対する定位放射線治療の観察研究、3.有転移性腎癌多発患者におけるNivolumabと定位放射線治療の併用の有無による治療効果の差についての比較研究（NIVOIGERCC)（phase II/III）【新規多施設研究の検討】1.中枢型IA（UICC 7版）期非小細胞肺癌に対する高精度少分割放射線治療の多施設前向き登録、2.III期非小細胞肺癌の従来型化学放射線療法後の残存腫瘍に対する定位放射線治療【各分担研究者による臨床試験継続】1. 保険適応外臓器に対する定位放射線治療の調査研究、観察研究、 2. 有転移性前立腺癌の定位照射のI/II相臨床試験、アンケート調査、 3. (1) M1前立腺癌, (2) 前立腺癌放射線治療後局所再発, (3) 前立腺癌術後マクロ再発に対する救済定位放射線治療、 4. 膵臓癌に対する定位放射線治療、5. 子宮頸癌に対する定位放射線治療、6. 婦人科がんのPALN孤発転移への定位放射線治療)、7. 直腸がん術後の吻合部以外の再発（仙骨前面の軟部組織）への定位放射線治療、8. 乳癌の根治的照射としてのブースト定位照射、9. リンパ節転移、胆管癌への定位照射、10. オリゴリンパ節転移に対する定位放射線治療の第II相研究、11. 5cm以上の肝癌・肺癌に対する定位放射線治療【研究発表】1.腎癌の定位放射線治療成績をまとめた。2.I期非小細胞肺癌の定位放射線治療と手術との比較論文のレビューを論文化した。3.定位放射線治療ｂにおけるマルチリーフコリメータ位置の医学物理的評価を行った。
体幹部定位放射線治療における視認下能動的呼吸停止システム基盤の開発研究

石川陽二郎, 神宮啓一, 角谷倫之

提供機関：Japan Society for the Promotion of Science

制度名：Grants-in-Aid for Scientific Research Grant-in-Aid for Young Scientists (B)

研究種目：Grant-in-Aid for Young Scientists (B)

研究機関：Tohoku University

2015年4月1日～ 2018年3月31日

詳細を見る詳細を閉じる

本邦における高齢化とそれに伴うがん羅患患者の上昇が続いている。しかし、検診の普及に伴い早期がんの割合も増加している。がんに罹患する高齢者の割合の増加にともない、合併症を持つ患者が多くなっている。がん治療においては、より非侵襲的な治療、特に根治を望める放射線治療が注目されている。肺がんは呼吸による腫瘍の位置移動が治療に影響する世病気の一つである。呼吸による位置移動が大きければ大きいほど治療範囲が大きくなってしまう。そこで、眼前モニターを使用し、患者本人による肉眼的腫瘍の確認の下、能動的に呼吸停止を行う新たなトレーニングシステムを構築した。
小児白血病長期生存患者の認知機能障害とMRI機能的画像の関係：照射群VS非照射群

麦倉俊司, 神宮啓一, 力石健, 高橋昭喜

提供機関：Japan Society for the Promotion of Science

制度名：Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)

研究種目：Grant-in-Aid for Scientific Research (C)

研究機関：Tohoku University

2014年4月1日～ 2018年3月31日

詳細を見る詳細を閉じる

小児白血病など小児がん長期生存者の約60％に、認知機能障害という困難な晩期障害が生じる危険があるとされている。これは90年代半ばまで広く行われていた予防的全脳放射線照射の影響が主たる原因と考えられ、現在、認知機能障害をも考慮した長期フォローアップガイドラインの作成が日本でも進行中である。一方、近年高磁場（３テスラ）を含むMRI技術の進歩に伴い、従来からの形態画像のみならず機能的画像による評価が可能になっている。本研究の目的は、小児がん長期生存者を対象に、MRI機能的画像所見と認知機能の有無、障害の程度との関係を明らかにすることで、晩期認知機能障害のバイオマーカーになり得るという仮説を検証した。
放射線治療における経皮的挿入型体内緩徐吸収性スペーサーの基礎的研究と臨床応用

神宮啓一, 武田一也

提供機関：Japan Society for the Promotion of Science

制度名：Grants-in-Aid for Scientific Research Grant-in-Aid for Young Scientists (B)

研究種目：Grant-in-Aid for Young Scientists (B)

研究機関：Tohoku University

2014年4月1日～ 2018年3月31日

詳細を見る詳細を閉じる

放射線治療において既に商品化されている固形のスペーサーもあるが、手術操作にて差し込むものでは感染や適切な部位に差し込むことの困難さがある。そこでＣＴガイド下で差し込むことができ、かつ体内で緩徐に自然吸収されるスペーサーの開発をおこなうこととした。我々は血管内治療で使用されているゼラチン (RM-100HS、ゼライス株式会社)に注目し、動物実験にてその安定性と安全性を検討した。マウスの背部に0.3ccを皮下へ注入し、ＣＴにてその安定性を検討するとともに組織反応を検討した。投与後24時間で112±31%と膨張し、その後３週間は安定し、35日目以降に急激に吸収された。明らかな毒性は認められなかった。
画像誘導放射線治療を用いたoligometastasesに対する標準治療の確立

新部譲, 白石憲史郎, 山下英臣, 寺原敦朗, 神宮啓一

提供機関：Japan Society for the Promotion of Science

制度名：Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)

研究種目：Grant-in-Aid for Scientific Research (C)

2013年4月1日～ 2018年3月31日

詳細を見る詳細を閉じる

「画像誘導放射線治療を用いたoligometastasesに対する標準治療の確立」に関して検討した。対象とした癌の種類、状態は、1.肺oligometastases, 2.非小細胞肺癌oligometastasesに対する定位放射線照射, 3.食道癌リンパ節oligo-recurrenceに対する(化学)放射線療法とした。結果、oligometastasesは、oligo-recurrenceとsync-oligometastasesに分けられるが、現状では、oligo-recurrenceは治癒をめざし、sync-oligometastasesは長期生存をめざすことがよいと示唆された。
心臓MRI検査を用いた放射線治療前後での心筋変化とその臨床的意義の検討

梅澤玲, 角谷倫之, 大田英揮, 神宮啓一

提供機関：Japan Society for the Promotion of Science

制度名：Grants-in-Aid for Scientific Research Grant-in-Aid for Young Scientists (B)

研究種目：Grant-in-Aid for Young Scientists (B)

研究機関：Tohoku University

2014年4月1日～ 2017年3月31日

詳細を見る詳細を閉じる

放射線治療前、治療後半年後、治療後1年半後に、心臓MRI検査を施行した。10Gy毎に各線量域を設定し、各線量域での照射前後においてのGd造影効果の信号強度変化を調べた。照射後半年後に検査した19例中13例（68%）で、1年半後に検査した12例中9例（75%）で、線量依存性に信号強度の変化を認めた。特に30Gy以上照射されている領域で信号強度の変化が明らかに出現した（20-30Gy領域では半年後・1年半後に1.1%・1.9%に対し、40-50Gy領域では35.7%・17.5%の信号強度変化が認められた。食道癌化学放射線療法後の心筋障害が線量依存性に出現する事が示唆された。
頭蓋内胚細胞腫瘍生存例における放射線誘発認知機能障害：ＭＲ機能画像による病態解明

神宮啓一, 李麗, LI Li

2013年4月1日～ 2016年3月31日

詳細を見る詳細を閉じる

全脳照射後のがんの長期生存者の40－50％に遅発性認知機能障害が生じることが明らかとなり、重大な社会問題となっている。一方、国内国外を問わず依然として認知機能の障害に結びつく科学的根拠は極めて少ない状況である。本研究では、頭蓋内胚細胞性腫瘍放射線照射後10年以上経過した症例を対象に、放射線による認知機能障害のMRI機能画像による病態解明を目的とした。頭蓋内胚細胞性腫瘍は、放射線治療に高感受性、予後良好、長期生存例が多い。また欧米で原発性脳腫瘍の0.4－3.4%を占めるのに対して、日本などの東アジアでは約11%を占めるため、照射後晩発性認知機能障害の病態解明は、特にアジアで臨床的意義が大きい。1983年から1996年12月までに当院放射線治療科にて初回の放射線治療を受けた頭蓋内胚細胞腫患者34例を登録した。34症例はカルテの情報に基づいて全脳照射群(全脳群、20症例)と拡大局所照射群(局所群、14症例)に分けた。2群間で、総線量、照射時の年齢、照射後のフォローアップ期間、化学療法の併用の有無には、いずれも有意差はなかった。94%（32/34例）に放射線による微小血管損傷が検出された。微小血管損傷の数は全脳群で平均9個、局所群では平均4個であった。全脳群は局所群に比べて微小血管損傷が有意に多かった。また、高線量照射域は低線量照射域に比べて微小血管損傷の数が有意に多かった。NAA/Cr比は神経細胞密度減少の指標であり、2群間で有意差を認めなかった。以上の結果から、脳微小血管障害は全脳照射を受けた患者で高度であり、放射線による認知機能障害の一因である可能性が示唆された。研究成果を論文にまとめ、「Radiotherapy and Oncology」誌（Li L et al）に掲載された。
放射線心筋障害に対するＮａ利尿ペプチド製剤の予防効果に関する基礎的研究

神宮啓一

提供機関：Japan Society for the Promotion of Science

制度名：Grants-in-Aid for Scientific Research Grant-in-Aid for Young Scientists (B)

研究種目：Grant-in-Aid for Young Scientists (B)

研究機関：Tohoku University

2012年4月1日～ 2015年3月31日

詳細を見る詳細を閉じる

マウスに対し、縦隔へ８Gy照射を行い、14日後から、ＡＮＰ製剤の持続静脈投与を行った。コントロールとして非投与群を置いた。照射後６か月の時点ですべて安楽死させ、心筋線維化率を検討した。６カ月後の経過観察中に非照射群で３匹が、照射群で５匹が死亡した。照射群で心外膜の肥厚および心筋の線維化を認めたが、ナトリウム利尿ペプチド投与群と非投与群で心筋の線維化の程度などに有意な差は認めなかった。このことからANP製剤には放射線による心筋線維化の抑制効果は認めないと判断した。
早期の癌に対する標準的放射線治療方法確立と適応決定に関する研究

山田章吾, 西村泰昌, 晴山雅人, 根本建二, 早渕尚文, 芝本雄太, 白土博樹, 中村和正, 大西洋, 戸板孝文, 有賀久哲, 佐々木良平, 手島昭樹, 高井良尋, 西尾禎治, 村上昌雄, 平岡眞寛, 鎌田正, 大内憲明, 土橋卓, 神宮啓一, 松下晴雄, 清水伸一, 深尾彰, 森谷卓也, 小川芳弘, 梅田みか(渡辺みか)

提供機関：Japan Society for the Promotion of Science

制度名：Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (A)

研究種目：Grant-in-Aid for Scientific Research (A)

研究機関：Tohoku University

2009年～ 2012年

詳細を見る詳細を閉じる

画像診断の進歩により早期の癌が高率に発見されるようになり、またQOL重視の風潮の中で早期のがんに対する放射線治療の役割が高まっている。しかし、治癒の可能性の高いこれらの癌に対する標準的放射線治療方法はいまだ確立していない。私どもは種々の早期のがんに対して全国集計を行い、結果を解析し、標準的と考えられる治療方法を提示してきた。さらに、標準的治療方法確立のために種々の臨床試験の提案を行い、実行してきた。また、放射線に感受性の高いがんの選別に関する研究も行った。
放射線増感剤ギメラシルを利用した、放射線増感のメカニズムの解明

有賀久哲, 神宮啓一, 仲田栄子

提供機関：Japan Society for the Promotion of Science

制度名：Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)

研究種目：Grant-in-Aid for Scientific Research (C)

2009年～ 2011年

詳細を見る詳細を閉じる

ギメラシルは抗腫瘍薬に配合された5FUの代謝阻害剤だが、単剤でも放射線増感作用が認められた。ギメラシルの増感活性は、細胞株によって、また腫瘍組織と正常組織の間で異なっており、放射線誘発DNA損傷の修復を阻害している可能性が考えられた。特に増殖細胞に特異的な相同組み替えを阻害することで、腫瘍細胞に選択的な増感効果が期待される。現在、東北大学臨床試験推進センターを活用した医師主導治験の登録準備中である。

︎全件表示 ︎最初の5件までを表示